<SEC-DOCUMENT>0001213900-25-079717.txt : 20250918
<SEC-HEADER>0001213900-25-079717.hdr.sgml : 20250918
<ACCEPTANCE-DATETIME>20250822113012
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-25-079717
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20250822
<PUBLIC-REL-DATE>20250918
DATE AS OF CHANGE:		20250822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NewGenIvf Group Ltd
		CENTRAL INDEX KEY:			0001981662
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			D8

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-08362
		FILM NUMBER:		251243938

	BUSINESS ADDRESS:	
		STREET 1:		13/F, PS TOWER, SUKHUMVIT 21 RD (ASOKE)
		CITY:			BANGKOK
		STATE:			W1
		ZIP:			0000
		BUSINESS PHONE:		852-2861-1666

	MAIL ADDRESS:	
		STREET 1:		1/F, PIER 2, CENTRAL
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASPAC I Mini Acquisition Corp.
		DATE OF NAME CHANGE:	20230614
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As confidentially submitted with the Securities
and Exchange Commission on August 22, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>



<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEWGENIVF GROUP LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact name of registrant as specified in its
charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British Virgin Islands</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8090</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not Applicable</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State or other jurisdiction of<BR>
incorporation or organization)</I></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary Standard Industrial<BR>
Classification Code Number)</I></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S. Employer<BR>
Identification Number)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Wing Fung Alfred Siu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>36/39-36/40, 13th Floor, PS Tower<BR>
Sukhumvit 21 Road (Asoke)<BR>
Khlong Toei Nuea Sub-district<BR>
Watthana District, Bangkok 10110<BR>
Thailand</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: +1 (212) 537-4406</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address, including zip code, and telephone
number,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>including area code, of registrant&rsquo;s principal
executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>(Name, address, including
zip code, and telephone number, including area code, of agent for service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Steve Lin</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Han Kun Law Offices LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rooms 4301-10, 43/F., Gloucester Tower</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Landmark</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>15, Queen&rsquo;s Road Central</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+852 2820 5600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approximate date of commencement of proposed
sale to the public:</B> As soon as practicable after the effective date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on this
form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities
Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may
determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The information in this preliminary prospectus
is not complete and may be changed. The selling shareholders named in this preliminary prospectus may not sell these securities until
the Registration Statement filed with the Securities and Exchange Commission, of which this preliminary prospectus is a part, is effective.
This preliminary prospectus is not an offer to sell these securities and the selling shareholders named in this preliminary prospectus
is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS (Subject to Completion)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: center; text-indent: -24pt">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: center; text-indent: -24pt"><B>Dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>50,000,000 Class A Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NewGenIvf Group Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the resale by the selling securityholders identified in this prospectus (&ldquo;Selling Securityholders&rdquo;) of up to 50,000,000 Class
A Ordinary Shares, no par value per share (&ldquo;Class A Ordinary Shares&rdquo;), consisting of (i) 20,000,000 Class A Ordinary Shares
issuable by the Company to White Lion Capital, LLC (&ldquo;White Lion&rdquo;) in connection with the Common Stock Purchase Agreement dated
as of November 21, 2024, by and between the Company and White Lion (the &ldquo;White Lion Purchase Agreement&rdquo;); and (ii) 30,000,000
Class A Ordinary Shares issuable to JAK Opportunities VI LLC upon the conversion of (a) the Remaining Additional Notes (as defined below),
(b) the senior convertible notes exchanged on August 8, 2024 (&ldquo;Exchange Notes&rdquo;), (c) the exercise of the Series A warrants
to purchase Class A Ordinary Shares (the &ldquo;Series A Warrants&rdquo;), (d) the exercise of Series B warrants to purchase Class A Ordinary
Shares (the &ldquo;Series B Warrants&rdquo;), (e) the exercise of Series C warrants to purchase Class A Ordinary Shares (the &ldquo;Exchange
Warrants&rdquo; and together with the Series A Warrants and the Series B Warrants, the &ldquo;Warrants&rdquo;), and (f) the New CB Initial
Note (as defined below) (the &ldquo;Resale Shares&rdquo;). The Resale Shares were issued in private placements to certain Selling Securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering the offer
and resale of the Resale Shares to satisfy certain registration rights we have granted. The Resale Shares will be resold from time to
time by the Selling Securityholders listed in the section titled &ldquo;Selling Securityholders&rdquo; beginning on page 91.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Resale Shares represent
more than the number of our outstanding Class A Ordinary Shares, and the sales of the Resale Shares, or the perception that those sales
might occur, could depress the market price of our Class A Ordinary Shares and could impair our ability to raise capital through the sale
of additional equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our registration of the securities
covered by this prospectus does not mean that the Selling Securityholders will offer or sell these securities. The Selling Securityholders
may offer all or part of the securities for resale from time to time through public or private transactions in amounts, at prices and
on terms determined at the time of offering. The Selling Securityholders may offer and sell these securities directly to purchasers, through
agents in ordinary brokerage transactions, in underwritten offerings, directly to market makers of our shares or through any other means
described in the section entitled &ldquo;Plan of Distribution&rdquo; herein. In connection with any sales of securities offered hereunder,
any underwriters, agents, brokers or dealers participating in such sales may be deemed to be &ldquo;underwriters&rdquo; within the meaning
of the Securities Act of 1933, as amended, or the &ldquo;Securities Act.&rdquo; White Lion is an &ldquo;underwriter&rdquo; within the
meaning of Section 2(a)(11) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The actual number of Class
A Ordinary Shares issuable to White Lion will vary depending on the then-current market price of Class A Ordinary Shares sold or issuable
to White Lion under the White Lion Purchase Agreement and are subject to the further limitations set forth in the White Lion Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not selling any securities
under this prospectus and will not receive any of the proceeds from the sale of the Resale Shares by the Selling Securityholders. However,
we may receive gross proceeds of up to $500 million from the sale of our Class A Ordinary Shares to White Lion pursuant to the White Lion
Purchase Agreement. The actual proceeds from White Lion may be less than this amount, depending on the number of Class A Ordinary Shares
sold and the price at which the Class A Ordinary Shares are sold. In addition, we may receive proceeds from the conversion of the Additional
Notes, Exchange Notes, Warrants, New CB Initial Note which proceeds will be used for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
will pay all brokerage fees and commissions and similar expenses attributable to the sales of the Resale Shares. We will pay the expenses
(except brokerage fees and commissions and similar expenses) incurred in registering the Resale Shares, including legal and accounting
fees. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Class A Ordinary Shares
currently trade on The Nasdaq Capital Market under the symbol &ldquo;NIVF.&rdquo; The last reported closing price of our Class A Ordinary
Shares on August 21, 2025 was $1.67.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as a &ldquo;foreign
private issuer,&rdquo; as defined in Rule 405 under the U.S. Securities Act of 1933, as amended, or the Securities Act, thus we are eligible
for reduced public company reporting requirements, and are permitted to rely on certain exemptions from Nasdaq corporate governance rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf Group Limited (&ldquo;NewGenIvf,&rdquo;
&ldquo;Company,&rdquo; &ldquo;our,&rdquo; &ldquo;we,&rdquo; or &ldquo;us&rdquo;) is a British Virgin Islands holding company with our
operations conducted through our subsidiaries in the Cayman Islands (our wholly-owned subsidiary, NewGenIvf Limited) and in Asia (Hong
Kong, Thailand, Kyrgyzstan, and the Kingdom of Cambodia). Under this holding company structure, investors are purchasing equity interests
in NewGenIvf, a British Virgin Islands holding company, and obtaining indirect ownership interests in our Cayman Islands and Asian operating
subsidiaries. Substantially all of NewGenIvf&rsquo;s operations and assets are based in Thailand, Cambodia and Kyrgyzstan. As a result,
its businesses and operations are subject to the changing economic conditions prevailing from time to time in such countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the &ldquo;Panel&rdquo;) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at&nbsp;an oral hearing&nbsp;on January 28, 2025 (the &ldquo;Hearing&rdquo;). On February 19, 2025, the Company
received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance with the
Nasdaq Stock Market&rsquo;s continued listing requirements, subject to meeting specific compliance criteria within designated timeframes.
As of the date of this prospectus, in accordance with the Panel&rsquo;s extension, the Company has already made progress on its compliance
plan, including carrying out a 1-for-20 reverse stock split of its issued and unissued shares which was effected on February 11, 2025.
The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share. On February 27, 2025, the
Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&rsquo;s securities had been at
$1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the Company had regained
compliance with the minimum bid price rule. In addition, on February 27, 2025, the Company received a confirmation from Nasdaq that its
application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company&rsquo;s securities would be transferred
to the Nasdaq Capital Market at the opening of business on February 28, 2025. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our Class
A Ordinary Shares involves a high degree of risk, including the risk of losing your entire investment. See &ldquo;<I>Risk Factors</I>&rdquo;
starting on page 25 to read about the factors you should consider before buying the Ordinary Shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission, or the SEC, nor any state or other foreign securities commission has approved nor disapproved these securities
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 90%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About this Prospectus</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glossary of Defined Terms</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions&nbsp;</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing Details</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Securityholders</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Share Capital</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforceability of Civil Liabilities</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find Additional Information</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>You should rely only on
the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred
you. Neither we nor the Selling Securityholder have authorized anyone to provide you with different information. Neither we nor the Selling
Securityholder are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that
the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable
document. Since the date of this prospectus, our business, financial condition, results of operations and prospects may have changed.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For investors outside of the
United States: Neither we nor the Selling Securityholder have done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to
inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; and the &ldquo;Company&rdquo; refer to NewGenIvf Group Limited and its wholly owned subsidiary, NewGenIvf
Limited, a Cayman Islands company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reporting currency is
the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to &ldquo;dollars&rdquo;
or &ldquo;$&rdquo; are to U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus includes statistical,
market and industry data and forecasts which we obtained from publicly available information and independent industry publications and
reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they obtain
their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the information.
Although we believe that these sources are reliable, we have not independently verified the information contained in such publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or
U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of Class A Ordinary
Shares and Class B Ordinary Shares currently issued and outstanding was 2,152,702 as of August 21, 2025. No new shares are being issued
by the Company pursuant to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus describes
the general manner in which the Selling Securityholders identified in this prospectus may offer from time to time up to 50,000,000 Class
A Ordinary Shares through any means described in the section entitled &ldquo;Plan of Distribution.&rdquo; You should rely only on the
information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated
by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Securityholders have
authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should
not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation
of an offer to purchase, the Resale Shares offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction
to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should
not assume that the information contained in this prospectus, any prospectus supplement or amendments thereto, as well as information
we have previously filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), is accurate as of any date other than
the date on the front cover of the applicable document. The information contained in this prospectus is current only as of the date on
the front cover of the prospectus. Our business, financial condition, results of operations, and prospects may have changed since that
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If necessary, the specific
manner in which the Class A Ordinary Shares may be offered and sold will be described in a supplement to this prospectus, which supplement
may also add, update or change any of the information contained in this prospectus. To the extent there is a conflict between the information
contained in this prospectus and the prospectus supplement, you should rely on the information in the prospectus supplement, provided
that if any statement in one of these documents is inconsistent with a statement in another document having a later date&mdash;for example,
any prospectus supplement&mdash;the statement in the document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>GLOSSARY OF DEFINED TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, unless
otherwise indicated or the context otherwise requires, references to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;ASCA&rdquo; means A
SPAC I Acquisition Corp., a British Virgin Islands business company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;A SPAC I Mini Acquisition
Corp.&rdquo; means A SPAC I Mini Acquisition Corp., a British Virgin Islands business company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Business Combination&rdquo;
means the transactions contemplated by the Merger Agreement, pursuant to which (i) ASCA reincorporated to the British Virgin Islands by
merging with and into the Company; and (ii) Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned
subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;BVI&rdquo; means British
Virgin Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;BVI Act&rdquo; means
BVI Business Companies Act (As Revised).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Class A Ordinary Share&rdquo;
means Class A ordinary shares of the Company, no par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Class B Ordinary Share&rdquo;
means (x) the Company&rsquo;s Class B ordinary shares with no par value per share, and (y) any shares into which such ordinary shares
shall have been changed or any shares resulting from a reclassification of such ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Closing&rdquo; means
the consummation of the Business Combination, which occurred on April 3, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Company&rdquo; means
NewGenIvf Group Limited, a British Virgin Islands business company, the surviving entity of the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;First Reverse Stock
Split&rdquo; means the 1-for-20 reverse stock split effected by the Company on February 11, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Legacy NewGenIvf&rdquo;
means NewGenIvf Limited, a Cayman Islands exempted company, which became a wholly owned subsidiary of ASCA upon the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Merger Agreement&rdquo;
means the Merger Agreement entered into on February 15, 2023, and as amended on June 12, 2023 and December 6, 2023, between ASCA, A SPAC
I Mini Acquisition Corp., Merger Sub, Legacy NewGenIvf, and certain shareholders of Legacy NewGenIvf, pursuant to which the Reincorporation
Merger and Acquisition Merger were consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Merger Sub&rdquo; means
A SPAC I Mini Sub Acquisition Corp., a Cayman Islands exempted company and former wholly-owned subsidiary of A SPAC I Mini Acquisition
Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Memorandum and Articles
of Association&rdquo; means the Company&rsquo;s Amended and Restated Memorandum and Articles of Association, as and restated on July 4,
2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;NewGenIvf&rdquo; means
NewGenIvf Group Limited, a British Virgin Islands business company, the surviving entity of the Business Combination, unless the context
so requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Ordinary Shares&rdquo;
means the Class A Ordinary Shares and Class B Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Preferred Shares&rdquo;
means preferred shares of the Company, no par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Reincorporation Merger&rdquo;
means the first step of the Business Combination which occurred pursuant to the Merger Agreement, in which ASCA reincorporated to the
British Virgin Islands by merging with and into A SPAC I Mini Acquisition Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Reverse Stock Splits&rdquo;
means the First Reverse Stock Split, the Second Reverse Stock Split, and the Third Reverse Stock Split. In this prospectus, where we state
historical share and per-share numbers, we have, where appropriate, reflected a retroactive adjustment due to the Reverse Stock Splits
in parentheses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Second Reverse Stock
Split&rdquo; means the 1-for-10 reverse stock split effected by the Company on May 5, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Third Reverse Stock
Split&rdquo; means the 1-for-5 reverse stock split effected by the Company on August 4, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing
in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully, including the &ldquo;Risk
Factors&rdquo; section and the financial statements and related notes appearing at the end of this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the context otherwise
requires, all references in this Prospectus Summary to &ldquo;NewGenIvf,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; and &ldquo;us&rdquo;
refer to Legacy NewGenIvf and its subsidiaries as they existed prior to the Closing if described in relation to a date prior to April
3, 2024. Any references to &ldquo;NewGenIvf,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; and &ldquo;us&rdquo; with respect to the present
time, a future time, or a date after April 3, 2024 refers to NewGenIvf, a British Virgin Islands company, and its subsidiaries, whose
existence continued after the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an assisted reproductive
services (&ldquo;ARS&rdquo;) provider in Asia-Pacific. Since the opening of our first clinic in Thailand in 2014, we have established
ourselves as a long-standing ARS provider in this region. Our strategic presence in Thailand, Cambodia, and Kyrgyzstan positions us to
take advantage of opportunities across Asia-Pacific. According to China Insights Consultancy (&ldquo;CIC&rdquo;), from 2014 to 2022, there
was a rising number of women in the key ARS-targeted age group (ages 15 to 49) in Asia Pacific and a growing trend towards later maternal
age. The number of married women of reproductive age in Asia Pacific has risen from 816.4&nbsp;million in 2014 to 833.2&nbsp;million in
2022. Additionally, according to CIC, there was increasing social acceptance of ARS use in Asia Pacific countries such as China, India,
and Thailand during the same period. For example, the number of ARS users in China has risen from 136.8 thousand in 2017 to 184.9 thousand
in 2022 approximately and that in Japan has risen from 98.0 thousand in 2017 to 128.5 thousand in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, the prevalence
of infertility in Asia-Pacific developing countries is substantial. For example, the infertility rate in Thailand, India and China was
about 15.4%, 13.8% and 17.8%, respectively, in 2022. In India, the infertility rate in 2020 was approximately 13.1%, representing an annual
growth of 2.6%. The infertility rate in China was around 17.6% in 2020, representing an annual growth of 0.6%. Infertility is increasingly
gaining society&rsquo;s attention as individuals are more openly discussing their struggles. Despite the prevalence of infertility, access
to treatment is often limited in the Asia Pacific region. According to CIC, financial challenges, costs of treatment, and limited availability
or capacity of fertility medical care are some of the main challenges in the fertility marketplace in Asia-Pacific region. Religious,
social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have children. We believe that we can help
address some of these key challenges of Asia-Pacific fertility industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>History and Development of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Business Combination,
on April&nbsp;29, 2021, A SPAC I Acquisition Corp. (&ldquo;ASCA&rdquo;), was incorporated as a British Virgin Islands business company,
specifically a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more target businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The Business Combination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&nbsp;15, 2023,
ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &ldquo;Merger Agreement,&rdquo; and the
transactions contemplated thereunder, the &ldquo;Business Combination&rdquo;) with A SPAC&nbsp;I Mini Acquisition Corp., Merger Sub, NewGenIvf
Limited, a Cayman Islands exempted company (&ldquo;Legacy NewGenIvf&rdquo;) and certain shareholders of Legacy NewGenIvf. Pursuant to
the Merger Agreement, the Business Combination was effected in two steps: (i)&nbsp;ASCA was reincorporated to the British Virgin Islands
by merging with and into A SPAC&nbsp;I Mini Acquisition Corp. (such transaction, the &ldquo;Reincorporation Merger&rdquo;); and (ii)&nbsp;Merger
Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the Company (such second step
in isolation, the &ldquo;Acquisition Merger&rdquo;). The surviving entity of the Business Combination, together with its subsidiaries
is referred to in this prospectus as &ldquo;NewGenIvf,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us,&rdquo;
unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;12, 2023, the
parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &ldquo;First Amendment&rdquo;), pursuant to
which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the &ldquo;Loan&rdquo;)
to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA&rsquo;s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from NewGenIvf, ASCA agreed
to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&rsquo;s failure to deliver audited financial
statements by no later than February&nbsp;28, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 6, 2023, the parties
to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &ldquo;Second Amendment&rdquo;) which amended and
modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&rsquo;s board of directors following the consummation
of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf and three (3)
of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the
conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in
connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible assets immediately
after the consummation of the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 3, 2024, the Business
Combination was consummated with the Company as the surviving entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NewGenIvf&rsquo;s Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a focus on providing
fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i) in vitro fertilization
(&ldquo;IVF&rdquo;) treatment service, comprising traditional IVF and egg donation; and (ii)&nbsp;surrogacy and ancillary caring services.
Currently, we have four clinics: two clinics in Thailand (one of which, whilst licensed, is yet to commence operations), one clinic in
Cambodia, and one clinic in Kyrgyzstan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IVF treatment service:</B> For the&nbsp;years ended December&nbsp;31, 2024 and 2023, we generated approximately 100% and 78.3, respectively of our revenue from IVF treatment services. We primarily provide our clients with conventional IVF/intracytoplasmic sperm injection (&ldquo;ICSI&rdquo;) and embryo transfer services. As technology has progressively advanced, we have been able to, through technologies and facilities provided by MicroSort technology, help fulfill the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases. IVF treatment involves the performance of a series of medical treatment as well as procedures and eventually brings benefits to clients when embryo is successfully implanted. Revenue from IVF treatment is recognized at a point in time when different treatment and/or procedure completed in clinic. The completion of the various and procedures are evidenced by written treatment cards and reports maintained in the patient files.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Surrogacy and ancillary caring services:</B> We also generate revenue from surrogacy services and related ancillary caring services in Kyrgyzstan. For the&nbsp;years ended December&nbsp;31, 2024 and 2023, we generated approximately Nil % and 21.7%, of our revenue from surrogacy and ancillary caring services. For surrogacy services, NewGenIvf conducts implantation of embryos from biological parents in surrogate mothers. In addition, NewGenIvf provides a &ldquo;success guarantee&rdquo; program for egg donation services in Cambodia and surrogacy services in Kyrgyzstan. Under this optional program, patients pay additional fees of approximately 40% of the original price and can have repeated attempts of IVF cycles, egg donation services and/or surrogacy services until the procedures are successful. The additional costs to NewGenIvf are generally limited and amount to approximately 30% of the original costs because NewGenIvf&rsquo;s clinics, together with the patients, can choose suitable egg donors and surrogate mothers to limit the additional costs. During the pregnancy period, NewGenIvf provides ancillary caring services including regular body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring services is recognized at a point in time when the surrogate mother gives birth. Surrogacy services provide infertile couples with an alternative method of having children. During 2024, we did not generate any revenue from surrogacy as we went through a series of reorganization in Kyrgyzstan, resulting in a sale of 100% equity interest in First Fertility Bishkek Limited Liability Company and acquisition of 100% equity interest in Bi Clinic Limited Liability Corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&nbsp;years ended December&nbsp;31,
2024 and 2023, NewGenIvf&rsquo;s revenue was US$5,433,375 and US$5,136,153, and its net income/(loss) was US$(474,101)&nbsp;and US$108,418,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that the
following competitive strengths have positioned it to meet growing opportunities in the fertility market across Asia-Pacific, and have
differentiated it from its competitors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Broad-range Assisted Reproductive Service (&ldquo;ARS&rdquo;)
Provider Offering Comprehensive Fertility Treatment Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With almost a decade of experience
in the fertility market, NewGenIvf has built a reputation in the IVF industry in Asia-Pacific. NewGenIvf has reinforced its long-standing
position through expanding its service offerings and locations to address the evolving clients&rsquo; needs or requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s comprehensive
fertility treatment offerings in Thailand, Cambodia, and Kyrgyzstan, primarily including IVF, egg donation (in Cambodia) and surrogacy
services (in Kyrgyzstan), make it convenient for clients in Asia-Pacific market to have access to various fertility services but with
a relatively low cost, as compared with the US market. Meanwhile, the average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding
medication). Each of NewGenIvf&rsquo;s clinics in Thailand, Cambodia, and Kyrgyzstan has its own specialty, and together, NewGenIvf is
able to provide more flexibility and options to its patients. For example, NewGenIvf&rsquo;s Thailand clinic focuses on IVF and related
ancillary services including HIV sperm washing, egg freezing, and chromosome screening. The clinic in Cambodia specializes in providing
both IVF services and egg donation services. NewGenIvf opened the clinic in Kyrgyzstan in 2019, which broadened NewGenIvf&rsquo;s services
by being legally qualified/received approval letter from The Ministry of Health of Kyrgyzstan to offer surrogacy services. As of December
31, 2024, NewGenIvf was the one of the few ARS providers in Kyrgyzstan and one of the few companies in Kyrgyzstan that is licensed to
offer surrogacy services in Kyrgyzstan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf attributes its track
record of success to its experienced physicians and its ability to provide comprehensive ARS services, allowing it to meet patients&rsquo;
increasing demand for advanced, high-end, and sophisticated ARS, a higher standard and a wider range of advanced services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has extensive experience
serving Asia-Pacific patients and a deep understanding of their general profiles. In particular, NewGenIvf has personnel speaking multiple
languages, including nurses, facilitators, and translators, who are familiar with the health condition and culture of Asia-Pacific patients
from different countries in the region. NewGenIvf believes that it is therefore well-positioned to benefit from market growth driven by
Asia-Pacific patients travelling to its clinics for treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Attractive Market with Significant Demand and
Fast Growth</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf operates in the
ARS market in Asia Pacific, positioning it to leverage on an attractive market with compelling underlying growth potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Built on years of experience,
NewGenIvf has established a strong reputation in its industry, which in turn attracted potential business partners to approach NewGenIvf
to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly held in the PRC to approach
potential business partners and establish new partnerships by entering into agency agreements with each agent. NewGenIvf has become a
significant partner with agents and sub-agents throughout China and India. Normally, each agency agreement has a maximum term of one year,
which is renewable upon mutual agreement. Agents typically market and promote NewGenIvf&rsquo;s services by word-to-mouth referrals and
other measures and NewGenIvf pays the agents commission at a range of 10% to 25% of the treatment fees upon the completion of client&rsquo;s
treatment. Normally, agents provide potential clients&rsquo; contact information to the sales team of NewGenIvf, who then approach potential
clients and provide consultation on services. With its partnerships in various countries, NewGenIvf believes it is able to better benefit
from the growing market opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Exclusively Owned and Licensed Technology for Family Planning and
Access to Mature Fertility Technologies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that its
licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient&rsquo;s
needs. These technologies include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>MicroSort Technology:</I> NewGenIvf acquired the MicroSort Technology from Genetics &amp; IVF Institute, Inc. (&ldquo;GIVF&rdquo;) pursuant to a Purchase Agreement dated January 21, 2025 between NewGenIvf and GIVF (&ldquo;Purchase Agreement&rdquo;). As such NewGenIvf exclusively owns the MicroSort Technology. Prior to the closing of the MicroSort Acquisition, NewGenIvf held an exclusive license granted by a division of the Genetics &amp; IVF Institute, Inc. to use MicroSort technology in Thailand and Cambodia. MicroSort technology is a form of pre-conception gender selection technology for humans. MicroSort technology aims to separate male sperm cells based on which gender chromosome they contain, which results in separated semen samples that contain a higher percentage of sperm cells that carry the same gender chromosome. The technology ultimately helps couples choose the gender of their future child by choosing semen samples that predominately contain sperm with the&nbsp;X chromosome for a female or Y chromosome for a male. Traditionally and naturally, gender selection occurs after conception, meaning after the eggs are fertilized. As a result, some fertilized eggs will go unused. However, with MicroSort technology, NewGenIvf is able to increase the ratio of male or female embryos, based on the patient&rsquo;s preference. Eggs are more likely to be fertilized according to the preferences of the parents. Other improvements that MicroSort treatment could help achieve include prevention of certain gender-related hereditary diseases.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preimplantation Genetic Screening (&ldquo;PGS&rdquo;)</I>: PGS is used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Next-Generation Sequencing (&ldquo;NGS&rdquo;)</I>: NGS is a high-throughput technology for determining the sequence of deoxyribonucleic acid (&ldquo;DNA&rdquo;) or ribonucleic acid (&ldquo;RNA&rdquo;) to study genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality and data output.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preimplantation Genetic Diagnosis (&ldquo;PGD&rdquo;)</I>: Similar to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process more enhanced than PGS since it scans for individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic fibrosis, where carrier status has been documented in each of the parents. By using this technique, physicians are able to check the genes or chromosomes for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help women better achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Well Established Brand with Reliable Reputation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The founders of NewGenIvf
entered the fertility market as agents in 2011 by introducing patients in need to a Thailand clinic for fertility treatments. The founders
of NewGenIvf started to operate their own clinic in Thailand in 2014 and subsequently added clinics in Cambodia and Kyrgyzstan. Since
then, NewGenIvf has attracted clients from countries throughout Asia-Pacific, including Mainland China, Hong&nbsp;Kong, India, Thailand,
Australia and Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf benefits from the
favourable geographic locations of its clinics, especially its clinic in Thailand. Located in central Bangkok and situated in one of the
biggest shopping malls of the city, the clinic is located in close proximity to various transportation facilities and popular tourist
attractions, such as the Erawan Shrine. In this regard, NewGenIvf believes that its business has benefited from, and will continue to
benefit from, the convenience of its locations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has developed a
relatively replicable and scalable operating model that supports high productivity at its assisted reproductive medical facilities in
Asia. Under this model, NewGenIvf&rsquo;s medical facilities have established standardized operating procedures to select the treatment
process according to each patient&rsquo;s profile. NewGenIvf&rsquo;s medical and operational personnel are organized into specialized
teams according to the different stages of the treatment process and different patient profiles. When patients are initially admitted
or would like to seek additional medical services later on, they are assigned to one of the optimal medical teams, which NewGenIvf believes
is better suited after taking into account the patient&rsquo;s diagnosis and preferences. NewGenIvf believes that this model allows each
team to improve its efficiency and arrange suitable physicians for patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The physicians of NewGenIvf
have also developed and employed an operating model that seeks to increase the effectiveness of physicians by utilizing standardized workflows
and operating procedures with teams of supporting nurses and medical assistants. This helps to increase the number of IVF treatment cycles
that physicians can perform while providing treatment customized based on patient conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With its established client
service history, accumulated experience as well as its continuous upgrades and development of treatment models, NewGenIvf believes that
it will be able to better monetize its brands through its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Experienced Management Team</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NewGenIvf management team
has considerable experience in the ARS market and the broader healthcare industry. A considerable number of NewGenIvf&rsquo;s management
are physicians or laboratory technicians who possess extensive experience in the ARS industry and are experts in their respective fields.
NewGenIvf&rsquo;s Chief Executive Officer, Mr.&nbsp;Alfred Siu, has more than 13&nbsp;years of experience in the fertility service market.
Dr.&nbsp;Wiphawee Luangtangvarodom had over 8&nbsp;years of experience as an obstetrician and gynecologist. NewGenIvf&rsquo;s two lab
supervisors, Ms. Anussara Phinyong, and Ms. Araya Boonchaisitthipong, each had over eight&nbsp;years of experience in the embryologist
field. These individuals have extensive experience in managing assisted reproductive medical facilities. NewGenIvf is also led by other
members of the professional management team, who are intimately involved in the operational and financial management of NewGenIvf&rsquo;s
Group. Leveraging their experience, NewGenIvf believes that it is well positioned to expand its network and aims to become a leader in
the Asia Pacific ARS market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Strategies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s vision is
to provide tailored ARS solutions to fulfil patients&rsquo; dreams of becoming a parent. To realize this vision, NewGenIvf plans to adopt
the following strategies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Offer Broad Fertility Services for Fertility
Tourists across Asia Pacific</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to provide
broad fertility services for fertility tourists seeking high quality, cost effective and comprehensive fertility solutions. According
to CIC, the demand for fertility tourism is driven by a variety of factors including the prevalence of infertility, the introduction of
the Three-Child policy in China, the improved understanding of assisted reproductive technology and increased affordability of ARS.&nbsp;To
address these needs, NewGenIvf plans to offer its customers a &ldquo;hassle-free&rdquo;, seamless and integrated ARS and hospitality arrangement
experience. To complement its fertility services, NewGenIvf intends to integrate its offerings with additional services for traveling
patients, most of whom are first-time fertility tourists, such as translation service, hotel arrangement and airport pickup services.
NewGenIvf plans to enhance its customers&rsquo; experience by entering into exclusive cooperation arrangements with local premium hospitality
providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Continue to Invest in Laboratories and Facilities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes laboratories
and treatment facilities are critical to supporting its future research, development and clients experience. NewGenIvf currently operates
two laboratories that offer IVF services, one in Thailand and one in Cambodia, and plans to continue to scale up its existing laboratories.
NewGenIvf plans to continue to invest in upgrading its laboratories and facilities to complement its growth and expansion, which it believes
will help NewGenIvf maintain an edge over its competitors with regard to technology, operational efficiency, scalability, and client experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to develop
advanced facilities for its existing laboratories, which will be conducting research on ARS related basic science and experiments relating
to emerging technologies to improve ARS success rates and lower costs. NewGenIvf also plans to correlate its data on patient treatment
protocols to the embryo physiologic data and the pregnancy success rate-related data to identify better treatment protocols to increase
ARS success rates. NewGenIvf intends to continue to actively promote technological cooperation with tertiary institutions to discover
ways to improve its IVF success rates. Furthermore, NewGenIvf seeks to actively deploy the technology that it possesses to expand the
services it provides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has accumulated
experience in treating patients over 40&nbsp;years old with premature ovarian failure and patients who have had recurrent ARS implementation
failure, by, for the example, injecting platelet rich plasma into the ovaries to stimulate and support growth of the follicles. NewGenIvf
is also implementing certain technological advancements relevant to the ARS industry, including microfluidics, automated sperm analysers,
time lapsed incubators, non-invasive preimplantation genetic testing (&ldquo;PGT&rdquo;) of cell-free DNA in spent media, automated systems
for oocyte/embryo vitrification to reduce reagent consumption and decrease labor intensity, mitochondria replacement therapy to reconstruct
oocytes by nuclear transfer of polar body genome from an MII oocyte into an enucleated donor MII cytoplasm, to increase the number of
oocytes available for the treatment of infertile women, preimplantation methylome screening. There are also breakthrough developments
in science including organ culture systems, induced pluripotent stem cells, embryonic stem cells, spermatogonial stem cells for creation
of functional gametes, but these techniques are not yet ready for human clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also intends to
develop clinically customised interior design concepts for its medical facilities, including improved service rooms, consultation rooms,
reception areas, nutrition food areas, and traditional Chinese medicine (such as acupuncture) facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Increase Brand Awareness and Market Share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to maintain
and strengthen its brand awareness and market share in Asia Pacific. In order to expand its reach and increase patient numbers, NewGenIvf
plans to collaborate with local hospitals, companies, premium hospitality providers and other key players in the ARS industry in Asia
Pacific. Additionally, NewGenIvf intends to increase brand awareness through social media promotions and marketing initiatives, and is
establishing its business development team with the goal of attracting new patients and partners across Asia Pacific. Meanwhile, NewGenIvf
intends to provide innovative treatment services to attract more clients. For example, NewGenIvf plans to introduce IVF mental health
services, which allows clients who fail in IVF treatments to access online consultation for further treatment plans such as egg donation
and surrogacy. These new treatments services aim to enable NewGenIvf to attract potential clients. By adopting a comprehensive strategy
to expand its market share, NewGenIvf aims to strengthen its reputation as a long-standing ARS provider and capture additional market
share of the growingly ARS market in Asia-Pacific.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Expand Service Reach Through Acquisitions and Partnerships</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Leveraging its reputation
and footprint in its current markets, NewGenIvf intends to expand its reach, services offering and client base through strategic acquisitions
and/or partnerships in Asia Pacific. Acquisitions of or by companies offering similar services could not only allow NewGenIvf to diversify
its client base, but also allow it to benefit from potential economies of scale and increasing efficiency through consolidation. NewGenIvf
could also leverage the acquired or acquiring company&rsquo;s customer base, reputation and expertise to further improve its offerings
and operations. NewGenIvf intends to focus on ARS providers in Asia Pacific which possess all conventional licenses and locally recognized
brands. For the global market beyond Asia Pacific, NewGenIvf intends to expand its footprint through partnerships with other IVF clinics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NewGenIvf plans
to explore expanding its client base by offering its fertility services as part of corporate benefit programs in Asia. NewGenIvf believes
that there is potential in Asia in offering fertility treatments as a benefit for employees, particularly in companies with a large number
of female employees of childbearing age. By partnering with corporate clients to provide fertility benefits, NewGenIvf can increase its
market reach, enhance its brand reputation, and drive client growth. NewGenIvf&rsquo;s broad range of fertility services, including IVF
and egg freezing, can help corporate partners differentiate their employee benefits in the competitive employment landscape, which could
make them more attractive to potential employees. Additionally, by offering these services, companies can help address the growing concern
of delayed childbearing, which is becoming more common among women according to CIC.&nbsp;NewGenIvf plans to collaborate with potential
corporate clients to develop customized fertility benefit programs that cater to their specific needs, and to provide comprehensive support
and counselling throughout the process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Meanwhile, NewGenIvf also
intends to attract more clients by establishing its &ldquo;home country gynecologist partnership program&rdquo;. Under the program, NewGenIvf
may, subject to its discretion and screening process, offer treatment services to clients with reduced time requirements to be spent overseas.
Depending on local laws, the potential clients may be able to complete their treatments with gynecologists NewGenIvf partners with, in
their home countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf had entered into
a non-binding term sheet dated June 3, 2024 (the &ldquo;Term Sheet&rdquo;) with COVIRIX Medical Pty Ltd (&ldquo;COVIRIX&rdquo;) for a
proposed reverse merger (the &ldquo;COVIRIX &ldquo;Proposed Transaction&rdquo;). However, on September 21, 2024, COVIRIX withdrew from
the Proposed Transaction, as such the Proposed Transaction was terminated with no cost to the Company.<B>&nbsp;</B>&nbsp;On December 11,
2024, NewGenIvf also announced its entry into a binding term sheet with European Wellness Investment Holdings Limited (&ldquo;EWIHL&rdquo;)
for a proposed reverse merger (&ldquo;EWIHL Proposed Transaction&rdquo;), completion of which was subject to, among other conditions,
the completion of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing. On March 31, 2025, NewGenIvf
terminated the term sheet for the EWIHL Proposed Transaction as EWIHL had failed to produce certain draft audited financials, which were
specifically required in the term sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 28, 2025, NewGenIvf
completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&ldquo;GIVF&rdquo;). Pursuant to a Purchase
Agreement dated January 21, 2025 between NewGenIvf and GIVF (&ldquo;Purchase Agreement&rdquo;), NewGenIvf purchased all of the Assets
(as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort Business (as defined
in the Purchase Agreement) from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Class A Ordinary Shares
(equivalent to 2,500 Class A Ordinary Shares post Third Reverse Stock Split) (&ldquo;MicroSort Acquisition&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><I>White Lion Transaction</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the
Company entered into a Common Shares Purchase Agreement (the &ldquo;White Lion Purchase Agreement&rdquo;) with White Lion Capital, LLC
(&ldquo;White Lion&rdquo;) and a related Registration Rights Agreement (the &ldquo;RRA&rdquo;). Pursuant to the White Lion Purchase Agreement,
the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars
($100,000,000) in aggregate gross purchase price of newly issued Class A Ordinary Shares, with an automatic increase to Three Hundred
Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement)
and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000)
has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth
in the White Lion Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the satisfaction
of certain customary conditions including, without limitation, the effectiveness of the registration statement of which this prospectus
forms a part (the &ldquo;Registration Statement&rdquo;) registering the resale of the shares issuable pursuant to the White Lion Purchase
Agreement, the Company&rsquo;s right to sell shares to White Lion commenced on the date of the execution of White Lion Purchase Agreement
and extends until (i) 36 months from the date of execution of the White Lion Purchase Agreement, or (ii) at the Company&rsquo;s option,
until 65 months from the date of the execution of the White Lion Purchase Agreement in the event that $100,000,000 of purchases under
the White Lion Purchase Agreement have been completed prior to the 36 month anniversary of the Execution Date (the &ldquo;Commitment Period&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Commitment Period,
subject to the terms and conditions of the White Lion Purchase Agreement, the Company may exercise its right to sell its Class A Ordinary
Shares to White Lion. The Company may deliver a Regular Purchase Notice (as such term is defined in the White Lion Purchase Agreement),
pursuant to which the Company can require White Lion to purchase up to a number of Ordinary Shares equal to the lesser of (i) $3,000,000
divided by the highest closing price of the Ordinary Shares over the most recent five (5) Business Days immediately preceding the Purchase
Notice, or (ii) 40% of Average Daily Trading Volume (as such term is defined in the White Lion Purchase Agreement), subject to a maximum
Investment Limit of $3,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may also deliver
a Rapid Purchase Notice (as such term is defined in the White Lion Purchase Agreement), pursuant to which the Company may require White
Lion to purchase up to a number of Ordinary Shares equal to $3,000,000 divided by the highest closing price of the Ordinary Shares over
the most recent five business days immediately prior to the receipt of the notice. White Lion may waive such limits under any notice at
its discretion and purchase additional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The price to be paid by White
Lion for any shares that the Company requires White Lion to purchase will depend on the type of purchase notice that the Company delivers.
For shares being issued pursuant to a Regular Purchase Notice, the purchase price per share will be the lower of (i) the closing price
of Ordinary Shares prior to the receipt of the applicable Purchase Notice, or (ii) the product of (a) the lowest daily VWAP of the Ordinary
Shares during the Regular Purchase Valuation Period (as defined in the White Lion Purchase Agreement), and (b) 98%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For shares being issued pursuant
to a Rapid Purchase Notice, the Company may opt for the purchase price per share to be (i) equal to the lowest traded price of the Ordinary
Shares on the date that the notice is delivered, or (ii) 97% of the lowest traded price of the Ordinary Shares one hour following White
Lion&rsquo;s written confirmation of the acceptance of the Rapid Purchase Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No purchase notice shall result
in White Lion beneficially owning (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule
13d-3 thereunder) more than 4.99% (subject to increase, in the sole discretion of White Lion, to 9.99%) of the number of Class A Ordinary
Shares outstanding immediately prior to the issuance of Class A Ordinary Shares issuable pursuant to a purchase notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has the right
to terminate the White Lion Purchase Agreement in the event of a material breach of the White Lion Purchase Agreement by White Lion. The
White Lion Purchase Agreement also automatically terminates upon the earlier of (i) the end of the Commitment Period and (ii) the date
that the Company commences a voluntary bankruptcy proceeding, a custodian is appointed for the Company or for all or substantially all
of its property, or the Company makes a general assignment for the benefit of its creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration for the commitments
of White Lion, as described above, the Company agreed to issue to White Lion 700,000 Class A Ordinary Shares (&ldquo;Commitment Shares&rdquo;
and equivalent to 700 Class A Ordinary Shares after Third Reverse Stock Split). Additional Class A Ordinary Shares may be issued to White
Lion under certain conditions, including in connection with material transactions or upon achieving specified investment thresholds. The
Commitment Shares will be fully earned by White Lion regardless of termination of the White Lion Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The White Lion Purchase Agreement
and the RRA contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations,
warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely
for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a focus on providing
fertility treatments to fulfil couples and individuals&rsquo; dreams of raising children, NewGenIvf offers mainly two services, namely:
(i)&nbsp;IVF treatment service, comprising traditional IVF and egg donation; and (ii)&nbsp;surrogacy and ancillary caring services. The
following table sets forth NewGenIvf&rsquo;s revenue by service offerings and as a percentage of total revenue for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">IVF Treatment Service</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,433,375</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,021,696</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">78.3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Surrogacy and Ancillary Caring Services</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,114,457</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total Revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,433,375</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,136,153</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>IVF Treatment Service</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf primarily provides
its clients with conventional IVF/ICSI and embryo transfer services. NewGenIvf is also able to, through MicroSort technology, help fulfill
the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IVF treatments that NewGenIvf
provides address tubal factor, ovulatory dysfunction, diminished ovarian reserve, endometriosis, uterine factor, male factor, unexplained
infertility and other causes. IVF bypasses the function of the fallopian tube by achieving fertilization within a laboratory environment.
Ovarian hyper-stimulation is common with IVF treatments to recruit numerous follicles to increase the chances for success. Follicles are
retrieved trans-vaginally using a vaginal probe and ultrasound guidance. Anaesthesia is frequently used due to the number of follicles
retrieved and the resulting discomfort experienced by the patient. The eggs are identified in the follicular fluid and combined with sperm
and culture medium in culture dishes, which are placed in an incubator with a temperature and gas environment designed to mimic the condition
of the fallopian tubes. Once the embryos develop, typically over a 3-to-5-day period, they are transferred to the uterine cavity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a long-standing IVF treatments
provider in Asia-Pacific, NewGenIvf had completed over 4,500 cycles of IVF treatments from 2014 to 2024. For the&nbsp;years ended December&nbsp;31,
2024 and 2023, the revenue from NewGenIvf&rsquo;s IVF treatments was US$5,433,375 and US$4,021,696, respectively, representing 100% and
78.3%&nbsp;of its total revenue in the corresponding periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IVF Treatments Process</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A typical IVF treatment process
mainly includes two stages, the pre-IVF treatment stage and the IVF treatment stage. During the IVF treatment process, NewGenIvf also
provides support services such as nutrition guidance and psychological counselling. The flow chart below shows the stages involved in
a typical IVF treatment process:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the pre-IVF treatment stage,
clients attend an initial consultation, undergo pre-IVF tests, and undergo treatment for gynaecological and andrological diseases, if
needed. At the initial consultation, a physician reviews the clients&rsquo; detailed medical history to collect more information relating
to the potential cause of their infertility. The client then undergoes various pre-IVF tests, which may include, among other things, blood
pressure, hormone level, ultrasound, infectious disease screening, uterine evaluation and male fertility test. The physician will then
design treatment plans based on the client&rsquo;s medical history and results of the tests. If the client is satisfied with treatment
plan and the test results are acceptable to the physician, the physician will prescribe medications and start stimulation treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first step of the cycle
is to boost egg production through injecting synthetic hormones. Over about one week of ovarian stimulation, clients are monitored on
a regular basis with blood test and transvaginal ultrasound. If follicles have reached at least 10 mm in size, an additional antagonist
drug will be added into the daily injection schedule. This is used to prevent ovulation before ovum pickup time. After another few&nbsp;days
of ovarian simulation, if follicle growth is consistent and majority of follicles are around 16 mm to 17 mm, the final injection of a
human chorionic gonadotropin will be administered. The trigger injection is the final step of the stimulation process and is for the maturation
of the eggs in the follicles before they are collected. The next major step is to retrieve the eggs with a minor surgical procedure called
Trans Vaginal Follicle Aspiration conducted under anaesthesia. At the same time the male partner collects the sperms for fertilizing the
eggs in the laboratory by a process known as intracytoplasmic sperm injection. The fertilized embryos are cultured in the laboratory for
two to six&nbsp;days. Embryos that grow well are biopsied and tested by PGT to detect potential genetic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The final step is to transfer
the embryos into the uterus using a catheter. Within eight&nbsp;days after the embryo transfer, a blood test can be conducted to detect
whether the implantation was successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MicroSort Technology</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroSort technology is a
preconception process developed by the Genetics &amp; IVF Institute, Inc (&ldquo;GIVF&rdquo;). that aims to improve the chances that the
baby to be conceived will be of the desired gender and prevents certain gender-related hereditary diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Semen samples usually contain
equal amounts of sperm carrying the Y chromosome (which will produce a boy), and sperm carrying the&nbsp;X chromosome (which will produce
a girl). During the MicroSort process, the sperm sample is washed to remove seminal liquid and nonmotile cells. After the washing, the
sample is stained with a special fluorescent material that attaches to the DNA contained in the sperm. The stained sperm cells are analyzed
one by one by a flow cytometer, in which cells pass through a laser to make the stain attach to the DNA fluoresce. The sperm containing
the&nbsp;X chromosome (which have more DNA and therefore more stain) will shine brighter than the sperm containing the Y chromosome. The
flow cytometer uses a special software to identify&nbsp;X&nbsp;and Y chromosome sperm based on their fluorescence signature. The sperm
carrying the chromosome that will produce the desired gender are separated from the rest of the sample -resulting in an enriched sperm
sample ready for use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf held an exclusive
license granted by a division of GIVF, MicroSort International, to use the MicroSort technology in Thailand and Cambodia. MicroSort&rsquo;s
licenses for NewGenIvf&rsquo;s operation in Thailand and Cambodia were each provided under a lease and service agreement. In April 2019,
First Fertility PGS entered into a Lease and Services Agreement with MicroSort International to use MicroSort equipment in Thailand and
in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort International to use MicroSort equipment in
Cambodia (together, the &ldquo;Lease and Services Agreements&rdquo;). Pursuant to the Lease and Services Agreements, First Fertility PGS
and Phnom Penh Center each had the exclusive right to utilize the MicroSort equipment and to market and sell MicroSort sperm sorting services
in Thailand and Cambodia, respectively. MicroSort International was responsible for the maintenance of MicroSort equipment and technical
and engineering support. The term of each Lease and Service Agreements was initially from 2019 to 2024, which shall be automatically renewed
for one year unless a written notice of at&nbsp;least 180 days prior to the intended termination date is provided. The consideration under
each of the Lease and Services Agreements was US$9,000 per month after six months.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 21, 2025, the Company
entered into a Purchase Agreement with Genetics&nbsp;&amp; IVF Institute, Inc. (&ldquo;Purchase Agreement&rdquo;), pursuant to which the
Company purchased all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating
to the MicroSort Business (as defined in the Purchase Agreement) from Genetics &amp; IVF Institute, Inc. for a cash consideration of $750,000
and a share consideration of 125,000 Class A Ordinary Shares (&ldquo;Share Consideration&rdquo; and equivalent to 2,500 Class A Ordinary
Shares after Third Reverse Stock Split). The Purchase Agreement is filed as Exhibit 10.30 of the Form F-1 registration statement filed
on May 29, 2025. MicroSort Lab Services, LLC (&ldquo;MicroSort&rdquo;) was incorporated by Genetics&nbsp;&amp; IVF Institute, Inc. in
January 2025 to hold all of the Assets (as defined in the Purchase Agreement) to be transferred to the Company at closing. The Company&rsquo;s
acquisition of MicroSort was completed on February 28, 2025, and the Share Consideration was issued to GIVF on the same day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The flow chart below shows
the process involved in MicroSort:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preimplantation Genetic Screening</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PGS is used in parallel with
an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing
embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of
implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate of
70.9% and reducing miscarriage rates by 26.6%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next-Generation Sequencing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NGS is a high-throughput technology
for determining the sequence of deoxyribonucleic acid DNA or RNA to study genetic variation associated with diseases or other biological
phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing determines
the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time and cost associated
with sequencing and increases the coverage quality and data output.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preimplantation Genetic Diagnosis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to PGS, PGD is also
used in parallel with an IVF treatment cycle. But PGD is a more enhanced process than PGS since it scans for individual genes. PGD is
the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic fibrosis, where carrier status
has been documented in each of the parents. By using this technique, physicians are able to check the genes or chromosomes for a specific
genetic condition. PGD can decrease the risk of miscarriage and this technology can help women achieve a healthy pregnancy. Individuals
who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Egg Freezing Service</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also provides egg
freezing services which is a fertility preservation service that allows individuals to freeze and store their eggs for future use. The
process begins with hormonal stimulation to encourage multiple egg production, followed by a minor surgical procedure to retrieve the
eggs under sedation. The eggs are then rapidly frozen using vitrification, a technique that prevents ice crystal formation, and stored
in liquid nitrogen at ultra-low temperatures. This service is ideal for those delaying childbearing due to career, medical reasons (like
cancer treatment), or personal choice. When ready to conceive, the eggs can be thawed, fertilized with sperm, and transferred as embryos.
While success rates vary by age and clinic, egg freezing offers a proactive option for preserving fertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Surrogacy and Ancillary Caring Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also generated revenue
from surrogacy services and related ancillary caring services in Kyrgyzstan. NewGenIvf conducts implantation of embryos from biological
parents in surrogate mothers. During the pregnancy period, NewGenIvf provides ancillary caring services including regular body check and
provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring services is recognized
when the surrogate mother gives birth. Surrogacy services provide infertile couples with an alternative method of having children. In
general, NewGenIvf provides certain discount to clients if they wish to pursue additional services such as egg donation and surrogacy,
after several cycles of IVF treatments failures due to medical reasons including, but not limited to, the poor egg quality of aged female
clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As compared to other countries,
Kyrgyzstan has the following features that allow NewGenIvf to operates its surrogacy services: (i)&nbsp;surrogacy is legal and regulated,
which means that there are less restrictions on either intended parents or surrogate mothers, and a parent-child relationship can be requested
before the child&rsquo;s birth; and (ii)&nbsp;the costs of operation and surrogate mother is favorable, given the cost of living in Kyrgyzstan
is relatively low.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the regular
surrogacy services, NewGenIvf is also able to assist the clients with birth certificate applications and facilitate the application of
infants&rsquo; passports and visas as supplemental services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&nbsp;years ended December&nbsp;31,
2024 and 2023, the revenue from NewGenIvf&rsquo;s surrogacy and ancillary caring services was US$ Nil and US$1,114,457, respectively,
representing Nil % and 21.7% of its total revenue in the corresponding periods. During 2024, we did not generate any revenue from surrogacy
as we went through a series of reorganization in Kyrgyzstan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The flow chart below shows
the stages involved in a typical surrogacy process:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_004.jpg" ALT=""></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Kyrgyzstan, NewGenIvf also
provides ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&nbsp;maternity
caring service, and (ii)&nbsp;documentation service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Network of Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, NewGenIvf
had one administrative support office located in Hong&nbsp;Kong and three clinics located in Thailand, in Cambodia, and in Kyrgyzstan,
respectively. The integration of the medical facilities in Thailand help NewGenIvf provide a more seamless one-stop experience to its
clients. Set out below is an illustration of the locations of NewGenIvf&rsquo;s clinics and marketing and sales office:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the approximate aggregate average gross floor area (&ldquo;<B>G.F.A.</B>&rdquo;) of each of NewGenIvf&rsquo;s clinics that were under
lease and actively used for client service as of August 1, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <BR> August&nbsp;1, <BR> 2025</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Square Feet)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Thailand</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Co., Ltd. &ndash; PS Tower<BR> (&ldquo;<B>First Fertility PGS Center</B>&rdquo;)</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">14,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Co., Ltd &ndash; Erawan Hotel <B><BR> (&ldquo;First Fertility PGS Center&rdquo;)</B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-indent: -9pt; padding-left: 9pt">Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Center <BR> (&ldquo;<B>Phnom Penh Center</B>&rdquo;)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-indent: -9pt; padding-left: 9pt">Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Bi Clinic Limited Liability Company <BR> (&ldquo;Bi Clinic&rdquo;)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,164</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Aggregate G.F.A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,096</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To increase the scale of NewGenIvf&rsquo;s
operations, NewGenIvf expanded its Thailand fertility services by leasing a new property for its second clinic Erawan Consultation Clinic
in May&nbsp;2023. Consisting of approximately 2,600 sq. ft., Erawan Consultation Clinic has obtained its license and has been open since
June 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, IVF treatments
are performed in its Thailand and Cambodia clinics, egg donation services are provided in its Cambodia clinic, and surrogacy services
are provided in its Kyrgyzstan clinic. The following table summarises the services available at NewGenIvf&rsquo;s clinics:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">IVF <BR> Treatments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Surrogacy <BR> Services</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; font-style: italic">Thailand</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">First Fertility PGS Centers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&times;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic">Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Phnom Penh Center (PS Tower)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&times;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">First Fertility PGS Center (Erawan Hotel)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&times;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic">Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">First Fertility Bishkek (Disposed of on December 18, 2024)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Bi Clinic (Acquired on December 17, 2024)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&times;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth a breakdown of revenue from services performed at NewGenIvf&rsquo;s medical centers for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">HK SAR</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">34,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Thailand</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,175,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,356,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26.4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">601,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Kyrgyzstan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,656,596</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,123,593</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total Revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,433,375</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,136,153</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Thailand Clinic</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, NewGenIvf
had two operating clinics in Thailand. At the clinic in Thailand, NewGenIvf offers its clients customized fertility treatment solutions
including IVF/ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening by PGT, hysteroscopy, sperm
analysis, sorting, washing and freezing, and egg freezing. Its medical and operational personnel are organized into specialized teams
according to the different stages of the IVF treatment process and different patient profiles. When clients are admitted, they are assigned
to a team which NewGenIvf believes is better suited to the clients after taking into account the clients&rsquo; diagnosis and preferences.
Furthermore, NewGenIvf also provides related value-added services such as nutrition guidance, psychological counselling, acupuncture,
and translation interpreters to supplement the IVF treatment. NewGenIvf prides itself on providing quality and customized treatment to
its clients on a&nbsp;day-to-day basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, the
clinics in Thailand had 8 nurses, 8 full time lab physicians and embryologists, 22 administrative staff, totaling 38 staff members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cambodia Clinic</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, NewGenIvf
has one clinic, Phnom Penh Center, in Cambodia. Phnom Penh Center is staffed with 4 Cambodian physician, 2 embryologists, 6 nurses and
12 other staff, and offers similar IVF treatments as in Thailand and egg donation services. Phnom Penh Center operates under a license
issued by Cambodia MOH for the Cambodian physician, who has entered into an agreement with Phnom Penh Center for the exclusive use of
such license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After eight&nbsp;years of
development since its opening in 2015, Phnom Penh Center has become one of the long-standing ARS providers in Cambodia. According to CIC,
it was the first to use conventional IVF technology which led to a successful birth in 2016 in Cambodia. Since its establishment, Phnom
Penh Center achieved more than 1,800 IVF treatment cycles as of August 1, 2025. As of August 1, 2025, Phnom Penh Center&rsquo;s IVF philosophy
concentrates on three key points in the treatment process: the mother&rsquo;s wellbeing, the technology used to assist mothers deliver
a strong and healthy baby and the medical science used to ensure every chance of success for women in various age spectrums.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Clinic in Kyrgyzstan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf established First
Fertility Bishkek in October&nbsp;2019 in Kyrgyzstan for its surrogacy services, as Kyrgyzstan has supply of surrogate candidates at a
relatively low cost and a more friendly legal environment for surrogacy services. In 2020, First Fertility Bishkek obtained the license
to provide ARS and surrogacy services, becoming one of the few facilities licensed to offer ARS and one of the facilities licensed to
offer surrogacy services in Kyrgyzstan as of December&nbsp;31, 2024, according to CIC.&nbsp;In addition, NewGenIvf also provide related
ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&nbsp;maternity caring
service, and (ii)&nbsp;documentation service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians at First Fertility
Bishkek have expertise in sourcing surrogate mothers, techniques of embryo transfers, prenatal care, baby delivery, and postnatal care.
First Fertility Bishkek also collaborates closely with Phnom Penh Center in arranging shipment of frozen embryos. NewGenIvf hires local
physicians and local staff. NewGenIvf also provides training for newly admitted Kyrgyzstan physicians and embryologists in Thailand. Some
personnel who had relevant experience in Kyrgyzstan had also been sent from Cambodia to Kyrgyzstan to help manage such operations from
time to time. However, during 2024, Kyrgyzstan operations had been reorganized, resulting in disposal of First Fertility Bishkek and acquisition
of Bi Clinic Limited Liability Corporation in December 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, Bi Clinic
had 1 full-time physician, 1 embryologist, 1 nurse, and 7 other staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Professionals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Licensed Physicians</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, NewGenIvf
employed 5 licensed physicians, among which one was based in Cambodia, one was based in Kyrgyzstan, and the other three were based in
Thailand. Most of NewGenIvf&rsquo;s physicians had over 10&nbsp;years of experience or above. The following table summarises the number
and types of such licensed physicians as of August 1, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensed physician</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licenses and<BR>
Approvals</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective Period</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 27%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuing<BR>
Authority</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cambodia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.&nbsp;Keut Serey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decision on permission for beauty treatment operation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;14, 2022&nbsp;&ndash; December&nbsp;14, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Ministry of Health of Cambodia</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Keatthisak Boonsimma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 31801 Medical Practitioner License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&nbsp;1, 2005&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royal Thai College of Obstetricians and Gynaecologists of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 22624/2554<BR>
OB-Gyn License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;1, 2014&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 40962/2563 Reproductive Medicine Diploma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;1, 2020&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Anurach Kulvanitchaiyanunt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Practice License No. 11755</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 1 2025&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Wiphawee Luangtangvarodom</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 38347/2562<BR>
OB-Gyn License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;1, 2019&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 43217/2564 Reproductive Medicine License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;1, 2021&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 48510 Medical Practitioner License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&nbsp;1, 2014&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyrgyzstan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Myrzalymbekova A.B.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp; numero; CO170001836 Medical Certificate </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 23. 2017&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;0002953 Medical Practitioner</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25 April 2018&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;11373\2565 Medical Certificate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16 August 2024&nbsp;&ndash; Indefinite </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;0003447 Medical Certificate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12 April 2023&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Customers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&nbsp;years ended December&nbsp;31,
2024 and 2023, the majority of NewGenIvf&rsquo;s clients were from China (including mainland China and Hong Kong). The number of Thai
and Cambodian local patients generally increased in 2023 and 2024 compared with earlier years due to the impact of COVID-19 on international
travel. NewGenIvf enters into a verbal contract with each of its customers that outline, among other things, the scope of services, service
fees, payment terms and rights, responsibilities and obligations of each party. Consent is obtained from the patients prior to the provision
of the various treatments. Customers are not entitled to enjoy the relevant services until outstanding amounts have been settled pursuant
to the relevant contract. Sales to individual consumers did not vary significantly and none of the customers contribute more than 10%
of NewGenIvf&rsquo;s revenue for the&nbsp;years ended December&nbsp;31, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to significant
customers using NewGenIvf&rsquo;s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
utilize the access to the freezing and storage facility and other relatively insignificant services, such as check-ups services, blood
test services and other minor services (the latter category of customers are referred to as &ldquo;consultation customers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&nbsp;years ended December&nbsp;31,
2024 and 2023, NewGenIvf promoted brand awareness through its sales teams and, in many cases, through cooperating with third-party agencies
and partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s sales teams
have broad experience in fertility services and are responsible for identifying potential clients and managing the overall sales process.
NewGenIvf&rsquo;s sales team primarily relies on social media marketing, word-of-mouth referrals, recognition of its brand, printed advertisements
and marketing events. NewGenIvf spends marketing expenses on placing advertisements through popular social media platforms, maintaining
the official website of NewGenIvf and sending information through its official accounts on social media platforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Supply and Procurement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s procurement
is mainly for medications, laboratory media and reagents, laboratory consumables, and blood test reagents. As of December&nbsp;31, 2024,
there was no supplier that individually contributed more than 10% of the Group&rsquo;s trade payable. As of December 31, 2023, there was
one supplier that individually contributed more than 10% of the Group&rsquo;s trade payable, accounting for 30.6% of the Group&rsquo;s
trade payables in aggregate. For both the years ended December&nbsp;31, 2024 and 2023, no vendor contributed more than 10% of total direct
cost of the Group. NewGenIvf&rsquo;s procurement team is experienced in selecting cost-effective supplies as well as selecting reliable
suppliers. NewGenIvf&rsquo;s major suppliers are pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that it
is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the value and comprehensiveness of the solutions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">treatment that is effective and achieves desired outcomes;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clients&rsquo; experience, including dedicated patient education, clinical guidance and emotional support; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">access to a network of high-quality fertility specialists.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf competes primarily
with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and
integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf&rsquo;s competitors may compete in a variety
of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting
brand promotions and other marketing activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As NewGenIvf may introduce
new ancillary services and other companies may introduce similar fertility services as NewGenIvf&rsquo;s, NewGenIvf may become subject
to additional competition.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Facilities</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, in
addition to its clinics, NewGenIvf leased one property in Hong&nbsp;Kong with an aggregate square footage of approximately 8,000 for its
administration support offices. NewGenIvf also operates its medical facilities as described above in &ldquo;&mdash;&nbsp;Network of Facilities&rdquo;
above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Organizational Structure</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a list of
our principal subsidiaries and consolidated affiliated entities as of the date of this prospectus:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Place of Formation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 52%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NewGenIvf Limited</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman Islands</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wholly-owned subsidiary</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated on January 16, 2019</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MicroSort Lab Services LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>U.S.A.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wholly-owned subsidiary</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acquired on February 28, 2025</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NewGenDigital Limited</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>British Virgin Islands</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wholly-owned subsidiary</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated on June 16, 2025</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FFPGS (HK) Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hong Kong</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indirect subsidiary, wholly owned by NewGenIvf Limited</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated on December 19, 2019</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bi Clinic LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kyrgyzstan</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indirect subsidiary, wholly owned by NewGenIvf Limited</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acquired on December 17, 2024</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First Fertility PGS Center Limited</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Thailand</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indirect subsidiary, 74% owned by Well Image Limited HK directly and indirectly</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated on March 6, 2014</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First Fertility Phnom Penh Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kingdom of Cambodia</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indirect subsidiary, wholly owned by NewGenIvf Limited</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated on August 10, 2015</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Med Holdings Limited</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Thailand</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indirect subsidiary, 48.99% owned by Well Image Limited HK</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated on January 21, 2015</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Well Image Limited HK</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hong Kong</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indirect subsidiary, wholly owned by NewGenIvf Limited</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated on July 11, 2008</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&rsaquo;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following subsidiaries
were disposed of::</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek LLC</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyrgyzstan</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, wholly owned by NewGenIvf Limited</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposed of on December 18, 2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#28145;&#22323;&#21069;&#28023;&#35920;&#27888;&#20161;&#21295;&#20581;&#24247;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496; (Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, 99% owned by FFPGS (HK) Ltd</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposed of on July 29, 2025</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Property, Plants and Equipment</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company leases the premises
for its principal executive office located at 36/39-36/40, 13th Floor, PS Tower, Sukhumvit 21 Road (Asoke) Khlong Toei Nuea Sub-district,
Watthana District, Bangkok 10110, Thailand. This property contains approximately 14,750 square feet. The Company leases one property in
Hong&nbsp;Kong with an aggregate square footage of approximately 8,000 for its administration support offices.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company also leases several
premises to operate its clinics in various countries. In Kyrgyzstan, the Company operated the First Fertility Bishkek Limited Liability
Company until December 18, 2024, of which premises have an aggregate area of 2,368 square feet. The Company operates the Bi Clinic Limited
Liability Company starting from December 17, 2024 in Kyrgyzstan, which premises have an aggregate area of 2,100 square feet. In Cambodia,
the Company operates the First Fertility Phnom Penh Center, which premises have an aggregate area of 18,567 square feet. In Thailand,
the Company operates a clinic named First Fertility PGS Center Co., Ltd., which premises have an aggregate area of 14,750 square feet.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company also leases premises
located in Thailand for its Erawan Consultation Clinic, with an aggregate area of approximately 2,500 square feet. Erawan has obtained
its license in May 2025. This property is used as the Company&rsquo;s second clinic in Thailand, which has been open since June 2025.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nasdaq Deficiency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 8, 2024, the Company
received a deficiency letter (&ldquo;Bid Price Deficiency Letter&rdquo;) from the Listing Qualifications Department (the &ldquo;Staff&rdquo;)
of Nasdaq notifying the Company that it is currently not in compliance with the closing bid price requirement under Nasdaq Listing Rule
5450(a)(1) (the &ldquo;Minimum Bid Price Rule&rdquo;). The Bid Price Deficiency Letter stated that, for the preceding 30 consecutive business
days, the Company&rsquo;s Class A Ordinary Shares did not meet the minimum closing bid price of $1 per share pursuant to the Minimum Bid
Price Rule. The Company has an initial compliance period of 180 calendar days, or until April 7, 2025 to regain compliance with the Minimum
Bid Price Rule. The Deficiency letter stated that if at any time the closing bid price of the Company&rsquo;s Class A Ordinary Shares
is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance with
this requirement, as applicable. On February 11, 2025, the Company effected a 1-for-20 reverse stock split of its issued and unissued
shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share. On February 27, 2025,
the Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&rsquo;s securities had been
at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the Company had regained
compliance with the Minimum Bid Price Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 24, 2024, the Company
received a deficiency letter (&ldquo;MVLS Deficiency Letter&rdquo;) from the Staff of Nasdaq notifying the Company that, for the preceding
35 consecutive business days, the Class A Shares did not meet the minimum $50,000,000 Market Value of Listed Securities requirement (&ldquo;MVLS
Requirement&rdquo;) for continued listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(A) (the &ldquo;MVLS Requirement,&rdquo;
and the Company&rsquo;s non-compliance with this requirement, the &ldquo;MVLS Deficiency&rdquo;). In accordance with Nasdaq Rule 5810(c)(3)(C),
the Company has been provided an initial period of 180 calendar days, or until November 20, 2024 (the &ldquo;Compliance Date&rdquo;),
to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the MVLS for the Class A Shares is at least
$50,000,000 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with
the MVLS Requirement. In the event the Company does not regain compliance with the above requirement prior to the expiration of the compliance
period, it will receive written notification that its securities are subject to delisting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 24, 2024, the Company
received a deficiency letter (&ldquo;MVPHS Deficiency Letter&rdquo;) from the Staff of Nasdaq notifying the Company that, for the preceding
35 consecutive business days, the Company&rsquo;s Class A Ordinary Shares did not meet the minimum $15,000,000 Market Value of Publicly
Held Shares (&ldquo;MVPHS&rdquo;) requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(C) (the &ldquo;MVPHS
Requirement,&rdquo; and the Company&rsquo;s non-compliance with this requirement, the &ldquo;MVPHS Deficiency&rdquo;). In accordance with
Nasdaq Rule 5810(c)(3)(D), the Company has until the Compliance Date to regain compliance with the MVPHS Requirement. If, at any time
before the Compliance Date, the MVPHS for the Class A Shares is at least $15,000,000 for a minimum of ten consecutive business days, the
Staff will provide the Company written confirmation of compliance with the MVPHS Requirement. In the event the Company does not regain
compliance with the above requirement prior to the expiration of the compliance period, it will receive written notification that its
securities are subject to delisting. Alternatively, the Company may apply to transfer the Company&rsquo;s securities to The Nasdaq Capital
Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the &ldquo;Panel&rdquo;) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at&nbsp;an oral hearing&nbsp;on January 28, 2025 (the &ldquo;Hearing&rdquo;). On February 19, 2025, the Company
received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance with the
Nasdaq Stock Market&rsquo;s (&ldquo;Nasdaq&rdquo; or the &ldquo;Exchange&rdquo;) continued listing requirements, subject to meeting specific
compliance criteria within designated timeframes. On February 11, 2025, the Company carried out a 1-for-20 reverse stock split of its
issued and unissued shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share.
On February 27, 2025, the Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&rsquo;s
securities had been at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the
Company had regained compliance with the minimum bid price rule. In addition, on February 27, 2025, the Company received a confirmation
from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company&rsquo;s securities
would be transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Capitalization and Indebtedness</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is the Company&rsquo;s
capitalization and indebtedness as of December 31, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Cash and Cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">457,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">EQUITY AND LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(204,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122,505</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(985,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total capitalization</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(609,749</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <BR> December 31, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Total Net Book Value</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(1,481,757</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total Share Outstanding*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,770</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares as presented have been adjusted retrospectively for the Reverse Share Splits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Statements of indebtedness
as of December 31, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Current liabilities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-left: 9pt">Account payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,298,964</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued liabilities and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,729</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Contract liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,489</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Due to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,453</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Operating lease liabilities, current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,526</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,447</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Income tax payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,746</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total current liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,720,354</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Lease liabilities, operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,231</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,328,916</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,339,147</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total Indebtedness</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,059,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dilution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following information is presented as of December 31,
2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Existing shareholder</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">31/12/2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Total comprehensive income attributable to the shareholders of the company</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(498,480</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Earning per share &ndash; basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66.2</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">- diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31.90</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average shares outstanding &ndash; Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,162</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">- Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,866</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to 2024 year end, the Company carried out the Reverse Stock Splits. The shares above have been adjusted retrospectively for the Reverse Stock Splits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of being a &ldquo;Foreign Private
Issuer&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act that are applicable to &ldquo;foreign private issuers,&rdquo; and under those requirements,
we file reports with the SEC. As a foreign private issuer, we are not subject to the same requirements that are imposed upon U.S. domestic
issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are less detailed and less
frequent than those of U.S. domestic reporting companies. For example, we are not required to issue quarterly reports, proxy statements
that comply with the requirements applicable to U.S. domestic reporting companies or individual executive compensation information that
is as detailed as that required of U.S. domestic reporting companies. We also have four months after the end of each fiscal year to file
our annual report with the SEC and are not required to file current reports as frequently or promptly as U.S. domestic reporting companies.
Our officers, directors and principal shareholders are exempt from the requirements to report transactions in our equity securities and
from the short-swing profit liability provisions contained in Section 16 of the Exchange Act. As a foreign private issuer, we are not
subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In addition, as a foreign private issuer,
we are permitted to follow certain home country corporate governance practices instead of those otherwise required under the rules of
Nasdaq for domestic U.S. issuers and are not required to be compliant with all Nasdaq rules as of the date of our initial listing on Nasdaq
as would domestic U.S. issuers. These exemptions and leniencies will reduce the frequency and scope of information and protections available
to you in comparison to those applicable to a U.S. domestic reporting company. We intend to take advantage of the exemptions available
to us as a foreign private issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary of Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our Class A Ordinary
Shares involves significant risks. You should carefully consider all of the information in this prospectus before making an investment
in our shares. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed
more fully in the section titled &ldquo;<I>Risk Factors</I>&rdquo; and in Part I, Item 3, D. Risk Factors in our most recent Annual Report
on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to NewGenIvf&rsquo;s Business
and Industry</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to continue operating as a going concern.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fertility market in which NewGenIvf participates is competitive, and if NewGenIvf does not continue to compete effectively, its results of operations could be materially and adversely affected.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf has a limited operating history with its current platform of solutions, which makes it difficult to predict its future prospects, financial performance and results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our planned Solana strategy may not be successful and exposes us to various risks, including risks associated with the Solana network, SOL token and the blockchain sector.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s marketing efforts depend significantly on its ability to receive positive references from its existing clients.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf is unable to attract new clients, its business, financial condition and results of operations would be adversely affected.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s business depends on its ability to maintain its existing client demographics. Any failure to do so would harm its business, financial condition and results of operations.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf fails to offer high-quality support, its reputation could suffer.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s failure to effectively develop and expand its marketing and sales capabilities could harm its ability to increase its client base and achieve broader market acceptance of solutions NewGenIvf provides.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf may experience net losses and may not sustain profitability in the future.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s future revenue may not grow at the rates it historically has, or at all.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of NewGenIvf&rsquo;s business.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the estimates and assumptions NewGenIvf uses to determine the size of the target markets for its services are inaccurate, its future growth rate may be impacted and its business would be harmed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf may not be able to successfully manage its growth, and if NewGenIvf is not able to grow efficiently, its business, financial condition and results of operations could be harmed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf&rsquo;s new solutions and services are not adopted by its clients, or if it fails to innovate and develop new offerings that are adopted by its clients, its revenue and results of operations may be adversely affected.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf fails to adapt and respond effectively to the changing medical landscape, changing regulations, changing client needs, requirements or preferences, its offerings may become less competitive.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf fails to maintain and enhance its brand, its ability to expand its client base will be impaired and its business, financial condition and results of operations may suffer.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf fails to retain and motivate members of its management team or other key employees, or fails to attract additional qualified personnel to support its operations, its business and future growth prospects could be harmed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To successfully market and sell its services and products in Asia-Pacific markets, NewGenIvf must address many international business risks with which NewGenIvf has limited experience.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ethical, legal and social concerns related to the use of assisted reproductive technology could reduce demand for the fertility services provided by the medical facilities in NewGenIvf&rsquo;s network, and thus may adversely affect the business, financial conditions and results of operations of the medical facilities in its network.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf is reliant on revenue from international clients.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuations in exchange rates could have a material and adverse effect on NewGenIvf&rsquo;s results of operations and the value of your investment.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental control of currency conversion may limit NewGenIvf&rsquo;s ability to utilize NewGenIvf&rsquo;s net revenue effectively and affect the value of your investment.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially all of NewGenIvf&rsquo;s assets and operations are located in Thailand, Cambodia and Kyrgyzstan and they are subject to economic, legal and regulatory uncertainties in such countries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to comply with the terms of future financing arrangements could result in default, which could have an adverse effect on NewGenIvf&rsquo;s cash flow and liquidity.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf requires a significant amount of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on acceptable terms, its business, financial condition, and prospects may be materially and adversely affected.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The defects in certain leased property interests and failure to register certain lease agreements may materially and adversely affect NewGenIvf&rsquo;s business, financial condition, results of operations, and prospects. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf currently has no insurance coverage for its operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf may not be successful in adapting to technological developments, which may affect its business and results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If its computer systems, or those of its providers, specialty pharmacies or other downstream vendors lag, fail or suffer security breaches, NewGenIvf may incur a material disruption of its services, which could materially impact its business and the results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to comply with the filing deadlines for reports that we file pursuant to the Exchange Act, and our failure to timely file such reports may have material adverse consequences on our business.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to continue to meet the listing requirements of Nasdaq, our Class A Ordinary Shares will be delisted</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to NewGenIvf&rsquo;s Relationships with Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s business depends on its ability to maintain its network of high-quality fertility specialists and other healthcare providers. If NewGenIvf is unable to do so, its future growth would be limited and its business, financial condition and results of operations would be harmed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The medical facilities and professionals in NewGenIvf&rsquo;s network could become the subject of litigation, allegations and other claims, and NewGenIvf is not insured against these liabilities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assisted reproductive medical facilities in NewGenIvf&rsquo;s network have limited control over the quality of the pharmaceuticals, medical equipment, medical consumables and other supplies used in its operations, and cannot guarantee that the products in use are not defective or counterfeit. NewGenIvf also has no control over independent sub-contractors and cannot guarantee the services thereof.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf loses its relationship with one or more key pharmaceutical manufacturers, its business and results of operations could be adversely affected.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf has engaged in transactions with related parties, and such transactions present potential conflicts of interest that could have an adverse effect on its business and results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf may be subject to claims and allegations relating to intellectual property and other causes.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain data and information in this prospectus relied on by NewGenIvf were obtained from third-party data and polls. These metrics were not independently verified by NewGenIvf and may not be accurate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf operates in a highly regulated industry and must comply with a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits applicable to NewGenIvf&rsquo;s business may have a material and adverse impact on NewGenIvf&rsquo;s business, financial condition, and results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising or offering of gender selection services in certain jurisdictions in which NewGenIvf operates could expose NewGenIvf and its directors and executive officers to significant legal and regulatory risks, including potential penalties.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in NewGenIvf&rsquo;s effective tax rate or tax liability may have an adverse effect on its results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s reported financial results may be adversely affected by changes in accounting principles generally accepted in relevant jurisdictions.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s reported financial results may be adversely affected by changes in accounting principles generally accepted in relevant jurisdictions.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf&rsquo;s estimates or judgments relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely affected.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it to criminal or civil liability and harm its business, financial condition and results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s digital strategy is subject to financial, operational and regulatory risks on investing Solana.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s investment in residential market of United Arab Emirates is exposed to significant market risks. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>2025 Debt Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 1, 2025, the Company
entered into a new Securities Purchase Agreement (&ldquo;2025 Securities Purchase Agreement&rdquo;) with certain investors named therein
(collectively, the &ldquo;Buyers&rdquo;), pursuant to which, amongst other things: (i) the Company agreed to sell, at an initial closing
(and such initial closing, the &ldquo;Initial Closing&rdquo;) a senior convertible note (the &ldquo;New CB Initial Note&rdquo;) in the
aggregate original principal amount not exceeding $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms; and (ii)
the Company may require each Buyer (or each Buyer may require the Company, as applicable) to participate in the sale of one or more additional
convertible notes (which aggregate original principal amount for all additional convertible notes shall not exceed $25,600,000) (the &ldquo;New
CB Additional Notes&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2025 Securities Purchase
Agreement is filed as Exhibit 4.1 of the Company&rsquo;s current report on Form 6-K dated April 3, 2025 and is incorporated by reference
herein. The first tranche of $3,200,000 was received on June 3, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Strategic Investments in Digital Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 19, 2024, the
Company announced its engagement OSL Digital Securities (&ldquo;OSL&rdquo;), a leading regulated digital asset platform in Hong Kong,
and its deployment of US$1 million to establish the Company&rsquo;s digital asset portfolio. On June 2, 2025, the Company announced plans
to invest up to US$30 million in staking the digital asset SOL (the native token of the Solana network) and funding such investment using
its existing credit facilities. As of July 25, 2025, the Company has accumulated total SOL holdings of 6,703.99, valued at approximately
US$1.24 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Strategic Investment in United Arab Emirates
(&ldquo;UAE&rdquo;) Real Estate Market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 21, 2025, NewGenDigital
Limited (&ldquo;NewGenDigital&rdquo;), a wholly owned subsidiary of the Company, signed a Memorandum of Understanding (the &ldquo;MOU&rdquo;)
with BNW Real Estate Development LLC (&ldquo;BNW&rdquo;), a prominent real estate developer in Ras Al Khaimah and Dubai, UAE. Per the
terms of the MOU, NewGenDigital and BNW will endeavor to negotiate and execute a definitive Joint Venture</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the resale by the Selling Securityholders identified in this prospectus of up to 50,000,000 Class A Ordinary Shares. All of the Class
A Ordinary Shares, when sold, will be sold by the Selling Securityholders. The Selling Securityholders may sell their Class A Ordinary
Shares from time to time at prevailing market prices. We will not receive any proceeds from the sale of the Class A Ordinary Shares by
the Selling Securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares currently issued and outstanding </FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 64%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,152,702 Ordinary Shares, consisting of 2,148,596 Class A Ordinary Shares and 4,106 Class B Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares offered by the Selling Securityholders </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 50,000,000 Class A Ordinary Shares, consisting of (i) up to 20,000,000 Class A Ordinary Shares that may be issued by us to White Lion pursuant to the White Lion Purchase Agreement, and (ii) 30,000,000 Class A Ordinary Shares underlying the Remaining Additional notes, the Exchange Notes, the Warrants, and the New CB Initial Note. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares after this offering</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 52,152,702 Ordinary Shares, consisting of 52,148,596 Class A Ordinary Shares and 4,106 Class B Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the securities offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their respective accounts. We will not receive any of the proceeds from such sales. However, we may receive up to $500,000,000 in gross proceeds under the White Lion Purchase Agreement from sales of Class A Ordinary Shares that we may elect to make to White Lion pursuant to the White Lion Purchase Agreement. In addition, we may receive proceeds from the conversion of the Additional Notes, the Exchange Notes, the Warrants and the New CB Initial Note. All proceeds from the conversion of the Additional Notes, Exchange Notes, Warrants, New CB Initial Note, and the sales of Class A Ordinary Shares to White Lion will be used for working capital and other general corporate purposes.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should read the &ldquo;<I>Risk Factors</I>&rdquo; section starting on page 25 of this prospectus for a discussion of factors to consider carefully before deciding to invest in our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq symbol</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;NIVF&rdquo; (Class A Ordinary Shares); &ldquo;NIVFW&rdquo; (Warrants to purchase Class A Ordinary Shares).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of Ordinary Shares
issued and outstanding is 2,152,702 as of August 21, 2025. No new Class A Ordinary Shares will be issued by us under this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our Class A Ordinary
Shares involves a high degree of risk. You should carefully consider the risks in this prospectus, the risk factors described under the
caption &ldquo;<I>Risk Factors</I>&rdquo; in any applicable prospectus supplement and any risk factors set forth in our other filings
with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, before
making a decision about investing in our Class A Ordinary Shares. The risks and uncertainties we have described are not the only ones
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.
If any risks actually occur, our business, financial condition and results of operations may be materially and adversely affected. In
such an event, the trading price of our Class A Ordinary Shares could decline and you could lose part or all of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we are also
subject to the following risk factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to NewGenIvf&rsquo;s Business
and Industry</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to continue operating
as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the
Company&rsquo;s cash and cash equivalents stood at approximately US$457,740. While the Company does not have immediate challenges to settle
its obligations when payments become due, the Company can make no assurance that it will have sufficient capital to bridge potential financial
and liquidity shortfalls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is always closely
monitoring the market for opportunities and has also been carrying out various fundraising projects to improve the Company&rsquo;s cash
flow position. As of April 10, 2025, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising
the Initial Note, the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the
Company. A further US$2,000,000 of the Third Mandatory Additional Note was issued subsequent to the 2024 year end and remains outstanding.
Moreover, the Company has access to an equity line of credit facility of up to US$100,000,000 from White Lion Capital, of which approximately
US$7.1 million has been drawn and become equity to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one
or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there
would likely be a material adverse effect on the Company and its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The fertility market in which NewGenIvf
participates is competitive, and if NewGenIvf does not continue to compete effectively, its results of operations could be materially
and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market for NewGenIvf&rsquo;s
solutions is competitive and is likely to attract increased competition, which could make it hard for it to succeed. NewGenIvf faces significant
competition from other fertility companies and other players in the fertility market. Some of NewGenIvf&rsquo;s competitors are more established,
have a longer operating history and a larger client base, benefit from greater brand recognition and have substantially greater financial,
technical and marketing resources than NewGenIvf does. NewGenIvf&rsquo;s competitors may compete with NewGenIvf in a variety of ways,
including seeking to develop or integrating solutions and services that may become more efficient or appealing to NewGenIvf&rsquo;s existing
and potential clients, achieving superior clinical outcomes, having access to a network of more high-quality fertility specialists, establishing
more comprehensive data reporting and sharing systems, conducting brand promotions and other marketing activities, and making investments
in and acquisitions of NewGenIvf&rsquo;s business partners. While NewGenIvf believes that one of its key competitive advantages is its
ability to provide a broad range of services, and NewGenIvf does not believe any competitors have developed a similar broad range services
in Asia Pacific at this time, current or future competitors may be successful in doing so in the future. If current or future competitors
are successful at developing a similar broad range of services, NewGenIvf&rsquo;s financial performance may be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NewGenIvf believes
that there is growing awareness of the demand for fertility services. As the fertility services field gains more attention, more competitors
may be drawn into the market. NewGenIvf also could be adversely affected if NewGenIvf fails to identify or effectively respond to changes
in market dynamics. As a result of any of these factors, NewGenIvf may not be able to continue to compete successfully against its current
or future competitors, and this competition could result in the decrease in its clients base and market share and the failure of its platform
to continue to maintain market acceptance, which would materially and adversely affect its business, financial condition and results of
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf has a limited operating history
with its current platform of solutions, which makes it difficult to predict its future prospects, financial performance and results of
operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The predecessor entity of
the Company prior to the Business Combination in April of 2024, NewGenIvf Limited, a Cayman Islands exempted company, was established
in 2019, and although its subsidiary First Fertility PGS Center Limited launched fertility services in 2014, has a limited operating history.
As a result of its limited operating history with its current platform of solutions, as well as a limited amount of time serving a majority
of its client base, its ability to accurately forecast its future results of operations, key operating data, net revenue, cash flows,
and operating margins is limited and subject to a number of uncertainties, including its ability to plan for and model future growth.
NewGenIvf&rsquo;s historical revenue growth should not be considered indicative of its future performance. Further, in future periods,
its revenue growth could slow or decline for a number of reasons, including risks, challenges and uncertainties that NewGenIvf has encountered
and may continue to encounter that are frequently experienced by companies at an early stage, slowing demand for its solutions and fertility
services in general, changes in utilization trends by its clients, general economic slowdown, an increase in unemployment, an increase
in competition, changes to health care trends and regulations, changes to science relating to the fertility market, a decrease in the
growth of the fertility market, or its failure, for any reason, to continue to take advantage of growth opportunities. If NewGenIvf&rsquo;s
assumptions regarding these risks and uncertainties and its future revenue growth are incorrect or change, or if it does not address these
risks successfully, its operating and financial results could differ materially from its expectations, and its business could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our planned Solana strategy may not be successful
and exposes us to various risks, including risks associated with the Solana network, SOL token and the blockchain sector.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 2, 2025, we announced
plans to invest up to US$30 million in staking the digital asset SOL (the native token of the Solana network) and funding such investment
using our existing credit facilities. SOL is a highly volatile cryptocurrency asset that has traded below US$105 and above $270 per SOL
in the 12 months preceding the date of this registration statement. The trading price of SOL has been highly volatile during prior periods,
experiencing multiple previous significant decreases, and such declines may occur again in the future. In addition, any participation
in staking activities of our SOL holdings could expose us to significant risks associated with staking of digital assets, including the
loss of staked assets due to technical failures, lock-up periods and illiquidity of our SOL holdings which subject us to market timing
risk, custodial risks associated with using third-party staking services. As of July 25, 2025, we have accumulated total SOL holdings
of 6703.99, valued at approximately US$1.24 million. We may not be able to acquire additional holdings of SOL or realize our Solana strategy
in the future. In addition, we and our management team do not have significant experience within the cryptocurrency and blockchain sectors,
and we may not be successful in realizing our Solana strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s marketing efforts depend
significantly on its ability to receive positive references from its existing clients.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s marketing
efforts depend significantly on its ability to call on its current clients to provide positive references to new, potential clients. Given
its limited number of long-term clients, the loss or dissatisfaction of any client could substantially harm its brand and reputation,
inhibit the market adoption of its offering and impair its ability to attract new clients and maintain existing clients. Any of these
consequences could have an adverse effect on its business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As a public reporting company, we are subject
to filing deadlines for reports that we file pursuant to the Exchange Act, and our failure to timely file such reports may have material
adverse consequences on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, we have not been
able to, and may continue to be unable to produce timely financial statements, and file these financial statements as part of a periodic
report in a timely manner with the SEC. For example, we failed to timely file with the SEC the requisite Form 20-F for the year ended
December 31, 2023. Consequently, we were not compliant with the periodic reporting requirements under the Exchange Act at such time. We
cannot guarantee that in the future our reporting will always be timely. Our failure to timely file future periodic reports with the SEC
could subject us to enforcement action by the SEC and shareholder lawsuits and could eventually result in the delisting of our Class A
Ordinary Shares from Nasdaq, regulatory sanctions from the SEC, and/or the breach of covenants in our credit facilities or of any preferred
equity or debt securities we may issue in the future, any of which could have a material adverse impact on our operations and your investment
in our Class A Ordinary Shares, and our ability to register with the SEC public offerings of our securities for our benefit or the benefit
of our security holders. Additionally, our failure to file our past periodic reports and future periodic reports has resulted in and could
result in investors not receiving adequate information regarding us with which to make investment decisions. As a result, investors may
not have access to current or timely financial information about our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to continue to meet the
listing requirements of Nasdaq, our Class A Ordinary Shares will be delisted.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 8, 2024, the Company
received a deficiency letter (&ldquo;Bid Price Deficiency Letter&rdquo;) from the Listing Qualifications Department (the &ldquo;Staff&rdquo;)
of Nasdaq notifying the Company that it is currently not in compliance with the closing bid price requirement under Nasdaq Listing Rule
5450(a)(1) (the &ldquo;Minimum Bid Price Rule&rdquo;). The Bid Price Deficiency Letter stated that, for the preceding 30 consecutive business
days, the Company&rsquo;s Class A Ordinary Shares did not meet the minimum closing bid price of $1 per share pursuant to the Minimum Bid
Price Rule. The Company has an initial compliance period of 180 calendar days, or until April 7, 2025 to regain compliance with the Minimum
Bid Price Rule. The Deficiency letter stated that if at any time the closing bid price of the Company&rsquo;s Class A Ordinary Shares
is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance with
this requirement, as applicable. On February 11, 2025, the Company effected a 1-for-20 reverse stock split of its issued and unissued
shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share. On February 27, 2025,
the Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&rsquo;s securities had been
at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the Company had regained
compliance with the Minimum Bid Price Rule. Notwithstanding the foregoing, if within one year of the First Reverse Stock Split or the
Second Reverse Stock Split, the Company&rsquo;s Class A Ordinary Shares fall below $1.00 per share for 30 consecutive business days, or
if within a two-year period from the First Reverse Stock Split or the Second Reverse Stock Split, the Company effects one or more reverse
stock splits with a cumulative ratio of 250 shares or more to one, then Nasdaq may not provide us with an additional compliance period
under its amended Listing Rule 5810(c)(3)(A)(iv) and our common stock could be delisted immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 24, 2024, the Company
received a MVLS Deficiency Letter from the Listing Qualifications Department (the &ldquo;Staff&rdquo;) of Nasdaq notifying the Company
that, for the preceding 35 consecutive business days, the Class A Shares did not meet the minimum MVLS Requirement for continued listing
on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(A). In accordance with Nasdaq Rule 5810(c)(3)(C), the Company has been provided
an initial period of 180 calendar days, or until November 20, 2024, the Compliance Date, to regain compliance with the MVLS Requirement.
If, at any time before the Compliance Date, the MVLS for the Class A Shares is at least $50,000,000 for a minimum of ten consecutive business
days, the Staff will provide the Company written confirmation of compliance with the MVLS Requirement. In the event the Company does not
regain compliance with the above requirement prior to the expiration of the compliance period, it will receive written notification that
its securities are subject to delisting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 24, 2024, the Company
received a MVPHS Deficiency Letter from the Staff of Nasdaq notifying the Company that, for the preceding 35 consecutive business days,
the Company&rsquo;s Class A Ordinary Shares did not meet the minimum $15,000,000 MVPHS Requirement for continued listing on Nasdaq pursuant
to Nasdaq Listing Rules 5450(b)(2)(C). In accordance with Nasdaq Rule 5810(c)(3)(D), the Company has until the Compliance Date to regain
compliance with the MVPHS Requirement. If, at any time before the Compliance Date, the MVPHS for the Class A Shares is at least $15,000,000
for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the MVPHS Requirement.
In the event the Company does not regain compliance with the above requirement prior to the expiration of the compliance period, it will
receive written notification that its securities are subject to delisting. Alternatively, the Company may apply to transfer the Company&rsquo;s
securities to The Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the &ldquo;Panel&rdquo;) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at&nbsp;an oral hearing&nbsp;on January 28, 2025 (the &ldquo;Hearing&rdquo;). On February 19, 2025, the Company
received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance with the
Nasdaq Stock Market&rsquo;s (&ldquo;Nasdaq&rdquo; or the &ldquo;Exchange&rdquo;) continued listing requirements, subject to meeting specific
compliance criteria within designated timeframes. On February 11, 2025, the Company carried out a 1-for-20 reverse stock split of its
issued and unissued shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share.
On February 27, 2025, the Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&rsquo;s
securities had been at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the
Company had regained compliance with the Minimum Bid Price Rule. In addition, on February 27, 2025, the Company received a confirmation
from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company&rsquo;s securities
would be transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025. On March 10, 2025, the Company received
a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of Nasdaq&rsquo;s listing requirements, as required
in the Panel&rsquo;s decision letter dated February 19, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to achieve
and maintain compliance with such listing standards or other Nasdaq listing requirements in the future, our Class A Ordinary Shares could
be delisted from Nasdaq. A delisting of our Class A Ordinary Shares and our inability to list on another national securities market could
negatively impact us by: (i) reducing the liquidity and market price of our Class A Ordinary Shares; (ii) reducing the number of investors
willing to hold or acquire our Class A Ordinary Shares, which could negatively impact our ability to raise equity financing; (iii) limiting
our ability to use certain registration statements to offer and sell freely tradable securities, thereby limiting our ability to access
the public capital markets; and (iv) impairing our ability to provide equity incentives to our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If NewGenIvf is unable to attract new clients,
its business, financial condition and results of operations would be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To increase its revenue, NewGenIvf
must continue to attract new clients. NewGenIvf&rsquo;s ability to do so depends in large part on the success of its sales and marketing
efforts, and the success of references through existing clients. Potential clients may seek out other options; therefore, NewGenIvf must
demonstrate that its solutions are valuable and superior to alternatives. If NewGenIvf fails to provide high-quality solutions and convince
clients of the benefits of its model and value proposition, NewGenIvf may not be able to attract new clients. If the markets for NewGenIvf&rsquo;s
solutions decline or grow more slowly than it expects, or if the number of clients that contract with it for its solutions declines or
fails to increase as it expects, its financial results could be harmed. As the markets in which NewGenIvf participate mature, fertility
solutions and services evolve and competitors begin to enter into the market and introduce differentiated solutions or services that are
perceived to compete with its solutions, particularly if such competing solutions are adopted by its competitors, its ability to sell
its solutions could be impaired. As a result of these and other factors, NewGenIvf may be unable to attract new clients, which would have
an adverse effect on its business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s business depends on its
ability to maintain its existing client demographics. Any failure to do so would harm its business, financial condition and results of
operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of its growth strategy,
NewGenIvf is focused on maintaining its services within its existing client demographics. NewGenIvf mainly competes with mid-level private
clinics and hospitals, which have improved and developed their services and equipment over the&nbsp;years. In addition to private clinics
and hospitals already existing, foreign medical companies may also enter the markets where NewGenIvf operates. Such foreign medical companies
may be well-placed to compete with NewGenIvf due to their larger network size, reputation as global players and access to more advanced
technology and financial resources. The expansion of existing competitors in the industry may erode NewGenIvf&rsquo;s existing market
share or decrease its traditional client pool. There can be no assurance that NewGenIvf will be able to compete effectively and therefore
its future business growth may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A significant reduction in the utilization
of NewGenIvf&rsquo;s solutions could have an adverse effect on its business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A significant reduction in
the number of clients using NewGenIvf&rsquo;s solutions could adversely affect its business, financial condition and results of operations.
Factors that could contribute to a reduction in the use of its solutions include: general economic downturn that results in adverse financial
conditions; regulatory changes; failure to adapt and respond effectively to changing medical landscape, changing regulations, changing
client needs, requirements or preferences; negative publicity, through social media or otherwise and news coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If NewGenIvf fails to offer high-quality
support, its reputation could suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf relies on its client
account management personnel and the patient navigators (the &ldquo;PNs&rdquo;) to resolve client issues and help clients realize the
full benefits that its solutions and services provide. High-quality support is also important for the renewal and expansion of its services
to existing clients. The importance of its support functions will increase as NewGenIvf expands its business and pursue new clients. If
NewGenIvf does not help its clients quickly resolve issues and provide effective ongoing supports, its ability to maintain and expand
its offerings to existing and new clients could suffer, and its reputation with existing or potential clients could suffer. Further, to
the extent that NewGenIvf is unsuccessful in hiring, training and retaining adequate PNs and client account management personnel, its
ability to provide adequate and timely support to its clients would be negatively impacted, and its clients&rsquo; satisfaction with its
solutions and services would be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s failure to effectively
develop and expand its marketing and sales capabilities could harm its ability to increase its client base and achieve broader market
acceptance of solutions NewGenIvf provides.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s ability
to increase its client base and achieve broader market acceptance of solutions it provides will depend to a significant extent on its
ability to expand its marketing and sales capabilities. NewGenIvf plans to continue expanding its direct sales force and to dedicate significant
resources to sales and marketing programs, including direct sales, inside sales, targeted direct marketing, advertising, digital marketing,
e-newsletter and conference sponsorships. All of these efforts will require it to invest significant financial and other resources. Its
business and results of operations could be harmed if its sales and marketing efforts do not generate significant increases in revenue.
NewGenIvf may not achieve anticipated revenue growth from expanding its sales and marketing efforts if it is unable to hire, develop,
integrate and retain talented and effective sales personnel, if its new and existing sales personnel, on the whole, are unable to achieve
desired productivity levels in a reasonable period of time, or if its sales and marketing programs are not effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf may experience net losses and
may not sustain profitability in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf experienced significant
revenue decrease from 2019 to 2020, due to the impact of COVID-19. NewGenIvf is not certain whether it will obtain sufficient levels of
sales to sustain its growth or maintain profitability in the future. NewGenIvf also expects its costs and expenses to increase in future
periods, which could negatively affect its future results of operations if its revenue does not increase accordingly. In particular, NewGenIvf
intends to continue to incrementally expand its sales and client account management teams to educate potential clients and drive new client
adoption. NewGenIvf also expects to incur additional costs as it introduces new solutions and services to enhance its comprehensive fertility
offering. NewGenIvf will also face increased compliance costs associated with growth, the expansion of its client base and being a public
company. NewGenIvf&rsquo;s efforts to grow its business may be costlier than it expects, and NewGenIvf may not be able to increase its
revenue enough to offset its increased operating expenses. NewGenIvf may incur significant losses in the future for a number of reasons,
including the other risks described herein, and unforeseen expenses, difficulties, complications and delays, and other unknown events.
If NewGenIvf is unable to sustain profitability, the value of its business and common stock may significantly decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s future revenue may not
grow at the rates it historically has, or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has experienced
growth since its business operations started in 2014. Revenue and NewGenIvf&rsquo;s client base may not grow at the same rates they historically
have, or they may decline in the future. NewGenIvf&rsquo;s future growth will depend, in part, on its ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to attract new clients and/or maintain existing clients;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price its solutions and services effectively so that it is able to attract new clients, expand sales to its existing clients and maintain profitability;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide its clients with client support that meets their needs, including through dedicated PNs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain successful collection of applicable receivable balances;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retain and maintain relationships with high-quality and respected fertility specialists;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract and retain highly qualified personnel to support all clients; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase awareness of its brand and successfully compete with other competitors.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf may not successfully
accomplish all or any of these objectives, which may affect its future revenue, and which makes it difficult for it to forecast its future
results of operations. In addition, if the assumptions that NewGenIvf uses to plan its business are incorrect or change in reaction to
changes in its market, it may be difficult for it to maintain profitability. NewGenIvf&rsquo;s shareholders should not rely on its revenue
for any prior quarterly or annual periods as any indication of its future revenue or revenue growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NewGenIvf expects
to continue to expend substantial financial and other resources on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales and marketing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">technology infrastructure, including systems architecture, scalability, availability, performance and security; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general administration, including increased legal and accounting expenses associated with being a public company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These investments may not
result in increased revenue growth in its business. If NewGenIvf is unable to increase its revenue at a rate sufficient to offset the
expected increase in its costs, its business, financial position, and results of operations will be harmed, and NewGenIvf may not be able
to maintain profitability over the long term. Additionally, NewGenIvf may encounter unforeseen operating expenses, difficulties, complications,
delays and other unknown factors that may result in losses in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If its revenue growth does
not meet its expectations in future periods, NewGenIvf may not maintain profitability in the future, its business, financial position
and results of operations may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s interim and annual results
may fluctuate significantly and may not fully reflect the underlying performance of NewGenIvf&rsquo;s business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s interim
and annual results of operations, including the levels of NewGenIvf&rsquo;s revenues, expenses, net (loss)/income and other key metrics,
may vary significantly in the future due to a variety of factors, some of which are outside of NewGenIvf&rsquo;s control, and period-to-period
comparisons of NewGenIvf&rsquo;s operating results may not be meaningful, especially given NewGenIvf&rsquo;s limited operating history.
Accordingly, the results for any one fiscal half year or any one fiscal year are not necessarily an indication of future performance.
Fluctuations in interim and/or annual financial results may adversely affect the price of NewGenIvf&rsquo;s ordinary shares. Factors that
may cause fluctuations in NewGenIvf&rsquo;s interim and annual financial results include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&rsquo;s ability to attract new customers and maintain relationships with existing customers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in NewGenIvf&rsquo;s products and services offered and introduction of new services and products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount and timing of operating expenses related to marketing and the maintenance and expansion of NewGenIvf&rsquo;s business, operations and infrastructure;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market price of Solana;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market situation of the residential property in the United Arab Emirates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic, industry and market conditions; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of expenses related to the development or acquisition of technologies or businesses.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the estimates and assumptions NewGenIvf
uses to determine the size of the target markets for its services are inaccurate, its future growth rate may be impacted and its business
would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market opportunity estimates
and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate.
Market opportunity estimates and growth forecasts included in this prospectus, including those NewGenIvf has generated itself, are subject
to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate, including the risks described
in this prospectus. Even if the markets in which NewGenIvf competes achieve the forecasted growth, its business could fail to grow at
similar rates, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s estimates
of the market opportunity for its services are based on the assumption that the purpose-built, data-driven and disruptive fertility services
platform with the plan design NewGenIvf offers will be attractive to clients. Clients may pursue alternatives or may not see the value
in providing enhanced fertility-related services. In addition, NewGenIvf believes that it is expanding the size of the fertility market
as NewGenIvf enhances demand and increase awareness for fertility services. If these assumptions prove inaccurate, or if the increase
in awareness of fertility services attracts potential competitors to the market and results in greater competition, NewGenIvf&rsquo;s
business, financial condition and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is difficult to predict
the demand for NewGenIvf&rsquo;s solutions, the entry of competitive solutions or the future growth rate and size of the fertility market.
The expansion of the fertility market depends on a number of factors, including, but not limited to: the continued trend of individuals
starting families later in life, increase in the number of single mothers by choice, adoption of non-traditional paths to parenthood and
continued de-stigmatization of infertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If there is a reduction in
demand caused by a lack of client acceptance, weakening economic conditions, data security or privacy concerns, governmental regulation,
competing offerings or otherwise, the market for its solutions and services might not continue to develop or might develop more slowly
than NewGenIvf expects, which would adversely affect its business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf may not be able to successfully
manage its growth, and if NewGenIvf is not able to grow efficiently, its business, financial condition and results of operations could
be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As usage of its solutions
grows, NewGenIvf will need to devote additional resources to improving and maintaining its infrastructure. In addition, NewGenIvf will
need to appropriately scale its internal business systems and its client account management and services personnel to serve its growing
client base. Any failure of or delay in these efforts could result in reduced client satisfaction, resulting in decreased sales to new
clients and lower renewal and utilization rates by existing clients, which could hurt its revenue growth and its reputation. Even if NewGenIvf
is successful in these efforts, they will require the dedication of management time and attention. NewGenIvf could also face inefficiencies
or service disruptions as a result of its efforts to scale its internal infrastructure. NewGenIvf cannot be sure that the expansion and
improvements to its internal infrastructure will be effectively implemented on a timely basis, and such failures could harm its business,
financial condition and results of operations.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If NewGenIvf&rsquo;s new solutions and services
are not adopted by its clients, or if it fails to innovate and develop new offerings that are adopted by its clients, its revenue and
results of operations may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, NewGenIvf has derived
a substantial majority of its revenue from sales of its fertility services. As NewGenIvf operates in an evolving industry, its long-term
results of operations and continued growth will depend on its ability to successfully develop and market new successful solutions and
services to its clients. If its existing clients do not value and/or are not willing to make additional payments for such new solutions
or services, it could adversely affect its business, financial condition and results of operations. If NewGenIvf is unable to predict
clients&rsquo; preferences, if the markets in which NewGenIvf participates change, including in response to government regulation, or
if NewGenIvf is unable to modify its solutions and services on a timely basis, NewGenIvf may lose clients. Its results of operations would
also suffer if its innovations were not responsive to the needs of the clients, appropriately timed with market opportunity or effectively
brought to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If NewGenIvf fails to adapt and respond
effectively to the changing medical landscape, changing regulations, changing client needs, requirements or preferences, its offerings
may become less competitive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market in which NewGenIvf
competes is subject to a changing medical landscape and changing regulations, as well as changing client needs, requirements and preferences.
The success of its business will depend, in part, on its ability to adapt and respond effectively to these changes on a timely basis.
NewGenIvf&rsquo;s business strategy may not effectively respond to these changes, and NewGenIvf may fail to recognize and position itself
to capitalize upon market opportunities. NewGenIvf may not have sufficient advance notice and resources to develop and effectively implement
an alternative strategy. There may be scientific or clinical changes that require it to change its solutions or that make its solutions
less competitive in the marketplace. If there are sensitivities to its model or its existing competitors and new entrants create new disruptive
business models and/or develop new solutions that clients prefer to its solutions, NewGenIvf may lose clients, and its results of operations,
cash flows and/or prospects may be adversely affected. The future performance of NewGenIvf&rsquo;s business will depend in large part
on its ability to design and implement market appropriate strategic initiatives, some of which will occur over several&nbsp;years in a
dynamic industry. If these initiatives of NewGenIvf do not result in met objectives, NewGenIvf&rsquo;s results of operations could be
adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If NewGenIvf fails to maintain and enhance
its brand, its ability to expand its client base will be impaired and its business, financial condition and results of operations may
suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The growth of NewGenIvf&rsquo;s
business partially depends on the recognition of NewGenIvf&rsquo;s brand and reputation. NewGenIvf believes that maintaining and enhancing
its brand is important to support the marketing and sale of its existing and future solutions to new clients and expand sales of its solutions
to existing clients. NewGenIvf also believes that the importance of brand recognition will increase as competition in its market increases.
Successfully maintaining and enhancing its brand will depend largely on the effectiveness of its marketing efforts, its ability to provide
reliable services that continue to meet the needs of its clients at competitive prices, its ability to maintain its clients&rsquo; trust,
its ability to continue to develop new solutions, and its ability to successfully differentiate its platform from competitive solutions
and services. NewGenIvf&rsquo;s brand promotion activities may not generate client awareness or yield increased revenue, and even if they
do, any increased revenue may not offset the expenses NewGenIvf incurs in building its brand. If NewGenIvf fails to successfully promote
and maintain its brand, its business, financial condition and results of operations may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If NewGenIvf fails to retain and motivate
members of its management team or other key employees, or fails to attract additional qualified personnel to support its operations, its
business and future growth prospects could be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s success
and future growth depend largely upon the continued services of its management team and its other key employees. From time to time, there
may be changes in its executive management team or other key employees resulting from the hiring or departure of these personnel. Its
executive officers and other key employees are employed on an at-will basis, which means that these personnel could terminate their employment
with it at any time. The loss of one or more of its executive officers, or the failure by its executive team to effectively work with
its employees and lead its company, could harm its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, to execute its
growth plan, NewGenIvf must attract and retain highly qualified personnel. Competition for these personnel is intense, especially for
experienced medical officers and scientific staffs and sales and client account management personnel. There is no guarantee NewGenIvf
will be able to attract such personnel or that competition among potential employers will not result in increased salaries or other benefits.
From time to time, NewGenIvf has experienced, and NewGenIvf expects to continue to experience, difficulty in hiring and retaining employees
with appropriate qualifications. Many of the companies with which NewGenIvf competes for experienced personnel have greater resources
than NewGenIvf has. If NewGenIvf hires employees from competitors or other companies, their former employers may attempt to assert that
these employees or NewGenIvf has breached their legal obligations, resulting in a diversion of its time and resources. In addition, prospective
and existing employees often consider the value of the equity awards they receive in connection with their contribution to the company.
If the perceived value of its equity awards declines, experiences significant volatility, or increases such that prospective employees
believe there is limited upside to the value of its equity awards, it may adversely affect its ability to recruit and retain key employees.
If NewGenIvf fails to attract new personnel or fails to retain and motivate its current personnel, its business and future growth prospects
could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, in order to attract
and retain key personnel and employees, the compensation amounts for NewGenIvf&rsquo;s executive officers may change significantly after
consummation of the Business Combination, although there are currently no agreements in place relating to any such post Business Combination
compensation arrangements. As a result, NewGenIvf&rsquo;s expenses associated with the compensation may increase, which may also have
an adverse effect on its results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s Share Incentive
Plan allows NewGenIvf to enhance its ability to attract and retain exceptionally qualified individuals and agents and to encourage them
to acquire a proprietary interest in the company&rsquo;s growth and performance. Competition for highly skilled personnel and agents is
often intense and NewGenIvf may incur significant costs or may not be successful in attracting, integrating, or retaining qualified personnel
and agents to fulfill NewGenIvf&rsquo;s current or future needs. NewGenIvf believes that the granting of share-based awards is of significant
importance to NewGenIvf&rsquo;s ability to attract and retain agents, key personnel and employees, and NewGenIvf will continue to grant
share-based awards in the future. In addition, NewGenIvf may, with the approval of its Compensation Committee and the Board, revise the
terms of, and increase the size of, its share incentive plan, to ensure that it is able to attract and retain agents, key personnel and
employees. On March 31, 2025, NewGenIvf&rsquo;s Board approved certain amendments to its Share Incentive Plan, including the increase
of the size of the share incentive plan to 20% of the outstanding shares of the Company from time to time, and on August 18, 2025, NewGenIvf&rsquo;s
Board approved the replenishment of its award pool to 20% of the outstanding shares of the Company as of August 18, 2025. As a result,
NewGenIvf&rsquo;s expenses associated with share-based compensation may increase, which may have an adverse effect on NewGenIvf&rsquo;s
results of operations. The amended share incentive plan is available as Exhibit 4.32.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>To successfully market and sell its services
and products in Asia-Pacific markets, NewGenIvf must address many international business risks with which NewGenIvf has limited experience.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s business
is subject to risks in connection with changes in international, national and local economic and market conditions, including the effects
of global financial crises, effects of terrorist acts and war and global pandemics. Such economic changes could negatively impact infertile
couples&rsquo; abilities to pay for fertility treatments around the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s strategy
is to increase its international presence in Asia-Pacific countries and its international sales are subject to a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased competition as a result of more products and procedures receiving regulatory approval or otherwise free to market in international markets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer accounts receivable payment cycles and difficulties in collecting accounts receivable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced or varied protection for intellectual property rights in some countries;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">export restrictions, trade regulations, and foreign tax laws;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations in currency exchange rates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign certification and regulatory clearance or approval requirements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customs clearance and shipping delays;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">political, social, and economic instability abroad, terrorist attacks, and security concerns in general;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preference for locally provided services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potentially adverse tax consequences, including the complexities of foreign value-added tax systems;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the burdens of complying with a wide variety of foreign laws and different legal standards; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased financial accounting and reporting burdens and complexities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If one or more of these risks
are realized, its business, financial condition and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Ethical, legal and social concerns related
to the use of assisted reproductive technology could reduce demand for the fertility services provided by the medical facilities in NewGenIvf&rsquo;s
network, and thus may adversely affect the business, financial conditions and results of operations of the medical facilities in its network.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patient sentiment and distrust
of the use of assisted reproductive technology may lead to less demand for fertility services. Assisted reproductive technologies, including
genetic testing, technologies used for surrogacy and egg donation and gender selection, have raised ethical, legal and social issues regarding
privacy and the appropriate uses of the resulting information. Government authorities could, for social or other purposes, limit or regulate
the use of assisted reproductive technology to certain conditions. Similarly, these concerns may lead patients to refuse to use, or physicians
to be reluctant to order, assisted reproductive services even if permissible. These and other ethical, legal and social concerns may limit
market acceptance of fertility services or reduce patient demand for such services, either of which could have a material adverse effect
on the business, financial condition and results of operations of the medical facilities in NewGenIvf&rsquo;s network, and NewGenIvf itself.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf is reliant on revenue from international
clients.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fertility services revenue
from international clients are an important part of NewGenIvf&rsquo;s revenue, though NewGenIvf is expanding rapidly into the local markets.
The number of international clients travelling to Thailand, Cambodia and Kyrgyzstan to seek fertility services may, however, be affected
by a number of factors, including the economic status of the foreign client&rsquo;s country of origin, the relative exchange rate of the
client&rsquo;s home currency to the relevant authorities, which may affect the cost of treatment, natural disasters, pandemics like COVID-19,
and political tension or acts of terrorism in such countries and the region. For example, the COVID-19 has had resulted in a number of
countries declaring a state of emergency and a number of countries, including the countries in Asian Pacific, imposing extensive travel
restrictions, which in turn caused a decrease in the numbers of internal clients traveling to Thailand, Cambodia or Kyrgyzstan for treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These events could cause a
postponement or a reduction in the number of clients traveling to Thailand, Cambodia or Kyrgyzstan, and could in turn affect revenues
from international clients, which is the significant contributor in terms of volume. A decline in the medical tourism industry may have
a material adverse effect on NewGenIvf&rsquo;s financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fluctuations in exchange rates could have
a material and adverse effect on NewGenIvf&rsquo;s results of operations and the value of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s reporting
currency is U.S.&nbsp;dollars. The functional currency of NewGenIvf and its subsidiaries include Hong&nbsp;Kong dollar (&ldquo;HK$&rdquo;),
Thai baht (&ldquo;THB&rdquo;), and United&nbsp;States dollar (&ldquo;USD&rdquo;). Accordingly, fluctuations in the value of HK$, and THB
relative to the USD could affect its results of operations due to translational remeasurements. As its international operations expand,
an increasing portion of its revenue and operating expenses may be denominated in non- HK$, and THB currencies. Accordingly, NewGenIvf&rsquo;s
revenue and operating expenses will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. If
NewGenIvf is not able to successfully hedge against the risks associated with currency fluctuations, NewGenIvf&rsquo;s business, financial
condition and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Governmental control of currency conversion
may limit NewGenIvf&rsquo;s ability to utilize NewGenIvf&rsquo;s net revenue effectively and affect the value of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s revenue
and expenses for its businesses are substantially denominated in THB, which are currently not freely convertible currencies. A portion
of such revenue must be converted into other currencies in order to meet its foreign currency obligations. For example, NewGenIvf&rsquo;s
subsidiaries will need to obtain foreign currency to make payments of declared dividends, if any, on its shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the existing foreign
exchange regulations in Thailand, NewGenIvf will be able to make current account foreign exchange transactions. However, in the future,
governments may take measures, at its discretion, to restrict access to foreign currencies for capital account and current account transactions
under certain circumstances. If such measures are implemented, NewGenIvf may not be able to pay dividends in foreign currencies to holders
of its shares. Foreign exchange transactions under its capital account are subject to significant foreign exchange controls and require
certain approvals. These limitations could affect our ability to obtain foreign exchange through offshore financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The value of the THB against
the U.S.&nbsp;dollar and other currencies fluctuates, and is subject to changes resulting from policies of the Thailand and other governments,
and depends to a large extent on domestic and international economic and political developments as well as supply and demand in the local
market. For example, the Bank of Thailand, which is the central bank of Thailand, is responsible for formulating and implementing monetary
policies in the country to maintain the price stability and promote economic stability and sustainable growth. The Bank of Thailand imposes
(four) measures in preventing THB fluctuation. Those are measures to limit THB liquidity, to curb capital inflows, to limit the flows
on Non-resident Bank Account and Non-resident Baht for Securities, and to limit the flows on Non-Deliverable Forward transactions. With
an increased floating range of the THB&rsquo;s value against foreign currencies and a more market-oriented mechanism for determining the
mid-point exchange rates, the THB may further appreciate or depreciate significantly in value against the U.S.&nbsp;dollar or other foreign
currencies in the long-term, depending on the fluctuation of the basket of currencies against which it is currently valued, or it may
be permitted to enter into a full float, which may also result in a significant appreciation or depreciation of the THB against the U.S.&nbsp;dollar
or other foreign currencies. It cannot be assured that THB will not experience significant appreciation or depreciation against the U.S.&nbsp;dollar
or other foreign currencies in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, NewGenIvf is
also currently required to obtain approvals before converting significant sums of foreign currencies into THB. All of these factors could
materially and adversely affect its business, results of operations, financial condition and prospects, and could reduce the value of,
and dividends payable on, its shares in foreign currency terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sales of a substantial number of our securities
in the public market by the Selling Securityholders and/or by our existing securityholders could cause the price of our Ordinary Shares
to decrease significantly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
can resell, under this prospectus, up to 50,000,000 Class A Ordinary Shares. The securities being offered in this prospectus represent
a substantial percentage of our issued and outstanding Class A Ordinary Shares, and the sale of such securities in the public market by
the Selling Securityholders, or the perception that those sales might occur, could depress the market price of our Class A Ordinary Shares,
and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that
such sales may have on the prevailing market price of our Class A Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our dual-class voting structure may limit
your ability to influence corporate matters and could discourage others from pursuing any change of control transactions that holders
of our Class A Ordinary Shares may view as beneficial.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized and issued
ordinary shares are divided into Class A Ordinary Shares and Class B Ordinary Shares. Each Class A Ordinary Share is entitled to one (1)
vote, while each Class B Ordinary Share is entitled to one hundred (100) votes with all Ordinary Shares voting together as a single class
on most matters. Each Class B Ordinary Share is convertible into one Class A Ordinary Share at any time by the holder thereof, while Class
A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. Only Class A Ordinary Shares are listed and
traded on NASDAQ, and we intend to maintain the dual-class voting structure. Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong beneficially
own all of the issued Class B Ordinary Shares. As of the date of this prospectus, these Class B Ordinary Shares constitute approximately
0.191% of our total issued and outstanding shares and 16.04% of the aggregate voting power of our total issued and outstanding shares
due to the disparate voting powers associated with our dual-class share structure. As a result of the dual-class share structure and the
concentration of control, holders of Class B Ordinary Shares have considerable influence over matters such as decisions regarding election
of directors and other significant corporate actions. Such holders may take actions that are not in the best interest of us or our other
shareholders. This concentration of control may discourage, delay, or prevent a change in control of us, which could have the effect of
depriving our other shareholders of the opportunity to receive a premium for their shares as part of a sale of us and may reduce our share
price. This concentrated control will limit the ability of holders of Class A Ordinary Shares to influence corporate matters and could
discourage others from pursuing any potential merger, takeover, or other change of control transactions that holders of Class A Ordinary
Shares may view as beneficial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Substantially all of NewGenIvf&rsquo;s assets
and operations are located in Thailand, Cambodia and Kyrgyzstan and they are subject to economic, legal and regulatory uncertainties in
such countries.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantially all of NewGenIvf&rsquo;s
operations and assets are based in Thailand, Cambodia and Kyrgyzstan.&nbsp;As a result, its businesses and operations are subject to the
changing economic conditions prevailing from time to time in such countries. Since 2020, Thailand&rsquo;s economy has been experiencing
a slowdown. According to the National Economic and Social Development Board of Thailand (the &ldquo;NESDB&rdquo;) the GDP growth rate
of Thailand declined to minus 6.1% in 2020 and slightly recovered to 1.6% in 2021 and 2.6% in 2022. Under such conditions, the NESDB projected
that Thailand&rsquo;s economy will only grow by 3.0% to 4.0% in 2023, lower than the previously growth in historical&nbsp;years. Meanwhile,
Cambodia&rsquo;s post-pandemic economic recovery has gained momentum, but remains uneven. Traditional growth drivers, especially manufacturing
and agricultural commodities exports, have fully recovered. However, while travel and tourism have improved, the sector remains well below
pre-COVID-19 levels. The subsequent impact also caused the vendors and customers preference change, lower the willingness travelling to
Kyrgyzstan for surrogacy services. The economy is projected to grow, underpinned by merchandise exports and domestic economic activity.
Foreign direct investment, while diversified, remains affected by China&rsquo;s related COVID-19 policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also derives a substantial
portion of its revenue from Chinese clients and as such, its maintenance of PRC-sourced revenues and access to new and existing clients
from the PRC are also subject to the economic conditions of China. However, the near-term growth prospects of the PRC economy are unclear
due to the uncertain effects of ongoing economic stress caused by policies to contain the COVID-19 pandemic, trade and national security
policies, and the elevated levels of private and public indebtedness, among others. According to the National Statistics Bureau of the
PRC, growth rate of China&rsquo;s GDP for the year 2022 slowed down to 3.0% on a year-on-year basis compared to the growth rate of approximately
8.4% for the year 2021. In 2023, China&rsquo;s GDP grew 5.2% while China&rsquo;s 2024 GDP growth rate was 5%. A prolonged downturn in
the PRC economy generally could materially and adversely affect NewGenIvf&rsquo;s results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Factors that may adversely
affect the economy and conditions in such countries include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">political instability;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">global economic conditions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exchange rate fluctuations and the exchange control policy of the banks;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a prolonged period of inflation or increase in regional interest rates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in taxation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in government policies affecting import and export volumes;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decline in tourism;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, including tsunamis, earthquakes, fires, floods, drought and similar events;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a potential recurrence or outbreak of avian influenza, severe acute respiratory syndrome or other infectious or contagious diseases like COVID-19 in Asian countries, and governmental policies to address such outbreak;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">scarcity of credit or other financing, resulting in lower demand for products and services provided by companies in the region;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases in oil prices and other commodity prices;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased consumer confidence;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other external recessions or potential economic downturns in the United&nbsp;States, Asia or other parts of the world; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other regulatory, political or economic developments in or affecting the countries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The economic conditions in
Thailand, Cambodia, Kyrgyzstan and China are also affected by global economic conditions. The global credit markets have experienced,
and may continue to experience, volatility and liquidity disruptions, which have resulted in the consolidation, failure or near failure
of a number of institutions in the banking and insurance industries. There remains a concern that a return of the debt crisis in Europe,
the political unrest in the Middle East and Eastern Europe as well as rumors or threats or actual terrorist attacks or conflicts in the
Middle East, Southeast Asia, Eastern Europe or other regions will impinge upon the health of the global financial system. These or other
such events could adversely affect NewGenIvf&rsquo;s business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
the economies and social conditions of Thailand, Cambodia, Kyrgyzstan and China will meet current projections or improve in the future.
Any instability or economic downturn could have a material adverse effect on NewGenIvf&rsquo;s business, financial condition, results
of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with the terms of future
financing arrangements could result in default, which could have an adverse effect on NewGenIvf&rsquo;s cash flow and liquidity.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf may from time to
time enter into credit facilities and debt financing arrangements containing financial and other covenants that could, among other things,
restrict NewGenIvf&rsquo;s business and operations. If NewGenIvf breaches any of these covenants, including the failure to maintain certain
financial ratios, NewGenIvf&rsquo;s lenders may be entitled to accelerate NewGenIvf&rsquo;s debt obligations. Any default under the credit
facility could result in the repayment of these loans prior to maturity as well as the inability to obtain additional financing, which
in turn may have a material adverse effect on NewGenIvf&rsquo;s cash flow and liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf requires a significant amount
of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on acceptable terms, its business, financial
condition, and prospects may be materially and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf requires a significant
amount of capital and resources for its operations and continued growth. NewGenIvf expects to make significant investments to fund operations,
laboratory upgrades, new strategic investments in Solana and residential property development in United Arab Emirates, among other things,
which may significantly increase NewGenIvf&rsquo;s net cash used in operating activities. In addition, NewGenIvf will continue to invest
in laboratory and facilities which are fundamental to NewGenIvf&rsquo;s business operation and future growth. However, NewGenIvf cannot
assure you that these investments will generate the optimal returns, if at all. To date, NewGenIvf has historically funded its cash requirements
primarily through operational, capital contributions from its shareholders and short-term or long-term borrowings. If these resources
are insufficient to satisfy NewGenIvf&rsquo;s cash requirements, NewGenIvf may seek to raise funds through additional equity offering
or debt financing or additional bank facilities. NewGenIvf&rsquo;s ability to obtain additional capital in the future, however, is subject
to a number of uncertainties, including those relating to its future business development, financial condition, and results of operations,
general market conditions for financing activities by companies in its industry, and macro-economic and other conditions in Thailand,
Cambodia, Kyrgyzstan and globally. If NewGenIvf cannot obtain sufficient capital on acceptable terms to meet its capital needs, NewGenIvf
may not be able to execute its growth strategies, and NewGenIvf&rsquo;s business, financial condition, and prospects may be materially
and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The defects in certain leased property interests
and failure to register certain lease agreements may materially and adversely affect NewGenIvf&rsquo;s business, financial condition,
results of operations, and prospects. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf leases premises
in Thailand, Cambodia and Kyrgyzstan in various locations. With respect to property leased by First Fertility PGS Center in Thailand,
the lessors did not have or provide NewGenIvf with property ownership certificates or other documents evidencing their rights to lease
such premises to First Fertility PGS Center. Therefore, NewGenIvf cannot assure that it will not be subject to any challenges, lawsuits,
or other actions taken against First Fertility PGS Center with respect to its leased premises for which the relevant lessors do not have
valid title or right to lease. If First Fertility PGS Center&rsquo;s lessors&rsquo; right to lease premises is successfully challenged
by any third party, First Fertility PGS Center&rsquo;s lease agreements may not be enforceable and NewGenIvf may be forced to vacate the
premises and relocate to a different location. Under such circumstances, NewGenIvf expects to incur relocation costs of up to THB3 million
and expects that there would not be material business interruption costs, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the failure of
the lessor to provide sufficient legal evidence of its right to lease the premises has prevented First Fertility PGS Center from registering
the clinic with the Bangkok Metropolitan Authority (&ldquo;BMA&rdquo;) as required under the Public Health Act B.E. 2535 (1992) (the &ldquo;PHA&rdquo;).
Under Section 71 of the PHA, First Fertility PGS Center and its directors are subject to imprisonment of up to 6 (six) months and a fine
of up to THB50,000, or both. The BMA could also order First Fertility PGS Center to stop operating the clinic which would require relocation
of the clinic if First Fertility PGS Center could not make the necessary registration. Under such circumstances, First Fertility PGS Center
expects to incur relocation costs of up to THB3 million and expects that there would not be material business interruption costs, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only one of NewGenIvf&rsquo;s
directors or officers, namely Ms. Fong, Hei Yue Tina, is also a director of First Fertility PGS Center. NewGenIvf believes that if First
Fertility PGS Center&rsquo;s directors, including Ms.&nbsp;Fong, are found guilty of the above offence and subject to imprisonment, the
resulting impact on NewGenIvf&rsquo;s business, results of operations and financial conditions would be limited, as Ms. Fong has limited
involvement in the day-to-day management of First Fertility PGS Center&rsquo;s operations and Mr. Siu, Wing Fung Alfred and the other
directors and officers of NewGenIvf and its subsidiaries would be able to keep operating the group&rsquo;s and First Fertility PGS Center&rsquo;s
activities with limited disruptions. Further, a second clinic has been set up in a separate location which will mitigate the risk of interruptions
to operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf currently has no insurance coverage
for its operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The assisted reproductive
medical facilities in NewGenIvf&rsquo;s network are exposed to potential liabilities that are inherent to the provision of services. Medical
and other liabilities may not be fully covered by insurance and the medical facilities may face claims in excess of the insurance coverage
or claims which are not covered by insurance due to other policy limitations or exclusions or where the medical facilities in NewGenIvf&rsquo;s
network have failed to comply with the terms of the policy. Any uninsured risks may result in substantial costs and the diversion of resources,
which could adversely affect its results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The insurance industries in
Thailand, Cambodia and Kyrgyzstan are still at early stages of development, and insurance companies in Thailand, Cambodia and Kyrgyzstan
currently offer limited business-related insurance products. NewGenIvf does not currently maintain insurance. NewGenIvf cannot assure
you that the medical facilities in its network will be able to obtain and/or maintain medical liability insurance on acceptable terms
or without substantial premium increases or at all in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as NewGenIvf&rsquo;s
business expands, the cost for each medical facility in its network and NewGenIvf to maintain an adequate level of insurance may become
increasingly high. NewGenIvf cannot ensure that the medical facilities in its network will be able to locate or purchase appropriate insurance
to cover the expanding operations in time, on commercially reasonable terms or at all. Any significant uninsured loss could have material
and adverse effects on the financial condition and results of operations of the medical facilities in NewGenIvf&rsquo;s network, and thus
may affect its business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, NewGenIvf does not
currently maintain professional malpractice liability insurance for its physicians and nurses. As a result, NewGenIvf may be subject to
medical disputes and claims arising under relevant laws from time to time, which could cause substantial damage to NewGenIvf if not covered
by professional malpractice liability insurance. Any dispute with clients, or any legal proceeding involving the physicians of the medical
facilities or medical professionals, regardless of its merit or eventual outcome, could result in significant legal costs and financial
and/or reputational damages to the medical facilities and NewGenIvf and materially and adversely affect the business, financial condition
and results of operations of the medical facilities in NewGenIvf&rsquo;s network, and further affect its business, financial condition,
results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf may not be successful in adapting
to technological developments, which may affect its business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that new technologies
could be developed or scientific advances made by NewGenIvf&rsquo;s competitors, or elsewhere and licensed to NewGenIvf&rsquo;s competitors,
which cannot be replicated by NewGenIvf without significant capital expenditure or at all, or that replace or reduce the requirement for
assisted reproductive services, ultrasound or specialized diagnostics. The consequences for NewGenIvf of the development of new technologies
could include lower or loss of revenues, loss of market position and reduced prospects of NewGenIvf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If its computer systems, or those of its
providers, specialty pharmacies or other downstream vendors lag, fail or suffer security breaches, NewGenIvf may incur a material disruption
of its services, which could materially impact its business and the results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s businesses
in Thailand, Cambodia and Kyrgyzstan are increasingly dependent on critical, complex and interdependent information technology systems
to support business processes as well as internal and external communications. NewGenIvf&rsquo;s success is therefore dependent in part
on its ability to secure, integrate, develop, redesign and enhance its (or contract with vendors to provide) technology systems that support
its business strategy initiatives and processes in a compliant, secure, and cost and resource efficient manner. If NewGenIvf or its providers,
specialty pharmacies or other downstream vendors have an issue with its or their respective technology systems, it may result in a disruption
to its operations or downstream disruption to its relationships with its clients or its selective network of high-quality fertility specialists.
Additionally, if NewGenIvf chooses to insource any of the services currently handled by a third party, it may result in technological
or operational disruptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, despite the implementation
of security measures, its internal computer systems, and those of its provider clinics, specialty pharmacies or other downstream vendors,
are potentially vulnerable to damage from malicious intrusion, malware, computer viruses, unauthorized access, natural disasters, terrorism,
war and telecommunication and electrical failures. While NewGenIvf is not aware that it has experienced any such system failure, accident
or security breach to date, if such an event were to occur and cause interruptions in its operations, it could result in a material disruption
to its ability to operate and deliver its solutions. In addition, to the extent that any disruption or security breach were to result
in a loss or inappropriate disclosure of confidential information, NewGenIvf could incur liability. See &ldquo;&mdash;<I>&nbsp;Risks Related
to Government Regulation&nbsp;&mdash;&nbsp;NewGenIvf operates in a highly regulated industry and must comply with a significant number
of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits applicable to NewGenIvf&rsquo;s business may
have a material and adverse impact on NewGenIvf&rsquo;s business, financial condition, and results of operations&nbsp;&mdash;&nbsp;Data
Protection and Breaches</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to NewGenIvf&rsquo;s Relationships with Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s business depends on its
ability to maintain its network of high-quality fertility specialists and other healthcare providers. If NewGenIvf is unable to do so,
its future growth would be limited and its business, financial condition and results of operations would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s performance
and success is dependent upon its continued ability to maintain a credentialed network of high-quality fertility specialists, including
its senior management team, other key employees, as well as research and development and operation maintenance personnel, many of whom
are difficult to replace. Fertility specialists could refuse to contract, demand higher payments or take other actions that could result
in higher medical costs, less attractive service for its clients or difficulty meeting regulatory or accreditation requirements. Identifying
high-quality fertility specialists, credentialing and negotiating contracts with them and evaluating, monitoring and maintaining its network,
requires significant time and resources. Competition in the healthcare industry for qualified employees is intense. NewGenIvf may need
to offer higher compensation and other benefits in order to attract and retain key personnel in the future, which could increase NewGenIvf&rsquo;s
compensation expenses, including stock-based compensation. NewGenIvf&rsquo;s continued ability to compete effectively depends on NewGenIvf&rsquo;s
ability to attract new employees and to retain and motivate NewGenIvf&rsquo;s existing employees. If NewGenIvf is not successful in maintaining
its relationships with top fertility specialists, these fertility specialists may refuse to renew their contracts with it, and potential
competitors may be effective in onboarding these or other high-quality fertility specialists to create a similarly high-quality network.
There may be additional shifts in the fertility specialty provider space as the fertility market matures, and high-quality fertility specialists
may become more demanding in re-negotiating to remain in its network. Its ability to develop and maintain satisfactory relationships with
high-quality fertility specialists also may be negatively impacted by other factors not associated with it, such as regulatory changes
impacting providers or consolidation activity among hospitals, physician groups and healthcare providers. In addition, certain organizations
of physicians, such as practice management companies (which group together physician practices for administrative efficiency), may change
the way in which healthcare providers do business with it and may compete directly with it, which could adversely affect its business,
financial condition and results of operations. NewGenIvf intends to grant, and may continue to grant, options and other types of awards,
which may result in increased share-based compensation expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s Share Incentive
Award will allow NewGenIvf to enhance its ability to attract and retain exceptionally qualified individuals and agents and to encourage
them to acquire a proprietary interest in the company&rsquo;s growth and performance. Competition for highly skilled personnel and agents
is often intense and NewGenIvf may incur significant costs or may not be successful in attracting, integrating, or retaining qualified
personnel and agents to fulfill NewGenIvf&rsquo;s current or future needs. NewGenIvf believes that the granting of share-based awards
is of significant importance to NewGenIvf&rsquo;s ability to attract and retain agents, key personnel and employees, and NewGenIvf will
continue to grant share-based awards in the future. In addition, NewGenIvf may, with the approval of its Compensation Committee and the
Board, revise the terms of, and increase the size of, its share incentive plan, to ensure that it is able to attract and retain agents,
key personnel and employees. On March 31, 2025, NewGenIvf&rsquo;s Board approved certain amendments to its Share Incentive Plan, including
the increase of the size of the share incentive plan to 20% of the outstanding shares of the Company from time to time. As a result, NewGenIvf&rsquo;s
expenses associated with share-based compensation may increase, which may have an adverse effect on NewGenIvf&rsquo;s results of operations.
The amended share incentive plan is available as Exhibit 4.32.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Meanwhile, the retirement
or loss of certain specialists, scientific staff or other key personnel, the activities of competitors, the introduction of a competing
service that is perceived to be superior to the services provided by NewGenIvf, or other events which impact NewGenIvf&rsquo;s reputation
could adversely affect NewGenIvf&rsquo;s relationships with fertility specialists. For example, one specialist who was previously engaged
by NewGenIvf brought a lawsuit against NewGenIvf regarding disputed remuneration, which resulted in a settlement for NewGenIvf to compensate
the specialist with a sum of approximately US$98,000. Also, fertility specialists&rsquo; relationship with NewGenIvf could affect their
behaviors in recommending NewGenIvf&rsquo;s services or referring patients to NewGenIvf, which could in turn adversely impact the number
of patients treated by NewGenIvf and adversely impact on its financial performance, market position and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the perceived
value of NewGenIvf&rsquo;s solutions and its reputation may be negatively impacted if the services provided by fertility specialists or
other healthcare providers are not satisfactory to NewGenIvf&rsquo;s clients, including as a result of error that could result in litigation.
For example, if fertility specialist or other healthcare provider releases sensitive information of its clients, it could incur additional
expenses and give rise to litigation against NewGenIvf. Any such issue with one of its providers may expose it to public scrutiny, adversely
affect its brand and reputation, expose it to litigation or regulatory action, and otherwise make its operations vulnerable. Further,
if its services result in less than favorable outcomes, this could cause it to fail to meet its contractually guaranteed specified service
metrics, and NewGenIvf could be obligated to provide the client with a fee reduction or a second chance for free, depending on their contract
terms. The failure to maintain its selective network of high-quality fertility specialists or the failure of those specialists to meet
and exceed its clients&rsquo; expectation, may result in a loss of or inability to grow or maintain its client base, which could adversely
affect its business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The medical facilities and professionals
in NewGenIvf&rsquo;s network could become the subject of litigation, allegations and other claims, and NewGenIvf is not insured against
these liabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf relies on the physicians
and other medical professionals of the assisted reproductive medical facilities in its network to make proper clinical decisions regarding
the diagnosis and treatment of clients. However, NewGenIvf does not have full and direct control over every step of clinical activities
undertaken at each of the medical facilities. In addition, physicians and medical professionals outside NewGenIvf&rsquo;s network may
introduce patients to NewGenIvf and conduct medical treatments and/or procedures for such patients in NewGenIvf&rsquo;s facilities. NewGenIvf
enters into independent contractor agreements with such physicians and medical professionals and treats such patients as NewGenIvf&rsquo;s
own patients. As such, NewGenIvf will have to bear any liabilities arising from their medical treatments and/or procedures conducted in
NewGenIvf&rsquo;s facilities. Any incorrect clinical decision or malpractice on the part of physicians and other medical professionals
(including those from outside of its network), or any failure by the medical facilities in its network to properly manage their clinical
activities may result in unsatisfactory treatment outcomes, patient injury or even death, which could lead to disputes with patients and/or
their families or the medical professionals, including those from outside its network. In its experience, moreover, clients of fertility
treatments tend to be more demanding on the medical services received. In addition, the relevant laws governing medical disputes and claims
grant claimants liberal rights in bringing claims against physicians and other medical professionals practicing in the jurisdiction. As
a result, the medical facilities in its network may be subject to medical disputes and claims arising under relevant laws, from time to
time, which could generate substantial damages imposed on such facilities if not covered by professional liability insurance. Any dispute
with its patients and/or their families or the medical professionals, including those from outside its network, or any legal proceeding
involving the physicians of the medical facilities or medical professionals, including those from outside its network, regardless of its
merit or eventual outcome, could result in significant legal costs and reputational damage to the medical facilities and materially and
adversely affect the business, financial condition and results of operations of the medical facilities in its network, and further affect
its business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The assisted reproductive medical facilities
in NewGenIvf&rsquo;s network have limited control over the quality of the pharmaceuticals, medical equipment, medical consumables and
other supplies used in its operations, and cannot guarantee that the products in use are not defective or counterfeit. NewGenIvf also
has no control over independent sub-contractors and cannot guarantee the services thereof.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The assisted reproductive
medical facilities in NewGenIvf&rsquo;s network procure a variety of pharmaceuticals, medical equipment, consumables and other supplies
in NewGenIvf&rsquo;s operations from third-party suppliers. As the medical facilities in NewGenIvf&rsquo;s network do not engage in the
direct manufacture of such supplies, NewGenIvf cannot assure you that such supplies are free of defects and meet relevant quality standards
or, in the case of imported supplies, verify the origin of such products. In addition, there may be counterfeit pharmaceutical products
manufactured without proper licenses or approvals or fraudulently mislabeled with respect to their content or manufacturer in the pharmaceutical
markets. In some cases these products are very similar in appearance to the authentic products. The quality control checks and processes
may not be able to identify all counterfeit pharmaceutical products in the inventory. Any sale of such products by the medical facilities
in NewGenIvf&rsquo;s network, regardless of its knowledge as to their authenticity, may subject the medical facilities to administrative
sanctions, civil claims, negative publicity or reputational damage. NewGenIvf cannot assure you that the medical facilities in our network
will be able to successfully claim full indemnity from such manufacturers of counterfeit pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also cannot assure
you that the medical facilities in our network will not encounter incidents relating to defective products, or that such incidents will
not materially and adversely affect our network of medical facilities. If the products provided by NewGenIvf&rsquo;s suppliers are defective,
of poor quality or are otherwise unsafe or ineffective, the medical facilities in NewGenIvf&rsquo;s network could be subject to liability
claims, complaints or adverse publicity, any of which would materially and adversely affect its results of operations and reputation.
NewGenIvf cannot assure you that the medical facilities in NewGenIvf&rsquo;s network will find suitable replacement suppliers on commercially
acceptable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The suppliers are also subject
to extensive laws, rules and regulations. If any suppliers violate applicable laws, rules and regulations, NewGenIvf&rsquo;s reputation
or procurement may be materially and adversely affected. In addition, the medical facilities in NewGenIvf&rsquo;s network may be exposed
to reputational damages or even liabilities for defective goods provided by the suppliers or negative publicity associated with any suppliers,
and the business and results of operations of the medical facilities in NewGenIvf&rsquo;s network and NewGenIvf could suffer as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Independent sub-contractors
and/or agents that work with NewGenIvf are also subject to extensive laws, rules, and regulations. If any sub-contractor and/or agent
violates any applicable laws, rules, regulations or breaches any agreements, NewGenIvf&rsquo;s reputation may be materially and adversely
affected and NewGenIvf may be penalized by regulatory or other parties. In addition, NewgenIvf&rsquo;s clients may engage Newgen&rsquo;s
sub-contractors and/or agents for ongoing services or additional services following the termination of contracts with NewGenIvf. NewGenIvf
has no control over the services provided by sub-contractors and cannot assure the quality of such services or ensure compliance with
applicable laws, rules and regulations. In addition, the services provided by independent sub-contractors may expose NewGenIvf to public
scrutiny, adversely affect its brand and reputation, expose it to litigation or regulatory action, and otherwise make its operations vulnerable
if such independent sub-contractors fail to meet their contractual obligations or to comply with applicable laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If NewGenIvf loses its relationship with
one or more key pharmaceutical manufacturers, its business and results of operations could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf maintains contractual
relationships with select pharmaceutical manufacturers in Thailand, Cambodia and Kyrgyzstan. The consolidation of pharmaceutical manufacturers,
the shortages of drugs provided by such manufacturers, the termination or material alteration of its contractual relationships, or its
failure to renew such contracts could have a material adverse effect on its business and results of operations. Adoption of new laws,
rules or regulations or changes in, or new interpretations of, existing laws, rules or regulations, relating to any of these programs
could materially adversely affect its business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf has engaged in transactions with
related parties, and such transactions present potential conflicts of interest that could have an adverse effect on its business and results
of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has entered into
a number of transactions with related parties. NewGenIvf may in the future enter into additional transactions with its related parties.
Interests of these related parties may not necessarily be aligned with NewGenIvf&rsquo;s or The Company&rsquo;s interests and the interests
of its other shareholders. For example, conflicts of interest may arise in connection with decisions regarding the transaction arrangements
which may be less favorable to NewGenIvf than similar arrangements negotiated with unaffiliated third parties. Conflicts of interest may
also arise in connection with the exercise of contractual remedies, such as the treatment of events of default. As a result, those related
party transactions, individually or in the aggregate, may have an adverse effect on NewGenIvf&rsquo;s business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf may be subject to claims and allegations
relating to intellectual property and other causes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf may from time to
time receive claims that NewGenIvf infringes on the intellectual property rights of others. Moreover, NewGenIvf may be subject to claims
by third parties who maintain that NewGenIvf&rsquo;s service providers&rsquo; technology infringes third-party&rsquo;s intellectual property
rights. If NewGenIvf fails to successfully defend against such claim or does not prevail in such litigation, it could be required to modify,
redesign or cease operating, pay monetary amounts as damages or enter into royalty or licensing arrangements with the valid intellectual
property holders. Any royalty or licensing arrangements that NewGenIvf may seek in such circumstances may not be available to it on commercially
reasonable terms or at all. Also, if NewGenIvf acquires technology licenses from third parties, NewGenIvf&rsquo;s exposure to infringement
actions may increase because NewGenIvf must rely upon these third parties to verify the origin and ownership of such technology. This
exposure to liability could result in disruptions in NewGenIvf&rsquo;s business that could materially and adversely affect NewGenIvf&rsquo;s
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of NewGenIvf&rsquo;s
employees may previously employed at other companies, including NewGenIvf&rsquo;s competitors. NewGenIvf may hire additional personnel
to expand its development team and technical support team as its business grows. To the extent these employees were involved in the development
of content or technology similar to NewGenIvf&rsquo;s at their former employers, NewGenIvf may become subject to claims that these employees
or NewGenIvf has appropriated these employees&rsquo; former employers&rsquo; proprietary information or intellectual properties. If NewGenIvf
fails to successfully defend such claims against itself, NewGenIvf may be exposed to liabilities which could have a material adverse effect
on its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf is currently not
a party to any material legal or administrative proceedings but may subject to legal or administrative actions for defamation, negligence,
copyright and trademark infringement, unfair competition, breach of service terms, or other purported injuries resulting from the content
NewGenIvf provides or the nature of NewGenIvf&rsquo;s services. Such legal and administrative actions, with or without merits, may be
expensive and time-consuming and may result in significant diversion of resources and management attention from NewGenIvf&rsquo;s business
operations. Furthermore, such legal or administrative actions may adversely affect NewGenIvf&rsquo;s brand image and reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain data and information in this prospectus
relied on by NewGenIvf were obtained from third-party data and polls. These metrics were not independently verified by NewGenIvf and may
not be accurate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain numbers and information
in this prospectus were obtained and provided from numerous sources including management data, third-party data or numbers generally estimated
by calculating infertile couples, fertility tourism number, etc. to generally assess potential customer numbers in Asia-Pacific countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These metrics were not independently
verified. Such databases, third-party information, and calculations may not accurately reflect actual statistics or numbers and NewGenIvf
does not have access to specific rating numbers. Similarly, any statistical data in any third-party publications also include projections
based on a number of assumptions. If any one or more of the assumptions underlying the market data is later found to be incorrect, actual
results may differ from the projections based on these assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf operates in a highly regulated
industry and must comply with a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or
permits applicable to NewGenIvf&rsquo;s business may have a material and adverse impact on NewGenIvf&rsquo;s business, financial condition,
and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operations of NewGenIvf
are subject to various laws, rules and regulations at the national, regional and local levels in Thailand, Cambodia, Kyrgyzstan, Hong
Kong, United Arab Emirates, United States of America and other applicable jurisdictions. Such laws and regulations mainly relate to (i)&nbsp;the
licensing of local and foreign medical professionals, nursing professionals, medical technology professionals, pharmaceutical professions
and other applicable licensing; (ii)&nbsp;the licensing, registration, and accreditation of medical facilities, laboratories, including
but not limited to the licensing, registration, and accreditation of persons performing related activities; (iii)&nbsp;the privacy and
security of confidential patient medical records; (iv)&nbsp;the corporate practice of medicine; (v)&nbsp;healthcare fraud and abuse laws;
(vi)&nbsp;the donation and transplantation of human cells, tissues and organs; (vii)&nbsp;potential prohibition on surrogacy or providing
intermediary assistance in surrogacy; and (viii)&nbsp;licensing and approval of the accommodation provided as parts of the services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has attempted to
structure its operations to comply with laws, regulations and other requirements applicable to it directly and to its clients and vendors,
but there can be no assurance that its operations will not be challenged or impacted by regulatory authorities or enforcement initiatives,
or that the relevant authorities in each jurisdiction could impose higher standards or requirements, which NewGenIvf may have difficulty
to adhere to, e.g. Medical Facilities Act B.E. 2541 (1998)&nbsp;and Protection of a Child Born by Medically Assisted Reproductive Technology
Act B.E. 2558 (2015)&nbsp;for Thailand jurisdiction, Law on Reproduction Rights and on Guarantees of Their Realization of July&nbsp;4,
2015 No. 148, Law on status of medical worker of May 28, 2013 No. 81 and Temporary Regulation on Procedure of Licensing Private Medical
Activity approved by the resolution of government of April&nbsp;4, 2017 No. 203 for Kyrgyz Republic. NewGenIvf in the future may become
involved in governmental investigations, audits, reviews and assessments. Any determination by a court or agency that NewGenIvf&rsquo;s
solutions or services violate, or cause its clients to violate, applicable laws, regulations or other requirements could subject it or
its clients to civil, criminal, or administrative penalties. Such a determination also could require it to change or terminate portions
of its business, disqualify it from serving clients that do business with government entities, or cause it to refund some or all of its
service fees or otherwise compensate its clients. In addition, failure to satisfy laws, regulations or other requirements could adversely
affect demand for its solutions and could force it to expend significant capital, research and development and other resources to address
the failure. Even an unsuccessful challenge by regulatory and other authorities or parties could be expensive and time-consuming, could
result in loss of business, exposure to adverse publicity, and injury to its reputation and could adversely affect its ability to retain
and attract clients. If NewGenIvf fails to comply with applicable laws, regulations and other requirements, its business, financial condition
and results of operations could be adversely affected. Such non-compliance could also require significant investment to address and may
prove costly. There are several additional state statutes, regulations, guidance and contractual provisions related to or impacting the
healthcare industry that may apply to its business activities directly or indirectly, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9679;</I></B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Licensing and Licensed Personnel. </I></B>Many countries have licensure or registration requirements for entities acting as a medical services provider. The scope of these laws differs from country to country, and the application of such laws to the activities of fertility treatment is often unclear. Given the nature and scope of the solutions and services that NewGenIvf provides, it is required to maintain the License to Operate Medical Facility Business (Sor.Por.7), the License to Manage Medical Facility Business (Sor.Por.19), License to Certify the Standard of Service relating to Medically Assisted Reproductive Technology (KorThorPhor.9), and personnel licenses, i.e., license of medical professionals, nursing professionals, medical technology professionals, pharmaceutical professions and other applicable licenses in Thailand, Approval on Opening of Medical Clinic, Approval on Opening of Pharmacy and relevant approvals to conduct IVF, embryo implant and/or transfer activities issued by the Ministry of Health of Cambodia (&ldquo;Cambodia MOH&rdquo;) in Cambodia and licenses to carry out private medical activities (including diagnostics and treatment gynecological diseases, supervision of pregnant women before childbirth, IVF in outpatient and&nbsp;day hospital conditions (for four (4) beds)) in Kyrgyzstan, respectively, and to ensure that such licenses and registrations are in good standing on an annual basis. NewGenIvf is licensed, has licensure applications pending before appropriate regulatory bodies, is exempt from licensure or registration, or is otherwise authorized under such laws in those countries in which it provides its services. These licenses require it to comply with the rules and regulations of the governmental bodies that issued such licenses. NewGenIvf&rsquo;s failure to comply with such rules and regulations could result in criminal and/ or administrative penalties, the suspension of a license, or the loss of a license, all of which could negatively impact its business. First Fertility PGS had provided arrangements of accommodation without additional charges for its patients without a tourism license in Thailand, all of which was subsequently ceased in early 2023. Pursuant to the Tourism Business and Guide Act 2551 (2008) of Thailand, a maximum fine of THB500,000 may be imposed on First Fertility PGS as a result of the above activity without a tourism license in Thailand. NewGenIvf is unable to predict, however, how its services may be viewed by regulators over time, how these laws and regulations will be interpreted, or the full extent of their applicable. If a regulatory authority in any country determines that the nature of its business requires that NewGenIvf be licensed under applicable laws, it may need to restructure its business or it may need to comply with any related requirements, such as obtaining relevant license, paying additional regulatory fees and/or penalties for previous non-compliance with relevant licensing requirements, which could adversely affect its results of operation. Additionally, in extreme case, NewGenIvf may need to cease operations until it is able to obtain appropriate licensure, which may adversely affect its revenue for a period of time that it cannot estimate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patients&rsquo; Right Protection. </I></B>There has been an increased awareness of patients&rsquo; rights in Thailand, Cambodia and Kyrgyzstan, especially with the issuance of the Constitution of the Kingdom of Thailand, the Act on Court Proceedings for Consumer Cases B.E. 2551 (2008)&nbsp;(as amended), National Health Act B.E. 2550 (2007), and other applicable laws in Thailand, the Civil Code dated December&nbsp;8, 2017 as amended by the Law on Implementation of the Civil Code dated May&nbsp;31, 2011, Law on Management of Donation and Transplantation of Human Cells, Tissues, and Organs (2016)&nbsp;and Sub-Decree No. 61 on the Code of Medical Ethics (2003) in Cambodia and Constitution of Kyrgyzstan of May&nbsp;5, 2021, Civil Code, Part&nbsp;I of May&nbsp;8, 1996 No. 15, Law on Health Protection of Civilians of Kyrgyzstan of January&nbsp;9, 2005 No. 6, Law on Reproduction Rights and on Guarantees of their Realization of July&nbsp;4, 2015 No. 148, Law on status of medical worker of May 28, 2013 No. 81 and other relevant applicable laws in Kyrgyzstan, which enables consumers and patients to file suits more easily against healthcare service providers. Furthermore, treatment of more complex medical conditions has no guaranteed positive outcome, which subjects it to an increased likelihood of medical malpractice suits. Such lawsuits could result in hefty compensation payments or damage to NewGenIvf&rsquo;s reputation, which may have a material adverse effect on its business, financial condition, results of operations and prospects.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Meanwhile, Thailand is considering
enacting a Patient Protection Bill &nbsp;(the &ldquo;Bill&rdquo;). The Bill, if issued, is intended to alleviate disputes between patients
and healthcare providers, which have an impact on the healthcare system in Thailand as a whole. The compensation outlined in the Bill
will assist patients in claiming damages, thereby fostering a positive relationship between patients and healthcare providers. Consequently,
the rate of disputes is expected to decrease. The provisions under the Bill would require healthcare providers to compensate patients
in a timely manner, sometimes without requiring proof of wrongdoing. The Bill also contemplates setting up a patient protection fund for
damages to patients pursuant to which healthcare providers have to make mandatory contributions according to the rules determined by a
patient protection committee. Failure by it to comply with applicable rules and regulations could result in penalties, the loss of regulatory
permits and damage to NewGenIvf&rsquo;s business reputation, each of which could have a material adverse effect on its financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Furthermore, the Protection of A Child
Born By Medically Assisted Reproductive Technology Act B.E. 2558 (2015)&nbsp;of Thailand was promulgated with the intention to appropriately
designate the legitimate parenthood status of a child born using medically assisted reproductive technology and regulate any medical scientific
research on embryology and medically assisted reproductive technologies to prevent the misuse of medically assisted reproductive technologies.
NewGenIvf is therefore under the supervision of a Committee of the Protection for Children Born through Medically Assisted Reproductive
Technology, which is a committee established to control, inspect, supervise and formulate various policies relating to such acts. In Cambodia
and Kyrgyzstan, all health establishments, including private medical clinics, are under the supervision of the Cambodia MOH and the Ministry
of Health of Kyrgyzstan, respectively, which each governs and regulates the operation of medical clinics and activities of medical practitioners
in respective countries. In particular, the Medical Council of Cambodia, Cambodian Council of Nurses, Cambodian Midwives Council and The
Pharmaceutical Council of Cambodia, all assist the Cambodia MOH to supervise and monitor the practice of health professionals in Cambodia.
IVF/embryo implant/transfer activities are subject to an approval by the Cambodia MOH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Privacy and Security Requirements. </I></B>There are numerous laws and regulations related to the privacy and security of health information in each country. In particular, regulations promulgated pursuant to the Personal Data Protection Act B.E. 2562 (2019)&nbsp;of Thailand (&ldquo;PDPA&rdquo;), Law on Data of Personal Character of April&nbsp;14, 2008 No. 58 of Kyrgyzstan (&ldquo;Data Protection Law&rdquo;), as well as Regulation of Registration of Personal Data Holders (Owners) approved by the Resolution of the Cabinet of Ministers of KR of November&nbsp;18, 2022, Offences Code No. 128 of October&nbsp;28, 2021 of Kyrgyzstan establish privacy and security standards in each country that limit the collection, use, and/ or disclosure of certain individually identifiable health information, whether directly or indirectly (excluding the information of the deceased person) and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. The privacy regulations established under the PDPA and Data Protection Law also provide patients with rights related to understanding and controlling how their protected health information is collected, used and/ or disclosed. As a provider of services to entities subject to the PDPA and Data Protection Law, NewGenIvf is directly subject to certain provisions of the regulations. To the extent permitted by applicable privacy regulations and contracts with its clients, NewGenIvf is permitted to use and disclose protected health information to perform its services and for other limited purposes, but other uses and disclosures, such as marketing communications, require written authorization from the patient or must meet an exception specified under the privacy regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">NewGenIvf also has downstream entities
which provide it with services and are also subject to applicable regulations. If NewGenIvf or any of its downstream entities are unable
to properly protect the privacy and security of protected health information entrusted to it, it could be found to have breached its contracts
with its clients and be subject to investigation by the relevant supervision institution, i.e., the Office of the Personal Data Protection
Committee of Thailand (the Government Authority under the PDPA), the Cambodia MOH and the State Data Protection Agency under the Cabinet
of Ministers of Kyrgyzstan (the &ldquo;Agency&rdquo;). In the event the Office of the Personal Data Protection Committee or the Agency
finds that NewGenIvf has failed to comply with applicable privacy and security standards, it could face civil, criminal, and/ or administrative
penalties. In addition, the Office of the Personal Data Protection Committee performs compliance audits in order to proactively enforce
the privacy and security standards. The Office of the Personal Data Protection Committee has become an increasingly active regulator and
has signaled its intention to continue this trend. The Office of the Personal Data Protection Committee has the discretion to impose penalties
and may require companies to enter into resolution agreements and corrective action plans which impose ongoing compliance requirements.
The Office of the Personal Data Protection Committee&rsquo;s enforcement activity, or audit related to incident regarding it or its downstream
entity, can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal
resources. Although NewGenIvf has implemented and maintain policies, processes and compliance program infrastructure to assist it in complying
with these laws and regulations and its contractual obligations, NewGenIvf cannot provide assurance regarding how these laws and regulations
will be interpreted, enforced or applied to its operations. In associated with enforcement activities and potential contractual liabilities,
its ongoing efforts to comply with evolving laws and regulations might also require it to make costly system purchases and/or modifications
or otherwise divert significant resources to compliance initiatives from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9679;</I></B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other Privacy and Security Requirements. </I></B>In addition, numerous other laws govern the collection, dissemination, use, access to and confidentiality of personal information. For example, the Law on E-Commerce of Cambodia (2019)&nbsp;places an obligation on those who electronically store private information to use all means to ensure that the information is protected by security safeguards in every reasonable circumstance to avoid the loss, access, use, modification, leakage, or disclosure of the information, except with the consent of the data owner or other lawfully authorized party. The Law on E-Commerce also prohibits individuals from dishonestly accessing, downloading, copying, extracting, leaking, deleting, modifying, or otherwise interfering with data stored by other persons. Applicable laws are contributing to increased enforcement activity and may also be subject to interpretation by various courts and other governmental authorities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Certain of NewGenIvf&rsquo;s solutions
and services involve the transmission and storage of client data in various jurisdictions, which subjects the operation of those solutions
and services to privacy or data protection laws and regulations in those jurisdictions. While NewGenIvf believes those solutions and services
comply with current regulatory and security requirements in the jurisdictions in which it provides these solutions and services, there
can be no assurance that such requirements will not change or that it will not otherwise be subject to legal or regulatory actions. The
laws and regulations are rapidly evolving and changing, and could have an adverse impact on its operations. These laws and regulations
are subject to uncertainty in how they may be interpreted and enforced by government authorities and regulators. The costs of compliance
with, and the other burdens imposed by, these and other laws or regulatory actions may increase its operational costs, prevent it from
providing its solutions, and/or impact its ability to invest in or jointly develop its solutions. NewGenIvf also may face audits or investigations
by one or more government agencies relating to its compliance with these laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">An adverse outcome under any such investigation
or audit could result in fines, penalties, other liability, or could result in adverse publicity or a loss of reputation, and adversely
affect NewGenIvf&rsquo;s business. Any failure or perceived failure by it or by NewGenIvf&rsquo;s solutions to comply with these laws
and regulations may subject it to legal or regulatory actions, damage its reputation or adversely affect its ability to provide its solutions
in the jurisdiction that has enacted the applicable law or regulation. Moreover, if these laws and regulations change, or are interpreted
and applied in a manner that is inconsistent with its policies and processes or the operation of its solutions NewGenIvf may Need to expend
resources in order to change its business operations, policies and processes or the manner in which it provides its solutions. This could
adversely affect NewGenIvf&rsquo;s business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data Protection and Breaches. </I></B>In recent&nbsp;years, there have been a number of well-publicized data breaches involving the improper dissemination of personal information of individuals both within and outside of the healthcare industry. Pursuant to the applicable data protection law of Thailand, the PDPA requires businesses to notify the data subjects and/or the government authorities upon the occurrence of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. Each country also constantly amending existing laws, requiring attention to frequently changing regulatory requirements. Most countries require holders of personal information to maintain safeguards and take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals. In some countries, these laws are limited to electronic data, but they increasingly are enacting or considering stricter and broader requirements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Despite NewGenIvf&rsquo;s security
management efforts with respect to physical and technological safeguards, employee training, vendor (and sub-vendor) controls and contractual
relationships, its infrastructure, data or other operation centers and systems used in its business operations, including the internet
and related systems of its vendors (including vendors to whom NewGenIvf outsources data hosting, storage and processing functions) are
vulnerable to, and may from time to time experience, unauthorized access to data and/or breaches of confidential information due to a
variety of causes. Techniques used to obtain unauthorized access to or compromise systems change frequently, are becoming increasingly
sophisticated and complex, and are often not detected until after an incident has occurred. As a result, NewGenIvf might not be able to
anticipate these techniques, implement adequate preventive measures, or immediately detect a potential compromise. If its security measures,
some of which are managed by third parties, or the security measures of its service providers or vendors, are breached or fail, it is
possible that unauthorized or illegal access to or acquisition, disclosure, use or processing of personal information, confidential information,
or other sensitive client or employee data, including protected health information, may occur. A security breach or failure could result
from a variety of circumstances and events, including third-party action, human negligence or error, malfeasance, employee theft or misuse,
phishing and other social engineering schemes, computer viruses, attacks by computer hackers, failures during the process of upgrading
or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, and catastrophic
events. If NewGenIvf&rsquo;s security measures, or those of its service providers or vendors, were to be breached or fail, its reputation
could be severely damaged, adversely affecting client or investor confidence. As a result, clients may curtail their use of or stop using
its offering and its business may suffer. In addition, NewGenIvf could face litigation, damages for contract breach, penalties and regulatory
actions for violation of laws or regulations applicable to data protection and significant costs for remediation and for measures to prevent
future occurrences. In addition, any potential security breach could result in increased costs associated with liability for stolen assets
or information, repairing system damage that may have been caused by such breaches, incentives offered to clients or other business partners
in an effort to maintain the business relationships after a breach and implementing measures to prevent future occurrences, including
organizational changes, deploying additional personnel and protection technologies, training employees and engaging third-party experts
and consultants. Negative publicity may also result from real, threatened or perceived security breaches affecting it or its industry
or clients, which could cause it to lose clients or partners and adversely affect its operations and future prospects. NewGenIvf may not
carry insurance or maintain coverage sufficient to compensate for all liability and such insurance may not be available for renewal on
acceptable terms or at all, and in any event, insurance coverage would not address the reputational damage that could result from a security
incident.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fraud and Abuse Laws. </I></B>NewGenIvf may be impacted directly and indirectly by certain fraud and abuse laws, including the Act Supplementing the Constitution Relating to the Prevention and Suppression of Corruption B.E. 2561 (2018)&nbsp;of Thailand, the Penal Code of Thailand, the Criminal Code of Cambodia, the Offences Code of October&nbsp;28, 2021 No. 128 of Kyrgyzstan, the Criminal Code of October&nbsp;28, 2021, No. 17 of Kyrgyzstan and the Law on prevention of corruption of August&nbsp;8, 2021 No. 153 of Kyrgyzstan. Because the solutions and services NewGenIvf provides are not reimbursed by government healthcare payors, such fraud and abuse laws generally do not directly apply to its business, however, some laws may be applicable. The laws, regulations and other requirements in this area are both broad and vague and judicial interpretation can also be inconsistent. NewGenIvf reviews its practices with regulatory experts in an effort to comply with all applicable laws, regulatory and other requirements. However, NewGenIvf is unable to predict how these laws, regulations and other requirements will be interpreted or the full extent of their application, particularly to services that are not directly reimbursed by healthcare programs. Any determination by a regulatory authority that any of NewGenIvf&rsquo;s activities or those of its clients or vendors violate any of these laws or regulations could subject NewGenIvf to civil or criminal penalties, require it to enter into corporate integrity agreements or similar agreements with ongoing compliance obligations, disqualify it from providing services to clients and/or have an adverse impact on its business, financial condition and results of operations. Even an unsuccessful challenge by a regulatory authority of NewGenIvf&rsquo;s activities could result in adverse publicity and could require a costly response from it.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Consumer Protection Laws. </I></B>Consumer protection laws are being applied increasingly by the Office of the Consumer Protection Board in Thailand and by the Cambodia Ministry of Health to regulate the collection, use, storage and disclosure of personal or health information, through websites or otherwise, and, in Cambodia, by the Consumer Protection Competition and Fraud Repression Directorate-General, to regulate the presentation of website content. Courts may also adopt the standards for fair information practices, which concern consumer notice, choice, security and access.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restrictions on Communication. </I></B>Communications with NewGenIvf&rsquo;s clients increasingly may be subject to and restricted by laws and regulations governing communications via telephone, fax, text, and email. NewGenIvf also uses email and social media platforms as marketing tools. For example, NewGenIvf maintains social media accounts. As laws and regulations rapidly evolve to govern the use of these platforms and devices, the failure by it, its employees or third parties acting at its direction to abide by applicable laws and regulations in the use of these platforms and devices could adversely impact its business, financial condition and results of operations or subject it to fines or other penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9679;</I></B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advertisement Laws. </I></B>NewGenIvf&rsquo;s advertisement and announcements, in particular, the messages releasing on the Internet related to medical facilities may subject to the laws and regulations of relevant jurisdictions (and potential prohibition in Cambodia on commercial advertisement of private medical services).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">For example, in Thailand, NewGenIvf
shall apply for and obtain the approval and/ or pre-approval from the relevant authority for the images, and text used in advertisements
or announcements which shall be in accordance with the Medical Facility Act B.E. 2541 (1998)&nbsp;(and its amendments) and the Notification
of the Department of Health Services Support on Rules, Procedures, Conditions, and Costs of Advertisements or Announcements of Healthcare
Facilities B.E. 2562 (2019)&nbsp;(and its amendments) and the Operational Manual for Approval of Advertisements or Announcements relating
to Healthcare Facilities. If such approval was not obtained by NewGenIvf, it could lead to significant liabilities and consequences, which
could adversely impact NewGenIvf&rsquo;s business, financial condition and results of operations or subject its sales and marketing director
to personal liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">For Cambodia, Prakas 028 on Advertisement
of Private Medical, Paramedical and Medical Aid Practices dated August&nbsp;23, 2004 issued by the Cambodia MOH prohibits commercial advertising
of private medical services. Advertisement of private health care services is only allowed for any advertisements within the professional
framework not affecting the ethics of private medical services and such advertisement requires a permit from the Cambodia MOH.&nbsp;In
addition, the Royal Government of Cambodia has recently issued Sub-Decree 232 on the Management of Commercial Advertisements of Goods
and Services on November&nbsp;4, 2022 to provide the legal framework for the management of commercial advertising of goods and services
for all types, forms and means in Cambodia. In light of this Sub-Decree, in addition to the permit requirement of the Cambodia MOH, a
person wishing to advertise their goods and/or services in Cambodia may also apply for a compliance certificate from the Ministry of Commerce,
which certifies that advertising text or content complies with the Law on Consumer Protection or other applicable regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">For Kyrgyzstan, the Law on Advertisements
of December&nbsp;24, 1998, No. 155 requires that if the activities of the advertiser subject to licensing, the advertisement of such advertiser
must include the license number and the name of the authority that issued the license, except for radio advertising, where it is sufficient
to state &ldquo;licensed activity&rdquo; on the territory of Kyrgyzstan. In advertising goods (including works and services), and other
objects of advertising, cost indicators must be stated in the national currency. There are also other requirements established in relation
to size, frequency, cost and other features of advertisements via different types of media.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New laws and regulations relevant
to the fertility services may be introduced in the future, or the current applicable regulations may otherwise be amended or replaced
requiring the assisted reproductive medical facilities in its network to conduct business with additional oversight and regulatory compliance.
If NewGenIvf fails to obtain the necessary licenses, permits and approvals, NewGenIvf may be subject to fines, confiscation of revenues
generated from incompliance operations, or the suspension of relevant operations. NewGenIvf may also experience adverse publicity arising
from such non-compliance with government regulations that negatively impacts its brand. NewGenIvf may experience difficulties or failures
in obtaining the necessary approvals, licenses, and permits for new spaces or new service offerings. If NewGenIvf fails to obtain the
material licenses, NewGenIvf&rsquo;s business activities could be severely delayed. In addition, there can be no assurance that NewGenIvf
will be able to obtain, renew, and/or convert all of the approvals, licenses, and permits required for its existing business operations
upon their expiration in a timely manner, in a cost-efficient manner or at all, which could adversely affect NewGenIvf&rsquo;s business
operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, considerable
uncertainties exist in relation to the interpretation and implementation of existing and future laws and regulations governing NewGenIvf&rsquo;s
business activities. NewGenIvf could be found not in compliance with any future laws and regulations or of the laws and regulations currently
in effect due to changes in the relevant authorities&rsquo; interpretation of those laws and regulations. It is possible that different
interpretations or enforcement of these regulations could subject the current or past practices to allegations of impropriety or illegality
or require the medical facilities in its network to implement changes in the facilities, equipment, personnel or services, or increase
capital expenditure and operating expenses. If NewGenIvf fails to complete, obtain, or maintain any of the required licenses or approvals
or make the necessary filings, NewGenIvf may be subject to various penalties, such as confiscation of unlawful gains, the imposition of
fines, revocation of licenses, and the discontinuation or restriction of NewGenIvf&rsquo;s operations. Any such penalties or changes in
policies, regulations, or enforcement by government authorities may disrupt NewGenIvf&rsquo;s operations and materially and adversely
affect NewGenIvf&rsquo;s business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Legal or regulatory restriction, government
regulation, industry standards and other requirements create risks and challenges with respect to NewGenIvf&rsquo;s compliance efforts
and its business strategies and could adversely impact NewGenIvf&rsquo;s business and limited the growth of NewGenIvf&rsquo;s operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare industry is
highly regulated and subject to frequently changing laws, regulations, industry standards and other requirements. Many healthcare laws
and regulations are complex, and their application to specific solutions, services and relationships may not be clear. In particular,
many existing healthcare laws and regulations, when enacted, did not anticipate the solutions and services that NewGenIvf provides, and
these laws and regulations may be applied to its solutions and services in ways that NewGenIvf does not anticipate. Efforts to reform
or revise aspects of the healthcare industry or to revise or create additional legal or and regulatory requirements could impact its operations,
the use of its solutions and services, and its ability to market new solutions and services, or could create unexpected liabilities for
it. NewGenIvf also may be impacted by laws, industry standards and other requirements that are not specific to the healthcare industry,
such as consumer protection laws and payment card industry standards. These requirements may impact its operations and, if not followed,
could result in fines, penalties and other liabilities and adverse publicity and injury to its reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a risk that existing
or future laws may be interpreted in a manner that is not consistent with the healthcare industry&rsquo;s current practices and could
have an adverse effect on NewGenIvf&rsquo;s business, financial condition, results of operations and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advertising or offering of gender selection
services in certain jurisdictions in which NewGenIvf operates could expose the Company and its directors and executive officers to significant
legal and regulatory risks, including potential penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The marketing or provision
of gender selection services in certain jurisdictions in which we operate is subject to stringent legal restrictions. In particular, in
Hong Kong, under the Human Reproductive Technology Ordinance (Cap. 561 of the Laws of Hong Kong), gender selection for non-medical purposes
is prohibited. Violation of these provisions may result in criminal liability. Any person found guilty of advertising or offering gender
selection services in Hong Kong may, on a first conviction, face a fine of up to HKD 25,000 and imprisonment for up to 6 months. If we,
our representatives, or our sub-contractors inadvertently violate, or are alleged to violate, these laws, we could face significant financial
penalties, reputational harm, and potential legal proceedings. Even if we do not directly market our gender selection services in Hong
Kong, promotional activities conducted by third parties, affiliates, or other associates on our behalf could also expose us to liability
under these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, increased scrutiny
or enforcement actions by regulatory authorities in the jurisdictions in which we operate, including Hong Kong, could result in adverse
publicity, increased compliance costs, and significant disruption of our business operations in the region. As a result, any failure to
comply with applicable laws and regulations related to gender selection services could have a material adverse effect on our business,
financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Significant tariffs or other restrictions
imposed on imports by the U.S. and related countermeasures taken by impacted countries could have a material adverse effect on our operations
and financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If significant tariffs or
other restrictions are imposed on imports by the U.S. and related countermeasures are taken by foreign countries, our business, including
results of operations, cash flows and financial condition, may be adversely affected. In January 2025, during the initial days of U.S.
President Trump&rsquo;s second term, the U.S. announced the imposition of additional substantial tariffs on imports from various countries,
including China, Canada and Mexico, and the subject countries have imposed or indicated their intention to impose counter measures. In
February 2025, the U.S. imposed tariffs of 10% on all imported goods from China, followed by an additional 10% tariff in March 2025. The
U.S. also imposed a 25% tariff on all steel and aluminum imports, beginning in March 2025. On February 13, 2025, President Trump ordered
his trade advisers to come up with &ldquo;reciprocal&rdquo; tariffs on U.S. trade partners to retaliate against taxes, tariffs, regulations
and subsidies and on April 2, 2025, announced new tariffs on many U.S. trading partners, including a universal baseline tariff of 10%
on all imported goods, and country specific tariffs such as an additional 34% tax on imports from China (leading to an effective rate
of 54% when combined with existing tariffs) and 20% on products from the E.U. Specific products that are being tariffed, such as automobiles,
were to be exempted from the new tariffs, and tariffs on products such as pharmaceutical drugs were to be announced at a later date. Following
a period of market turbulence, on April 9, 2025, President Trump announced a 90-day pause to the tariffs announced on April 2, 2025 for
most countries. Countries subject to the pause on the tariffs are still to be subject to the baseline 10% tariff. This consequently lowers
the tariff rate for the E.U., Japan, and South Korea, among other countries. However, U.S. President Trump announced an increased tariff
rate against Chinese imports of a minimum 145%. These and other tariffs and countermeasures could increase the cost of equipment necessary
for our operations, disrupt global supply chains and create additional operational challenges. Additionally, ongoing trade tensions and
uncertainty regarding future trade policies could negatively impact global economic conditions and consumer confidence, further affecting
our business performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any litigation against NewGenIvf could be
costly and time-consuming to defend and could harm its business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has in the past
and may in the future become subject to regulatory actions, litigation, disputes, or claims of various types, legal proceedings and claims
that arise in the ordinary course of business, such as claims brought by its clients or vendors in connection with commercial disputes
or employment claims made by its current or former employees, as well as claims brought by relevant regulatory authorities or NewGenIvf&rsquo;s
competitors, patients, employees, or other third parties against NewGenIvf. NewGenIvf is unable to predict the outcome of any of these
legal proceedings. Such regulatory actions, disputes, allegations, complaints, or legal proceedings may damage NewGenIvf&rsquo;s reputation,
evolve into litigation, or otherwise have a material adverse impact on NewGenIvf&rsquo;s reputation and business. Such proceedings might
result in substantial costs, regardless of the outcome, and may significantly divert management&rsquo;s attention and resources from operating
NewGenIvf&rsquo;s business, which might seriously harm its business, financial condition and results of operations. Insurance might not
cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims, and might not continue
to be available on terms acceptable to it. A claim brought against it that is uninsured or underinsured could result in unanticipated
costs, potentially harming its business, financial condition and results of operations. The outcomes of actions NewGenIvf institutes may
not be successful or favorable to NewGenIvf. Lawsuits against NewGenIvf may also generate negative publicity that significantly harms
NewGenIvf&rsquo;s reputation, which may adversely affect NewGenIvf&rsquo;s client base. NewGenIvf may also need to pay damages or settle
lawsuits with a substantial amount of cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acquisitions, strategic investments, partnerships,
or alliances could be difficult to identify, pose integration challenges, divert the attention of management, disrupt NewGenIvf&rsquo;s
business, dilute stockholder value, and adversely affect its business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf may in the future
seek to acquire or invest in businesses, joint ventures, products and services, or technologies that it believes could complement or expand
its platform, enhance its technical capabilities, or otherwise offer growth opportunities. Any such acquisition or investment may divert
the attention of management and cause NewGenIvf to incur various expenses in identifying, investigating and pursuing suitable opportunities,
whether or not the transactions are completed, and may result in unforeseen operating difficulties and expenditures. In particular, NewGenIvf
may encounter difficulties assimilating or integrating the businesses, technologies, products and services, personnel or operations of
the acquired companies, particularly if the key personnel of the acquired company choose not to work for it, they are operationally difficult
to integrate, or NewGenIvf has difficulty retaining the clients of any acquired business due to changes in ownership, management or otherwise.
These transactions may also disrupt its business, divert its resources, and require significant management attention that would otherwise
be available for development of its existing business and may not benefit NewGenIvf&rsquo;s business strategy, may not generate sufficient
revenues to offset the associated acquisition costs or may not otherwise result in the intended benefits. Any such transactions that NewGenIvf
is able to complete may not result in any synergies or other benefits it had expected to achieve, which could result in impairment charges
that could be substantial. In addition, NewGenIvf may not be able to find and identify desirable acquisition targets or business opportunities
or be successful in entering into an agreement with any particular strategic partner. These transactions could also result in dilutive
issuances of equity securities or the incurrence of debt, which could adversely affect its results of operations. In addition, if the
resulting business from such a transaction fails to meet NewGenIvf&rsquo;s expectations, or it fails to successfully integrate such businesses
into its own, its business, financial condition and results of operations may be adversely affected or it may be exposed to unknown risks
or liabilities. Even when NewGenIvf identifies an appropriate acquisition or investment target, it may not be able to negotiate the terms
of the acquisition or investment successfully, obtain financing for the proposed transaction, or integrate the relevant businesses into
its existing business and operations. Strategic investments or acquisitions will involve risks commonly encountered in business relationships,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in assimilating and integrating the operations, personnel, systems, data, technologies, products and services of the acquired business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability of the acquired technologies, products or businesses to achieve expected levels of revenue, profitability, productivity or other benefits;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in retaining, training, motivating and integrating key personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management&rsquo;s time and resources from NewGenIvf&rsquo;s normal daily operations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in maintaining uniform standards, controls, procedures and policies within the combined organizations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in retaining relationships with customers, employees and suppliers of the acquired business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks of entering markets in which NewGenIvf have limited or no prior experience;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory risks, including remaining in good standing with existing regulatory bodies or receiving any necessary pre-closing or post-closing approvals, as well as being subject to new regulators with oversight over an acquired business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assumption of contractual obligations that contain terms that are not beneficial to NewGenIvf, require it to license or waive intellectual property rights or increase its risk for liability;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to further successfully develop the acquired technology;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability for activities of the acquired business before the acquisition, including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities and other known and unknown liabilities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential disruptions to NewGenIvf&rsquo;s ongoing businesses; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected costs and unknown risks and liabilities associated with strategic investments or acquisitions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if the transaction is
consummated, NewGenIvf may only have limited control over the companies in which it only has minority stake, it cannot ensure that these
companies will always comply with applicable laws and regulations in their business operations. Non-compliance of regulatory requirements
by NewGenIvf&rsquo;s investees may cause substantial harm to NewGenIvf&rsquo;s reputations and the value of NewGenIvf&rsquo;s investment.
In addition, if the resulting business from such a transaction fails to meet NewGenIvf&rsquo;s expectations, or it fails to successfully
integrate such businesses into its own, its business, financial condition and results of operations may be adversely affected or it may
be exposed to unknown risks or liabilities. If NewGenIvf is unable to effectively address these challenges, its ability to execute acquisitions
as a component of its long-term strategy will be impaired, which could have an adverse effect on its growth. As a result of the above,
NewGenIvf&rsquo;s strategies may not be successfully implemented beyond the current markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any investment might not achieve
the synergies, operational or financial benefits it expects and may adversely impact NewGenIvf&rsquo;s operating results. In addition,
NewGenIvf cannot assure you that any future investment in or acquisition of new businesses or technology will lead to the successful development
of new or enhanced products and services or that any new or enhanced products and services, if developed, will achieve market acceptance,
or prove to be profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in NewGenIvf&rsquo;s effective tax
rate or tax liability may have an adverse effect on its results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s effective
tax rate could increase due to several factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the relative amounts of income before taxes in the various jurisdictions in which NewGenIvf operates that have differing statutory tax rates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in tax laws, tax treaties, and regulations or the interpretation of them;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to its assessment about its ability to realize its deferred tax assets that are based on estimates of its future results, the prudence and feasibility of possible tax planning strategies, and the economic and political environments in which NewGenIvf does business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome of future tax audits, examinations, or administrative appeals; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations or adverse findings regarding its ability to do business in some jurisdictions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these developments
could have an adverse effect on its results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s reported financial results
may be adversely affected by changes in accounting principles generally accepted in the U.S.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A change in the U.S. accounting
principles could have a significant effect on NewGenIvf&rsquo;s reported results of operations and could affect the reporting of transactions
already completed before the announcement of a change.The adoption of new or revised accounting principles may require it to make changes
to its systems, processes and control, which could have a significant effect on its reported financial results, cause unexpected financial
reporting fluctuations, retroactively affect previously reported results or require it to make costly changes to its operational processes
and accounting systems upon or following the adoption of these standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If NewGenIvf&rsquo;s estimates or judgments
relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the amounts reported in
NewGenIvf&rsquo;s consolidated financial statements and accompanying notes appearing elsewhere in this prospectus. NewGenIvf bases its
estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided
in the section titled &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations of NewGenIvf&nbsp;&mdash;&nbsp;Critical
Accounting Policies, Judgments and Estimates</I>.&rdquo; The results of these estimates form the basis for making judgments about the
carrying values of assets, liabilities and equity, and the amount of revenue and expenses that are not readily apparent from other sources.
Significant estimates and judgments used in preparing NewGenIvf&rsquo;s consolidated financial statements include those related to the
determination of fair value of its Class A Ordinary Shares and Warrants and revenue recognition relating to services rendered but for
which no claim has yet been reported, among other things. NewGenIvf&rsquo;s results of operations may be adversely affected if its assumptions
change or if actual circumstances differ from those in its assumptions, which could cause its results of operations to fall below the
expectations of securities analysts and investors, resulting in a decline in the market price of its Class A Ordinary Shares and Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf is subject to anti-corruption,
anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it to criminal or civil liability
and harm its business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf is subject to the
Anti-Money Laundering Act B.E. 2542 (1999)&nbsp;of Thailand, the Act Supplementing the Constitution Relating to the Prevention and Suppression
of Corruption B.E. 2561 (2018)&nbsp;of Thailand, and the Penal Code of Thailand, domestic bribery laws, and other anticorruption and anti-money
laundering laws in the countries in which it conducts activities. Anti-corruption and anti-bribery laws have been enforced aggressively
in recent&nbsp;years and are interpreted broadly to generally prohibit companies, their employees and their third-party intermediaries
from authorizing, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private
sector. If NewGenIvf expands its business and sales and to the public sector, it may engage with business partners and third-party intermediaries
to market its services and to obtain for it the necessary permits, licenses, and other regulatory approvals. In addition, NewGenIvf or
its third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state-owned
or affiliated entities. NewGenIvf can be held liable for the corrupt or other illegal activities of these third-party intermediaries,
its employees, representatives, contractors, partners and agents, even if it does not explicitly authorize such activities. Detecting,
investigating, and resolving actual or alleged violations of anti-corruption laws can require a significant diversion of time, resources,
and attention from senior management. In addition, noncompliance with anti-corruption, anti-bribery, or anti-money laundering laws could
subject it to whistleblower complaints, investigations, prosecution, enforcement actions, sanctions, settlements, fines, damages, other
civil or criminal penalties or injunctions, suspension or debarment from contracting with certain persons, reputational harm, adverse
media coverage, and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions
are imposed, or if NewGenIvf does not prevail in any possible civil or criminal proceeding, its business, financial condition and results
of operations could be harmed. In addition, responding to any action will likely result in a materially significant diversion of management&rsquo;s
attention and resources and significant defense costs and other professional fees, which could adversely affect its business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s digital strategy is subject
to financial, operational and regulatory risks on investing Solana.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Acquiring Solana (SOL) exposes
the company to financial, operational, and regulatory risks, including extreme price volatility, potential technological failures (such
as network outages or security exploits), uncertain and evolving global regulations that may classify SOL as a security or restrict its
use, counterparty risks if held through exchanges or custodians, liquidity constraints during market stress, and the inherent challenges
of securely managing digital assets, any of which could result in substantial or total loss of the investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NewGenIvf&rsquo;s investment in residential
market of United Arab Emirates is exposed to significant market risks. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating a residential property
development business in the United Arab Emirates carries significant risks, primarily driven by market volatility and potential oversupply,
particularly in the area of Ras Al Khaimah&rsquo;s Beach District. Property values and rental yields are highly sensitive to fluctuations
in oil prices, global economic conditions, and regional geopolitics, leading to sharp boom-bust cycles. Intense competition from new developments
can rapidly saturate specific submarkets, driving down rents and occupancy rates, while regulatory changes (such as adjustments to rental
increase caps, visa rules, or ownership laws) can unexpectedly impact profitability and operational models. Furthermore, reliance on expatriate
tenants creates vulnerability to shifts in population demographics, employment trends, and government policies affecting residency, alongside
inherent operational challenges including management costs, tenant defaults, and maintaining asset quality in a competitive environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more information about
our SEC filings, please see &ldquo;<I>Where You Can Find More Information</I>&rdquo; and &ldquo;<I>Incorporation by Reference</I>.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the statements made
under &ldquo;<I>Prospectus Summary</I>,&rdquo; &ldquo;<I>Risk Factors</I>,&rdquo; &ldquo;<I>Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations</I>,&rdquo; &ldquo;<I>Business</I>&rdquo; and elsewhere in this prospectus constitute
forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;predicts,&rdquo; &ldquo;potential&rdquo; &ldquo;intends&rdquo; or &ldquo;continue,&rdquo; or the negative of these terms or other
comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or
developments that we intend, expect, project, believe or anticipate will or may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on
assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Important factors that could
cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements
include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our planned level of revenues and capital expenditures;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to market and sell our products and services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our plans to continue to invest in research and development to develop technology for both existing and new products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain our relationships with suppliers, manufacturers and other partners;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain or protect the validity of our intellectual property and know-how;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to retain key executive members;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to internally develop and protect new inventions and intellectual property;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to expose and educate the industry about the use of our services and products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding our tax classifications;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interpretations of current laws and the passages of future laws; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of the coronavirus (COVID-19) pandemic and resulting government actions on us, our manufacturers, suppliers and facilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements are only
current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry&rsquo;s
actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
statements. We discuss many of these risks in this prospectus in greater detail under the heading &ldquo;<I>Risk Factors</I>&rdquo; and
elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance
or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as
a result of new information, future events or otherwise, after the date of this prospectus.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers and directors as of the date of this prospectus.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid; padding-right: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 56%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wing Fung Alfred Siu</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors, Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hei Yue Tina Fong</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chief Marketing Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hok Man Jefferson Au</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florianna Ann Chi Wan Chan</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chun Wa Tam</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ho Fai Chung</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Wing Fung Alfred Siu</I></B><I>.&nbsp;</I>NewGenIvf&rsquo;s
co-founder, Mr. Wing Fung Alfred Siu, has served as the Chairman of the Board and the Chief Executive Officer of NewGenIvf (before the
Closing, Legacy NewGenIvf) since 2019. Prior to establishing Legacy NewGenIvf in 2019, Mr.&nbsp;Siu served as a director of First Fertility
PGS Center Co., Ltd. since 2014. Mr.&nbsp;Siu received his master&rsquo;s degree in science and bachelor&rsquo;s degree in science from
Stanford University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Hei Yue Tina Fong.&nbsp;</I></B>Ms.
Fong has served as a Director and the Chief Marketing Officer of NewGenIvf (before the Closing, Legacy NewGenIvf) since 2019. Prior to
establishing NewGenIvf in 2019, Ms. Fong served as a director of First Fertility PGS Center Co., Ltd. since 2014. Ms. Fong received her
bachelor&rsquo;s degree in marketing from Indiana University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Ho Fai Chung</I></B>.
Mr. Chung has served as NewGenIvf&rsquo;s Chief Financial Officer since October 10, 2024. Mr. Chung has over 30 years of working experience
in Asia. He is a certified public accountant in the U.S. Born in Hong Kong, Mr. Chung holds a Bachelor of Law degree from University of
London and a Master&rsquo;s degree in Accounting and Finance from Lancaster University (UK). Mr. Chung also holds a Master&rsquo;s degree
in International and Public Affairs from Hong Kong University. He started his career with Price Waterhouse (&ldquo;PwC&rdquo;) in Hong
Kong and then joined a number of companies to take up financial control as well as general management jobs in industries including fashion,
office products, telecommunications/internet and advertising. He had worked and based in China, Taiwan, Singapore and Malaysia before
and had extensive regional financial controlling exposure in Asia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Hok Man Jefferson Au</I></B>.
Mr. Au has served as NewGenIvf&rsquo;s independent director since April 3, 2024. Mr. Au has served as the Assistant Financial Controller
and the Company Secretary at Coolpoint Innonism Holding Limited since May 2017 and a director of JWMG CPA Limited, Certified Public Accountants
since August 2014. He previously worked as the audit supervisor at Clement C.W. Chan &amp; Co., Certified Public Accountants from September
2010 to March 2014. Mr. Au obtained his honours diploma in accounting from Hong Kong Shue Yan University (formerly known as Hong Kong
Shue Yan College) and received his Master of Science in professional accountancy from the University of London. Mr. Au is a member of
the Hong Kong Institute of Certified Public Accountants and an associate of the Association of Chartered Certified Accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Florianna Ann Chi Wan
Chan</I></B> has served as NewGenIVF&rsquo;s independent director since April 15, 2025. Ms Chan has over 20 years of experience in project
management, real estate development, and luxury hospitality, she is a proven leader in driving growth and operational excellence. Since
2015, Ms. Chan has led Lab Concept Company Limited, a subsidiary of The Lane Crawford Joyce Group, where she successfully restructured
operations, spearheaded rebranding, and digitized processes, achieving significant revenue growth. Previously, she held senior roles at
VCC Company Limited, Eton Properties, and Crown Macau, excelling in real estate development, marketing, and VIP services. She holds a
Bachelor of Hospitality Management from Central Queensland University in Australia and an Advanced Diploma from William Angliss Institute
of TAFE. Fluent in Cantonese, Mandarin, and English, Ms. Chan brings a deep understanding of Asia Pacific markets and a strategic vision
that will drive the Company&rsquo;s continued growth and success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Tam Chun Wa</I></B>.
Mr. Tam has served as NewGenIvf&rsquo;s independent director since November 29, 2024. Mr. Tam is currently the chief financial officer,
the company secretary, and the authorised representative of China Asia Valley Group Limited since December 2023. Mr. Tam was appointed
as an independent non-executive director of Green Energy Group Limited on 24 August 2011. Mr. Tam was also the chief financial officer,
the company secretary and the authorised representative of Perfect Group International Holdings Limited from February 2017 to November
2023. The shares of these three companies are listed on the Main Board of the Stock Exchange with stock codes 63, 979 and 3326 respectively.
He was the executive director of Chinasing Investment Holdings Limited from February 2009 to August 2015, a company whose shares were
listed on the Main Board of Singapore Exchange Limited. Mr. Tam obtained a Master degree of Business Administration from the University
of Sydney. Mr. Tam is also a member of Hong Kong Institute of Certified Public Accountants, CPA (Australia) and Institute of Singapore
Chartered Accountants. Mr. Tam has more than 30 years in the areas of auditing, accounting, tax, investment banking and company secretarial
work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Election of Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers are
appointed by, and serve at the discretion of, the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Wing Fung Alfred Siu and
Ms. Hei Yue Tina Fong are husband and wife. Other than as disclosed in this prospectus, none of the directors or executive officers has
a family relationship as defined in Item 401 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Involvement in Certain
Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the best of our knowledge,
none of our directors or executive officers has, during the past ten years, been involved in any legal proceedings described in subparagraph
(f) of Item 401 of Regulation S-K. Our directors and officers have not been involved in any transactions with us or any of our affiliates
or associates which are required to be disclosed pursuant to the rules and regulations of the SEC.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the amount of compensation, including base salary, discretionary bonus, equity compensation, contractual benefits and contributions to
defined contribution plans, which was paid, earned and/or accrued during the fiscal years ended December 31, 2024 and 2023, for each of
the officers and directors for Legacy NewGenIvf prior to the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024<BR> Compensation<BR> US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023<BR> Compensation<BR> US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Directors and Officers</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Wing Fung Alfred Siu</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">190,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">125,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Hei Yue Tina Fong</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">190,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">125,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">380,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">250,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Board Practices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><B>Committees
of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We established three committees
under the Board: an audit committee (&ldquo;Audit Committee&rdquo;), a Compensation Committee (&ldquo;Compensation Committee&rdquo;) and
a nominating and corporate governance committee (&ldquo;Nominating and Corporate Governance Committee). We have adopted a charter for
each of the three committees. Each committee&rsquo;s members and functions are described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Audit Committee. Our Audit
Committee consists of Mr. Hok Man Jefferson Au (Chairman of Audit Committee), Ms, Florianna Ann Chi Wan Chan, and Mr. Tam Chun Wa. We
have determined that all of these individuals satisfy the &ldquo;independence&rdquo; requirements of NASDAQ Rule 5605 and Rule 10A-3 under
the Exchange Act. Our Board has determined that Mr. Hok Man Jefferson Au qualifies as an audit committee financial expert and has the
accounting or financial management expertise as required under Item 407(d)(5)(ii) and (iii) of Regulation S-K. The audit committee will
oversee our accounting and financial reporting processes and the audits of the financial statements of our company. The Audit Committee
will be responsible for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing clear hiring policies for employees or former employees of the independent auditors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the Board for approval, the appointment, reappointment or removal of the independent auditor, after considering its annual performance evaluation of the independent auditor;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the remuneration and terms of engagement of the independent auditor and pre-approving all auditing and non-auditing services permitted to be performed by the Company&rsquo;s independent auditors at least annually;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining a written report from the Company&rsquo;s independent auditor describing matters relating to its independence and quality control procedures;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with the independent registered public accounting firm any audit problems or difficulties and management&rsquo;s response;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing with the Company&rsquo;s independent auditor, among other things, the audits of the financial statements, including whether any material information should be disclosed, in addition to issues regarding accounting and auditing principles and practices;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving all proposed related party transactions, as defined in Item&nbsp;404 of Regulation&nbsp;S-K under the Securities Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending the financial statements for inclusion within the Company&rsquo;s quarterly earnings releases and to the Board for inclusion in its annual reports;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing the annual audited financial statements with management and the independent registered public accounting firm;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing policies with respect to risk assessment and risk management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the adequacy and effectiveness of the Company&rsquo;s accounting and internal control policies and procedures and any special steps taken to monitor and control major financial risk exposures;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically reviewing and reassessing the adequacy of the committee charter;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving annual audit plans, and undertaking an annual performance evaluation of the internal audit function;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and overseeing procedures for the handling of complaints and whistleblowing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting separately and periodically with management, the internal auditors and the independent registered public accounting firm;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with the Company&rsquo;s code of business conduct and ethics, including reviewing the adequacy and effectiveness of its procedures to ensure proper compliance;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting periodically to the Board; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such other matters that are specifically delegated to the Company&rsquo;s Audit Committee by the Board from time to time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the audit committee&rsquo;s
current charter is available at our corporate website at www.newgenivf.com.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Compensation Committee</I>.
Our Compensation Committee (&ldquo;Compensation Committee&rdquo;) consists of Mr. Wing Fung Alfred Siu, Ms. Hei Yue Tina Fong, and Ms
Florianna Ann Chi Wan Chan. The Chairman of the Compensation Committee is Mr. Siu. The Company has determined that Ms. Chan satisfies
the &ldquo;independence&rdquo; requirements of Rule&nbsp;5605(c)(2)&nbsp;of the Nasdaq Stock Market Listing Rules. The Compensation Committee
assists the Board in reviewing and approving compensation structure, including all forms of compensation relating to the Company&rsquo;s
directors and executive officers. The Company&rsquo;s Chief Executive Officer may not be present at any committee meeting during which
their compensation is deliberated upon. The Compensation Committee is responsible for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and evaluating the Company&rsquo;s executive compensation and benefits policies generally;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending any incentive compensation or equity plans, programs or other similar arrangements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically reviewing and reassessing the adequacy of the Compensation Committee charter;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting compensation consultant, legal counsel or other adviser only after taking into consideration all factors relevant to that person&rsquo;s independence from management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting periodically to the Board; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such other matters that are specifically delegated to the Compensation Committee by the Board from time to time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Compensation
Committee&rsquo;s current charter is available at our corporate website at: www.newgenivf.com.&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Nominating and Corporate
Governance Committee</I>. The Company&rsquo;s Nominating and Corporate Governance Committee consist of Mr. Wing Fung Alfred Siu, Ms. Hei
Yue Tina Fong, and Mr. Hok Man Jefferson Au. The Chairman of the Nominating and Corporate Governance Committee is Mr. Siu. The Company
has determined that Mr. Au satisfies the &ldquo;independence&rdquo; requirements of Rule&nbsp;5605(c)(2)&nbsp;of the Nasdaq Stock Market
Listing Rules. The Nominating and Corporate Governance Committee assists the Board of Directors in selecting individuals qualified to
become the Company&rsquo;s directors and in determining the composition of the Board of Directors and its committees. The Nominating and
Corporate Governance Committee is responsible for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending nominees to the Board for election or re-election to the Board, or for appointment to fill any vacancy or newly created directorships on the Board;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing periodically with the Board the current composition of the Board with regards to characteristics such as judgment, experience, expertise, diversity and background;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the Board of criteria with respect to nomination or appointment of members of its Board of Directors and chairs and members of its committees or other corporate governance matters as may be required pursuant to any SEC or Nasdaq Stock Market Listing Rules, or otherwise considered desirable and appropriate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the Board the names of directors to serve as members of the Audit Committee and the Compensation Committee, as well as of the Nominating and Corporate Governance Committee itself;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically and reassessing the adequacy of the committee charter;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing compliance with the corporate governance guidelines and code of business conduct and ethics; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing and leading the self-evaluation of the Board in its performance and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness as a whole.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Nominating and
Corporate Governance Committee&rsquo;s current charter is available at our corporate website at www.newgenivf.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Duties and Functions
of Directors</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the laws of the British
Virgin Islands, the Company&rsquo;s directors owe fiduciary duties to the Company, including duty to act honestly and in good faith in
what the directors believe to be in the best interests of the company, duty to exercise powers for a proper purpose and directors shall
not act, or agree to act, in a matter that contravenes the BVI Act or the Memorandum and Articles of Association, duty to exercise the
care, diligence and skill that a reasonable director would exercise in the circumstances, and duty to avoid conflicts of interest. In
fulfilling their duty of care to the Company, the Company&rsquo;s directors must ensure compliance with the Company&rsquo;s Memorandum
and Articles of Association, as amended and restated from time to time. The Company has the right to seek damages if a duty owed by its
directors is breached. In limited exceptional circumstances, a shareholder may have the right to seek damages in the Company&rsquo;s name
if a duty owed by the Company&rsquo;s directors is breached. The functions and powers of the Board include, among other things, (i)&nbsp;convening
shareholder meetings at such times and in such manner and places as the director considers necessary or desirable, (ii)&nbsp;declaring
dividends, (iii)&nbsp;appointing directors or officers and determining their terms of offices and responsibilities, and (iv)&nbsp;approving
the transfer of shares of the Company, including the registering of such shares in the Company&rsquo;s share register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Terms of Directors
and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s officers
are elected by and serve at the discretion of the Board. Each director holds office for the term fixed by the resolution of shareholders
or the resolution of directors appointing him until such time as his successor takes office or until the earlier of his death, resignation
or removal from office by resolution of directors with or without cause or be removed by the shareholders for cause only by a resolution
approved at a duly convened and constituted meeting of the shareholders of the Company by the affirmative vote of not less than 75% of
the votes of the shares entitled to vote thereon which were present at the meeting and were voted. The directors may at any time appoint
any person to be a director either to fill a vacancy or as an addition to the existing directors. Where the directors appoint a person
as director to fill a vacancy, the term shall not exceed the term that remained when the person who has ceased to be a director ceased
to hold office. A vacancy in relation to directors occurs if a director dies or otherwise ceases to hold office prior to the expiration
of his term of office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Interested Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director may, subject to
any separate requirements for Audit Committee approval under applicable laws or applicable Nasdaq Stock Market Listing Rules, vote on
a matter relating to the transaction in which he or she is interested, provided that the interest of any directors in such transaction
is disclosed by him or her to all other directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Director Agreements&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into director
agreements with our directors, which require us to maintain director and officer liability insurance for our directors, provide reimbursements
for business related travel and accommodation and other reasonable expenses, and an annual remuneration of between $20,000 to $25,000
for our independent directors, and a total of $250,000 and $380,000 for both of our executive directors in the years of 2023 and 2024
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has 87 full-time
employees, of which 72 are based in Thailand, Cambodia and Kyrgyzstan. NewGenIvf aims to attract and retain employees with the skills,
and experience necessary to implement its growth strategy. The following table sets forth the number of its employees in Thailand, Cambodia
and Kyrgyzstan by function as of August 1, 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Function</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of <BR> employees</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Thailand</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">Medical professionals</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Administrative staff and others</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Sub-total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Medical professionals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Administrative staff and others</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Sub-total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Medical professionals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Administrative staff and others</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Sub-total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">China</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Administrative staff and others</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Hong&nbsp;Kong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Administrative staff and others</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">87</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we maintain
a good working relationship with our employees and we have not experienced any significant labor disputes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Share Ownership</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as specifically noted,
the following table sets forth information with respect to the beneficial ownership of our ordinary shares as of the date of this prospectus
by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and executive officers; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our principal shareholders who beneficially own more than 5% of our total outstanding ordinary shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The calculations in the table
below are based on 2,152,702 ordinary shares outstanding, including 2,148,596 Class A Ordinary Shares and 4,106 Class B Ordinary Shares,
as of August 21, 2025.&nbsp;Unless otherwise indicated, each person has sole investment and voting power with respect to all shares shown
as beneficially owned. The term &ldquo;beneficial owner&rdquo; of securities refers to any person who, even if not the record owner of
the securities, has or shares the underlying benefits of ownership. These benefits include the power to direct the voting or the disposition
of the securities or to receive the economic benefit of ownership of the securities. A person also is considered to be the &ldquo;beneficial
owner&rdquo; of securities that the person has the right to acquire within 60 days by option or other agreement. Beneficial owners include
persons who hold their securities through one or more trustees, brokers, agents, legal representatives or other intermediaries, or through
companies in which they have a &ldquo;controlling interest&rdquo;, which means the direct or indirect power to direct the management and
policies of the entity. The Company&rsquo;s directors and executive officers do not have different voting rights than other shareholders
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Class A Ordinary shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Class B Ordinary Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of Total Ordinary Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of Voting Power</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><U>Directors and Named Executive Officers:</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Wing Fung Alfred Siu</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,780</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.08</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6.95</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Hei Yue Tina Fong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,326</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.11</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.09</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Hok Man Jefferson Au</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Florianna Ann Chi Wan Chan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ho Fai Chung</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All Directors and Executive Officers as Group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.19</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.04</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Related Party Transactions</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of related parties
of the Company is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina*</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders and directors</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harcourt Limited</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled by Mr. Siu</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Fong is the spouse of Mr. Siu</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Transaction with Mr.
Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, certain amount
of cash provided by operating activities was distributed to Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong, resulting in amount due
from them. For the year ended December 31, 2023, the largest aggregate amount due from Mr. Siu, Wing Fung Alfred and Ms. Fong, Hei Yue
Tina was US$2,240,872. Mr. Siu and Ms.&nbsp;Fong had repaid the outstanding amounts due pursuant to the terms and conditions of the repayment
agreement dated August 14, 2023. As of December 31, 2024, the aggregate balance of amount due to Mr. Siu and Ms. Fong was US$92,651.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NewGenIvf also
recorded remuneration to its directors, Mr. Siu and Ms. Fong. The remuneration to Mr. Siu, Wing Fung Alfred was US$125,000 and US$190,000
during the year ended December 31, 2023 and 2024, respectively. The remuneration during the years ended December 31, 2023 and 2024 was
all in the nature of the fair value of the services provided by Mr. Siu and Ms. Fong. Mr. Siu Wing Fung also entered into agreement to
waive the balance of due from the Company US$88,151 in 2023.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>LISTING DETAILS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Class A Ordinary Shares
currently trade on Nasdaq under the symbol &ldquo;NIVF.&rdquo; As of the date of this prospectus, our only listed class of securities
are our Class A Ordinary Shares. All of our Class A Ordinary Shares, including those to be offered by the Selling Securityholder pursuant
to this prospectus, have the same rights and privileges. For more information, see &ldquo;<I>Description of Share Capital&mdash;Ordinary
Shares</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the Resale Shares will
be sold by the Selling Securityholders for their own accounts. We will not receive any proceeds from the resale of the Resale Shares.
However, we may receive gross proceeds of up to $500 million from the sale of our Ordinary Shares to White Lion pursuant to the White
Lion Purchase Agreement. We expect to use such proceeds for working capital and other general corporate purposes. The actual proceeds
from White Lion may be less than this amount, depending on the number of Class A Ordinary Shares sold and the price at which the Class
A Ordinary Shares are sold. In addition, we may receive proceeds of up to $42,443,500 from the conversion of the Additional Notes, Exchange
Notes, Warrants, New CB Initial Note which proceeds will be used for working capital and other general corporate purposes. We will also
bear the costs incurred in connection with this prospectus and the registration of the Resale Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any cash dividend on our Class A Ordinary Shares as of the date of this prospectus. We currently intend to retain any future earnings
and do not expect to pay any dividends in the near future. Any further determination to pay dividends on our ordinary shares would be
at the discretion of our Board of Directors, subject to applicable laws, and would depend on our financial condition, results of operations,
capital requirements, general business conditions, and other factors that our Board of Directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following discussion
and analysis of our results of operations and financial condition should be read together with our consolidated financial statements and
the notes thereto and other financial information, which are included elsewhere in this prospectus. Our financial statements have been
prepared in accordance with U.S. generally accepted accounting principles (&ldquo;U.S. GAAP&rdquo;). In addition, our financial statements
and the financial information included in this prospectus reflect our organizational transactions and have been prepared as if our current
corporate structure had been in place throughout the relevant periods.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This section contains forward-looking
statements. These forward-looking statements are subject to various factors, risks and uncertainties that could cause actual results to
differ materially from those reflected in these forward-looking statements. Further, as a result of these factors, risks and uncertainties,
the forward-looking events may not occur. Relevant factors, risks and uncertainties include, but are not limited to, those discussed in
the section entitled &ldquo;Business,&rdquo; &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. Readers are cautioned not to
place undue reliance on forward-looking statements, which reflect management&rsquo;s beliefs and opinions as of the date of this prospectus.
We are not obligated to publicly update or revise any forward -looking statements, whether as a result of new information, future events
or otherwise. See &ldquo;Cautionary Note Regarding Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf is an assisted reproductive
services (&ldquo;ARS&rdquo;) provider in Asia Pacific. Since the establishment of its first clinic in Thailand in 2014, it has established
itself as a long-standing ARS provider in the region. NewGenIvf&rsquo;s mission is to assist couples and individuals across Asia Pacific,
regardless of fertility challenges that they may face, to fulfil their dreams of building families and to increase their access to fertility
treatments. Its strategic presence in Thailand, Cambodia, and Kyrgyzstan positions the company to take advantage of opportunities across
Asia Pacific.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf is still in the
early stage of materializing its long-term objective of building a comprehensive, sophisticated and high-end ARS platform for its clients
and providing personalized solutions based on NewGenIvf&rsquo;s brands and client-generated services. NewGenIvf plans to offer full fertility
services for fertility tourists across Asia Pacific, continue to invest in laboratories and facilities updates, increase its brand awareness
and market share, as well as expand service reach through acquisitions and partnerships, which NewGenIvf believes will help expand its
client base and enhance expertise attraction, and in turn strengthen NewGenIvf&rsquo;s monetization capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Factors Affecting NewGenIvf&rsquo;s Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s results
of operation are principally affected by the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Regulatory environment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ARS market in Asia-Pacific
region is highly regulated. The implementation and enforcement of laws, regulations and government policies in Thailand, Cambodia, Kyrgyzstan
and other applicable jurisdictions significantly impact the design, pricing and sale of fertility services and cost of compliance for
clinics across Asia Pacific. Medical facilities providing fertility services generally must be filed and registered with the relevant
supervision institutions and such filing and registration must be renewed periodically. Any change in laws, regulations or policies in
relation to such filing or registration could affect NewGenIvf&rsquo;s ability and plans to launch new services and renew registration
for existing services. The regulatory framework for medical facilities and services, especially those involving ARS, is, and will continue,
evolving. Any changes in the applicable regulatory frameworks in the jurisdictions where NewGenIvf operates may materially affect its
financial condition and results of operations.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Growth and competitive landscape of Asia Pacific&rsquo;s ARS
market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s revenue
has historically been primarily derived from clients in Asia Pacific. As such, NewGenIvf&rsquo;s financial performance and future growth
depend primarily on the demand for ARS, as well as changes in its competitive landscape, in Asia Pacific. Population growth, infertility
rates, and demand for facility treatments in the region will ultimately determine the demand for NewGenIvf&rsquo;s services. According
to CIC, infertility is increasingly becoming prevalent globally, primarily driven by increasing average age of first birth, as well as
various lifestyle and environmental factors. Driven by an increased infertility rate and growing demand for children without birth defects,
resulting from improving living standards and improved awareness about birth defects and prevention, the global ARS market is expected
to continue to grow. Furthermore, according to CIC, a growing number of governments around the world has granted legal recognition to
same-sex marriages, which brings more desires for having children to form a complete family. According to CIC, because of the fertility
rate and recent government incentive policies, such as the Three-child Policy of China in 2021, the ARS market increased significantly
in Asia Pacific. Leveraging its status as a long-standing ARS provider in Asia Pacific, NewGenIvf expects to continue to be well positioned
to capture the expected growth in the demand for ARS in the area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
NewGenIvf owns and uses MicroSort technology in Thailand and Cambodia, which is a form of pre-conception gender selection technology for
humans. While NewGenIvf expects to benefit from first-mover advantages for this technology in the two regions, market entry by potential
competitors or faster-than-expected development of potential competitors may affect its market position and demand for its services and
cause downward pricing pressure on its treatments, which may in turn materially and adversely affect its results of operations. Meanwhile,
ARS market could also be affected by the macroeconomic environment and geopolitical events. Uncertainty in the macroeconomic environment,
resulting from a range of events and trends, including the rise in global inflation and interest rates, supply chain disruptions, geopolitical
pressures, including the unknown impact of current and future trade regulations, changes in Asian-Pacific relations, fluctuation in foreign
exchange rates, and associated global economic conditions may result in volatility in ARS market and NewGenIvf&rsquo;s operating performance.
For example, NewGenIvf derives a substantial portion of its revenue from Chinese clients and as such, its failure to maintain PRC-sourced
revenues and access to new and existing clients from the PRC could materially and adversely affect its results of operations and competitive
position. However, the near-term growth prospects of the PRC economy are unclear due to the uncertain effects of ongoing economic stress
caused by policies to contain the COVID-19 pandemic, trade and national security policies, and the elevated levels of private and public
indebtedness, among others. According to the National Statistics Bureau of the PRC, growth rate of China&rsquo;s GDP for the year 2022
slowed down to 3.0% on a year-on-year basis compared to the growth rate of approximately 8.4% for the year 2021. In the second quarter
of 2023, China&rsquo;s GDP grew only 0.8% on a quarter basis, a significant slowdown from the 2.2% quarter growth registered in the first
quarter of 2023. A prolonged downturn in the PRC economy generally could materially and adversely affect NewGenIvf&rsquo;s results of
operations and there is a significant likelihood that NewGenIvf&rsquo;s actual results over the time periods and under the scenarios covered
by the projections would be different. However, according to World Bank Group, China&rsquo;s GDP grew 5.2% and 3% in 2023 and 2022 respectively.
In 2024, according to National Bureau of Statistics of China, China GDP grew 5%. NewGenIvf believes that if recovery of the PRC economy
is sustainable, it might increase the demand for NewgenIvf&rsquo;s services and therefore in turn affect NewGenIvf&rsquo;s results of
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fluctuation of costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s costs primarily
include clinic costs, cost of goods sold, selling and marketing expenses and general and administrative expenses, details of which are
set out below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinic costs.</I> NewGenIvf&rsquo;s clinic costs primarily consisted of sub-contracting charges, office supplies and staff salaries and bonus, most of which are recognized during the provision of surrogacy services. Its clinic costs represented approximately 48.8%, 55.7% of its revenue for the&nbsp;years ended December 31, 2024 and 2023, respectively. As NewGenIvf gradually expands the scale of its operation and presence in Asia Pacific, its clinic costs are expected to increase in the foreseeable future, which will affect its profitability.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cost of goods sold.</I> NewGenIvf&rsquo;s cost of goods sold primarily consisted of purchase and direct cost for IVF treatment services and surrogacy and ancillary caring services, most of which are recognized during the provision of IVF treatment services. Its cost of goods sold represented approximately 11.6% and 11.6% of the revenue for the&nbsp;years ended December&nbsp;31, 2024 and 2023, respectively. NewGenIvf expects its cost of goods sold to increase in the foreseeable future as it gradually grows its revenues and expand its sales network.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Selling and marketing expenses.</I> NewGenIvf&rsquo;s selling and marketing expenses primarily consisted of social media expense. Its selling and marketing expenses represented approximately 3.8% and 0.4% of its revenue for the&nbsp;years ended December 31, 2024 and 2023, respectively. NewGenIvf expects its selling and marketing expenses to increase as it plans to expand its sales and scale its operation in Asia-Pacific.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General and administrative expenses.</I> NewGenIvf&rsquo;s general and administrative expenses primarily consisted of depreciation in operating lease right-of-use (&ldquo;ROU&rdquo;) assets and staff salaries&nbsp;and director fees. Its general and administrative expenses represented approximately 51.2% and 24.5% of its revenue for the&nbsp;years ended December 31, 2024 and 2023, respectively. NewGenIvf expects its general and administrative expenses to increase in line with its expansion plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf expects its cost
structure to evolve as it develops and expands its business. As NewGenIvf continues to develop new services and technologies, NewGenIvf
expects to incur additional costs in relation to its raw materials procurement, production and sales and marketing, among other things.
Moreover, to support NewGenIvf&rsquo;s business growth, it expects to increase its headcount, particularly for its lab and nurse team,
and incur higher staff costs as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ability to maintain trust of clients and reputation in the industry</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The success of NewGenIvf&rsquo;s
business will depend to a large extent on its ability to gain broad acceptance of its services from clients. Reputation is crucial in
keeping existing clients and attracting new clients. NewGenIvf&rsquo;s reputation depends on a number of factors, including for example
the success, effectiveness, quality and pricing of its services, service offerings of its competitors, the effectiveness of its marketing
efforts to drive awareness and the demand for fertility services, which eventually will affect its ability to maintain clients and attract
new clients. Therefore, NewGenIvf&rsquo;s success will depend to a large extent on its ability to maintain its reputation in the industry
and its clients&rsquo; trust, which would affect the number of its clients and treatment cycles that will in turn affect its revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that the
medical facilities in its network are increasingly recognized among clients, for their service quality, technological expertise and patient
experience. NewGenIvf also hopes to keep its clients by providing discounts in treatment services and via the &ldquo;success guarantee&rdquo;
program for egg donation services in Cambodia and surrogacy services in Kyrgyzstan, which provides treatments to clients until a success
is achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on its increasingly
recognized reputation, NewGenIvf believes that there is substantial opportunity to continue to grow its revenue through attracting new
clients. NewGenIvf&rsquo;s addressable market is couples who want to have children, egg freezing patients, LGBT groups and couples with
genetic abnormalities, particularly those in Asia Pacific. NewGenIvf believes that its current client base represents a small percentage
of its total market opportunity. NewGenIvf intends to attract new clients by, among other things, making significant investments in sales
and marketing to engage, educate and drive awareness of the unmet need of fertility treatment among its potential clients and by its customer-reference
discounts mechanism. Additionally, NewGenIvf believes that its expanding presence has resulted in a heightened awareness of the need to
offer fertility services and the value it provides to its clients, which it believes will help facilitate its growth. In addition, NewGenIvf
is continuously utilizing its established client relationships to evaluate other potential services that could benefit its clients and
simultaneously drive its growth.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>International traveling conditions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The revenue from international
clients is a critical component of NewGenIvf&rsquo;s revenue. International traveling to Thailand, Cambodia and Kyrgyzstan may be affected
by a number of factors, including local and global political, economic and cultural conditions. Furthermore, an outbreak, or threatened
outbreak, of any severe contagious disease may also in turn significantly reduce the demand of traveling. For example, the COVID-19 pandemic
has had resulted in a number of countries declaring a state of emergency and a number of countries, including the countries in Asian Pacific,
imposing extensive travel restrictions. NewGenIvf&rsquo;s revenue in the year 2021 was significantly adversely affected due to the impact
from COVID-19 travel restrictions. In addition, a Chinese crime thriller, <I>No More Bets</I>, which has grossed more than $500 million
at the international box office since its August 2023 release and which tells the harrowing story of characters being lured and kidnapped
into a violent scam ring in an unnamed Southeast Asian country after accepting lucrative overseas job offers, and the continuing social
media coverage may have brought fears and safety concerns to Chinese tourists of being scammed and kidnapped in Thailand&nbsp;and&nbsp;Cambodia.
In addition, in October 2023, a 14-year-old with a gun opened fire in a luxury shopping mall in downtown Bangkok, killing two people and
injuring five in one of Thailand&rsquo;s most popular tourist destinations. These conditions may cause NewGenIvf difficulty in attracting
clients from the PRC to travel to Thailand, Cambodia and Kyrgyzstan for NewGenIvf&rsquo;s services, which could materially and adversely
affect NewGenIvf&rsquo;s operations and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the uncertainty of the
local and global conditions and the countries&rsquo; future policy regarding international traveling, all of which are beyond NewGenIvf&rsquo;s
control, NewGenIvf&rsquo;s results of operation may be materially and adversely affected by any changes in international travelling conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Components of Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s revenues
were derived from two types of services: IVF treatment services and surrogacy and ancillary caring services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
a breakdown of NewGenIvf&rsquo;s revenue by the types of services, in absolute amounts and as percentages of total revenue, for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year ended December&nbsp;31,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IVF treatment services<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,433,375</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100.0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,021,696</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">78.3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Surrogacy and ancillary caring services</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,114,457</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total revenues</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,433,375</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,136,153</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Include an insignificant amount of revenue derived from consultation customers who used NewGenIvf&rsquo;s non-IVF treatment and insignificant services, such as check-ups services, blood test services and other minor services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf generated revenue
from facilities located in various geographic regions. The following table sets forth a breakdown of NewGenIvf&rsquo;s revenue based on
the locations where the revenue originated, in absolute amounts and as percentages of total revenue, for the periods indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year ended December&nbsp;31,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">HK SAR</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">34,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,656,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,123,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60.8</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">601,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Thailand</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,175,253</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,356,903</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26.4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total revenues</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,433,375</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,136,153</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s revenue
results are affected by, among others, changes in sales price and the fluctuation of foreign currency rates with US dollars. A 5% change
in sales price would cause 5% change in NewGenIvf&rsquo;s revenue. Based on the breakdown of the revenue contribution in terms of currencies
used by customers for 2024, a 5% change in foreign currency rates with US dollars would cause approximately 2.4% change in NewGenIvf&rsquo;s
revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>IVF treatment services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf generated revenue
from IVF treatment services provided at facilities that NewGenIvf operated in Thailand and Cambodia. In addition, NewGenIvf also recognized
revenues from IVF treatments included in surrogacy services performed in Kyrgyzstan. NewGenIvf&rsquo;s revenue from IVF treatment service
amounted to US$5,433,375 and US$4,021,696, representing approximately 100% and 78.3% of its total revenues in 2024 and 2023, respectively.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IVF treatment involves the
performance of a series of medical treatment and procedures and eventually brings benefits to clients when embryo is successfully implanted.
Revenue from IVF treatment is recognized at a point in time when different treatment and/or procedure completed in clinic. The completion
of the respective treatments and/or procedures are evidenced by treatment cards and reports maintained in the patient files indicating
successful completion of respective promised obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Surrogacy and ancillary caring services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also generated revenue
of US$1,114,457 from surrogacy and related ancillary caring services, approximately 21.7% of its total revenue in 2023, provided at facilities
that NewGenIvf operated in Kyrgyzstan. In 2024, due to the reorganization of the Kyrgyzstan operations, NewGenIvf did not generate any
revenue from surrogacy and related ancillary caring services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In surrogacy and ancillary
caring services, embryo from intending parents is implanted in the surrogate mother sub-contracted by NewGenIvf. During the pregnancy
period of the surrogate mother, NewGenIvf provides ancillary caring services including maternity caring services such as regular body
check and provision of vitamins, supplements and medicines to surrogate mothers, documentation service, and hotel accommodation services.
Revenue from surrogacy and ancillary caring services is recognized at a point in time when the surrogate mother gives birth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cost of revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
a breakdown of NewGenIvf&rsquo;s cost of revenue by the nature of the cost, in absolute amounts and as percentages of total cost of revenues,
for the periods indicated.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cost of revenues</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of goods sold</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">629,620</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17.5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">594,984</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17.2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Clinic costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,976,861</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">82.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,859,384</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">82.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total cost of revenues</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,606,481</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,454,368</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Cost of goods sold. </I>Cost
of goods sold primarily consisted of purchase and direct cost for IVF treatment services and surrogacy and ancillary caring services.
NewGenIvf&rsquo;s cost of goods was mostly recognized during the provision of IVF treatment services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Clinic costs. </I>Clinic
costs primarily consisted of sub-contracting charges, office supplies and staff salaries and bonus. The largest portion of clinic costs
was sub-contracting charges, representing fees paid to agents who recruited surrogate mothers and assisted in the documentation, consulting
and medical treatment arrangement throughout treatment procedure. NewGenIvf&rsquo;s clinic costs of goods were mostly recognized during
the provision of surrogacy services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Gross profit and gross margin</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
NewGenIvf&rsquo;s gross profit in absolute amounts and its gross margin as percentages of total revenues, for the periods indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Gross profit</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,826,894</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">33.6</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,681,785</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">32.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Revenues</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,433,375</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,136,153</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf expects that gross
profit and gross margin will continue to be affected by various factors including the geographic locations where treatments are performed,
as well as the pricing with its clients, agent subcontracting charges and the costs of the supplies provided by major pharmaceutical companies,
all of which are negotiated separately.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Operating expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s operating
expenses consist primarily of selling and marketing expenses and general and administrative expenses. NewGenIvf&rsquo;s selling and marketing
expenses are primarily social media expenses. NewGenIvf&rsquo;s general and administrative expenses mainly include depreciation in operating
lease ROU assets, and staff salaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s other income
consists primarily of partial waiver of promissory note</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Interest expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s interest
expense is incurred in relation to its interest-bearing convertible bonds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Taxation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>British Virgin Islands</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf is incorporated
in the British Virgin Islands and is not subject to tax on income or capital gains under current British Virgin Islands law. In addition,
upon payment of dividends to shareholders, no British Virgin Islands withholding tax will be imposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Hong&nbsp;Kong</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the two-tiered profits
tax rates regime, Hong&nbsp;Kong tax residents are subject to Hong&nbsp;Kong profits tax in respect of profits arising in or derived from
Hong&nbsp;Kong at 8.25% for the first HK$2&nbsp;million of profits of the qualifying group entity, and profits above HK$2&nbsp;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed
at a flat rate of 16.5%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, the Hong&nbsp;Kong
profits tax is calculated at 8.25% on the first HK$2&nbsp;million of the estimated assessable profits and at 16.5% on the remaining estimated
assessable profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Thailand</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The companies incorporated
in Thailand are taxed on worldwide income. A company incorporated outside of Thailand is taxed on its profits arising from or in consequence
of the business carried on in Thailand. The Thailand corporate income tax rate is 20%. A foreign company not carrying on business in Thailand
is subject to a final withholding tax on certain types of assessable income (e.g., interest, dividends, royalties, rentals, and service
fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%, while other rates may apply under
the provisions of a double tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cambodia</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The standard rate of corporate
income tax for companies and permanent establishments in Cambodia who are classified as medium and large taxpayers is 20%. For companies
and permanent establishments who are classified as small taxpayers, the corporate income tax rates are progressive rates from 0% to 20%.
In view of the annual turnover of the company, which ranges from KHR1 billion to KHR6 billion for service and commercial sectors, the
company is considered a medium-sized company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Kyrgyzstan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf is subject to a
corporate income tax on its aggregate annual income earned worldwide. Non-resident legal entities carrying out business activities through
a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that permanent establishments.
Profit tax is calculated at a rate of 10% of aggregate annual income less allowed deductions.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended<BR> December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold">Revenues</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">5,433,375</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">5,136,153</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cost of revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,606,481</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,454,368</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Gross profit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,826,894</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,681,785</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Selling and marketing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(206,314</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,030</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,651,075</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,259,364</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Auditor&rsquo;s fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(130,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(362,149</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total operating expenses</B></FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,987,389</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,639,543</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating (loss) income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,160,495</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">42,242</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expenses), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">971,391</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,837</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,953</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">518</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(778,656</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46,179</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total other income (expenses), net</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">199,688</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">66,176</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">(Loss) Income before taxes</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(960,807</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">108,418</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tax income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">486,706</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net (loss) income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(474,101</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">108,418</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less: net income attributable to non-controlling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,542</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,775</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net (loss) income attributable to the shareholders of the Company</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(524,643</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">130,193</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,529</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,704</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total comprehensive (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(441,572</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,714</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Less: Total comprehensive (loss) income attributable to non-controlling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,908</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,621</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total comprehensive (loss) income attributable to the shareholders of the Company</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(498,480</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,335</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Earnings per share&nbsp;&ndash;&nbsp;basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66.2</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&ndash;&nbsp;diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31.9</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average shares outstanding * &ndash; basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">- diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to 2024 yearend, the Company carried out a 1-for-20 reverse stock split, a 1-for-10 reverse stock split and a 1-for-5 reverse stock split of its issued and unissued shares which was effected on February 11, 2025, May 5, 2025, and August 4, 2025, respectively. The shares above have been adjusted retrospectively for these reverse stock splits.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended December&nbsp;31, 2024 Compared with Year Ended December&nbsp;31,
2023</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">NewGenIvf&rsquo;s
revenue increased by approximately 5.8% from US$5,136,153 in 2023 to US$5,433,375 in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>IVF treatment services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s IVF treatment
service revenue increased by approximately 35.1% from US$4,021,696 in 2023 to 5,433,375 in 2024. This increase was primarily the result
of our continued expansion of clinics in Thailand and clinic in Kyrgyzstan focusing on IVF services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Surrogacy and ancillary caring services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s surrogacy
and ancillary caring services revenue decreased by approximately 100.0% from US$1,114,457 in 2023 to US$ Nil in 2024. This decrease was
primarily the result of temporary cessation of surrogacy business due to the reorganization of Kyrgyzstan business operation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cost of revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s cost of
revenue increased by approximately 4.4% from US$3,454,368 in 2023 to 3,606,481 in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cost of goods sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s cost of
goods sold increased by approximately 5.8% from US$594,984 in 2023 to US$629,620 in 2024, primarily attributed to the increase on procurement
costs. The increase in IVF treatment services, directly leading to increase in cost of goods sold.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinic costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s clinic costs
increased by approximately 4.1% from US$2,859,384 in 2023 to US$2,976,861 in 2024, primarily due to the relocation arrangement, certain
daily operating schedules stopped, resulting in the clinic&rsquo;s service being temporarily ceased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Gross profit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s gross profit
increased by approximately 8.6% from US$1,681,785 in 2023 to US$1,826,894 in 2024 to, primarily attributable to a reorganizing of our
cooperation model with subcontractors and the increased efficiency of our marketing services, resulting in a decrease in unit service
costs per customer, directly leading to increases in gross profit margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s gross margin
slightly increased from 32.7% in 2023 to 33.6% in 2024.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Operating expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s operating
expenses increased by approximately 82.2% from US$1,639,543 in 2023 to US$2,987,389 in 2024, primarily attributable to (i) professional
fees of US$769,820 incurred in 2024 being related to business combination with ACSA and the convertible note financing; (ii) license fee
of US$123,000 in 2024 related to the use of MicroSort technology; and (iii) staff and director salary and personnel cost of US$888,861
in 2024 due to enlargement of sales force and administrative staff to implement our business expansion pan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s other income
increased from US$111,837 in 2023 to US$971,391 in 2024, primarily attributable to a partial waiver of promissory note and legal fee payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Interest expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s interest
expense increased from US$46,179 in 2023 to US$778,656 in 2024 as a result of more interest expenses on convertible note issuance in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Tax income (expense)&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf made no provision
for income taxes in 2024 and 2023. Thailand&rsquo;s taxable income in 2024, if any, would be offset by the tax loss carryforward from
previous years. With the disposition of First Fertility Bishkek LLC in 2024, income tax liabilities, if any, in Kyrgyzstan would be borne
by the new shareholder of First Fertility Bishkek LLC. There was no assessable income generated from Hong Kong and Cambodia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024 excess provision of US$486,706 was reversed as they are no longer deemed to be payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Net income </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s incurred
a net loss of US$474,101 in 2024 while there was a net income of US$108,418 in 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash flows and working capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s principal
sources of liquidity have been cash flows generated from its business operations and external financing via various instruments. As of
December&nbsp;31, 2024 and 2023, NewGenIvf had US$457,740 and US$54,104, respectively, in cash and cash equivalents. NewGenIvf had working
capital (defined as total current assets deducted by total current liabilities) of a surplus of $452,391 and US$79,000, respectively,
as of December&nbsp;31, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, NewGenIvf
owed US$154,453 to shareholders. Nevertheless, NewGenIvf is able to generate sufficient cash flow from its business operations and financing
activities to operate and grow its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf continually seeks
to monetize from positive cash flow contracts and increase revenue from its operating activities. NewGenIvf monitors its current and expected
liquidity requirements to help ensure that it maintains sufficient cash balances to meet its existing and reasonably likely long-term
liquidity needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to finance
its future working capital requirements and capital expenditures from cash generated from operating activities, in addition to funds raised
from financing activities. NewGenIvf may, however, require additional cash due to changing business conditions or other future developments,
including any investments or acquisitions it may decide to pursue. If its existing cash is insufficient to meet its requirements, NewGenIvf
may seek to issue debt or equity securities or obtain additional credit facilities. Financing may be unavailable in the amounts NewGenIvf
needs or on terms acceptable to it, if at all. Issuance of additional equity securities, including convertible debt securities, would
dilute NewGenIvf&rsquo;s earnings per share. The incurrence of debt would divert cash for working capital and capital expenditures to
service debt obligations and could result in operating and financial covenants that restrict NewGenIvf&rsquo;s operations and its ability
to pay dividends to its shareholders. If NewGenIvf is unable to obtain additional equity or debt financing as required, its business operations
and prospects may suffer. Please see &ldquo;<I>Risk Factors &mdash; Risks Relating to NewGenIvf&rsquo;s Business and Industry&nbsp;&mdash;
NewGenIvf requires a significant amount of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on
acceptable terms, its business, financial condition, and prospects may be materially and adversely affected</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
NewGenIvf&rsquo;s selected consolidated cash flow data for the periods indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended <BR> December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; font-style: italic; text-align: center">US$</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(8,264,074</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(1,766,135</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(53,045</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69,848</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,675,790</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,881,493</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Net increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">358,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Effect of foreign currency translation on cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,962</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Cash and cash equivalents, beginning of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,556</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Cash and cash equivalents, end of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,104</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Operating activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was US$8,264,074 for the year ended December&nbsp;31, 2024. The difference between NewGenIvf&rsquo;s net loss of US$474,101
for the year ended December 31, 2024 and the net cash used in operating activities was primarily attributable to (i)&nbsp;an increase
of agent&rsquo;s receivable of US$1,191,795, (ii)&nbsp;a cash deposit of US$1,000,000 with a digital trading platform and settlement of
charges in relation to the de-spac and business reorganisation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was US$1,766,135 for the year ended December 31, 2023. The difference between NewGenIvf&rsquo;s net profit of US$108,418 for
the year ended December 31, 2023 and the net cash used in operating activities was primarily attributable to refund of payment from clients
from the contract liabilities and the expenses spent on the legal and professional cost which was capitalized in the book of 2023.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Investing activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities in 2024 was US$53,045, primarily representing purchase of plant and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities in 2023 was US$69,848, primarily representing purchase of plant and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financing activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities in 2024 was US$8,675,790, primarily representing issuance of share capital utilizing equity line of credit, convertible note
issuance and proceeds from issuance of promissory notes all totaling to an amount of $8,583,597.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities in 2023 was US$1,881,493, primarily representing amounts advanced to shareholder and repayment of prior loans from related
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
NewGenIvf&rsquo;s main contractual obligations and commitments as of December 31, 2024 and December 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating lease</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; font-style: italic; text-align: center">US$</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">- Payable less than 1 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">111,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">209,303</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">- Payable 1 &ndash; 2 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,613</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">- Payable 2.- 5 years</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,373</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">121,621</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">331,289</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance; lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Lease liabilities &ndash; current portion</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,446</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.5in">-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Convertible bonds-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">516,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">507,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2029</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,269,625</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,207,625</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The convertible bonds have
the option of being converted to Class A ordinary shares at the discretion of the holder, any time after issuance. The conversion, however,
is subject to certain terms and conditions, including the requirement of the shareholdings not to exceed 9.99% of the Company&rsquo;s
shares. As of December 31, 2024, this criterion has been met.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Commitments and Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has not entered
into any financial guarantees or other commitments to guarantee the payment obligations of any third parties, nor any derivative contracts
that are indexed to its shares and classified as shareholder&rsquo;s equity or that are not reflected in its consolidated financial statements.
Furthermore, NewGenIvf does not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves
as credit, liquidity or market risk support to such entity. NewGenIvf does not have any variable interest in any unconsolidated entity
that provides financing, liquidity, market risk or credit support to it or engages in leasing, hedging or product development services
with it.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf Group Limited is
a holding company with no material operations of its own. NewGenIvf Group Limited conducts all of its operations through its subsidiaries.
As a result, NewGenIvf Group Limited&rsquo;s ability to pay dividends depends upon dividends paid by its subsidiaries. If our subsidiaries
or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their
ability to pay dividends to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf Group Limited is
permitted under BVI law to provide funding to its subsidiaries in Hong&nbsp;Kong, Thailand, Cambodia and Kyrgyzstan through loans or capital
contributions without restrictions on the amount of the funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company&rsquo;s
subsidiaries are currently permitted to pay dividends to the Company in accordance with relevant laws and regulations. Payment of dividends
requirements in a company incorporated under the laws of Thailand is governed by the Civil and Commercial Code of Thailand. For example,
the company may not declare dividends if the company has incurred losses, the company must appropriate to a reserved fund at each dividend
contribution of dividend of at least one-twentieth of the profits until the fund reaches one-tenth of the capital, or the dividends payment
must be made to the shareholders within one (1)&nbsp;month from the dividend declaration date. On the capital remittance or payment of
dividends to the shareholders from outside of Thailand, it is regulated by the regulations issued by the Bank of Thailand, including the
Exchange Control Act B.E. 2485 (1942). The fund remittance from Thailand to a foreign jurisdiction may require an approval from the Bank
of Thailand or require notifying the Bank of Thailand for such transfer, depending on the types of the remittance transactions, through
the commercial bank in the country. For a company incorporated under the laws of Kyrgyzstan, under Kyrgyz regulations of dividends (net
profit), the dividends can be paid once a year depending on the results of the financial year of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Quantitative and Qualitative Disclosure about Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Accounts receivable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to minimize the credit
risk, NewGenIvf&rsquo;s management team monitors and ensures that follow-up action is taken to recover overdue debts. NewGenIvf considers
the probability of default upon initial recognition of the asset and whether there has been a significant increase in credit risk on an
ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, NewGenIvf compares the
risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition. It considers
available reasonable and supportive forwarding-looking information, such as GDP growth rate and nominal GDP per capita. Based on the impairment
assessment performed by NewGenIvf, the directors considered the loss allowance for account receivables as of December&nbsp;31, 2023 and
December&nbsp;31, 2024 is $19 and $19, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash and cash equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf is exposed to concentration
of credit risk on liquid funds which are deposited with several banks with high credit ratings. The credit risk on liquid funds is limited
because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Deposits and other receivables, amount due
from shareholders and loan to A SPAC I</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf assessed the impairment
for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on internal credit rating and ageing
of these debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition. Based
on the impairment assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables and
due from shareholders as of December 31, 2024 was US$4 and Nil respectively. The loss allowance for deposits and other receivables, and
due from shareholders and loan to A SPAC I as of December&nbsp;31, 2023 is $14, $17,818 and Nil, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash flow interest rate risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf is exposed to cash
flow interest rate risk through the changes in interest rates related mainly to its variable-rates bank balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf currently does not
have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors monitor
NewGenIvf&rsquo;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sensitivity analysis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sensitivity analysis below
has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied to
the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is used when reporting interest
rate risk internally to key management personnel and represents management&rsquo;s assessment of the reasonably possible change in interest
rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If interest rates had been
1% higher or lower and all other variables were held constant, NewGenIvf&rsquo;s post tax loss for the&nbsp;years ended December&nbsp;31,
2024 and 2023 would have increased or decreased by approximately US$26,894 and US$122, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Foreign currency risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign currency risk is the
risk that the holding of foreign currency assets will affect NewGenIvf&rsquo;s financial position as a result of a change in foreign currency
exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s monetary
assets and liabilities are mainly denominated in HK$ and THB which are the same as the functional currencies of the relevant group entities.
Hence, in the opinion of the directors of NewGenIvf, the currency risk of US$ is considered insignificant. NewGenIvf currently does not
have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related foreign currency exposure
closely and will consider hedging significant foreign currency exposures should the need arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Economic and political risks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s operations
are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, NewGenIvf&rsquo;s business, financial condition, and results of
operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s operations
in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks not typically associated with companies
in North America and Western Europe. These include risks associated with, among other things, the political, economic and legal environment
and foreign currency exchange. NewGenIvf&rsquo;s results may be adversely affected by changes in the political and social conditions in
Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures,
currency conversion, remittances abroad, and rates and methods of taxation, among other things.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Travel restriction risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International clients contribute
a large portion of NewGenIvf&rsquo;s revenue. International clients need to travel to Thailand, Cambodia and Kyrgyzstan for treatment
services, where NewGenIvf&rsquo;s operations are mainly conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International traveling to
Thailand, Cambodia and Kyrgyzstan may be affected by a number of factors, including local and global political and economic conditions.
Furthermore, an outbreak, or threatened outbreak, of any severe contagious disease may also in turn significantly reduce the demand of
traveling or cause extensive travel restrictions. NewGenIvf&rsquo;s results may be materially and adversely affected if travel restriction
was imposed or difficulties in cross-border flow arose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Inflation risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management of NewGenIvf monitors
changes in prices levels. Historically inflation has not materially impacted NewGenIvf&rsquo;s consolidated financial statements; however,
significant increases in the price of labor that cannot be passed to NewGenIvf&rsquo;s customers could adversely impact its results of
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies, Judgments and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf prepares its financial
statements in conformity with U.S.&nbsp;GAAP, which requires NewGenIvf to make judgments, estimates and assumptions. NewGenIvf continually
evaluates these estimates and assumptions based on the most recently available information, its historical experience and various other
assumptions that NewGenIvf&rsquo;s management believes to be reasonable under the circumstances. Since the use of estimates is an integral
component of the financial reporting process, actual results could differ from its expectations as a result of changes in NewGenIvf&rsquo;s
estimates. Some of NewGenIvf&rsquo;s accounting policies require a higher degree of judgment than others in their application and require
NewGenIvf to make significant accounting estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selection of critical
accounting policies, the judgments and other uncertainties affecting application of those policies and the sensitivity of reported results
to changes in conditions and assumptions are factors that should be considered when reviewing NewGenIvf&rsquo;s financial statements.
NewGenIvf&rsquo;s management believes the following accounting policies involve the most significant judgments and estimates used in the
preparation of their financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Going Concern</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The going concern assumption
is a fundamental principle in the preparation of financial statements, and it is management&rsquo;s responsibility to evaluate whether
there are any conditions or events that raise substantial doubt about the Company&rsquo;s ability to continue operating for the foreseeable
future. Management&rsquo;s assessment of the Company&rsquo;s ability to continue as a going concern for the financial year ending 2024
has been addressed in the foregoing paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is always closely
monitoring the market for opportunities and has also been carrying out various fundraising projects to improve the Company&rsquo;s cash
flow position. As of April 10, 2025, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising
the Initial Note, the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the
Company. A further $2,000,000 of the Third Mandatory Additional Note was issued subsequent to year end and remains outstanding. Moreover,
the Company has access to an equity line of credit facility of up to $100,000,000 from White Lion Capital, of which approximately $11.66
million has been drawn and become equity to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one
or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there
would likely be a material adverse effect on the Company and its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Equity Line of Credit </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into an
equity line of credit agreement with White Lion Capital in November 2024. As part of the agreement, the Company is required to pay a commitment
fee of 700,000 shares to the White Lion Capital. The commitment fee is a cost incurred to secure the equity line of credit. The relevant
US GAAP guidance for this treatment can be found in ASC 340-10-S99-1, which states that costs incurred to raise capital should be recorded
as a reduction of Additional Paid in Capital (&ldquo;APIC&rdquo;) and shall be excluded from the determination of net income or the results
of operations under all circumstances. The commitment fee of 700,000 shares was directly offset against APIC. The financing arrangement
resulting from the commitment fee is that of equity financing and not debt financing in characteristics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commitment fee paid in
the form of shares, are recorded at fair value of the shares issued, determined based on the market price of the shares at the date of
issuance. The fair market value of the shares is recorded as APICs (since we do not have par value), and APIC &ndash; deferred cost of
financing, both of which are presented in the Statement of Equity. The APIC &ndash; deferred financing cost is amortised over the term
of the facility and credited into APIC. There is no impact nevertheless on the total equity of the Company and for purposes of presentation
in the Statement of Equity, APIC and APIC &ndash; deferred financing cost are not segregated.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Principles of consolidation and basis of preparation </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company balances and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The business combination transaction
between Legacy NewGenIvf and SPAC I was accounted for as a reverse recapitalization under ASC 805, Business Combinations, with NewGenIvf
Group Limited, and deemed to be the accounting acquirer. As SPAC I did not meet the definition of a business under ASC 805, the transaction
was not treated as a business combination. Instead, it was accounted for as a recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, the consolidated
assets, liabilities and results of operations of the accounting acquirer will become the historical financial statements of the Company,
and the accounting acquirer&rsquo;s assets, liabilities and results of operations will be consolidated with the Company beginning on the
acquisition date. The Legacy NewGenIvf was the legal acquiree but deemed to be the accounting acquirer. The Company was the legal acquirer
but deemed to be the accounting acquiree in the reverse merger. The historical financial statements prior to the acquisition are those
of the accounting acquirer (Legacy NewGenivf). After completion of the Merger Transaction, the Company&rsquo;s consolidated financial
statements include the assets and liabilities, the operations and cash flow of the accounting acquirer. Any excess of the value of shares
issued by the Company over the net book value of the accounting acquirer will be recognized as a reduction to equity (APIC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Revenue recognition </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company adopted ASC Topic
606, Revenue from Contracts with Customers. The Company derives revenue principally from provision of In vitro fertilization (&ldquo;IVF&rdquo;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its contracts with customers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its performance obligations under those contracts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction prices of those contracts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction prices to its performance obligations in those contracts; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services that are inter dependent. All the contracts have commercial substance, and it is probable
that the Company will collect considerations from its customers for service component as settlement is predominantly required prior to
performance of the promised service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company derives its revenues
from two sources: (1) revenue from IVF treatment, and (2) revenue from surrogacy and ancillary caring services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Revenue from IVF treatment </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In vitro fertilization (&ldquo;IVF&rdquo;)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
as well as procedures and brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized
at a point in time when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various
procedures and treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion
of the service.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Revenue from surrogacy and ancillary caring services </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&rsquo;s result of operations
can be found in Note 8 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Revenue from egg freezing and storage facility </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company provides access
to the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the
customer, the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point
in time when the facility is made available to the customer at the agreed consideration by the provision of specific address within the
facility as maintained in the patient file. The receipt of consideration is assured as payment is required upfront.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Principal versus agency considerations </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company follows the guidance
provided in ASC 606, Revenue from Contracts with Customers, for determining whether the Company is the principal or an agent in arrangements
with customers that involve another party that contributes to the provision of services to a customer. In these instances, the Company
determines whether it has promised to provide the service itself (as principal) or to arrange for the specified service to be provided
by another party (as an agent). This determination is a matter of judgment that depends on the facts and circumstances of each arrangement.
The Company recognizes revenue from the performance of the procedures and treatment on a gross basis as the Company is responsible for
the fulfillment, controls the delivery of the promised service, and has full discretion in establishing prices and therefore is the principal
in the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Lease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf adopted ASU 2016-02,
&ldquo;Leases&rdquo; (Topic 842). Lease terms used to calculate the present value of lease payments generally do not include any options
to extend, renew, or terminate the lease, as NewGenIvf does not have reasonable certainty at lease inception that these options will be
exercised. NewGenIvf generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar
owned assets. NewGenIvf has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include
leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset
also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, there
were $98,570 ROU assets and $118,757 in lease liabilities based on the present value of the future minimum rental payments of leases,
respectively. NewGenIvf&rsquo;s management believes that using an incremental borrowing rate of the minimum loan rate and Hong Kong Dollar
Best Lending Rate (&ldquo;BLR&rdquo;) minus 0.125% was the most indicative rate of NewGenIvf&rsquo;s borrowing cost for the calculation
of the present value of the lease payments; the rate used by NewGenIvf was 6.6% and 5.5% respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, there
were $283,847 ROU assets and $326,107 in lease liabilities based on the present value of the future minimum rental payments of leases,
respectively. NewGenIvf&rsquo;s management believes that using an incremental borrowing rate of the Hong Kong Dollar Best Lending Rate
(&ldquo;BLR&rdquo;) minus 0.125%&nbsp;&nbsp;&nbsp;was the most indicative rate of NewGenIvf&rsquo;s borrowing cost for the calculation
of the present value of the lease payments; the rate used by NewGenIvf was 5.0%.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financial instruments</I></B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s financial
instruments, including cash and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and
amounts due from (to) shareholders, have carrying amounts that approximate their fair values due to their short maturities. ASC Topic&nbsp;820,
&ldquo;Fair Value Measurements and Disclosures&rdquo; requires disclosing the fair value of financial instruments held by NewGenIvf. ASC
Topic&nbsp;825, &ldquo;Financial Instruments&rdquo; defines fair value and establishes a three-level valuation hierarchy for disclosures
of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated
balance sheets for cash and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and amounts
due from (to) shareholders each qualify as financial instruments and are a reasonable estimate of their fair values because of the short
period between the origination of such instruments and their expected realization and their current market rate of interest. NewGenIvf
analyzes all financial instruments with features of both liabilities and equity under ASC&nbsp;480, &ldquo;Distinguishing Liabilities
from Equity&rdquo; and ASC&nbsp;815. See &ldquo;<I>Note&nbsp;2 &mdash; Summary of Significant Accounting Policies</I>&rdquo; for details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recent accounting pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FASB has introduced expanded
income tax disclosure requirements under ASU 2023-09 to improve transparency. Companies will now need to provide a detailed reconciliation
of their effective tax rate, breaking down federal, state, and foreign taxes, as well as specific categories like tax credits and foreign
earnings. Additionally, businesses must disclose income taxes paid by jurisdiction, offering investors greater clarity on tax obligations.
These changes apply to both public and private companies, with annual reporting periods beginning after December 15, 2024 (2025 for calendar-year
entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2024, the FASB issued
ASU No. 2024-01, Compensation-Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, which provides
illustrative guidance to help entities determine whether profits interest and similar awards should be accounted for as share-based payment
arrangements within the scope of ASC 718. ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim periods
within those annual periods. The Group is currently evaluating the impact of the adoption of ASU 2024-01 on its consolidated financial
statements and related disclosures.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A major shift in digital asset
accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than applying
the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December 15,
2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair value
accounting seen in other investment holdings, addressing criticisms of the old impairment approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, the FASB issued
ASU 2025-02, Liabilities (Topic 405): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 122. (&ldquo;ASU 2025-02&rdquo;)
which amends the Accounting Standards Codification to remove the text of SEC Staff Accounting Bulletin (&ldquo;SAB&rdquo;) 121 &ldquo;Accounting
for Obligations to Safeguard Crypto-Assets an Entity Holds for its Platform Users&rdquo; as it has been rescinded by the issuance of SAB
122. ASU 2025-02 is effective immediately and on a fully retrospective basis to annual periods beginning after December 15, 2024. It is
not expected to have an impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an assisted reproductive
services (&ldquo;ARS&rdquo;) provider in Asia-Pacific. Since the opening of our first clinic in Thailand in 2014, we have established
ourself as a long-standing ARS provider in this region. Our strategic presence in Thailand, Cambodia, and Kyrgyzstan positions us to take
advantage of opportunities across Asia-Pacific. According to China Insights Consultancy (&ldquo;CIC&rdquo;), from 2014 to 2022, there
was a rising number of women in the key ARS-targeted age group (ages 15 to 49) in Asia Pacific and a growing trend towards later maternal
age. The number of married women of reproductive age in Asia Pacific has risen from 816.4&nbsp;million in 2014 to 833.2&nbsp;million in
2022. Additionally, according to CIC, there was increasing social acceptance of ARS use in Asia Pacific countries such as China, India,
and Thailand during the same period. For example, the number of ARS users in China has risen from 136.8 thousand in 2017 to 184.9 thousand
in 2022 approximately and that in Japan has risen from 98.0 thousand in 2017 to 128.5 thousand in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, the prevalence
of infertility in Asia-Pacific developing countries is substantial. For example, the infertility rate in Thailand, India and China was
about 15.4%, 13.8% and 17.8%, respectively, in 2022. In India, the infertility rate in 2020 was approximately 13.1%, representing an annual
growth of 2.6%. The infertility rate in China was around 17.6% in 2020, representing an annual growth of 0.6%. Infertility is increasingly
gaining society&rsquo;s attention as individuals are more openly discussing their struggles. Despite the prevalence of infertility, access
to treatment is often limited in the Asia Pacific region. According to CIC, financial challenges, costs of treatment, and limited availability
or capacity of fertility medical care are some of the main challenges in the fertility marketplace in Asia-Pacific region. Religious,
social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have children. We believe that we can help
address some of these key challenges of Asia-Pacific fertility industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>History and Development of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Business Combination,
on April&nbsp;29, 2021, A SPAC I Acquisition Corp. (&ldquo;ASCA&rdquo;), was incorporated as a British Virgin Islands business company,
specifically a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more target businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The Business Combination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&nbsp;15, 2023,
ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &ldquo;Merger Agreement,&rdquo; and the
transactions contemplated thereunder, the &ldquo;Business Combination&rdquo;) with A SPAC&nbsp;I Mini Acquisition Corp., Merger Sub, NewGenIvf
Limited, a Cayman Islands exempted company (&ldquo;Legacy NewGenIvf&rdquo;) and certain shareholders of Legacy NewGenIvf. Pursuant to
the Merger Agreement, the Business Combination was effected in two steps: (i)&nbsp;ASCA was reincorporated to the British Virgin Islands
by merging with and into A SPAC&nbsp;I Mini Acquisition Corp. (such transaction, the &ldquo;Reincorporation Merger&rdquo;); and (ii)&nbsp;Merger
Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the Company (such second step
in isolation, the &ldquo;Acquisition Merger&rdquo;). The surviving entity of the Business Combination, together with its subsidiaries
is referred to in this prospectus as &ldquo;NewGenIvf,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us,&rdquo;
unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;12, 2023, the
parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &ldquo;First Amendment&rdquo;), pursuant to
which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the &ldquo;Loan&rdquo;)
to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA&rsquo;s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from NewGenIvf, ASCA agreed
to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&rsquo;s failure to deliver audited financial
statements by no later than February&nbsp;28, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 6, 2023, the parties
to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &ldquo;Second Amendment&rdquo;) which amended and
modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&rsquo;s board of directors following the consummation
of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf and three (3)
of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the
conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in
connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible assets immediately
after the consummation of the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 3, 2024, the Business
Combination was consummated with the Company as the surviving entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NewGenIvf&rsquo;s Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a focus on providing
fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i) in vitro fertilization
(&ldquo;IVF&rdquo;) treatment service, comprising traditional IVF and egg donation; and (ii)&nbsp;surrogacy and ancillary caring services.
Currently, we have three clinics: one clinic in Thailand, one clinic in Cambodia, and one clinic in Kyrgyzstan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IVF treatment service: </B>For the&nbsp;years ended December&nbsp;31, 2024 and 2023, we generated approximately 100% and 78.3% respectively of our revenue from IVF treatments. We primarily provide our clients with conventional IVF/intracytoplasmic sperm injection (&ldquo;ICSI&rdquo;) and embryo transfer services. As technology has progressively advanced, we have been able to, through technologies and facilities provided by MicroSort technology, help fulfill the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases. IVF treatment involves the performance of a series of medical treatment and procedures that are not separately distinct and only brings benefits to clients when embryo is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time when it is completed in clinic. The completion of this treatment is evidenced by a written IVF report indicating successful embryo implantation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Surrogacy and ancillary caring services: </B>We also generate revenue from surrogacy services and related ancillary caring services in Kyrgyzstan. For the&nbsp;years ended December&nbsp;31, 2024 and 2023, we generated approximately Nil % and 21.7%, of our revenue from surrogacy and ancillary caring services. For surrogacy services, NewGenIvf conducts implantation of embryos from biological parents in surrogate mothers. In addition, NewGenIvf provides a &ldquo;success guarantee&rdquo; program for egg donation services in Cambodia and surrogacy services in Kyrgyzstan. Under this optional program, patients pay additional fees of approximately 40% of the original price and can have repeated attempts of IVF cycles, egg donation services and/or surrogacy services until the procedures are successful. The additional costs to NewGenIvf are generally limited and amount to approximately 30% of the original costs because NewGenIvf&rsquo;s clinics, together with the patients, can choose suitable egg donors and surrogate mothers to limit the additional costs. During the pregnancy period, NewGenIvf provides ancillary caring services including regular body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring services is recognized at a point in time when the surrogate mother gives birth. Surrogacy services provide infertile couples with an alternative method of having children. During 2024, we did not generate any revenue from Surrogacy as we went through a series of reorganization in Kyrgyzstan, resulting in a sale of 100% equity interest in First Fertility Bishkek Limited Liability Company and acquisition of 100% equity interest in Bi Clinic Limited Liability Corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&nbsp;years ended December&nbsp;31,
2024 and 2023, NewGenIvf&rsquo;s revenue was US$5,433,375 and US$5,136,153, and its net income/(loss) was US$(474,101)&nbsp;and US$108,418,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, NewGenIvf&rsquo;s
core market for fertility services is substantial and growing rapidly, driven by, among other things, societal and cultural shifts, such
as people starting families later in life and other health-related challenges which could impact couples&rsquo; and individuals&rsquo;
ability to have children. In addition, NewGenIvf believes that continued overall de-stigmatization of infertility will help drive better
access to, and stronger demand for, fertility treatment services, thereby further enabling the expansion of NewGenIvf&rsquo;s addressable
market. According to CIC, the market size of fertility treatments in Asia Pacific was increasing steadily and the potential size of the
Asia fertility market is expected to reach US$37.4&nbsp;billion by 2030. NewGenIvf believes its market opportunity is substantial and
is continuing to grow as a result of the rising demand for fertility services, the lack of adequate offerings in the market and the increasing
awareness of the challenges of infertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that the
following competitive strengths have positioned it to meet growing opportunities in the fertility market across Asia-Pacific, and have
differentiated it from its competitors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Broad-range ARS Provider Offering Comprehensive
Fertility Treatment Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With almost a decade of experience
in the fertility market, NewGenIvf has built a reputation in the IVF industry in Asia-Pacific. NewGenIvf has reinforced its long-standing
position through expanding its service offerings and locations to address the evolving clients&rsquo; needs or requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s comprehensive
fertility treatment offerings in Thailand, Cambodia, and Kyrgyzstan, primarily including IVF, egg donation (in Cambodia) and surrogacy
services (in Kyrgyzstan), make it convenient for clients in Asia-Pacific market to have access to various fertility services but with
a relatively low cost, as compared with the US market. Meanwhile, the average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding
medication). Each of NewGenIvf&rsquo;s clinics in Thailand, Cambodia, and Kyrgyzstan has its own specialty, and together, NewGenIvf is
able to provide more flexibility and options to its patients. For example, NewGenIvf&rsquo;s Thailand clinic focus on IVF and related
ancillary services including HIV sperm washing, egg freezing, and chromosome screening. The clinic in Cambodia specializes in providing
both IVF services and egg donation services. NewGenIvf opened the clinic in Kyrgyzstan in 2019, which broadened NewGenIvf&rsquo;s services
by being legally qualified/received approval letter from The Ministry of Health of Kyrgyzstan to offer surrogacy services. As of December
31, 2024, NewGenIvf was the one of the few ARS providers in Kyrgyzstan and one of the few companies in Kyrgyzstan that is licensed to
offer surrogacy services in Kyrgyzstan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf attributes its track
record of success to its experienced physicians and its ability to provide comprehensive ARS services, allowing it to meet patients&rsquo;
increasing demand for advanced, high-end, and sophisticated ARS, a higher standard and a wider range of advanced services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has extensive experience
serving Asia-Pacific patients and a deep understanding of their general profiles. In particular, NewGenIvf has personnel speaking multiple
languages, including nurses, facilitators, and translators, who are familiar with the health condition and culture of Asia-Pacific patients
from different countries in the region. NewGenIvf believes that it is therefore well-positioned to benefit from market growth driven by
Asia-Pacific patients travelling to its clinics for treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Attractive Market with Significant Demand and
Fast Growth</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf operates in the
ARS market in Asia Pacific, positioning it to leverage on an attractive market with compelling underlying growth potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Built on years of experience,
NewGenIvf has established a strong reputation in its industry, which in turn attracted potential business partners to approach NewGenIvf
to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly held in the PRC to approach
potential business partners and establish new partnerships by entering into agency agreements with each agent. NewGenIvf has become a
significant partner with approximately 90 fertility service agents in China as well as in India. Normally, each agency agreement has a
maximum term of one year, which is renewable upon mutual agreement. Agents typically market and promote NewGenIvf&rsquo;s services by
word-to-mouth referrals and other measures and NewGenIvf pays the agents commission at a range of 10% to 25% of the treatment fees upon
the completion of client&rsquo;s treatment. Normally, agents provide potential clients&rsquo; contact information to the sales team of
NewGenIvf, who then approach potential clients and provide consultation on services. With its partnerships in various countries, NewGenIvf
believes it is able to better benefit from the growing market opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exclusively Owned and Licensed Technology for
Family Planning and Access to Mature Fertility Technologies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that its
licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient&rsquo;s
needs. These technologies include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>MicroSort Technology:</I> NewGenIvf acquired the MicroSort Technology from Genetics &amp; IVF Institute, Inc. (&ldquo;GIVF&rdquo;) pursuant to a Purchase Agreement dated January 21, 2025 between NewGenIvf and GIVF (&ldquo;Purchase Agreement&rdquo;). As such NewGenIvf exclusively owns the MicroSort Technology. Prior to the closing of the MicroSort Acquisition, NewGenIvf held an exclusive license granted by a division of the Genetics &amp; IVF Institute, Inc. to use MicroSort technology in Thailand and Cambodia. MicroSort technology is a form of pre-conception gender selection technology for humans. MicroSort technology aims to separate male sperm cells based on which gender chromosome they contain, which results in separated semen samples that contain a higher percentage of sperm cells that carry the same gender chromosome. The technology ultimately helps couples choose the gender of their future child by choosing semen samples that predominately contain sperm with the&nbsp;X chromosome for a female or Y chromosome for a male. Traditionally and naturally, gender selection occurs after conception, meaning after the eggs are fertilized. As a result, some fertilized eggs will go unused. However, with MicroSort technology, NewGenIvf is able to increase the ratio of male or female embryos, based on the patient&rsquo;s preference. Eggs are more likely to be fertilized according to the preferences of the parents. Other improvements that MicroSort treatment could help achieve include prevention of certain gender-related hereditary diseases.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preimplantation Genetic Screening (&ldquo;PGS&rdquo;)</I>: PGS is used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Next-Generation Sequencing (&ldquo;NGS&rdquo;)</I>: NGS is a high-throughput technology for determining the sequence of deoxyribonucleic acid (&ldquo;DNA&rdquo;) or ribonucleic acid (&ldquo;RNA&rdquo;) to study genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality and data output.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preimplantation Genetic Diagnosis (&ldquo;PGD&rdquo;)</I>: Similar to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process more enhanced than PGS since it scans for individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic fibrosis, where carrier status has been documented in each of the parents. By using this technique, physicians are able to check the genes or chromosomes for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help women better achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Well Established Brand with Reliable Reputation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The founders of NewGenIvf
entered the fertility market as agents in 2011 by introducing patients in need to a Thailand clinic for fertility treatments. The founders
of NewGenIvf started to operate their own clinic in Thailand in 2014 and subsequently added clinics in Cambodia and Kyrgyzstan. Since
then, NewGenIvf has attracted clients from countries throughout Asia-Pacific, including Mainland China, Hong&nbsp;Kong, India, Thailand,
Australia and Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf benefits from the
favourable geographic locations of its clinics, especially its clinic in Thailand. Located in central Bangkok and situated in one of the
biggest shopping malls of the city, the clinic is located in close proximity to various transportation facilities and popular tourist
attractions, such as the Erawan Shrine. In this regard, NewGenIvf believes that its business has benefited from, and will continue to
benefit from, the convenience of its locations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has developed a
relatively replicable and scalable operating model that supports high productivity at its assisted reproductive medical facilities in
Asia. Under this model, NewGenIvf&rsquo;s medical facilities have established standardized operating procedures to select the treatment
process according to each patient&rsquo;s profile. NewGenIvf&rsquo;s medical and operational personnel are organized into specialized
teams according to the different stages of the treatment process and different patient profiles. When patients are initially admitted
or would like to seek additional medical services later on, they are assigned to one of the optimal medical teams, which NewGenIvf believes
is better suited after taking into account the patient&rsquo;s diagnosis and preferences. NewGenIvf believes that this model allows each
team to improve its efficiency and arrange suitable physicians for patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The physicians of NewGenIvf
have also developed and employed an operating model that seeks to increase the effectiveness of physicians by utilizing standardized workflows
and operating procedures with teams of supporting nurses and medical assistants. This helps to increase the number of IVF treatment cycles
that physicians can perform while providing treatment customized based on patient conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With its established client
service history, accumulated experience as well as its continuous upgrades and development of treatment models, NewGenIvf believes that
it will be able to better monetize its brands through its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Experienced Management Team</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NewGenIvf management team
has considerable experience in the ARS market and the broader healthcare industry. A considerable number of NewGenIvf&rsquo;s management
are physicians or laboratory technicians who possess extensive experience in the ARS industry and are experts in their respective fields.
NewGenIvf&rsquo;s Chief Executive Officer, Mr.&nbsp;Alfred Siu, has more than 13&nbsp;years of experience in the fertility service market.
Dr.&nbsp;Wiphawee Luangtangvarodom had over 8&nbsp;years of experience as an obstetrician and gynecologist. NewGenIvf&rsquo;s two lab
supervisors, Ms. Anussara Phinyong, and Ms. Araya Boonchaisitthipong, each had over eight&nbsp;years of experience in the embryologist
field. These individuals have extensive experience in managing assisted reproductive medical facilities. NewGenIvf is also led by other
members of the professional management team, who are intimately involved in the operational and financial management of NewGenIvf&rsquo;s
Group. Leveraging their experience, NewGenIvf believes that it is well positioned to expand its network and aims to become a leader in
the Asia Pacific ARS market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strategies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s vision is
to provide tailored ARS solutions to fulfil patients&rsquo; dreams of becoming a parent. To realize this vision, NewGenIvf plans to adopt
the following strategies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Offer Broad Fertility Services for Fertility
Tourists across Asia Pacific</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to provide
broad fertility services for fertility tourists seeking high quality, cost effective and comprehensive fertility solutions. According
to CIC, the demand for fertility tourism is driven by a variety of factors including the prevalence of infertility, the introduction of
the Three-Child policy in China, the improved understanding of assisted reproductive technology and increased affordability of ARS.&nbsp;To
address these needs, NewGenIvf plans to offer its customers a &ldquo;hassle-free&rdquo;, seamless and integrated ARS and hospitality arrangement
experience. To complement its fertility services, NewGenIvf intends to integrate its offerings with additional services for traveling
patients, most of whom are first-time fertility tourists, such as translation service, hotel arrangement and airport pickup services.
NewGenIvf plans to enhance its customers&rsquo; experience by entering into exclusive cooperation arrangements with local premium hospitality
providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Continue to Invest in Laboratories and Facilities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes laboratories
and treatment facilities are critical to supporting its future research, development and clients experience. NewGenIvf currently operates
two laboratories that offer IVF services, one in Thailand and one in Cambodia, and plans to continue to scale up its existing laboratories.
NewGenIvf plans to continue to invest in upgrading its laboratories and facilities to complement its growth and expansion, which it believes
will help NewGenIvf maintain an edge over its competitors with regard to technology, operational efficiency, scalability, and client experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to develop
advanced facilities for its existing laboratories, which will be conducting research on ARS related basic science and experiments relating
to emerging technologies to improve ARS success rates and lower costs. NewGenIvf also plans to correlate its data on patient treatment
protocols to the embryo physiologic data and the pregnancy success rate-related data to identify better treatment protocols to increase
ARS success rates. NewGenIvf intends to continue to actively promote technological cooperation with tertiary institutions to discover
ways to improve its IVF success rates. Furthermore, NewGenIvf seeks to actively deploy the technology that it possesses to expand the
services it provides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has accumulated
experience in treating patients over 40&nbsp;years old with premature ovarian failure and patients who have had recurrent ARS implementation
failure, by, for the example, injecting platelet rich plasma into the ovaries to stimulate and support growth of the follicles. NewGenIvf
is also implementing certain technological advancements relevant to the ARS industry, including microfluidics, automated sperm analysers,
time lapsed incubators, non-invasive preimplantation genetic testing (&ldquo;PGT&rdquo;) of cell-free DNA in spent media, automated systems
for oocyte/embryo vitrification to reduce reagent consumption and decrease labor intensity, mitochondria replacement therapy to reconstruct
oocytes by nuclear transfer of polar body genome from an MII oocyte into an enucleated donor MII cytoplasm, to increase the number of
oocytes available for the treatment of infertile women, preimplantation methylome screening. There are also breakthrough developments
in science including organ culture systems, induced pluripotent stem cells, embryonic stem cells, spermatogonial stem cells for creation
of functional gametes, but these techniques are not yet ready for human clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also intends to
develop clinically customised interior design concepts for its medical facilities, including improved service rooms, consultation rooms,
reception areas, nutrition food areas, and traditional Chinese medicine (such as acupuncture) facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Increase Brand Awareness and Market Share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to maintain
and strengthen its brand awareness and market share in Asia Pacific. In order to expand its reach and increase patient numbers, NewGenIvf
plans to collaborate with local hospitals, companies, premium hospitality providers and other key players in the ARS industry in Asia
Pacific. Additionally, NewGenIvf intends to increase brand awareness through social media promotions and marketing initiatives, and establishing
its business development team with the goal of attracting new patients and partners across Asia Pacific. Meanwhile, NewGenIvf intends
to provide innovative treatment services to attract more clients. For example, NewGenIvf plans to introduce IVF mental health services,
which allows clients who fail in IVF treatments to access online consultation for further treatment plans such as egg donation and surrogacy.
These new treatments services aim to enable NewGenIvf to attract potential clients. By adopting a comprehensive strategy to expand its
market share, NewGenIvf aims to strengthen its reputation as a long-standing ARS provider and capture additional market share of the growingly
ARS market in Asia-Pacific.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Expand Service Reach Through Acquisitions and Partnerships</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Leveraging its reputation
and footprint in its current markets, NewGenIvf intends to expand its reach, services offering and client base through strategic acquisitions
and/or partnerships in Asia Pacific. Acquisitions of or by companies offering similar services could not only allow NewGenIvf to diversify
its client base, but also allow it to benefit from potential economies of scale and increasing efficiency through consolidation. NewGenIvf
could also leverage the acquired or acquiring company&rsquo;s customer base, reputation and expertise to further improve its offerings
and operations. NewGenIvf intends to focus on ARS providers in Asia Pacific which possess all conventional licenses and locally recognized
brands. For the global market beyond Asia Pacific, NewGenIvf intends to expand its footprint through partnerships with other IVF clinics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NewGenIvf plans
to explore expanding its client base by offering its fertility services as part of corporate benefit programs in Asia. NewGenIvf believes
that there is potential in Asia in offering fertility treatments as a benefit for employees, particularly in companies with a large number
of female employees of childbearing age. By partnering with corporate clients to provide fertility benefits, NewGenIvf can increase its
market reach, enhance its brand reputation, and drive client growth. NewGenIvf&rsquo;s broad range of fertility services, including IVF
and egg freezing, can help corporate partners differentiate their employee benefits in the competitive employment landscape, which could
make them more attractive to potential employees. Additionally, by offering these services, companies can help address the growing concern
of delayed childbearing, which is becoming more common among women according to CIC.&nbsp;NewGenIvf plans to collaborate with potential
corporate clients to develop customized fertility benefit programs that cater to their specific needs, and to provide comprehensive support
and counselling throughout the process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Meanwhile, NewGenIvf also
intends to attract more clients by establishing its &ldquo;home country gynecologist partnership program&rdquo;. Under the program, NewGenIvf
may, subject to its discretion and screening process, offer treatment services to clients with reduced time requirements to be spent overseas.
Depending on local laws, the potential clients may be able to complete their treatments with gynecologists NewGenIvf partners with, in
their home countries.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf had entered into
a non-binding term sheet dated June 3, 2024 (the &ldquo;Term Sheet&rdquo;) with COVIRIX Medical Pty Ltd (&ldquo;COVIRIX&rdquo;) for a
proposed reverse merger (the &ldquo;Proposed Transaction&rdquo;). However, on September 21, 2024, COVIRIX withdrew from the Proposed Transaction,
as such the Proposed Transaction was terminated with no cost to the Company. On December 11, 2024, NewGenIvf also announced its entry
into a binding term sheet with European Wellness Investment Holdings Limited (&ldquo;EWIHL&rdquo;) for a proposed reverse merger (&ldquo;EWIHL
Proposed Transaction&rdquo;), completion of which was subject to, among other conditions, the completion of due diligence, the negotiation
of a definitive agreement, and obtaining adequate financing. On March 31, 2025, NewGenIvf terminated the term sheet for the EWIHL Proposed
Transaction as EWIHL had failed to produce certain draft audited financials, which were specifically required in the term sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 28, 2025, NewGenIvf
completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&ldquo;GIVF&rdquo;). Pursuant to a Purchase
Agreement dated January 21, 2025 between NewGenIvf and GIVF (&ldquo;Purchase Agreement&rdquo;), NewGenIvf purchased all of the Assets
(as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort technology (as
described below from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Class A Ordinary Shares (equivalent
to 2,500 Class A Ordinary Shares after Third Reverse Stock Split) (&ldquo;MicroSort Acquisition&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>White Lion Transaction</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the
Company entered into a Common Shares Purchase Agreement (the &ldquo;White Lion Purchase Agreement&rdquo;) with White Lion Capital, LLC
(&ldquo;White Lion&rdquo;) and a related Registration Rights Agreement (the &ldquo;RRA&rdquo;). Pursuant to the White Lion Purchase Agreement,
the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars
($100,000,000) in aggregate gross purchase price of newly issued Class A Ordinary Shares, with an automatic increase to Three Hundred
Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement)
and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000)
has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth
in the White Lion Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the satisfaction
of certain customary conditions including, without limitation, the effectiveness of the Registration Statement registering the resale
of the shares issuable pursuant to the White Lion Purchase Agreement, the Company&rsquo;s right to sell shares to White Lion commenced
on the date of the execution of White Lion Purchase Agreement and extends until (i) 36 months from the date of execution of the White
Lion Purchase Agreement, or (ii) at the Company&rsquo;s option, until 65 months from the date of the execution of the White Lion Purchase
Agreement in the event that $100,000,000 of purchases under the White Lion Purchase Agreement have been completed prior to the 36 month
anniversary of the Execution Date (the &ldquo;Commitment Period&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Commitment Period,
subject to the terms and conditions of the White Lion Purchase Agreement, the Company may exercise its right to sell its Class A Ordinary
Shares to White Lion. The Company may deliver a Regular Purchase Notice (as such term is defined in the White Lion Purchase Agreement),
pursuant to which the Company can require White Lion to purchase up to a number of Ordinary Shares equal to the lesser of (i) $3,000,000
divided by the highest closing price of the Ordinary Shares over the most recent five (5) Business Days immediately preceding the Purchase
Notice, or (ii) 40% of Average Daily Trading Volume (as such term is defined in the White Lion Purchase Agreement), subject to a maximum
Investment Limit of $3,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may also deliver
a Rapid Purchase Notice (as such term is defined in the White Lion Purchase Agreement), pursuant to which the Company may require White
Lion to purchase up to a number of Ordinary Shares equal to $3,000,000 divided by the highest closing price of the Ordinary Shares over
the most recent five business days immediately prior to the receipt of the notice. White Lion may waive such limits under any notice at
its discretion and purchase additional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The price to be paid by White
Lion for any shares that the Company requires White Lion to purchase will depend on the type of purchase notice that the Company delivers.
For shares being issued pursuant to a Regular Purchase Notice, the purchase price per share will be the lower of (i) the closing price
of Ordinary Shares prior to the receipt of the applicable Purchase Notice, or (ii) the product of (a) the lowest daily VWAP of the Ordinary
Shares during the Regular Purchase Valuation Period (as defined in the White Lion Purchase Agreement), and (b) 98%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For shares being issued pursuant
to a Rapid Purchase Notice, the Company may opt for the purchase price per share to be (i) equal to the lowest traded price of the Ordinary
Shares on the date that the notice is delivered, or (ii) 97% of the lowest traded price of the Ordinary Shares one hour following White
Lion&rsquo;s written confirmation of the acceptance of the Rapid Purchase Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No purchase notice shall result
in White Lion beneficially owning (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule
13d-3 thereunder) more than 4.99% (subject to increase, in the sole discretion of White Lion, to 9.99%) of the number of Class A Ordinary
Shares outstanding immediately prior to the issuance of Class A Ordinary Shares issuable pursuant to a purchase notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has the right
to terminate the White Lion Purchase Agreement in the event of a material breach of the White Lion Purchase Agreement by White Lion. The
White Lion Purchase Agreement also automatically terminates upon the earlier of (i) the end of the Commitment Period and (ii) the date
that the Company commences a voluntary bankruptcy proceeding, a custodian is appointed for the Company or for all or substantially all
of its property, or the Company makes a general assignment for the benefit of its creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration for the commitments
of White Lion, as described above, the Company has agreed that it will issue to White Lion 700,000 Class A Ordinary Shares (&ldquo;Commitment
Shares&rdquo; and equivalent to 700 Class A Ordinary Shares after Third Reverse Stock Split). Additional Ordinary Shares may be issued
to White Lion under certain conditions, including in connection with material transactions or upon achieving specified investment thresholds.
The Commitment Shares will be fully earned by White Lion regardless of termination of the White Lion Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The White Lion Purchase Agreement
and the RRA contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations,
warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely
for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a focus on providing
fertility treatments to fulfil couples and individuals&rsquo; dreams of raising children, NewGenIvf offers mainly two services, namely:
(i)&nbsp;IVF treatment service, comprising traditional IVF and egg donation; and (ii)&nbsp;surrogacy and ancillary caring services. The
following table sets forth NewGenIvf&rsquo;s revenue by service offerings and as a percentage of total revenue for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">IVF Treatment Service</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,433,375</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100.0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,021,696</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">78.3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Surrogacy and Ancillary Caring Services</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,114,457</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,433,375</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,136,153</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>IVF Treatment Service</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf primarily provides
its clients with conventional IVF/ICSI and embryo transfer services. NewGenIvf is also able to, through MicroSort technology, help fulfill
the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IVF treatments that NewGenIvf
provides address tubal factor, ovulatory dysfunction, diminished ovarian reserve, endometriosis, uterine factor, male factor, unexplained
infertility and other causes. IVF bypasses the function of the fallopian tube by achieving fertilization within a laboratory environment.
Ovarian hyper-stimulation is common with IVF treatments to recruit numerous follicles to increase the chances for success. Follicles are
retrieved trans-vaginally using a vaginal probe and ultrasound guidance. Anaesthesia is frequently used due to the number of follicles
retrieved and the resulting discomfort experienced by the patient. The eggs are identified in the follicular fluid and combined with sperm
and culture medium in culture dishes, which are placed in an incubator with a temperature and gas environment designed to mimic the condition
of the fallopian tubes. Once the embryos develop, typically over a 3-to-5-day period, they are transferred to the uterine cavity. According
to CIC, the average clinical pregnancy success rates, using 5-day incubation, averaged approximately 64.6% (with no PGT) for IVF, with
live birth rate at approximately 28.7%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a long-standing IVF treatments
provider in Asia-Pacific, NewGenIvf had completed over 4,500 cycles of IVF treatments from 2014 to 2024. For the&nbsp;years ended December&nbsp;31,
2024 and 2023, the revenue from NewGenIvf&rsquo;s IVF treatments was US$5,433,375 and US$4,021,696, respectively, representing 100% and
78.3%&nbsp;of its total revenue in the corresponding periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IVF Treatments Process</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A typical IVF treatment process
mainly includes two stages, the pre-IVF treatment stage and the IVF treatment stage. During the IVF treatment process, NewGenIvf also
provides support services such as nutrition guidance and psychological counselling. The flow chart below shows the stages involved in
a typical IVF treatment process:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_006.jpg" ALT=""></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the pre-IVF treatment stage,
clients attend an initial consultation, undergo pre-IVF tests, and undergo treatment for gynaecological and andrological diseases, if
needed. At the initial consultation, a physician reviews the clients&rsquo; detailed medical history to collect more information relating
to the potential cause of their infertility. The client then undergoes various pre-IVF tests, which may include, among other things, blood
pressure, hormone level, ultrasound, infectious disease screening, uterine evaluation and male fertility test. The physician will then
design treatment plans based on the client&rsquo;s medical history and results of the tests. If the client is satisfied with treatment
plan and the test results are acceptable to the physician, the physician will prescribe medications and start stimulation treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first step of the cycle
is to boost egg production through injecting synthetic hormones. Over about one week of ovarian stimulation, clients are monitored on
a regular basis with blood test and transvaginal ultrasound. If follicles have reached at least 10 mm in size, an additional antagonist
drug will be added into the daily injection schedule. This is used to prevent ovulation before ovum pickup time. After another few&nbsp;days
of ovarian simulation, if follicle growth is consistent and majority of follicles are around 16 mm to 17 mm, the final injection of a
human chorionic gonadotropin will be administered. The trigger injection is the final step of the stimulation process and is for the maturation
of the eggs in the follicles before they are collected. The next major step is to retrieve the eggs with a minor surgical procedure called
Trans Vaginal Follicle Aspiration conducted under anaesthesia. At the same time the male partner collects the sperms for fertilizing the
eggs in the laboratory by a process known as intracytoplasmic sperm injection. The fertilized embryos are cultured in the laboratory for
two to six&nbsp;days. Embryos that grow well are biopsied and tested by PGT to detect potential genetic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The final step is to transfer
the embryos into the uterus using a catheter. Within eight&nbsp;days after the embryo transfer, a blood test can be conducted to detect
whether the implantation was successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MicroSort Technology</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroSort technology is a
preconception process developed by the Genetics and IVF Institute, Inc. that aims to improve the chances that the baby to be conceived
will be of the desired gender and prevents certain gender-related hereditary diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Semen samples usually contain
equal amounts of sperm carrying the Y chromosome (which will produce a boy), and sperm carrying the&nbsp;X chromosome (which will produce
a girl). During the MicroSort process, the sperm sample is washed to remove seminal liquid and nonmotile cells. After the washing, the
sample is stained with a special fluorescent material that attaches to the DNA contained in the sperm. The stained sperm cells are analyzed
one by one by a flow cytometer, in which cells pass through a laser to make the stain attach to the DNA fluoresce. The sperm containing
the&nbsp;X chromosome (which have more DNA and therefore more stain) will shine brighter than the sperm containing the Y chromosome. The
flow cytometer uses a special software to identify&nbsp;X&nbsp;and Y chromosome sperm based on their fluorescence signature. The sperm
carrying the chromosome that will produce the desired gender are separated from the rest of the sample -resulting in an enriched sperm
sample ready for use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf held an exclusive
license granted by a division of GIVF, MicroSort International, to use the MicroSort technology in Thailand and Cambodia. MicroSort&rsquo;s
licenses for NewGenIvf&rsquo;s operation in Thailand and Cambodia were each provided under a lease and service agreement. In April 2019,
First Fertility PGS entered into a Lease and Services Agreement with MicroSort International to use MicroSort equipment in Thailand and
in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort International to use MicroSort equipment in
Cambodia (together, the &ldquo;Lease and Services Agreements&rdquo;). Pursuant to the Lease and Services Agreements, First Fertility PGS
and Phnom Penh Center each had the exclusive right to utilize the MicroSort equipment and to market and sell MicroSort sperm sorting services
in Thailand and Cambodia, respectively. MicroSort International was responsible for the maintenance of MicroSort equipment and technical
and engineering support. The term of each Lease and Service Agreements was initially from 2019 to 2024, which shall be automatically renewed
for one year unless a written notice of at least 180 days prior to the intended termination date is provided. The consideration under
each of the Lease and Services Agreements was US$9,000 per month after six months.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 28, 2025, NewGenIvf
completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&ldquo;GIVF&rdquo;). Pursuant to a Purchase
Agreement dated January 21, 2025 between NewGenIvf and GIVF (&ldquo;Purchase Agreement&rdquo;), NewGenIvf purchased all of the Assets
(as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort technology from
GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Ordinary Shares (equivalent to 2,500 Class A Ordinary Shares
after Third Reverse Stock Split) (&ldquo;MicroSort Acquisition&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the closing of the
MicroSort Acquisition, NewGenIvf held an exclusive license granted by a division of GIVF, MicroSort International, to use the MicroSort
technology in Thailand and Cambodia. MicroSort&rsquo;s licenses for NewGenIvf&rsquo;s operation in Thailand and Cambodia were each provided
under a lease and service agreement. In April 2019, First Fertility PGS entered into a Lease and Services Agreement with MicroSort International
to use MicroSort equipment in Thailand and in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort
International to use MicroSort equipment in Cambodia (together, the &ldquo;Lease and Services Agreements&rdquo;). Pursuant to the Lease
and Services Agreements, First Fertility PGS and Phnom Penh Center each had the exclusive right to utilize the MicroSort equipment and
to market and sell MicroSort sperm sorting services in Thailand and Cambodia, respectively. MicroSort International was responsible for
the maintenance of MicroSort equipment and technical and engineering support. The term of each Lease and Service Agreements was initially
from 2019 to 2024, which shall be automatically renewed for one year unless a written notice of at&nbsp;least 180 days prior to the intended
termination date is provided. The consideration under each of the Lease and Services Agreements was US$9,000 per month after six months
from the effective date of the agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The flow chart below shows
the process involved in MicroSort:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_007.jpg" ALT=""></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preimplantation Genetic Screening</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PGS is used in parallel with
an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing
embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of
implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate of
70.9% and reducing miscarriage rates by 26.6%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next-Generation Sequencing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NGS is a high-throughput technology
for determining the sequence of deoxyribonucleic acid DNA or RNA to study genetic variation associated with diseases or other biological
phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing determines
the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time and cost associated
with sequencing and increases the coverage quality and data output.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preimplantation Genetic Diagnosis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to PGS, PGD is also
used in parallel with an IVF treatment cycle. But PGD is a more enhanced process than PGS since it scans for individual genes. PGD is
the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic fibrosis, where carrier status
has been documented in each of the parents. By using this technique, physicians are able to check the genes or chromosomes for a specific
genetic condition. PGD can decrease the risk of miscarriage and this technology can help women achieve a healthy pregnancy. Individuals
who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Surrogacy and Ancillary Caring Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also generated revenue
from surrogacy services and related ancillary caring services in Kyrgyzstan. NewGenIvf conducts implantation of embryos from biological
parents in surrogate mothers. During the pregnancy period, NewGenIvf provides ancillary caring services including regular body check and
provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring services is recognized
when the surrogate mother gives birth. Surrogacy services provide infertile couples with an alternative method of having children. In
general, NewGenIvf provides certain discount to clients if they wish to pursue additional services such as egg donation and surrogacy,
after several cycles of IVF treatments failures due to medical reasons including, but not limited to, the poor egg quality of aged female
clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As compared to other countries,
Kyrgyzstan has the following features that allow NewGenIvf to operates its surrogacy services: (i)&nbsp;surrogacy is legal and regulated,
which means that there are less restrictions on either intended parents or surrogate mothers, and a parent-child relationship can be requested
before the child&rsquo;s birth; and (ii)&nbsp;the costs of operation and surrogate mother is favourable, given the cost of living in Kyrgyzstan
is relatively low.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the regular
surrogacy services, NewGenIvf is also able to assist the clients with birth certificate applications and facilitate the application of
infants&rsquo; passports and visas as supplemental services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&nbsp;years ended December&nbsp;31,
2024 and 2023, the revenue from NewGenIvf&rsquo;s surrogacy and ancillary caring services was US$ Nil and US$1,114,457, respectively,
representing Nil % and 21.7% of its total revenue in the corresponding periods. During 2024, we did not generate any revenue from surrogacy
as we went through a series of reorganization in Kyrgyzstan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The flow chart below shows
the stages involved in a typical surrogacy process:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_008.jpg" ALT=""></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Kyrgyzstan, NewGenIvf also
provides ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&nbsp;maternity
caring service, and (ii)&nbsp;documentation service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Network of Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, NewGenIvf
had one administrative support office located in Hong&nbsp;Kong and three clinics located in Thailand, in Cambodia, and in Kyrgyzstan,
respectively. The integration of the medical facilities in Thailand help NewGenIvf provide a more seamless one-stop experience to its
clients. Set out below is an illustration of the locations of NewGenIvf&rsquo;s clinics and marketing and sales office:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the approximate aggregate average gross floor area (&ldquo;<B>G.F.A.</B>&rdquo;) of each of NewGenIvf&rsquo;s clinics that were under
lease and actively used for client service as of August 1, 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <BR> August 1, 2025</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">(Square Feet)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic">Thailand</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Co., Ltd. &ndash; PS Tower<BR> (&ldquo;<B>First Fertility PGS Center</B>&rdquo;)</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">14,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Co., Ltd &ndash; Erawan Hotel <B><BR> (&ldquo;First Fertility PGS Center&rdquo;)</B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-indent: -9pt; padding-left: 9pt">Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Center <BR> (&ldquo;<B>Phnom Penh Center</B>&rdquo;)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-indent: -9pt; padding-left: 9pt">Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Bi Clinic Limited Liability Company <BR> (&ldquo;Bi Clinic&rdquo;)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,164</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Aggregate G.F.A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,096</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To increase the scale of NewGenIvf&rsquo;s
operations, NewGenIvf expanded its Thailand fertility services by leasing a new property for its second clinic Erawan Consultation Clinic
in May&nbsp;2023. Consisting of approximately 2,500 sq. ft., Erawan Consultation Clinic has been open since June 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, IVF treatments
are performed in its Thailand and Cambodia clinics, egg donation services are provided in its Cambodia clinic, and surrogacy services
are provided in its Kyrgyzstan clinic. The following table summarises the services available at NewGenIvf&rsquo;s clinics:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">IVF <BR> Treatments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Surrogacy <BR> Services</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; font-style: italic">Thailand</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">First Fertility PGS Centers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&times;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic">Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Phnom Penh Center &nbsp;(PS Tower)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&times;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">First Fertility PGS Center (Erawan Hotel)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&times;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic">Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">First Fertility Bishkek (Disposed of on December 18, 2024)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">BiClinic (Acquired on December 17, 2024)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&radic;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&times;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
a breakdown of revenue from services performed at NewGenIvf&rsquo;s medical centers for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">HK SAR</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">34,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Thailand</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,175,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,356,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26.4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">601,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Kyrgyzstan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,656,596</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,123,593</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total Revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,433,375</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,136,153</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Thailand Clinic</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, NewGenIvf
had two operating clinics in Thailand. At the clinic in Thailand, NewGenIvf offers its clients customized fertility treatment solutions
including IVF/ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening by PGT, hysteroscopy, sperm
analysis, sorting, washing and freezing, and egg freezing. Its medical and operational personnel are organized into specialized teams
according to the different stages of the IVF treatment process and different patient profiles. When clients are admitted, they are assigned
to a team which NewGenIvf believes is better suited the clients after taking into account the clients&rsquo; diagnosis and preferences.
Furthermore, NewGenIvf also provides related value-added services such as nutrition guidance, psychological counselling, acupuncture,
and translation interpreters to supplement the IVF treatment. NewGenIvf prides itself on providing quality and customized treatment to
its clients on a&nbsp;day-to-day basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, the
clinics in Thailand had 8 nurses, 8 full time lab physicians and embryologists, 22 administrative staff, totaling 38 staff members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cambodia Clinic</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, NewGenIvf
has one clinic, Phnom Penh Center, in Cambodia. Phnom Penh Center is staffed with 4 Cambodian physicians, 2 embryologists, 6 nurses and
12 other staff, and offers similar IVF treatments as in Thailand and egg donation services. Phnom Penh Center operates under a license
issued by Cambodia MOH for the Cambodian physician, who has entered into an agreement with Phnom Penh Center for the exclusive use of
such license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After eight&nbsp;years of
development since its opening in 2015, Phnom Penh Center has become one of the long-standing ARS providers in Cambodia. According to CIC,
it was the first to use conventional IVF technology which led to a successful birth in 2016 in Cambodia. Since its establishment, Phnom
Penh Center achieved more than 1,600 IVF treatment cycles as of December 31, 2024. As of December 31, 2024, Phnom Penh Center&rsquo;s
IVF philosophy concentrates on three key points in the treatment process: the mother&rsquo;s wellbeing, the technology used to assist
mothers deliver a strong and healthy baby and the medical science used to ensure every chance of success for women in various age spectrums.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Clinic in Kyrgyzstan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf established First
Fertility Bishkek in October&nbsp;2019 in Kyrgyzstan for its surrogacy services, as Kyrgyzstan has supply of surrogate candidates at a
relatively low cost and a more friendly legal environment for surrogacy services. In 2020, First Fertility Bishkek obtained the license
to provide ARS and surrogacy services, becoming one of the few facilities licensed to offer ARS and one of the facilities licensed to
offer surrogacy services in Kyrgyzstan as of December&nbsp;31, 2024, according to CIC.&nbsp;In addition, NewGenIvf also provide related
ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&nbsp;maternity caring
service, and (ii)&nbsp;documentation service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians at First Fertility
Bishkek have expertise in sourcing surrogate mothers, techniques of embryo transfers, prenatal care, baby delivery, and postnatal care.
First Fertility Bishkek also collaborates closely with Phnom Penh Center in arranging shipment of frozen embryos. NewGenIvf hires local
physicians and local staff. NewGenIvf also provides training for newly admitted Kyrgyzstan physicians and embryologists in Thailand. Some
personnel who had relevant experience in Kyrgyzstan had also been sent from Cambodia to Kyrgyzstan to help manage such operations from
time to time. However, during 2024, Kyrgyzstan operations had been reorganized, resulting in disposal of First Fertility Bishkek and acquisition
of Bi Clinic Limited Liability Corporation in December 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, Bi Clinic
had 1 full-time physician, 1 embryologist, 1 nurse, and 7 other staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Professionals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Licensed Physicians</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 1, 2025, NewGenIvf
employed 5 licensed physicians, among which one was based in Cambodia, one was based in Kyrgyzstan, and the other three were based in
Thailand. Most of NewGenIvf&rsquo;s physicians had over 10&nbsp;years of experience or above. The following table summarises the number
and types of such licensed physicians as of August 1, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensed physician</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licenses and<BR>
Approvals</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective Period</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 27%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuing<BR>
Authority</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cambodia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.&nbsp;Keut Serey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decision on permission for beauty treatment operation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;14, 2022&nbsp;&ndash; December&nbsp;14, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Ministry of Health of Cambodia</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Keatthisak Boonsimma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 31801 Medical Practitioner License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&nbsp;1, 2005&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royal Thai College of Obstetricians and Gynaecologists of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 22624/2554<BR>
OB-Gyn License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;1, 2014&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 40962/2563 Reproductive Medicine Diploma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;1, 2020&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Anurach Kulvanitchaiyanunt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Practice License No. 11755</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 1 2025&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Wiphawee Luangtangvarodom</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 38347/2562<BR>
OB-Gyn License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&nbsp;1, 2019&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 43217/2564 Reproductive Medicine License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;1, 2021&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 48510 Medical Practitioner License</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&nbsp;1, 2014&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyrgyzstan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Myrzalymbekova A.B.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp; numero; CO170001836 Medical Certificate </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 23. 2017&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;0002953 Medical Practitioner</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25 April 2018&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;11373\2565 Medical Certificate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16 August 2024&nbsp;&ndash; Indefinite </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;0003447 Medical Certificate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12 April 2023&nbsp;&ndash; Indefinite</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Customers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&nbsp;years ended December&nbsp;31,
2024 and 2023, the majority of NewGenIvf&rsquo;s clients were from China (including mainland China and Hong Kong). The number of Thai
and Cambodian local patients generally increased in 2023 and 2024 compared with earlier years due to the impact of COVID-19 on international
travel. NewGenIvf enters into a service agreement with each of its customers that outline, among other things, the scope of services,
service fees, payment terms and rights, responsibilities and obligations of each party. Consent is obtained from the patients prior to
the provision of the various treatments. Customers are not entitled to enjoy the relevant services until outstanding amounts have been
settled pursuant to the relevant contract. Sales to individual consumers did not vary significantly and none of the customers contribute
more than 10% of NewGenIvf&rsquo;s revenue for the&nbsp;years ended December&nbsp;31, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to significant
customers using NewGenIvf&rsquo;s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
utilize the access to the freezing and storage facility and other relatively insignificant services, such as check-ups services, blood
test services and other minor services (the latter category of customers are referred to as &ldquo;consultation customers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to significant
customers using NewGenIvf&rsquo;s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
only use its relatively insignificant services, such as check-ups services, blood test services and other minor services (the latter category
of customers are referred to as &ldquo;consultation customers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&nbsp;years ended December&nbsp;31,
2024 and 2023, NewGenIvf promoted brand awareness through its sales teams and, in many cases, through cooperating with third-party agencies
and partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s sales teams
have broad experience in fertility services and are responsible for identifying potential clients and managing the overall sales process.
NewGenIvf&rsquo;s sales team primarily relies on social media marketing, word-of-mouth referrals, recognition of its brand, printed advertisements
and marketing events. NewGenIvf spends marketing expenses on placing advertisements through popular social media platforms, maintaining
the official website of NewGenIvf and sending information through its official accounts on social media platforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Supply and Procurement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&rsquo;s procurement
is mainly for medications, laboratory media and reagents, laboratory consumables, and blood test reagents. As of December&nbsp;31, 2023,
there was one supplier that individually contributed more than 10% of the Group&rsquo;s trade payable, accounting for 30.6% of the Group&rsquo;s
trade payables. For both the years ended December&nbsp;31, 2024 and 2023, no vendor contributed more than 10% of total direct cost of
the Group. NewGenIvf&rsquo;s procurement team is experienced in selecting cost-effective supplies as well as selecting reliable suppliers.
NewGenIvf&rsquo;s major suppliers are pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that it
is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the value and comprehensiveness of the solutions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">treatment that is effective and achieves desired outcomes;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clients&rsquo; experience, including dedicated patient education, clinical guidance and emotional support; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">access to a network of high-quality fertility specialists.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf competes primarily
with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and
integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf&rsquo;s competitors may compete in a variety
of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting
brand promotions and other marketing activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As NewGenIvf may introduce
new ancillary services and other companies may introduce similar fertility services as NewGenIvf&rsquo;s, NewGenIvf may become subject
to additional competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, in
addition to its clinics, NewGenIvf leased one property in Hong&nbsp;Kong with an aggregate square footage of approximately 8,000 for its
administration support offices. NewGenIvf also operates its medical facilities as described above in &ldquo;&mdash;&nbsp;Network of Facilities&rdquo;
above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>SELLING SECURITYHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the possible resale from time to time by the Selling Securityholders of up to 50,000,000 Class A Ordinary Shares, which includes (i) up
to 20,000,000 Class A Ordinary Shares issuable by the Company to White Lion Capital, LLC (&ldquo;White Lion&rdquo;) in connection with
the Common Stock Purchase Agreement dated as of November 21, 2024, by and between the Company and White Lion (the &ldquo;White Lion Purchase
Agreement&rdquo;), and (ii) up to 30,000,000 Class A Ordinary Shares issuable upon the conversion of (a) the Remaining Additional Notes
(as defined below), (b) the senior convertible notes exchanged on August 8, 2024 (the &ldquo;Exchange Notes&rdquo;), (c) the exercise
of Series A warrants to purchase Class A Ordinary Shares (the &ldquo;Series A Warrants&rdquo;), (d) the exercise of Series B warrants
to purchase Class A Ordinary Shares (the &ldquo;Series B Warrants&rdquo;), (e) the exercise of Series C warrants to purchase Class A Ordinary
Shares (the &ldquo;Exchange Warrants and together with the Series A Warrants, and the Series B Warrants, the &ldquo;Warrants&rdquo;),
and (f) the New CB Initial Note. We are registering the Resale Shares to satisfy certain registration rights that we have granted to the
Selling Securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
may from time to time offer and sell any or all of the securities set forth below pursuant to this prospectus. When we refer to the &ldquo;Selling
Securityholders&rdquo; in this prospectus, we mean the persons listed in the tables below, and the pledgees, donees, transferees, assignees,
successors and others who later come to hold any of the Selling Securityholders&rsquo; interest in our securities after the date of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below presents information
regarding the Selling Securityholders and the Resale Shares that they may offer from time to time under this prospectus. This table is
prepared based on information known to us as of August 21, 2025. The number of shares in the column &ldquo;Maximum Number of Ordinary
Shares to be Sold Pursuant to this Prospectus&rdquo; represents all of the Class A Ordinary Shares that the Selling Securityholders may
offer under this prospectus. The Selling Securityholders may sell some, all or none of its shares in this offering. We do not know how
long the Selling Securityholders will hold the shares before selling them, and we currently have no agreements, arrangements or understandings
with the Selling Securityholders regarding the sale of any of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Beneficial ownership is determined in accordance
with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes Class A Ordinary Shares with respect to which a Selling
Securityholder has voting and investment power. The percentage of Class A Ordinary Shares beneficially owned by the Selling Securityholder
prior to the offering shown in the table below is based on an aggregate of 2,152,702 Ordinary Shares outstanding as of August 21, 2025.
The fourth column assumes the sale of all of the shares offered by the Selling Securityholder pursuant to this prospectus.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may require the
Selling Securityholders to suspend the sales of the Resale Shares offered by this prospectus upon the occurrence of any event that makes
any statement in this prospectus or the Registration Statement untrue in any material respect or that requires the changing of statements
in these documents in order to make statements in those documents not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Selling Securityholders</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary <BR> Shares <BR> Beneficially <BR> Owned<BR> Prior to <BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage&nbsp;of <BR> Ordinary Shares Beneficially Owned <BR> Prior to<BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum <BR> Number of <BR> Ordinary<BR> Shares <BR> to be <BR> Sold<BR> Pursuant to<BR> this<BR> Prospectus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary <BR> Shares Beneficially Owned<BR> Immediately<BR> After Sale of <BR> Maximum<BR> Number&nbsp;of Shares <BR> in this<BR> Offering<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage&nbsp;of<BR> Ordinary Shares Beneficially Owned Immediately<BR> After <BR> Sale of<BR> Maximum<BR> Number&nbsp;of Shares<BR> in this<BR> Offering<SUP>(1)(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAK Opportunities VI LLC <SUP>(3)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">30,000,000</TD><TD STYLE="width: 1%; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">White Lion Capital LLC <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The applicable percentage of beneficial ownership is calculated based on the total number of ordinary shares issued and outstanding, being 2,152,702 shares as of the date of this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the amount of ordinary shares that will be held by the Selling Securityholder after completion of this offering based on the assumptions that (a) all ordinary shares, including all ordinary shares underlying the Notes and Warrants, registered for sale by the registration statement of which this prospectus is part of will be sold, and (b) no other shares of ordinary shares are acquired or sold by the Selling Securityholder prior to completion of this offering.&nbsp;&nbsp;However, the Selling Securityholder is not obligated to sell all or any portion of the ordinary shares offered pursuant to this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: -35.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify">The Selling Securityholder, JAK Opportunities VI LLC (&ldquo;JAK VI&rdquo;), is wholly-owned by ATW Opportunities Master Fund II, L.P. (the &ldquo;Fund&rdquo;). ATW Partners Opportunities Management, LLC serves as the investment manager to the Fund (the &ldquo;Adviser&rdquo;). The Fund and the Adviser may be deemed to have shared voting and dispositive power with respect to the shares of common stock beneficially owned by the Selling Securityholder and may be deemed to be the beneficial owner of these shares. Antonio Ruiz-Gimenez and Kerry Propper serve as the managing members of the Adviser (the &ldquo;Managing Members&rdquo;). The Managing Members, in their capacity as Managing Members of the Adviser, may also be deemed to have investment discretion and voting power over the shares of common stock beneficially owned by the Selling Securityholder. The Fund, the Adviser and the Managing Members each disclaim any beneficial ownership of such holdings. The address of this Selling Securityholder is c/o ATW Partners Opportunities Management, LLC, 1 Pennsylvania Plaza, Suite 4810, New York, NY 10119.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -35.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -35.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The business address of White Lion is 17631 Ventura Blvd, Suite 1008, Encino, CA 91316</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -35.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the terms of the Registration Rights Agreement with this Selling Securityholder, for purposes of the calculations of ordinary shares to be sold by this Selling Securityholder pursuant to the prospectus we are assuming (i) an event of default under the Fifth Tranche Note and the Additional Remaining Notes has not occurred and the issuance of 250% of the ordinary shares underlying the Fourth Tranche Note, assuming that (x) all Additional Notes issuable under the Securities Purchase Agreement (as defined below) have been issued and (y) the Notes, including payment of 14.75% interest on the Notes through the fifty-four (54) month anniversary of the issuance date of such Notes, are converted in full at an alternate conversion price of $0.2388 per share, without regard to any limitations set forth therein and (ii) the issuance of the maximum amount of ordinary shares underlying the Warrants, exercised in full at the applicable exercise price without regard to any limitations set forth therein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering the Class
A Ordinary Shares previously issued and the Class A Ordinary Shares issuable upon conversion of the Notes and exercise of the Warrants,
to permit the resale of these Class A Ordinary Shares by the holders of these securities from time to time after the date of this prospectus.
We will not receive any of the proceeds from the sale by the Selling Securityholders of the Class A Ordinary Shares, although we will
receive (i) the exercise price of any Warrants not exercised by the Selling Securityholders on a cashless exercise basis, and (ii) gross
proceeds of up to $500 million from the sale of our Class A Ordinary Shares to White Lion pursuant to the White Lion Purchase Agreement.
We will bear all fees and expenses incident to our obligation to register the Selling Securityholder&rsquo;s Class A Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
may sell all or a portion of the Class A Ordinary Shares held by them and offered hereby from time to time directly or through one or
more underwriters, broker-dealers or agents. If the Class A Ordinary Shares are sold through underwriters or broker-dealers, the Selling
Securityholders will be responsible for underwriting discounts or commissions or agent&rsquo;s commissions. The Class A Ordinary Shares
may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined
at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions,
pursuant to one or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions other than on these exchanges or systems or in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or settlement of options, whether such options are listed on an options exchange or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short sales made after the date the Registration Statement is declared effective by the SEC;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers may agree with the selling securityholders to sell a specified number of such shares at a stipulated price per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such methods of sale; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
may also sell Class A Ordinary Shares under Rule 144 promulgated under the Securities Act, if available, rather than under this prospectus.
In addition, the Selling Securityholders may transfer the Class A Ordinary Shares by other means not described in this prospectus. If
the Selling Securityholders effect such transactions by selling Class A Ordinary Shares to or through underwriters, broker-dealers or
agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from
the Selling Securityholders or commissions from purchasers of the Class A Ordinary Shares for whom they may act as an agent or to whom
they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be
in excess of those customary in the types of transactions involved). In connection with sales of the Class A Ordinary Shares or otherwise,
the Selling Securityholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the Class
A Ordinary Shares in the course of hedging in positions they assume. The Selling Securityholders may also sell Class A Ordinary Shares
short and deliver Class A Ordinary Shares covered by this prospectus to close out short positions and to return borrowed shares in connection
with such short sales. The Selling Securityholders may also loan or pledge Class A Ordinary Shares to broker-dealers that in turn may
sell such shares.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
may pledge or grant a security interest in some or all of the Class A Ordinary Shares owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the Ordinary Shares from time to time pursuant to this
prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if
necessary, the list of Selling Securityholders to include the pledgee, transferee or other successors in interest as Selling Securityholders
under this prospectus. The Selling Securityholders also may transfer and donate the Class A Ordinary Shares in other circumstances in
which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus. To the extent required by the Securities Act and the rules and regulations thereunder, the Selling Securityholders and any
broker-dealer participating in the distribution of the shares may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the
Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting
commissions or discounts under the Securities Act. At the time a particular offering of the shares is made, a prospectus supplement, if
required, will be distributed which will set forth the aggregate amount of Class A Ordinary Shares being offered and the terms of the
offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation
from the Selling Securityholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the securities laws
of some states, the Class A Ordinary Shares may be sold in such states only through registered or licensed brokers or dealers. In addition,
in some states, the Class A Ordinary Shares may not be sold unless such shares have been registered or qualified for sale in such state
or an exemption from registration or qualification is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that any Selling Securityholders will sell any or all of the Class A Ordinary Shares registered pursuant to the registration statement,
of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act, and the rules and
regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the
timing of purchases and sales of any of the shares by the Selling Securityholders and any other participating person. To the extent applicable,
Regulation M may also restrict the ability of any person engaged in the distribution of the Class A Ordinary Shares to engage in market-making
activities with respect to the shares. All of the foregoing may affect the marketability of the Class A Ordinary Shares and the ability
of any person or entity to engage in market-making activities with respect to the Class A Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay all expenses of
the registration of the Class A Ordinary Shares, estimated to be $. in total, including, without limitation, SEC filing fees and expenses
of compliance with state securities or &ldquo;blue sky&rdquo; laws; provided, however, that a Selling Securityholders will pay all underwriting
discounts and selling commissions if any. We will indemnify the Selling Securityholders against liabilities, including some liabilities
under the Securities Act in accordance with the Registration Rights Agreement, or the Selling Securityholders will be entitled to contribution.
We may be indemnified by the Selling Securityholders against civil liabilities, including liabilities under the Securities Act, that may
arise from any written information furnished to us by the Selling Securityholders specifically for use in this prospectus, in accordance
with the related registration rights agreements or we may be entitled to contribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once sold under the registration
statement, of which this prospectus forms a part, the Class A Ordinary Shares will be freely tradable in the hands of persons other than
our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A><B>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Class A and Class B Ordinary Shares </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Memorandum and Articles
of Association authorize the issuance of unlimited Class A Ordinary Shares, unlimited Class B Ordinary Shares and unlimited preferred
shares with no par value (&ldquo;Preferred Shares&rdquo;). As of the date of this prospectus, we have 2,148,596 Class A Ordinary Shares
outstanding, 4,106 Class B Ordinary Shares outstanding, and no Preferred Shares outstanding. All of our outstanding Class A Ordinary Shares
are validly issued, and fully paid. Our Class A Ordinary Shares and Class B Ordinary Shares are not subject to any preemptive right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Hei
Yue Tina Fong and Wing Fung Alfred Siu control the voting power of all of the outstanding Class&nbsp;B Ordinary Shares. Although Ms. Fong
and Mr. Siu control the voting power of all of the outstanding Class&nbsp;B Ordinary Shares, their control over those shares is not permanent
and is subject to reduction or elimination at any time or after certain periods as a result of a variety of factors. As further described
below, upon any transfer of Class&nbsp;B Ordinary Shares by a holder thereof to any person which is not a Permitted Transferee of such
holder, those shares will automatically and immediately convert into Class&nbsp;A Ordinary Shares. In addition, all Class&nbsp;B Ordinary
Shares will automatically convert to Class&nbsp;A Ordinary Shares in other events described below. See &ldquo;&mdash; Optional and Mandatory
Conversion.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividends<I>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our Class A
Ordinary Shares and Class B Ordinary Shares are entitled to such dividends as may be declared by its Board of Directors subject to its
Memorandum and Articles of Association and applicable law. No dividend may be declared and paid unless the Board of Directors determine
that, immediately after the payment, the value of the Company assets will exceed its liabilities and the Company will be able to pay its
debts as and when they fall due. Holders of Class A ordinary shares and Class B ordinary shares will be entitled to the same amount of
dividends, if declared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting Rights</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Holders
of Class A Ordinary Shares and Class B Ordinary Shares have the right to receive notice of, attend, speak and vote at general meetings
of the shareholders. In respect of all matters upon which holders of our shares are entitled to vote, each Class&nbsp;A Ordinary Share
are entitled to one (1)&nbsp;vote and each Class&nbsp;B Ordinary Share are entitled to one hundred (100)&nbsp;votes. At any meeting of
shareholders a resolution put to the vote of the meeting shall be decided by way of a poll and not by way of a show of hands. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A meeting of the shareholders
is duly constituted if, at the commencement of the meeting, there are present in person or by proxy not less than 50 per cent of the votes
of the shares entitled to vote on resolutions of the shareholders to be considered at the meeting. As a BVI business company, the Company
is not obliged by the BVI Act to call shareholders&rsquo; annual general meetings. The Memorandum and Articles of Association provide
that the Company may (but is not obliged to) in each calendar year hold a general meeting as its annual general meeting in which case
the Company will specify the meeting as such in the notices calling it, and the annual general meeting will be held at such time and place
as may be determined by its directors. Each general meeting, other than an annual general meeting, shall be an extraordinary general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders&rsquo; annual
general meetings and any other general meetings of the Company&rsquo;s shareholders may be convened by any director or, upon a requisition
of shareholders holding at the date of deposit of the requisition not less than 30 percent of the votes attaching to the issued and outstanding
shares entitled to vote at general meetings in respect of the matter for which the meeting is requested, in which case the directors are
obliged to convene such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, the Memorandum and Articles
of Association do not provide its shareholders with any right to put any proposals before any annual general meetings or any extraordinary
general meetings not called by such shareholders. Advance notice of at least ten (10) days and not more than sixty (60) days is required
for the convening of the Company&rsquo;s annual general meeting and other general meetings unless such notice is waived in accordance
with its articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any resolution to be passed
at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the shares cast by those
shareholders entitled to vote who are present in person or by proxy at a general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conversion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to any applicable
adjustment pursuant to the Memorandum and Articles of Association, each Class B Ordinary Share is convertible into one (1) Class A Ordinary
Share at any time at the option of the holder thereof. The right to convert shall be exercisable by the holder of the Class B Ordinary
Share delivering a written notice to the Company that such holder elects to convert a specified number of Class B Ordinary Shares into
Class A Ordinary Shares. In no event shall Class A Ordinary Shares be convertible into Class B Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted by the BVI Act
and the Memorandum and Articles of Association, the Company may be voluntarily liquidated under Part XII of the BVI Act by resolution
of directors and resolution of shareholders if the Company&rsquo;s assets exceed the Company&rsquo;s liabilities and the Company is able
to pay the Company&rsquo;s debts as they fall due. The Company may also be wound up in circumstances where the Company is insolvent in
accordance with the terms of the BVI Insolvency Act (As Revised).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company is wound up
and the assets available for distribution among the Company&rsquo;s shareholders are more than sufficient to repay all amounts paid to
the Company on account of the issue of shares immediately prior to the winding up, the excess shall be distributable pari passu among
those shareholders in proportion to the amount paid up immediately prior to the winding up on the shares held by them, respectively. If
the Company is wound up and the assets available for distribution among the shareholders as such are insufficient to repay the whole of
the amounts paid to the Company on account of the issue of shares, those assets shall be distributed so that, to the greatest extent possible,
the losses shall be borne by the shareholders in proportion to the amounts paid up immediately prior to the winding up on the shares held
by them, respectively. If the Company is wound up, the liquidator appointed by the Company may, in accordance with the BVI Act, divide
among the Company&rsquo;s shareholders in specie or kind the whole or any part of the Company&rsquo;s assets (whether they shall consist
of property of the same kind or not) and may, for such purpose, set such value as the liquidator deems fair upon any property to be divided
and may determine how such division shall be carried out as between the shareholders or different classes of shareholder</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Redemption, Repurchase and Surrender of Ordinary
Shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may issue shares
on terms that such shares are subject to redemption, at the Company&rsquo;s option or at the option of the holders thereof, on such terms
and in such manner as may be determined, before the issue of such shares, by the Board of Directors. The Company may also repurchase any
of its shares provided that the Company may not purchase, redeem or otherwise acquire its own shares without the consent of the shareholder
whose Shares are to be purchased, redeemed or otherwise acquired unless the Company is permitted or required by the Act or any other provision
in the Memorandum or Articles to purchase, redeem or otherwise acquire the Shares without such consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Variations of Rights of Shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the Company&rsquo;s
share are divided into different classes or series of shares, the rights attached to any class or series of shares (unless otherwise provided
by the terms of issue of the shares of that class or series), whether or not the Company is being wound-up, may be varied by a resolution
passed at a meeting by the holders of more than fifty percent of the issued shares of that class that have voted (and are entitled to
vote thereon) in relation to any such resolution, unless otherwise provided by the terms of issue of such class. The rights conferred
upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares
of that class, be deemed to be varied by the creation or issue of further shares ranking pari passu with such existing class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Inspection of Books and Records. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our Class A Ordinary
Shares and Class B Ordinary Shares have no general right under BVI law to inspect or obtain copies of the Company&rsquo;s list of shareholders
or its corporate records. However, the Company will provide its shareholders with annual audited financial statements. See &ldquo;Where
You Can Find Additional Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Issuance of Additional Shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Memorandum and Articles
of Association authorize the Board of Directors to issue additional Class A or Class B Ordinary Shares from time to time as the Board
of Directors shall determine, to the extent of available authorized but unissued shares. The Memorandum and Articles of Association also
authorize the Board of Directors to establish from time to time one or more series of preferred shares and to determine, with respect
to any series of preferred shares, the terms and rights of that series, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dividend rights, dividend rates, conversion rights, voting rights; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rights and terms of redemption and liquidation preferences.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may
issue preferred shares without action by its shareholders to the extent authorized but unissued. Issuance of these shares may dilute the
voting power of holders of Class A Ordinary Shares and Class B Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some provisions of the Memorandum
and Articles of Association may discourage, delay or prevent a change of control of the Company or management that shareholders may consider
favorable, including (i) provisions that authorize the Board of Directors to issue preferred shares in one or more series and to designate
the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by its shareholders;
and (ii) provisions providing that directors may not be removed by the shareholders except for cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Preferred Shares</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable law
and the Memorandum and Articles of Association, the Board of Directors may issue Preferred Shares with such preferred rights as they shall
determine. The rights, privileges, restrictions and conditions attaching to the Preferred Shares shall be stated in the Memorandum and
Articles of Association, which shall be amended accordingly prior to the issue of such Preferred Shares.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_016"></A>TAXATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following is a general
summary of the material U.S. federal income tax consequences relevant to an investment in our Ordinary Shares. The discussion is not intended
to be, nor should it be construed as, legal or tax advice to any particular prospective purchaser. The discussion is based on laws and
relevant interpretations thereof as of the date of this prospectus, all of which are subject to change or different interpretations, possibly
with retroactive effect. The discussion does not address U.S. state or local tax laws. You should consult your own tax advisors with respect
to the consequences of acquisition, ownership and disposition of our Ordinary Shares.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion is based on
provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative rulings
of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing interpretations or
change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of all potential U.S.&nbsp;federal
income tax considerations that may apply to a securityholder of the Company as a result of the ownership and disposition of the Company
Securities. In addition, this discussion does not address all aspects of U.S.&nbsp;federal income taxation that may be relevant to particular
holders nor does it take into account the individual facts and circumstances of any particular holder that may affect the U.S.&nbsp;federal
income tax consequences to such holder, and accordingly, is not intended to be, and should not be construed as, tax advice. This discussion
does not address the U.S.&nbsp;federal 3.8% Medicare tax imposed on certain net investment income or any aspects of U.S.&nbsp;federal
taxation other than those pertaining to the income tax, nor does it address any tax consequences arising under any U.S.&nbsp;state and
local, or non-U.S.&nbsp;tax laws, or, except as discussed here, any tax reporting obligations of a holder of the Company Securities. Holders
should consult their own tax advisors regarding such tax consequences in light of their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No ruling has been requested
or will be obtained from the IRS regarding the U.S.&nbsp;federal income tax consequences discussed below; thus, there can be no assurance
that the IRS will not challenge the U.S.&nbsp;federal income tax treatment described below or that, if challenged, such treatment will
be sustained by a court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is limited to
considerations relevant to U.S.&nbsp;Holders that hold the Company Securities as &ldquo;capital assets&rdquo; within the meaning of section
1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S.&nbsp;federal income taxation
that may be important to holders in light of their individual circumstances, including holders subject to special treatment under the
U.S.&nbsp;tax laws, such as, for example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks or other financial institutions, underwriters, or insurance companies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">traders in securities who elect to apply a mark-to-market method of accounting;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts and regulated investment companies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax- deferred accounts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expatriates or former citizens or long-term residents of the United&nbsp;States;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subchapter S corporations, partnerships or other pass-through entities or investors in such entities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any holder that is not a U.S.&nbsp;Holder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dealers or traders in securities, commodities or currencies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">grantor trusts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons subject to the alternative minimum tax;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.&nbsp;persons whose &ldquo;functional currency&rdquo; is not the U.S.&nbsp;dollar;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who receive stock of the Company through the issuance of restricted share under an incentive plan or through a tax-qualified retirement plan or otherwise as compensation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.&nbsp;shareholders of controlled foreign corporations, as those terms are defined in Sections 951(b)&nbsp;and 957(a), respectively;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding Class A Ordinary Shares (excluding treasury shares);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders holding ASCA securities, or, after the Business Combination, the Company Securities, as a position in a &ldquo;straddle,&rdquo; as part of a &ldquo;synthetic security&rdquo; or &ldquo;hedge,&rdquo; as part of a &ldquo;conversion transaction,&rdquo; or other integrated investment or risk reduction transaction.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this prospectus,
the term &ldquo;U.S.&nbsp;Holder&rdquo; means a beneficial owner of the Company Securities, that is, for U.S.&nbsp;federal income tax
purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United&nbsp;States;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity that is classified as a corporation for U.S.&nbsp;federal income tax purposes) that is created or organized in or under the laws of the United&nbsp;States or any State thereof or the District of Columbia;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate the income of which is subject to U.S.&nbsp;federal income tax regardless of its source; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust (i)&nbsp;if a court within the United&nbsp;States is able to exercise primary supervision over the administration of the trust and one or more U.S.&nbsp;persons have the authority to control all substantial decisions of the trust, or (ii)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S.&nbsp;person for U.S.&nbsp;federal income tax purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a partnership, including
for this purpose any entity or arrangement that is treated as a partnership for U.S.&nbsp;federal income tax purposes, holds the Company
Securities, the U.S.&nbsp;federal income tax treatment of a partner in such partnership will generally depend on the status of the partner
and the activities of the partnership. A holder that is a partnership and the partners in such partnership should consult their own tax
advisors with regard to the U.S.&nbsp;federal income tax consequences of ownership and disposition of the Company Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SUMMARY DOES NOT PURPORT
TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S.&nbsp;FEDERAL INCOME TAX CONSEQUENCES OF OWNERSHIP AND DISPOSITION
OF THE COMPANY SECURITIES.&nbsp;IN ADDITION, THE U.S.&nbsp;FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF THE COMPANY SECURITIES
MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND INTERPRETATIONS OF COMPLEX
PROVISIONS OF U.S.&nbsp;FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE.&nbsp;HOLDERS OF THE COMPANY
SECURITIES SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE OWNERSHIP AND DISPOSITION OF
THE COMPANY SECURITIES, INCLUDING THE APPLICABILITY AND EFFECTS OF U.S.&nbsp;FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Distribution on the Class A Ordinary Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the PFIC rules
discussed below &ldquo;&mdash;&nbsp;Passive Foreign Investment Company Status,&rdquo; the gross amount of any distribution on the Class
A Ordinary Shares that is made out of the Company&rsquo;s current and accumulated earnings and profits (as determined for U.S.&nbsp;federal
income tax purposes) will generally be taxable to a U.S.&nbsp;Holder as ordinary dividend income on the date such distribution is actually
or constructively received by such U.S.&nbsp;Holder. Any such dividends paid to corporate U.S.&nbsp;Holders generally will not qualify
for the dividends-received deduction that may otherwise be allowed under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends received by non-corporate
U.S.&nbsp;Holders, including individuals, from a &ldquo;qualified foreign corporation&rdquo; may be eligible for reduced rates of taxation,
provided that certain holding period requirements and other conditions are satisfied. For these purposes, a non-U.S.&nbsp;corporation
will be treated as a qualified foreign corporation with respect to dividends paid by that corporation on shares that are readily tradable
on an established securities market in the United&nbsp;States. U.S.&nbsp;Treasury Department guidance indicates that shares listed on
Nasdaq will be considered readily tradable on an established securities market in the United&nbsp;States. Even if the Class A Ordinary
Shares are listed on Nasdaq, there can be no assurance that the Class A Ordinary Shares will be considered readily tradable on an established
securities market in future&nbsp;years. Non-corporate U.S.&nbsp;Holders that do not meet a minimum holding period requirement or that
elect to treat the dividend income as &ldquo;investment income&rdquo; pursuant to Section&nbsp;163(d)(4) of the Code (dealing with the
deduction for investment interest expense) will not be eligible for the reduced rates of taxation regardless of the Company&rsquo;s status
as a qualified foreign corporation. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated
to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the
minimum holding period has been met. Finally, the Company will not constitute a qualified foreign corporation for purposes of these rules
if it is a PFIC for the taxable year in which it pays a dividend or for the preceding taxable year. See the discussion below under &ldquo;&mdash;&nbsp;Passive
Foreign Investment Company Status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any dividend
paid in foreign currency will be the U.S.&nbsp;dollar value of the foreign currency distributed by the Company, calculated by reference
to the exchange rate in effect on the date the dividend is includible in the U.S.&nbsp;Holder&rsquo;s income, regardless of whether the
payment is in fact converted into U.S.&nbsp;dollars on the date of receipt. Generally, a U.S.&nbsp;Holder should not recognize any foreign
currency gain or loss if the foreign currency is converted into U.S.&nbsp;dollars on the date the payment is received. However, any gain
or loss resulting from currency exchange fluctuations during the period from the date the U.S.&nbsp;Holder includes the dividend payment
in income to the date such U.S.&nbsp;Holder actually converts the payment into U.S.&nbsp;dollars will be treated as ordinary income or
loss. That currency exchange income or loss (if any) generally will be income or loss from U.S.&nbsp;sources for foreign tax credit limitation
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that the amount
of any distribution made by the Company on the Class A Ordinary Shares exceeds the Company&rsquo;s current and accumulated earnings and
profits for a taxable year (as determined under U.S.&nbsp;federal income tax principles), the distribution will first be treated as a
tax-free return of capital, causing a reduction in the adjusted basis of the U.S.&nbsp;Holder&rsquo;s the Class A Ordinary Shares, and
to the extent the amount of the distribution exceeds the U.S.&nbsp;Holder&rsquo;s tax basis, the excess will be taxed as capital gain
recognized on a sale or exchange as described below under &ldquo;&mdash;&nbsp;Sale, Exchange, Redemption or Other Taxable Disposition
of the Company Securities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sale, Exchange, Redemption or Other Taxable Disposition of the Company
Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
below under &ldquo;&mdash;&nbsp;Passive Foreign Investment Company Status,&rdquo; a U.S.&nbsp;Holder will generally recognize gain or
loss on any sale, exchange, redemption, or other taxable disposition of the Class A Ordinary Shares and the Warrants in an amount equal
to the difference between the amount realized on the disposition and such U.S.&nbsp;Holder&rsquo;s adjusted tax basis in such the Class
A Ordinary Shares or Warrants. Any gain or loss recognized by a U.S.&nbsp;Holder on a taxable disposition of the Class A Ordinary Shares
or Warrants will generally be capital gain or loss and will be long-term capital gain or loss if the holder&rsquo;s holding period in
the Class A Ordinary Shares or Warrants exceeds one year at the time of the disposition. Preferential tax rates may apply to long-term
capital gains of non-corporate U.S.&nbsp;Holders (including individuals). The deductibility of capital losses is subject to limitations.
Any gain or loss recognized by a U.S.&nbsp;Holder on the sale or exchange of the Class A Ordinary Shares or the Warrants will generally
be treated as U.S.&nbsp;source gain or loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercise or Lapse of a Warrant</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as discussed below
with respect to the cashless exercise of a Warrant, a U.S.&nbsp;Holder generally will not recognize gain or loss upon the acquisition
of an ordinary share of the Company on the exercise of a Warrant for cash. A U.S.&nbsp;Holder&rsquo;s tax basis in an ordinary share received
upon exercise of the Warrant generally will be an amount equal to the sum of the U.S.&nbsp;Holder&rsquo;s tax basis in the Warrant exchanged
therefor and the exercise price. The U.S.&nbsp;Holder&rsquo;s holding period for an ordinary share received upon exercise of the Warrant
will begin on the date following the date of exercise (or possibly the date of exercise) of the Warrants and will not include the period
during which the U.S.&nbsp;Holder held the Warrants. If a Warrant is allowed to lapse unexercised, a U.S.&nbsp;Holder generally will recognize
a capital loss equal to such holder&rsquo;s tax basis in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences of a
cashless exercise of a warrant are not clear under current tax law. A cashless exercise may be tax-free, either because the exercise is
not a gain realization event or because the exercise is treated as a recapitalization for U.S.&nbsp;federal income tax purposes. In either
tax-free situation, a U.S.&nbsp;Holder&rsquo;s basis in the Class A Ordinary Shares received would equal the holder&rsquo;s basis in the
Warrant. If the cashless exercise were treated as not being a gain recognition event, a U.S.&nbsp;Holder&rsquo;s holding period in the
Class A Ordinary Shares would be treated as commencing on the date following the date of exercise (or possibly the date of exercise) of
the Warrant. If the cashless exercise were treated as a recapitalization, the holding period of the Class A Ordinary Share would include
the holding period of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that a
cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S.&nbsp;Holder
would recognize gain or loss with respect to the portion of the exercised Warrants treated as surrendered to pay the exercise price of
the Warrants (the &ldquo;surrendered warrants&rdquo;). The U.S.&nbsp;Holder would recognize capital gain or loss with respect to the surrendered
warrants in an amount generally equal to the difference between (i)&nbsp;the fair market value of the Class A Ordinary Shares that would
have been received with respect to the surrendered warrants in a regular exercise of the Warrants and (ii)&nbsp;the sum of the U.S.&nbsp;Holder&rsquo;s
tax basis in the surrendered warrants and the aggregate cash exercise price of such warrants (if they had been exercised in a regular
exercise). In this case, a U.S.&nbsp;Holder&rsquo;s tax basis in the Class A Ordinary Shares received would equal the U.S.&nbsp;Holder&rsquo;s
tax basis in the Warrants exercised plus (or minus) the gain (or loss) recognized with respect to the surrendered warrants. A U.S.&nbsp;Holder&rsquo;s
holding period for the Class A Ordinary Shares would commence on the date following the date of exercise (or possibly the date of exercise)
of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the absence of authority
on the U.S.&nbsp;federal income tax treatment of a cashless exercise, there can be no assurance which, if any, of the alternative tax
consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S.&nbsp;Holders should
consult their tax advisors regarding the tax consequences of a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Passive Foreign Investment Company Status</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain adverse U.S.&nbsp;federal
income tax consequences could apply to a U.S.&nbsp;Holder if the Company or any of its subsidiaries is treated as a PFIC for any taxable
year during which the U.S.&nbsp;Holder holds the Company Securities. A non-U.S.&nbsp;corporation will be classified as a PFIC for any
taxable year (a)&nbsp;if at least 75% of its gross income in a taxable year, including its pro rata share of the gross income of any entity
in which it is considered to own at least 25% of the interest by value, is passive income, or (b)&nbsp;if at least 50% of its assets in
a taxable year of the foreign corporation, ordinarily determined based on fair market value and averaged quarterly over the year, including
its pro rata share of the assets of any entity in which it is considered to own at least 25% of the interest by value, are held for the
production of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than rents
or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company is not a PFIC
in the 2024 taxable year, such U.S.&nbsp;Holder would likely recognize gain (but not loss if the Reincorporation Merger qualifies as a
&ldquo;reorganization&rdquo;) upon the exchange of ASCA securities for The Company securities pursuant to the Reincorporation Merger.
The gain (or loss) would be computed as described above under &ldquo;&mdash;&nbsp;If the Reincorporation Merger Does Not Qualify as a
Reorganization.&rdquo; Any such gain recognized by such U.S.&nbsp;Holder on the exchange of ASCA securities for The Company securities
would be allocated ratably over the U.S.&nbsp;Holder&rsquo;s holding period for the ASCA securities. Such amounts allocated for the current
taxable year and any taxable year prior to the first taxable year in which ASCA was a PFIC would be treated as ordinary income, and not
as capital gain, in the U.S.&nbsp;Holder&rsquo;s taxable year, and such amounts allocated to each other taxable year beginning with the
year that ASCA became a PFIC would be taxed at the highest tax rate in effect for each year to which the gain was allocated, together
with a special interest charge on the tax attributable to each such year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether the Company is a PFIC
for any taxable year is a factual determination that depends on, among other things, the composition of the Company&rsquo;s income and
assets, the market value of its assets, and potentially the composition of the income and assets of one or more of the Company&rsquo;s
subsidiaries and the market value of their assets in that year. Whether a Company subsidiary is a PFIC for any taxable year is likewise
a factual determination that depends on, among other things, the composition of the subsidiary&rsquo;s income and assets and the market
value of such assets in that year. One or more changes in these factors may cause the Company and/or one or more of its subsidiaries to
become a PFIC for a taxable year even though it has not been a PFIC for one or more prior taxable years. Whether the Company or a subsidiary
is treated as a PFIC for U.S.&nbsp;federal income tax purposes is a factual determination that must be made annually at the close of each
taxable year and, thus, is subject to significant uncertainty. Moreover, there can be no assurance that the Company will timely provide
a PFIC annual information statement for 2024 or going forward. The failure to provide such information on an annual basis could preclude
U.S.&nbsp;Holders from making or maintaining a &ldquo;qualified electing fund&rdquo; election under Section&nbsp;1295 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company were determined
to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S.&nbsp;Holder of Class A Ordinary
Shares, the U.S.&nbsp;Holder did not make a valid &ldquo;mark-to-market&rdquo; election, such U.S.&nbsp;Holder generally will be subject
to special rules&nbsp;with respect to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any gain recognized by the U.S.&nbsp;Holder on the sale or other disposition of the Company Securities (including a redemption treated as a sale or exchange); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any &ldquo;excess distribution&rdquo; made to the U.S.&nbsp;Holder (generally, any distributions to such U.S.&nbsp;Holder during a taxable year of the U.S.&nbsp;Holder that are greater than 125% of the average annual distributions received by such U.S.&nbsp;Holder in respect of the Class A Ordinary Shares during the three preceding taxable&nbsp;years of such U.S.&nbsp;Holder or, if shorter, such U.S.&nbsp;Holder&rsquo;s holding period for such ordinary shares).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under these rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S.&nbsp;Holder&rsquo;s gain or excess distribution will be allocated ratably over the U.S.&nbsp;Holder&rsquo;s Company Securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to the U.S.&nbsp;Holder&rsquo;s taxable year in which the U.S.&nbsp;holder recognized gain or received the excess distribution, or to the period in the U.S.&nbsp;Holder&rsquo;s holding period before the first&nbsp;day of the Company&rsquo;s first taxable year in the Company is a PFIC, will be taxed as ordinary income;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to other taxable&nbsp;years (or portions thereof) of the U.S.&nbsp;Holder and included in its holding period will be taxed at the highest tax rate in effect for that year and applicable to the&nbsp;U.S.&nbsp;Holder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the interest charge generally applicable to underpayments of tax will be imposed in respect of the tax attributable to each such other taxable year of the U.S.&nbsp;Holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although a determination as
to the Company&rsquo;s PFIC status will be made annually, an initial determination that the Company is a PFIC will generally apply for
subsequent&nbsp;years to a U.S.&nbsp;Holder who held Company Securities while the Company was a PFIC, whether or not the Company meets
the test for PFIC status in those subsequent&nbsp;years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a U.S.&nbsp;Holder, at
the close of its taxable year, owns shares in a PFIC that are treated as marketable stock, the U.S.&nbsp;Holder may make a mark-to-market
election with respect to such shares for such taxable year. If the U.S.&nbsp;Holder makes a valid mark-to-market election for the first
taxable year of the U.S.&nbsp;Holder in which the U.S.&nbsp;Holder holds (or is deemed to hold) the Class A Ordinary Shares and for which
the Company is determined to be a PFIC, such holder generally will not be subject to the PFIC rules&nbsp;described above in respect to
the Class A Ordinary Shares as long as such shares continue to be treated as marketable stock. Instead, in general, the U.S.&nbsp;Holder
will include as ordinary income each year that the Company is treated as a PFIC the excess, if any, of the fair market value of its Class
A Ordinary Shares at the end of its taxable year over the adjusted basis in its Class A Ordinary Shares. The U.S.&nbsp;Holder also will
be allowed to take an ordinary loss in respect of the excess, if any, of the adjusted basis of its Class A Ordinary Shares over the fair
market value of its Class A Ordinary Shares at the end of its taxable year (but only to the extent of the net amount of previously recognized
income as a result of the mark-to-market election). The U.S.&nbsp;Holder&rsquo;s adjusted tax basis in its Class A Ordinary Shares will
be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable disposition of the
Class A Ordinary Shares in a taxable year in which the Company is treated as a PFIC will be treated as ordinary income. Special tax rules
may also apply if a U.S.&nbsp;Holder makes a mark-to-market election for a taxable year after the first taxable year in which the U.S.&nbsp;Holder
holds (or is deemed to hold) its Class A Ordinary Shares and for which the Company is treated as a PFIC.&nbsp;Currently, a mark-to-market
election may not be made with respect to the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The mark-to-market election
is available only for stock that is regularly traded on a national securities exchange that is registered with the SEC, including Nasdaq
(on which the Company Securities are traded), or on a foreign exchange or market that the IRS determines has rules&nbsp;sufficient to
ensure that the market price represents a legitimate and sound fair market value. Such stock generally will be &ldquo;regularly traded&rdquo;
for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15&nbsp;days during each calendar
quarter, but no assurances can be given in this regard with respect to the Class A Ordinary Shares. U.S.&nbsp;Holders should consult their
own tax advisors regarding the availability and tax consequences of a mark-to-market election in respect of the Class A Ordinary Shares
under their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company is a PFIC and,
at any time, has a foreign subsidiary that is classified as a PFIC, U.S.&nbsp;Holders generally would be deemed to own a portion of the
shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge described above if the Company
were to receive a distribution from, or dispose of all or part of the Company&rsquo;s interest in, the lower-tier PFIC (even though such
U.S.&nbsp;Holder would not receive the proceeds of those distributions or dispositions) or the U.S.&nbsp;Holders otherwise were deemed
to have disposed of an interest in the lower-tier PFIC.&nbsp;A mark-to-market election generally would not be available with respect to
such lower-tier PFIC.&nbsp;U.S.&nbsp;Holders are urged to consult their own tax advisors regarding the tax issues raised by lower-tier
PFICs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S.&nbsp;Holder that owns
(or is deemed to own) shares in a PFIC during any taxable year of the U.S.&nbsp;Holder, may have to file an IRS Form&nbsp;8621 (whether
or not a mark-to-market election is or has been made) with such U.S.&nbsp;Holder&rsquo;s U.S.&nbsp;federal income tax return and provide
any such other information as may be required by the U.S.&nbsp;Treasury Department. Failure to do so, if required, will extend the statute
of limitations until such required information is furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rules&nbsp;dealing with
PFICs and mark-to-market elections are very complex and are affected by various factors in addition to those described above. Accordingly,
U.S.&nbsp;Holders of Company Securities should consult their own tax advisors concerning the application of the PFIC rules&nbsp;to the
Company Securities under the U.S. Holders&rsquo; particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Information Reporting and Backup Withholding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, information reporting
requirements may apply to dividends received by U.S.&nbsp;Holders of the Class A Ordinary Shares (including constructive dividends), and
the proceeds received on sale or other taxable disposition of the Class A Ordinary Shares or Warrants effected within the United&nbsp;States
(and, in certain cases, outside the United&nbsp;States), in each case, other than U.S.&nbsp;Holders that are exempt recipients (such as
corporations). Backup withholding (currently at a rate of 24%) may apply to such amounts if the U.S.&nbsp;Holder fails to provide an accurate
taxpayer identification number (generally on an IRS Form&nbsp;W-9 provided to the paying agent or the U.S.&nbsp;Holder&rsquo;s broker)
or is otherwise subject to backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S.&nbsp;Holders
holding specified foreign financial assets with an aggregate value in excess of the applicable dollar threshold are required to report
information to the IRS relating to the Company Securities, subject to certain exceptions (including an exception for the Company Securities
held in accounts maintained by U.S.&nbsp;financial institutions), by attaching a complete IRS Form&nbsp;8938, Statement of Specified Foreign
Financial Assets, with their tax return, for each year in which they hold the Company Securities. In addition to these requirements, U.S.&nbsp;Holders
may be required to annually file FinCEN Report 114 (Report of Foreign Bank and Financial Accounts) with the U.S.&nbsp;Department of Treasury.
U.S.&nbsp;Holders should consult their own tax advisors regarding information reporting requirements relating to their ownership of the
Company Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against a holder&rsquo;s
U.S.&nbsp;federal income tax liability, if any, provided the required information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This summary does not contain a detailed description
of all the United States federal income tax consequences that may be applicable to you in light of your particular circumstances and,
except as set forth below with respect to PRC tax considerations, does not address the effects of any state, local or non-United States
tax laws. If you are considering the purchase, ownership or disposition of our Ordinary Shares, you should consult your own tax advisors
concerning the United States federal income tax consequences to you in light of your particular situation as well as any consequences
arising under the laws of any other taxing jurisdiction.</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_017"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters as to
U.S. federal securities law concerning this offering will be passed upon for us by Han Kun Law Offices LLP. Certain legal matters as to
BVI law will be passed upon for us by Ogier. Han Kun Law Offices LLP may rely upon Ogier with respect to matters governed by BVI law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_018"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
NewGenIvf Limited as of December 31, 2024 and 2023 included in this prospectus have been so included in reliance on the report of J &amp;
S Associate PLT (&ldquo;J &amp; S&rdquo;), an independent registered public accounting firm, given on the authority of said firm as an
expert in auditing and accounting. For the years ended December 31, 2022 included in this prospectus have been so included in reliance
on the report of WWC, P.C., an independent registered public accounting firm, given on the authority of said firm as an expert in auditing
and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_019"></A><B>EXPENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are the estimated
expenses of the issuance and distribution of the securities being registered under the Registration Statement of which this prospectus
forms a part, all of which will be paid by us. With the exception of the SEC registration fee, all amounts are estimates and may change:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC registration fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printer fees and expenses</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This is an estimate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020"></A><B>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the British Virgin Islands with limited liability. We are incorporated in the British Virgin Islands because of certain benefits
associated with being a British Virgin Islands company, such as political and economic stability, an effective judicial system, a favorable
tax system, the absence of exchange control or currency restrictions and the availability of professional and support services. However,
the British Virgin Islands has a less developed body of securities laws as compared to the United States and provides protections for
investors to a lesser extent. In addition, British Virgin Islands companies may not have standing to sue before the federal courts of
the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantially all of our assets
are located outside the United States. In addition, a majority of our directors and officers are nationals and/or residents of countries
other than the United States, and all or a substantial portion of such persons&rsquo; assets are located outside the United States. As
a result, it may be difficult for investors to effect service of process within the United States upon us or such persons or to enforce
against them or against us, judgments obtained in United States courts, including judgments predicated upon the civil liability provisions
of the securities laws of the United States or any state thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have appointed [&nbsp;&nbsp;&nbsp;&nbsp;], as our agent to receive service of process
with respect to any action brought against us in the United States District Court for districts in the State of New York under the federal
securities laws of the United States or of any State of the United States or any action brought against us in the Supreme Court of the
State of New York under the securities laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The British Virgin Islands courts are unlikely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to recognize or enforce against the Company, judgments of courts of the U.S. based on certain civil liability provisions of U.S. securities laws where that liability is in respect of penalties, taxes, fines or similar fiscal or revenue obligations of the company; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to impose liabilities against the Company, in original actions brought in the British Virgin Islands, based on certain civil liability provisions of U.S. securities laws that are penal in nature.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no statutory enforcement
in the British Virgin Islands of judgments obtained in the U.S., however, the courts of the British Virgin Islands will in certain circumstances
recognize such a foreign judgment and treat it as a cause of action in itself which may be sued upon as a debt at common law so that no
retrial of the issues would be necessary, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S. court issuing the judgment had jurisdiction in the matter and the company either submitted to such jurisdiction or was resident or carrying on business within such jurisdiction and was duly served with process;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is final and for a liquidated sum;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment given by the U.S. court was not in respect of penalties, taxes, fines or similar fiscal or revenue obligations of the company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in obtaining judgment there was no fraud on the part of the person in whose favor judgment was given or on the part of the court;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition or enforcement of the judgment in the British Virgin Islands would not be contrary to public policy; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proceedings pursuant to which judgment was obtained were not contrary to natural justice.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In appropriate circumstances,
a British Virgin Islands Court may give effect in the British Virgin Islands to other kinds of final foreign judgments such as declaratory
orders, orders for performance of contracts and injunctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_021"></A><B>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form F-1 under the Securities Act relating to this registration of the Ordinary Shares to be sold by the Selling
Securityholders. This prospectus, which is part of the Registration Statement, does not contain all of the information contained in the
Registration Statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included
in the Registration Statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document
are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents.
If we filed any of these documents as an exhibit to the Registration Statement, you may read the document itself for a complete description
of its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the periodic
reporting and other information requirements of the Exchange Act as applicable to a &ldquo;Foreign Private Issuer,&rdquo; and we will
file annual reports and other information from time to time with the SEC in accordance with such requirements. Our filings with the SEC
are also available to the public through the SEC&rsquo;s website at <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and
our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained
in Section&nbsp;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial
statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at www.newgenivf.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus.
We have included our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials
required to be so posted on such website under applicable corporate or securities laws and regulations, including, posting any XBRL interactive
financial data required to be filed with the SEC and any notices of general meetings of our shareholders.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>50,000,000 Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="image_009.jpg" ALT=""></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NewGenIvf Group Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEWGENIVF LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 92%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AUDITED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID: 1171)</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID: 6743)</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2024 and 2023</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Income (Loss) for the&nbsp;Years Ended December 31, 2024, 2023 and 2022</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&rsquo; Equity (Deficit) for the&nbsp;Years Ended December 31, 2024, 2023 and 2022</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the&nbsp;Years Ended December 31, 2024, 2023 and 2022</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 115; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_022"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors and Shareholders of NewGenIvf Limited</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have audited the accompanying
consolidated balance sheets of NewGenIvf Limited and its subsidiaries (collectively the &ldquo;Company&rdquo;) as of December&nbsp;31,
2021 and 2022, and the related consolidated statements of operations and comprehensive income (loss), changes in shareholders&rsquo; equity
(deficit), and cash flows in each of the&nbsp;years for the two-year&nbsp;period ended December&nbsp;31, 2022, and the related notes (collectively
referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December&nbsp;31, 2021 and 2022, and the results of its operations and its cash flows for each of the&nbsp;years
in the two-year&nbsp;period ended December&nbsp;31, 2022, in conformity with accounting principles generally accepted in the United&nbsp;States
of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Restatement of Previously Issued Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As discussed in Note&nbsp;2,
the Company has restated its consolidated financial statements as of December&nbsp;31, 2021 and 2022, and for the years then ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Correction of errors in the classification
of subscription receivable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company had previously
erroneously presented subscription receivable as an asset; that classification was incorrect. According to Article 5-02.29 of Regulation
S-X, subscription receivable should be presented as a deduction from equity rather than an asset. The Company has reassessed the classification
of subscription receivable and has determined that it should be deducted from equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Recognition of directors&rsquo; remuneration
for principal shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has previously
recorded no directors&rsquo; remuneration to Mr.&nbsp;Siu Wing Fung, Alfred and Ms. Fong Hei Yue, Tina, who are concurrently directors
and principal shareholders of the Company. The absent of cost recognition was incorrect. According to SAB Topics 1:B and 5.T., principal
shareholders not receiving compensation for their time and effort serving as directors are making a capital contribution to the Company.
The Company has reassessed the fair value of services rendered by these directors and has determined that it should be recorded as an
operating expense and additional paid-in&nbsp;capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Emphasis of Matter &mdash; Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. As of December&nbsp;31, 2021, the Company had
a working capital deficit and shareholders&rsquo; deficit, accordingly, these factors gave rise to substantial doubt that the Company
would continue as a going concern. As of December&nbsp;31, 2022, the Company had an improvement in its capital position where the Company
had net positive shareholders&rsquo; equity position, but the Company still had a working capital deficit; accordingly, the Company had
not alleviated the substantial doubt that it would continue as a going concern. Management closely monitors the Company&rsquo;s financial
position and result of operations and has prepared a plan that includes raising additional capital and implementing improvements to increase
profitability to address this substantial doubt. Details of this plan are also found in Note 1. These financial statements do not include
any adjustments that might result from the outcome of this uncertainly.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These consolidated financial
statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United&nbsp;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&nbsp;federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We conducted our audits in
accordance with the standards of the PCAOB.&nbsp;Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we
are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audits included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits
provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ WWC, P.C.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WWC, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PCAOB ID No.1171</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">San Mateo, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">September&nbsp;28, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&rsquo;s auditor
since 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="6" STYLE="width: 11%; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="fin_001.jpg" ALT=""></FONT></TD>
    <TD STYLE="width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>J&amp;S ASSOCIATE PLT</B></FONT></TD>
    <TD STYLE="width: 25%; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(formerly known as J &amp; S Associate)</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202206000037 (LLP0033395-LCA) &amp; AF002380</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registered with PCAOB and MIA)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +603-4813 9469</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-11-14, Megan Avenue II</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email : info@jns-associate.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,Jalan Yap Kwan Seng, 50450, Kuala Lumpur, Malaysia</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Website : jns-associate.com</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_023"></A><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors and Shareholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NEWGENIVF GROUP LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Opinion on the Financial Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Newgenivf Group Limited and its subsidiaries (collectively, the &ldquo;Company&rdquo;) as of December 31, 2024 and December
31, 2023, the related consolidated statements of operations and comprehensive income, shareholders&rsquo; equity, and cash flows for the
years then ended, and the related notes to the consolidated financial statements and schedule (collectively, the financial statements).
In our opinion, the financial statements present fairly, in all material respects, the financial positions of the Company as of December
31, 2024, and December 31, 2023, and the results of its operations and its cash flows for the years ended then, in conformity with accounting
principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Substantial Doubt about the Company&rsquo;s
Ability to Continue as a Going Concern</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3, the Company
has generated a loss and suffered from an accumulated deficit of $985,994 as of December 31, 2024 and a deficit in shareholders&rsquo;
equity of $1,481,757 as of that date. These matters raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
Management&rsquo;s plans with regards to these matters are also described in Note 3 to the financial statements. These financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Basis for Opinion</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ J&amp;S Associate PLT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Firm ID: 6743</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kuala Lumpur, Malaysia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 20, 2025,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(reissued for 2024 for effects of Reverse Stock Split effected on May
5, 2025)&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_024"></A><B>NEWGENIVF GROUP LIMITED<BR>
CONSOLIDATED BALANCE SHEETS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS OF DECEMBER 31, 2024 AND 2023<BR>
(Stated in US Dollars)</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023**</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Current assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">457,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">54,104</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,813</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,264</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Deposits, other receivables and deferred legal &amp; IPO cost, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">512,581</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Deposit with a digital asset trading platform</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Receivable from agents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,191,795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Prepayments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">197,706</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,262,228</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Loan to A SPAC I</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Due from shareholders</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">354,285</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,172,745</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,458,836</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Plant and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">273,096</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162,157</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Right-of-use assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,847</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Prepayments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">33,333</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,582,156</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">404,999</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,028,160</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,577,744</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,486,996</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,298,964</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">172,626</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued liabilities and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241,613</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Contract liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,489</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,937</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Due to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,453</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Operating lease liabilities, current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">207,128</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance lease liabilities, current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,446</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,447</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Taxes payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,746</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">486,706</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,720,354</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,122,456</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Non-current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Operating lease liabilities, non-current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,231</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">118,979</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Convertible notes, non-current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,328,916</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,339,147</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">118,979</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,059,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,241,435</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Ordinary shares, no par value, 50,000,000 shares authorized and 113,852* and 50,747* shares issued and outstanding as of December 31, 2024 and 2023 respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(204,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(127,564</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122,505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,331,815</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(985,994</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(461,351</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated other comprehensive (loss) income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,875</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,288</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Equity attributable to the shareholders of the Company</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,048,614</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,735,612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-controlling interests</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(433,143</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(490,051</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,481,757</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,245,561</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,577,744</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,486,996</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares as presented have been adjusted retrospectively for two Reverse Share Splits effected in February 2025 of 1 share for every 20 existing shares issued and in May 2025 of 1 share for every 10 existing share issued respectively.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_025"></A><B>NEWGENIVF GROUP LIMITED<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)<BR>
FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022<BR>
(Stated in US Dollars)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: bold">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,433,375</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,136,153</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,944,190</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Cost of revenues</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,606,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,454,368</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,406,421</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,826,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,681,785</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,537,769</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Selling and marketing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(206,314</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,030</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,194</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,781,075</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,621,513</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,102,870</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,987,389</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,639,543</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,139,064</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,160,495</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">398,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expenses), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Other income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">971,391</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,837</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,019</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,953</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">518</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(778,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(46,179</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(77,757</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expenses), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">199,688</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(54,717</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">(Loss) Income before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(960,807</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,418</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">343,988</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Tax income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">486,706</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(208,141</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(474,101</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,418</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,847</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: net income (loss) attributable to non-controlling interests</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50,542</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,775</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(322,820</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net (loss) income attributable to the shareholders of the Company</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(524,643</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">130,193</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">458,667</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">32,529</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,704</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,920</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total comprehensive (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(441,572</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,714</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,927</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: total comprehensive (loss) income attributable to non-controlling interests</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">56,908</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(27,621</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(323,458</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive (loss) income attributable to the shareholders of the Company</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(498,480</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">113,335</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">457,385</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Earnings per share&nbsp;&ndash;&nbsp;basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(13.2</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&ndash; diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average shares outstanding *- basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,811</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,880</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">- diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,880</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted retrospectively for the two reverse stock splits&nbsp;that was effected in February 2025 of 1 share for every 20 existing share issued and in May 2025 of 1 share for every 10 existing share issued.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_026"></A>NEWGENIVF GROUP LIMITED<BR>
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; EQUITY (DEFICIT)<BR>
FOR THE YEARS ENDED DECEMBER 31, 2024,&nbsp;2023 AND 2022<BR>
(Stated in US Dollars)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary<BR> shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subscription<BR> receivable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Additional <BR> paid-in <BR> capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<BR> deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<BR> other<BR> comprehensive<BR> income/(loss)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> attributable<BR> to the<BR> shareholders<BR> of the<BR> Company</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non- controlling<BR> interests</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt; width: 23%">Balance, January&nbsp;1, 2022**</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">50,747</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">263,421</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(1,050,211</TD><TD STYLE="width: 0.5%; text-align: left">)</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">10,852</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">(775,938</TD><TD STYLE="width: 0.5%; text-align: left">)</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(138,972</TD><TD STYLE="width: 0.5%; text-align: left">)</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(914,910</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">458,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">458,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(322,820</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,847</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign currency translation&nbsp;adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,282</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,282</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(638</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,920</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Capital injection by directors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Issuance of shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(319,872</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">961,538</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">641,666</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">641,666</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, December&nbsp;31, 2022**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(319,872</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,464,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(591,544</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">563,113</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(462,430</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100,683</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January&nbsp;1, 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(319,872</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,464,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(591,544</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">563,113</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(462,430</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100,683</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,775</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,418</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign currency translation&nbsp;adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,858</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,858</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,846</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,704</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Settlement of subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Issuance of shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,866,856</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,866,856</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,866,856</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, December&nbsp;31, 2023**</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">50,747</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(127,564</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,331,815</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(461,351</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(7,288</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,735,612</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(490,051</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,245,561</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January&nbsp;1, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(127,564</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,331,815</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(461,351</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,288</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,735,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(490,051</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,245,561</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net (loss) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(524,643</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(524,643</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,542</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(474,101</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign currency translation&nbsp;adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,529</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Reverse capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,028,690</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,028,690</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,028,690</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Settlement of subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,564</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,564</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,564</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Remeasurement of share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,766,856</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,766,856</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,766,856</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Issuance of shares under ELOC/Note Conversion arrangement</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">63,105</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(204,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,586,236</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,382,236</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,382,236</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, December&nbsp;31, 2024</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">113,852</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(204,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">122,505</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(985,994</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">18,875</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,048,614</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(433,143</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,481,757</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The no of shares as presented have been adjusted retrospectively for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share issued and a Reverse Share Split effected in May 2025 of 1 share for every 10 existing share issued respectively.</FONT></TD></TR>
  </TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_027"></A><B>NEWGENIVF GROUP LIMITED<BR>
CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>
FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022<BR>
(Stated in US Dollars)</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023**</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022**</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Net (loss) income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(474,101</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">108,418</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">135,847</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Depreciation of plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,502</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,533</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Amortization of right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186,762</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">198,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,411</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Loss on disposal of plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Amortisation of share-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Non cash discount on convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">402,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Provision of expected credit loss allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,777</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">778,656</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Waiver of related party balance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88,151</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Gain on lease modification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,092</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Gain on promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(953,861</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Directors&rsquo; remuneration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Legal and professional fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">(Gain on) Provision for income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(486,706</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,141</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,871</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,922</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,451</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(80,665</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,219</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Deposit and other receivables, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,000,851</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(448,266</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,197</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,126,338</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,752</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued liabilities and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,750,587</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,167</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,689</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Contract liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,352,231</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">548,010</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Operating lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(204,846</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(230,433</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(175,132</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Finance lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,476</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Tax paid</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,746</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(12,170</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,264,074</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,766,135</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,710,901</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Purchase of plant and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(53,045</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(69,848</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(94,452</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(53,045</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(69,848</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(94,452</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amount due from A SPAC I</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(140,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,446</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,317</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,476</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other borrowings, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,583,597</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,204</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of shares (net of reverse capitalization effect)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(677,663</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,704</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amount with related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">508,738</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,863,206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,742,509</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Subscription receivable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">127,564</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,675,790</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,881,493</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,633,781</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase/(decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">358,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,332</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of foreign currency translation on cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,962</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,124</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">54,104</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27,556</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">28,764</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Cash and cash equivalents, end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">457,740</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">54,104</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">27,556</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Supplementary cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Taxes paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,170</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(768,068</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(24,704</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,469</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2024, no cash was exchanged in respect
of these transactions:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,650,000 of convertible debt was converted into equity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal arising from remeasurement of share-based compensation&nbsp;within prepayment amounting to $2,739,856.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_028"></A>NEWGENIVF GROUP LIMITED<BR>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022<BR>
(Stated in US Dollars)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 1 &mdash;&nbsp;ORGANIZATION AND PRINCIPAL ACTIVITIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to the Business Combination,
on April 29, 2021, A SPAC I Acquisition Corp. (&ldquo;ASCA&rdquo;), was incorporated as a British Virgin Islands business company, specifically
a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more target businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>The Business Combination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 15, 2023, ASCA
entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &ldquo;Merger Agreement,&rdquo; and the transactions
contemplated thereunder, the &ldquo;Business Combination&rdquo;) with A SPAC I Mini Acquisition Corp., Merger Sub, NewGenIvf Limited,
a Cayman Islands exempted company (&ldquo;Legacy NewGenIvf&rdquo;) and certain shareholders of Legacy NewGenIvf. Pursuant to the Merger
Agreement, the Business Combination was effected in two steps: (i) ASCA was reincorporated to the British Virgin Islands by merging with
and into A SPAC I Mini Acquisition Corp. (such transaction, the &ldquo;Reincorporation Merger&rdquo;) and then the listed company was
renamed as NewGenIvf Group Limited; and (ii) Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned
subsidiary of the Company (such second step in isolation, the &ldquo;Acquisition Merger&rdquo;). The surviving entity of the Business
Combination, together with its subsidiaries is referred to in this prospectus as &ldquo;NewGenIvf,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
&ldquo;our,&rdquo; or &ldquo;us,&rdquo; unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 12, 2023, the parties
to the Merger Agreement entered into the First Amendment to Merger Agreement (the &ldquo;First Amendment&rdquo;), pursuant to which Legacy
NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the &ldquo;Loan&rdquo;) to
ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA&rsquo;s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from Legacy NewGenIvf, ASCA
agreed to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&rsquo;s failure to deliver audited
financial statements by no later than February 28, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 6, 2023, the
parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &ldquo;Second Amendment&rdquo;) which amended
and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&rsquo;s board of directors following the consummation
of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf and three (3)
of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the
conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in
connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible assets immediately
after the consummation of the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 3, 2024, the Business
Combination was consummated with the Company as the surviving entity.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is an organization chart of the
Company and its subsidiaries as of December 31, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="fin_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s subsidiaries are detailed
in the table as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 21%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 30%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership %</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 38%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal activity</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenivf Limited</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;A Cayman Islands
    company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;Incorporated
    on 16 January, 2019</P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;A Hong&nbsp;Kong
    company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;Incorporated
    on December&nbsp;19, 2019</P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;A
    Hong&nbsp;Kong company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;Incorporated
    on July&nbsp;11, 2008</P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&ldquo;Med Holdings&rdquo;) (Note)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;A Thailand company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;Incorporated
    on January&nbsp;21, 2015</P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%*</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&ldquo;FFC&rdquo;) (Note)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;A Thailand company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;Incorporated
    on March&nbsp;6, 2014</P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&ldquo;FFPP&rdquo;)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;A Cambodia company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&nbsp;&nbsp;&nbsp;Incorporated
    on August&nbsp;10, 2015</P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bi Clinic Ltd (&ldquo;FFBi&rdquo;)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&nbsp;&nbsp;&nbsp;A Kyrgyzstan company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&nbsp;&nbsp;&nbsp;Incorporated on December 16, 2021</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&nbsp;&nbsp;&nbsp;Acquired on December 17, 2024</P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment, surrogacy and ancillary caring services</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (&ldquo;SZ QianHai&rdquo;)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&nbsp;&nbsp;&nbsp;A Shenzhen China, PRC company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&nbsp;&nbsp;&nbsp;Incorporated on October 24, 2024</P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Marketing and administrative services</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">According to Thailand&rsquo;s
Foreign Business Act (the &ldquo;FBA&rdquo;), the majority shareholdings of limited company incorporated in Thailand is required to be
owned by Thai nationals.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With reference to the capital
structure and voting rights structure of ordinary shares and preference shares (the &ldquo;Share Structure&rdquo;) of Med Holdings and
FFC, all the preference share capital shall be owned by a Thai national. No preference shares, however, have been issued to date. The
ordinary shares and preference shares have the same rights and status in all respects except for the distribution of profits by way of
dividends with details as follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed 15% of the total amount of dividends declared from time to time;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After allocation of dividends as per (a)&nbsp;above, the rest of the dividends shall be distributed equally amongst the holders of ordinary shares according to their shareholding ratio;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of preferred shares shall be entitled to dividends only in respect of the&nbsp;years for which the Company has declared a dividend payment, and there shall be no cumulative dividends; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends allocated to the holders of preferred shares in each year shall be limited at the rate as stated in (a)&nbsp;only. No additional dividends shall be paid to the holders of preferred shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based upon the management&rsquo;s
judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board meeting, the Company accounts
for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings and FFC by exercising its majority
voting power in any board meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 17, 2024, the Company
entered into a non-binding term sheet (the &ldquo;Non-Binding Term Sheet&rdquo;) with European Wellness Investment Holdings Limited (&ldquo;EWIHL&rdquo;)
for (i) the potential acquisition of the entire equity interest of EWIHL by the Company for a consideration of US$268,000,000 to be payable
by issuing 53,600,000 ordinary shares of the of the Company to the shareholder(s) of EWIHL or its associate and (ii) the fund-raising
activity by the Company from public or private shareholders, and in a form mutually acceptable to the parties, including structured equity
investment for up to US$30 million. On December 11, 2024, NewGenIvf announced its entry into a binding term sheet with European Wellness
Investment Holdings Limited (&ldquo;EWIHL&rdquo;) for the above proposed reverse merger, completion of which was subject to, among other
conditions, the completion of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 24, 2024, the Company
received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) notifying
the Company of its non-compliance with two (2) listing requirements for continued listing on Nasdaq pursuant to Nasdaq Listing Rules.
On November 21, 2024, a delisting notice was received from the continued non-compliance. The Company had filed to appeal the delisting
determination and undertook several strategic actions to regain compliance with Nasdaq&rsquo;s listing require. On February 27, 2025.
received approval for the transfer the Company&rsquo;s securities from the Nasdaq Global Market to the Nasdaq Capital Market and on March
10, 2025 its compliance with the listing requirements thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 3, 2024, the Company
announced the execution of a non-binding term sheet (the &ldquo;Term Sheet&rdquo;) regarding a proposed reverse merger (the &ldquo;Proposed
Transaction&rdquo;) with pharmaceutical company COVIRIX Medical Pty Ltd (&ldquo;COVIRIX&rdquo;). The consideration was to be settled by
way of the issuance of 102,890,000 (pre Reverse Stock Splits) of its ordinary shares to the shareholder(s) of COVIRIX or their respective
nominees (the &ldquo;COVIRIX Shareholders&rdquo;) in exchange for 100% equity interest of COVIRIX, at a deemed price per share of US$6,
representing an aggregate amount of US$617,340,000. Simultaneously, it is proposed that COVIRIX undertakes to introduce investors to raise
US$6 million at US$6 per share for NIVF, in a form mutually acceptable to both NewGen and COVIRIX. Following stockholder approval of the
Proposed Transaction, COVIRIX Shareholders are expected to hold approximately 85.8% equity interest in NewGen. However, on September 21,
2024, COVIRIX withdrew from the Proposed Transaction, as such the Proposed Transaction was terminated with no cost to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 7, 2024, the Company
entered into a Securities Purchase Agreement with certain investors named therein (collectively, the &ldquo;Buyers&rdquo;), pursuant to
which, amongst other things: (i) the Company agreed to sell, at an initial closing with JAK Opportunities VI LLC (&ldquo;JAK&rdquo; and
such initial closing, the &ldquo;Initial Closing&rdquo;), pursuant to which the Company agreed to sell to JAK (a) a senior convertible
note (the &ldquo;Initial Note&rdquo;) in the aggregate original principal amount of $1,100,000, and which terms are further set forth
below under the subheading &ldquo;(ii) Initial Closing with JAK&rdquo;, (b) a warrant to purchase 1,325,301 Class A Ordinary Shares of
the Company (subject to Reverse Stock Split adjustments), no par value (&ldquo;Class A Shares&rdquo; and such warrant, the Series A Warrant),
and (c) a warrant to purchase 180,722 Class B Ordinary Shares (subject to Reverse Stock Split adjustments) of the Company, no par value
(&ldquo;Class B Shares&rdquo; and such warrant, the Series B Warrant, and the Series B Warrants, together with the Series A Warrants,
the &ldquo;Warrants&rdquo;); and (ii) the Company may require each Buyer (or each Buyer may require the Company, as applicable) to participate
in the sale of (a) one or more additional convertible notes (which aggregate original principal amount for all additional convertible
notes shall not exceed $9,500,000) (the &ldquo;Additional Notes,&rdquo; and, together with the Initial Note, the &ldquo;Notes&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 12, 2024, the Company
and JAK consummated the Initial Closing. The Initial Note sold to JAK in connection with the Securities Purchase Agreement bears an interest
rate of 14.75% per annum and is convertible into the Company&rsquo;s Class A Shares as follows: the Conversion Amount (as defined below)
into validly issued, fully paid and non-assessable Class A at the Conversion Rate determined by dividing the aggregate of the principal
sum plus the interest rates (including late interest charges, if any) and the Make-Whole Amount, if any, by conversion price of $0.83.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the Initial Closing, the
Company also sold to JAK a Series A Warrant to purchase 1,325,301 Class A Shares and a Series B Warrant to purchase 180,722 Class B Shares
subject to Reverse Stock Split adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, in connection
with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with certain holders of its convertible
promissory notes (the &ldquo;Existing Notes&rdquo; and each of such amendment and exchange agreements, &ldquo;Amendment and Exchange Agreement&rdquo;),
pursuant to which the Company will exchange the Existing Notes by issuing, among other things, (i) senior convertible notes in the aggregate
principal amount of $2,700,000 (the &ldquo;Exchange Notes&rdquo;) and (b) a series of warrants to initially acquire up to a certain number
of ordinary shares to the holders of the Existing Notes set forth therein or in the Amendment and Exchange Agreement (the &ldquo;Exchange
Warrants&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 28, 2024, the Company
consummated the second tranche of its debt financing under the terms of the Securities Purchase Agreement. At the closing of the second
tranche, the Company sold to JAK Opportunities VI LLC (&ldquo;JAK&rdquo;) a senior convertible note (the &ldquo;Note&rdquo;) in the principal
amount of $500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 11, 2024, the
Company consummated the third tranche of its debt financing under the terms of the Securities Purchase Agreement (&ldquo;SPA&rdquo;) referenced
in the current report on Form 6-K filed with the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on August 16,
2024. The Form 6-K filed with the SEC on August 16, 2024 is incorporated by reference herein. Pursuant to the terms of the SPA, the Company
may elect at the second additional mandatory closing to sell and the institutional investor party to the SPA shall be required to purchases,
subject to certain conditions, an additional note (&ldquo;Second Additional Mandatory Note&rdquo;) in the principal amount of $1,500,000,
after the effective date of the Registration Statement (as defined in the SPA). The sale of the Second Additional Mandatory Note resulted
in $1,395,000 of gross proceeds to the company before fees and expenses. The Notes bears an interest rate of 14.75% per annum and may
be adjustable from time to time pursuant to its terms, with maturity at the 4.5 years anniversary of the date of issuance, subject to
extension at the option of the holders in certain circumstances. The Second Additional Note are convertible at any time, at an initial
conversion price of $0.658.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November. 18, 2024, the
Company entered into a binding term sheet (the &ldquo;Term Sheet&rdquo;) with White Lion Capital, LLC, (&ldquo;White Lion&rdquo;) a California-based
institutional investor focused on high-growth, early-stage public companies, setting out the principal terms and conditions for a $100
million equity line of credit, expandable to $500 million. Pursuant to the Term Sheet, NewGen will have the option, but not the obligation,
to sell to White Lion up to $100.0 million in shares of common stock over an initial 36-month period, with the potential to increase to
$300.0 million upon substantial M&amp;A or merger activity, and further to $500.0 million after $250.0 million has been drawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 29, 2024, the
Company appointed Tam, Chun Wa to the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;). Mr. Tam will serve as an independent
director. In addition, Mr. Tam has been named to the Audit Committee of the Board. Following the appointment of Mr. Tam, the Board consists
of five members.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 2 &mdash;&nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Principles of consolidation and basis of preparation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&nbsp;balances and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management has prepared the
accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the United&nbsp;States
of America (&ldquo;U.S.&nbsp;GAAP&rdquo;). The Company maintains its general ledger and journals with the accrual method accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The business combination
transaction between Legacy NewGenIvf and SPAC I was accounted for as a reverse recapitalization under ASC 805, Business Combinations,
with NewGenIvf Group Limited, and deemed to be the accounting acquirer. As SPAC I did not meet the definition of a business under ASC
805, the transaction was not treated as a business combination. Instead, it was accounted for as a recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the consolidated
assets, liabilities and results of operations of the accounting acquirer will become the historical financial statements of the Company,
and the accounting acquirer&rsquo;s assets, liabilities and results of operations will be consolidated with the Company beginning on the
acquisition date. The Legacy NewGenIvf was the legal acquiree but deemed to be the accounting acquirer. The Company was the legal acquirer
but deemed to be the accounting acquiree in the reverse merger. The historical financial statements prior to the acquisition are those
of the accounting acquirer (Legacy NewGenivf). After completion of the Share Exchange Transaction, the Company&rsquo;s consolidated financial
statements include the assets and liabilities, the operations and cash flow of the accounting acquirer. Any excess of the value of shares
issued by the Company over the net book value of the accounting acquirer will be recognized as a reduction to equity (APIC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Use of estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Foreign currency translation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements are presented in United&nbsp;States dollar (&ldquo;$&rdquo;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&nbsp;Kong dollar (&ldquo;HK$&rdquo;).
Med Holdings and FFC use Thai baht (&ldquo;THB&rdquo;) as their functional currencies. First Fertility Phnom Penh Limited and Bi Clinic
Ltd (&ldquo;FFBi&rdquo;) uses United&nbsp;States dollar (&ldquo;USD&rdquo;) as their functional currencies. Shenzhen Qianhai Fengtai Renhui
Health Technology Co., Ltd. (&ldquo;SZ QianHai&rdquo;) uses Chinese Renminbi (&ldquo;CNY&rdquo;) as its functional currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assets and liabilities denominated
in currencies other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the
balance sheet date. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the
functional currency using the applicable exchange rates at the balance sheet dates. Translation gains and losses are recognized in the
consolidated statements of operations and comprehensive income as other comprehensive income or loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The value of foreign currencies
including, the HK$, THB and RMB, may fluctuate against the United&nbsp;States dollar. Any significant variations of the aforementioned
currencies relative to the United&nbsp;States dollar may materially affect the Company&rsquo;s financial condition in terms of reporting
in USD.&nbsp;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Period-end</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">$: HK$</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7.8000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7.8000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7.8000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Period average</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$: HK$</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.8000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.8000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.8000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Period-end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$: THB</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34.3353</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34.2265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34.6153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Period average</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$: THB</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.2262</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34.7867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.1428</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Period-end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$: RMB</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.2994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0971</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.9091</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Period average</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$: RMB</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.1946</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0835</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.4569</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Cash and cash equivalents</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&nbsp;deposits with original maturities of three&nbsp;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Deposits, other receivables and deferred legal&amp;
IPO cost, net</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deposits, other receivables
and deferred Initial Public Offering (&ldquo;IPO&rdquo;) cost, net primarily include deposits paid to suppliers, prepaid expenses, the
prepaid professional fee which meets the definition of deferred IPO cost, and a cash deposit of US$1,000,000 with OSL Group, a digital
asset trading platform listed in Hong Kong Stock Exchange, for the Company&rsquo;s future digital asset diversification strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to additional paid-in capital upon the completion of the Initial Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Legal and professional fees
incurred in connection with issuing convertible debt are deferred and amortized over the life of the debt. These costs are presented as
a direct deduction from the carrying amount of the debt liability on the balance sheet (per ASC 835-30).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Share based compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company accounts for
stock-based compensation in accordance with ASC Topic 718-10, <I>Compensation-Stock Compensation</I>, which requires the measurement and
recognition of compensation expense for all share-based payment arrangements related to the acquisition of goods and services from both
nonemployees and employees based on fair values of the shares to be issued estimated at grant date. The stock-based compensation expense
recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during
the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Fair value is determined
based on the estimated market prices of the Company&rsquo;s Common Stock at the respective issuance date in accordance with ASC 718, taking
into consideration the volatility of the market price of the shares, the terms of the instruments and the conditions upon which they were
granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Property and equipment, net</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Plant and equipment are stated
at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&nbsp;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 75%; text-align: left; text-indent: -10pt; padding-left: 10pt">Furniture and fixtures</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: center">3&nbsp;&ndash;&nbsp;5&nbsp;years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -10pt; padding-left: 10pt">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">the lesser of useful life or&nbsp;term of lease</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Medical instruments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3&nbsp;&ndash;&nbsp;10&nbsp;years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Motor vehicle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3&nbsp;&ndash;&nbsp;5&nbsp;years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3&nbsp;&ndash;&nbsp;5&nbsp;years</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&rsquo;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Impairment of&nbsp;long-lived&nbsp;assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluates the
long-lived&nbsp;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&nbsp;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Inventories</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&nbsp;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete inventory
will be made based primarily on products approaching expiry period and forecasts of product demand. The excess balance above the product
demand as determined by this analysis becomes the basis for excess inventory charge and the written-down&nbsp;value of the inventory becomes
its cost. Written-down&nbsp;inventory would not be reversed if market conditions improve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Other borrowings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Convertible Instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Convertible Instruments are
categorized as equity or debt based on the terms of the notes. Convertible Notes are recorded at amounts equal to the proceeds of the
issuance, including the embedded conversion feature, and net of discounts and unamortized debt issuance in accordance with ASC 480-10-55-44
on the consolidated balance sheets. An evaluation of all conversion, purchase and redemption features contained in a debt instrument is
performed to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is recorded
separately as a derivative liability at its fair value, calculated using the Black-Scholes model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Debt issuance and offering
costs are amortized over the contractual term of the Convertible Notes, to the consolidated statements of operations in accordance with
ASC 835-30-45-1A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The convertible notes are
subsequently recorded at amortized cost, with interest expense recognized using the effective interest method. The derivative liability,
if any is remeasured at fair value at each reporting date and any gain or loss on fair value is recognized in the statement of comprehensive
income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Promissory Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Promissory notes, originated
from ASCA&rsquo;s transaction and being taken over by NewGenIVF Group Limited upon merger, are of non-interest bearing and recorded at
original cost. They are subsequently measured at amortised cost, with interest expense recognized using the effective interest method
in the consolidated statement of income.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Ordinary shares</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&rsquo;s ordinary
shares are stated at no par value. The difference between the consideration received, net of issuance cost, is recorded in additional
paid-in&nbsp;capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 21, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company&rsquo;s issued and unissued shares, including the
Class A ordinary shares with no par value (the &ldquo;Class A Ordinary Shares&rdquo;), Class B ordinary shares with no par value and preferred
shares with no par value, at an exchange ratio of one (1) share for twenty (20) shares (the &ldquo;Reverse Stock Split&rdquo;). Upon the
opening of the market on February 11, 2025, the Company&rsquo;s Class A Ordinary Shares will begin trading on the Nasdaq Global Market
(&ldquo;Nasdaq&rdquo;) on a post-Reverse Stock Split basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 15, 2025, the Board
of Directors of the Company approved a reverse stock split of all of the Company&rsquo;s issued and unissued shares, including the Class
A ordinary shares with no par value (the &ldquo;Class A Ordinary Shares&rdquo;), Class B ordinary shares with no par value and preferred
shares with no par value, at an exchange ratio of one (1) share for ten (10) shares (the &ldquo;Reverse Stock Split&rdquo;). Upon the
opening of the market on May 5, 2025, the Company&rsquo;s Class A Ordinary Shares began trading on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
on a post-Reverse Stock Split basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with ASC 505,
the reverse stock split is to be accounted for retrospectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC Topic&nbsp;606,
Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&nbsp;606 on April&nbsp;1, 2017 using the full retrospective
method which requires the Company to present the financial statements for all periods as if Topic&nbsp;606 had been applied to all prior
periods. The Company derives revenue principally from provision of In vitro fertilization (&ldquo;IVF&rdquo;) treatment and surrogacy
and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its contracts with customers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its performance obligations under those contracts;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction prices of those contracts;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction prices to its performance obligations in those contracts; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company derives its revenues
from two sources: (1)&nbsp;revenue from IVF treatment, and (2)&nbsp;revenue from surrogacy and ancillary caring services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue from IVF treatment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In vitro fertilization (&ldquo;IVF&rdquo;)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
as well as procedures and brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized
at a point in time when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various
procedures and treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion
of the service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue from surrogacy and ancillary caring
services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&rsquo;s result of operations
can be found in Note&nbsp;8 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue from egg freezing and storage facility</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides access
the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the customer,
the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point in time when
the facility is made available to the customer at the agreed consideration by the provision of specific address within the facility as
maintained in the patient file. The receipt of consideration is assured as payment is required upfront.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Principal versus agency considerations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company follows the guidance
provided in ASC 606, Revenue from Contracts with Customers, for determining whether the Company is the principal or an agent in arrangements
with customers that involve another party that contributes to the provision of services to a customer. In these instances, the Company
determines whether it has promised to provide the service itself (as principal) or to arrange for the specified service to be provided
by another party (as an agent). This determination is a matter of judgment that depends on the facts and circumstances of each arrangement.
The Company recognizes revenue from the performance of the procedures and treatment on a gross basis as the Company is responsible for
the fulfillment, controls the delivery of the promised service, and has full discretion in establishing prices and therefore is the principal
in the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract related assets and
liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Account receivables, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&rsquo;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&rsquo;s customers&rsquo; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Contract liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract liabilities represent
considerations received from customers in advance of satisfying the Company&rsquo;s performance obligations under the contract. These
amounts are expected to be earned within 12&nbsp;months and are classified as current liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Expected credit loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ASU No.&nbsp;2016-13, Financial
Instruments&nbsp;&mdash;&nbsp;Credit Losses (Topic&nbsp;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&nbsp;estimates of credit
losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due to the
entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest
rate of the financial asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Retirement benefits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Retirement benefits in the
form of mandatory government-sponsored&nbsp;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Segment information</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines its
reportable segments using the management approach based on internal reporting used by the Chief Operating Decision Maker (&ldquo;CODM&rdquo;),
comprising the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), for decision-making, resource allocation, and performance
assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company does not distinguish
revenues, costs, or expenses by segments, operational or geographical, but reports them in aggregate. Based on this assessment, management
has determined that the Company operates as a single reportable segment under ASC 280. Accordingly, all required segment financial information
is included in the consolidated financial statements. However, we segregate IVF revenue from surrogacy revenue as these two revenue types
are critical to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&rsquo;s CODM
is Mr. Siu Wing Fund Alfred, its CEO. Geographic disclosures of long-lived assets and revenue from external customers as of December 31,
2024 and 2023 are presented in Note 15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Leases</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company measured the
lease in accordance to ASU&nbsp;2016-02, &ldquo;Leases&rdquo; (Topic&nbsp;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&nbsp;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of twelve&nbsp;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&nbsp;basis
over the lease term.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Income Taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences
are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not realizable
or recoverable in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions in
income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Comprehensive Income</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company presents comprehensive
income in accordance with ASC Topic&nbsp;220,&nbsp;<I>Comprehensive Income</I>. ASC Topic&nbsp;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&nbsp;years and the foreign currency translation adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Earnings per share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company computes earnings
per share (&ldquo;EPS&rdquo;) following ASC Topic&nbsp;260, &ldquo;Earnings per share&rdquo;. Basic EPS is measured as the income or loss
available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents the dilutive
effect on a per-share&nbsp;basis from the potential conversion of convertible securities or the exercise of options and or warrants; the
dilutive impacts of potentially convertible securities are calculated using the as-if&nbsp;method; the potentially dilutive effect of
options or warranties are computed using the treasury stock method. Potentially anti-dilutive&nbsp;securities (i.e., those that increase
income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive securities
that were in-the-money&nbsp;that were outstanding during the&nbsp;years ended December&nbsp;31, 2024, 2023 and 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Related parties</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC&nbsp;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Commitments and contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the normal course of business,
the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range
of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency if it determines
it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making
these assessments including historical and the specific facts and circumstances of each matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Non-controlling&nbsp;interests</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-controlling&nbsp;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&nbsp;interests respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Concentration of risks</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Concentration of credit risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers. Furthermore, the risk is mitigated by ascertaining upfront payments for
services prior to their performance.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Concentration of customers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, one and two customers respectively which individually contributed more than 10% of trade receivable, and accounted for 89% and 96.3%
of the Company&rsquo;s trade receivable respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of the customers contributed
more than 10% of revenue for&nbsp;years ended December&nbsp;31, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Concentration of suppliers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, nil and one supplier respectively which individually contributed more than 10% of trade payable, accounted for nil % and 30.6% of
the Company&rsquo;s trade payable respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For both the years ended
December 31, 2024 and 2023, no vendor contributed more than 10% of total purchases of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Financial instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&rsquo;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net, loan
to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that approximate
their fair values due to their short maturities. ASC Topic&nbsp;820, &ldquo;Fair Value Measurements and Disclosures&rdquo; requires disclosing
the fair value of financial instruments held by the Company. ASC Topic&nbsp;825, &ldquo;Financial Instruments&rdquo; defines fair value
and establishes a three-level&nbsp;valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts and
other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify as financial
instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments
and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&nbsp;&mdash;&nbsp;inputs to the valuation methodology used quoted prices for identical assets or liabilities in active markets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&nbsp;&mdash;&nbsp;inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&rsquo;s full term</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&nbsp;&mdash;&nbsp;inputs to the valuation methodology are unobservable and significant to the fair value measurement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&nbsp;480, &ldquo;Distinguishing Liabilities from Equity&rdquo;
and ASC&nbsp;815.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Recently issued accounting pronouncements </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FASB has introduced expanded
income tax disclosure requirements under ASU 2023-09 to improve transparency. Companies will now need to provide a detailed reconciliation
of their effective tax rate, breaking down federal, state, and foreign taxes, as well as specific categories like tax credits and foreign
earnings. Additionally, businesses must disclose income taxes paid by jurisdiction, offering investors greater clarity on tax obligations.
These changes apply to both public and private companies, with annual reporting periods beginning after December 15, 2024 (2025 for calendar-year
entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A major shift in digital
asset accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than
applying the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December 15,
2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair value
accounting seen in other investment holdings, addressing criticisms of the old impairment approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&rsquo;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 3 &mdash; GOING CONCERN.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated a loss and
suffered from an accumulated deficit of $985,994 as of December 31, 2024. These matters raise substantial doubt about the Company&rsquo;s
ability to continue as a going concern. Management&rsquo;s plans with regards to these include but not limited to issuance of share through
equity line of credit with White Lion Capital and conversion of JAK&rsquo;s promissory notes. These financial statements do not include
any adjustments that might result from the outcome of this uncertainty.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company closely monitors
the market for opportunities and has also been carrying out various fundraising projects to improve the Company&rsquo;s cash flow position.
As of this report date, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising the Initial Note,
the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the Company. A further
$2,000,000 of the Third Mandatory Additional Note was issued subsequent to year end and remains outstanding. Moreover, the Company has
access to an equity line of credit facility of up to $100,000,000 from White Lion Capital, of which approximately $7.1 million has been
drawn and become equity to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one
or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there
would likely be a material adverse effect on the Company and its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 4 &mdash;&nbsp;ACCOUNTS RECEIVABLE, NET</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accounts receivable, net consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Accounts receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">49,264</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,393</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">49,245</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,374</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the end of each of
the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1.5pt">Within 90&nbsp;days</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">49,245</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">9,374</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">49,245</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,374</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Balance at beginning of the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(19</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(26</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Reversal of expected credit losses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Ending balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 5 &mdash;&nbsp;INVENTORIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inventories consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1.5pt">Medicines, consumables and reagents for clinical and laboratory analyses</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">80,813</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">126,264</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">80,813</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">126,264</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 6 &mdash;&nbsp;DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND
DEFERRED IPO COST, NET</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><U>Current</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Other receivables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">121,533</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">15,910</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,008</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred initial public offering &ldquo;IPO&rdquo; cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">373,677</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: allowance for expected credit loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(14</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">195,446</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">512,581</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Deposit with a digital asset trading platform</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,000,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Receivable from agents</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,191,795</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Prepayments</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">197,706</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,262,228</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline">Non-current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Prepayment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">33,333</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,582,156</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,582,156</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Included in prepayment is
an amount of $22,000 and $2,839,536 as of December 31, 2024 and 2023 respectively, being share-based compensation cost paid to consultants
for services ranging from three to ten years and with termination clauses of one to three years respectively without any penalties. During
the year, the scope of service was amended and accordingly the excess compensation was reversed against Additional Paid in Capital and
the remaining value of service is recognized over the period of service in the Statement of Income.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Balance at beginning of the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(14</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(141</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Reversal of provision (Provision)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">127</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Ending balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(14</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 7 &mdash;&nbsp;PROPERTY AND EQUIPMENT, NET</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Plant and equipment, net consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>At cost:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Building improvement</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">196,929</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">92,438</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Furniture and fixtures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,493</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Medical instruments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">785,776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">844,809</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Motor vehicle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,936</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,936</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Office equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">361,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">150,688</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,512,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,481,364</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,239,320</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,319,207</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">273,096</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">162,157</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Depreciation expenses for
the&nbsp;years ended December 31, 2024 and 2023 were $19,502 and $31,173, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No impairment loss was recorded for the&nbsp;years
ended December&nbsp;31, 2024, and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 8 &mdash;&nbsp;ACCRUED LIABILTIES AND OTHER PAYABLES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities and other payables consist
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Accrued expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">201,455</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">43,633</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Customer deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,349</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Withholding tax payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,349</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Independent director fee payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Compensation payable (Note&nbsp;1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other payables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">167,762</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">46,616</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">500,729</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">241,613</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represents a claim relating to an employee of the subsidiary. On April 23, 2023, a settlement agreement was entered into with the employee, with compensation payable over 12 instalments commencing April 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 9 &mdash;&nbsp;CONTRACT LIABILITIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Contract liabilities consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Balance at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,937</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,360,168</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,006</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Recognized to revenue during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,788</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(122,662</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Refund to customers (Note 1)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,341,575</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Balance at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">63,489</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,937</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund to customers are in relation to China-based clients who prepaid for surrogacy and ancillary caring services but requested for refund of fees so that they may appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 10 &mdash;&nbsp;CONVERTIBLE NOTES, PROMISSORY NOTES, DERIVATIVE
LIABILITY AND WARRANTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Convertible Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Convertible notes, at amortised cost are as follows:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Convertible notes at amortised cost</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,059,595</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: Deferred debt issuance cost</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">648,232</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Convertible notes, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,411,363</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>The convertible notes are repayable as follows:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Current liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">82,447</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-current liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,328,916</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,411,363</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024, the Company had the following
outstanding convertible notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Principal</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Conversion</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Coupon</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Issuance</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Maturity</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Note Holders</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; text-align: left">JAK &amp; affiliated holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.830</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">14.75</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">April 3, 2024</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">October 2, 2028</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">JAK &amp; affiliated holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.830</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.75</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August&nbsp;3, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 2, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">JAK &amp; affiliated holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.950</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.75</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August 30, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 1, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">JAK &amp; affiliated holders</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.686</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">14.75</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">November 11, 2024</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">May 10, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,150,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2024, a total of $5,800,000 of convertible promissory notes were issued with a discount of 7%. These Notes are to be settled by way
of cash or may be converted to Class A ordinary shares. The conversion of these notes are subject to certain criterions as mentioned in
the Convertible Note Agreements, which include a beneficiary cap of 9.9% of shareholdings in the Company by JAK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
$2,650,000 of convertible notes were converted into 7,020,975 ordinary shares (equivalent to 35,105 post Reverse Stock Splits) by the
note holder, thereby increasing our shareholder equity by the same amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The effective interest expense
calculated at 16.96 % amounted to $765,177 and $nil for the year ended December 31, 2024 and December 31, 2023 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transaction costs incurred
on issuance of the Notes are capitalized and amortised over the term of the Notes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Transaction costs on issuance of Notes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Balance at beginning of the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left">Add: capitalized during the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">929,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: amortized during the year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(281,268</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Ending balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">648,232</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth the Company&rsquo;s contractual obligations as of December 31, 2024 relating to the convertible notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Convertible bonds-</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">2025</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">516,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">507,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2029</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,269,625</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,207,625</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Promissory Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Balance at beginning of the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left">Issued during the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,453,861</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Waiver of liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">953,861</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Ending balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">500,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
the Company has outstanding non-interest-bearing unsecured promissory notes with a total principal balance of US$500,000, which was settled
fully in February 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Derivative liability </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to ASC 815, a derivative
liability had arisen from the issuance of convertible bonds which have the option of being converted to or exchanged for Class A ordinary
shares at any time from date of issuance. The derivative liability is assessed to be a debt requiring to be bifurcated from the host contract
and recorded at the fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, the conversion to
ordinary shares is subject to certain terms and criteria as set within the Agreement, which includes restriction of conversion if the
shareholdings by the note holder before and after the conversion exceeds 9.99%, as revised. As of December 31, 2024, the threshold has
been met, and accordingly the derivative is assessed to have no value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Free standing instruments &ndash; warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The convertible bond agreements
as mentioned above granted the note holders 6,174,690 series A warrant, 180,722 series B warrant and 3,253,012 series C warrant, allowing
the warrant holders to purchase additional Class A ordinary shares at an exercise price of $0.913, $0.001 and $0.924 respectively, subject
to adjustments arising from the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The exercise of these warrants
is subject to a 9.99% beneficial cap, as revised, which restricts the holder from exceeding shareholdings in excess of the cap in the
Company. As of December 31, 2024, the threshold has been met, and accordingly the derivative is assessed to have no value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 11 &mdash;&nbsp;LEASES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has various operating
leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The Company&rsquo;s management believes
that the interest rate of 6.6% and 5.5% was the most indicative rate of the Company&rsquo;s borrowing cost for the calculation of the
present value of the lease payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024 and 2023, the right-of-use&nbsp;assets
totaled $98,570, and $283,847, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024 and 2023, lease liabilities
consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">Operating lease</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Lease liabilities&nbsp;&ndash;&nbsp;current portion</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">108,526</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">207,128</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Lease liabilities&nbsp;&ndash;&nbsp;non-current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,231</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">118,979</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">118,757</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">326,107</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">Finance lease</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Lease liabilities&nbsp;&ndash;&nbsp;current portion</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,446</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a schedule of future minimum
payments under operating leases as of December&nbsp;31, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">Not later than 1 year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">111,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Between 1 to 2&nbsp;years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,621</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,864</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total operating lease liabilities, net of interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">118,757</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other lease information is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.75 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92&nbsp;years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left">Weighted-average discount rate&nbsp;&ndash;&nbsp;operating leases</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Short term lease cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">234,767</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">114,937</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, there were $98,570 and $283,847 right of use (&ldquo;ROU&rdquo;) assets and $118,757 and $326,107 lease liabilities based on the
present value of the future minimum rental payments of leases, respectively. The Company&rsquo;s management believes that using an incremental
borrowing rate of the minimum loan rate and the Hong&nbsp;Kong Dollar Best Lending Rate (&ldquo;BLR&rdquo;) minus 0.125%&nbsp;was the
most indicative rate of the Company&rsquo;s borrowing cost for the calculation of the present value of the lease payments; the rate used
by the Company was 6.6% and 5.5% respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 12 &mdash;&nbsp;EQUITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Ordinary shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As at December&nbsp;31, 2023
and December 31, 2024, the Company is authorized to issue 10,000,000 ordinary shares. Each ordinary share is entitled to one vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board
of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The equity of the Company
as of December 31, 2024 and 2023 represents 113,852 and 50,747 ordinary shares with par value of $Nil. The number of shares as above have
taken into consideration the reverse stock splits effected on February 11, 2025 at an exchange ratio of one (1) share for twenty (20)
shares and on May 5, 2025 at an exchange ratio of one (1) share for ten (10) shares. Pursuant to ASC 505 the reverse stock split has been
applied retrospectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Additional paid-in capital</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">Balance as at January 1,2023</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,464,959</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of shares&nbsp;as compensation for services (<I>Note 1</I>)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,866,856</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance as at December 31, 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,331,815</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of shares through Equity Line of Credit (<I>Note 2</I>)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,936,236</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of shares through conversion of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,650,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease in subscription receivable due to reduction of work by professionals <I>(Note 1)</I></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,766,856</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Combination (<I>Note 3</I>)</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,028,690</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Balance as at December 31, 2024</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">122,505</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- the number of shares below have been amended to apply the two reverse stock splits in February 2025 and in May 2025 retrospectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 1:&nbsp;On January 10, 2023, the Company
issued 137 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300.
On December 4, 2023, the Company issued additional 345 shares to DoubleClick Services Limited for consulting service of 10 years, increasing
the additional paid-in capital by $2,054,556. During 2024, the service scope and duration were reduced and the service value was adjusted
accordingly pursuant to addendums to respective agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note 2:</U> On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the &ldquo;White Lion Purchase Agreement&rdquo;) with White Lion Capital, LLC (&ldquo;White
Lion&rdquo;) and a related Registration Rights Agreement (the &ldquo;RRA&rdquo;). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One
Hundred Million Dollars ($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to
Three Hundred Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase
Agreement) and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars
($250,000,000) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions
set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration
statement filed on December 5, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 10, 2024, 3,500 Class A Ordinary Shares
were issued to White Lion amounting $276,850, in consideration for White Lion&rsquo;s commitment pursuant to the White Lion Purchase Agreement.
In addition, on December 12, 2024, pursuant to this Agreement, the Company issued 19,000 Class A Ordinary Shares for a purchase price
of $1,572,186. On December 24, 2024, the Company issued 2,500 Class A Ordinary Shares for a purchase price of $160,050. On December 31,
2024, the Company issued 3,000 Class A Ordinary Shares for a purchase price of $204,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 3: Upon de-spac business combination, additional
paid-in capital and capital reserve of Legacy NewGenIvf was combined with additional paid-in capital and accumulated net losses of the
A SPAC I Acquisition Corp and added into the additional paid-in capital of NewGenIvf Group upon the reverse take-over.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 13 &mdash;&nbsp;EMPLOYEE BENEFIT PLANS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>HK SAR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 5% of the employees&rsquo;
basic salaries on monthly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Thailand</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is obliged to
make social security payments within the first 15&nbsp;days of the month over which it is accrued. In 2024, the Company and its employees
are each required to make contributions to the scheme calculated at 5% of the employee&rsquo;s salary with a cap of THB750 per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cambodia</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Every business employing
one or more workers must register its business and workers with the National Social Security Fund (the &ldquo;NSSF&rdquo;) for the Occupational
Risk Scheme (for work-related&nbsp;accidents and occupational diseases), the Health Care Scheme and the Pension Scheme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once registered, the business
must pay to the NSSF:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to 0.8% of each worker&rsquo;s monthly average wages (between $0.40 and $2.40 per month per worker) for the Occupational Risk Scheme.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to 2.6% of a worker&rsquo;s monthly average wages (between $1.30 and $7.80 per month per worker) for the Health Care Scheme.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of 2% (total of 4%) of the contributable wage for the first five&nbsp;years. The contributable wage for the Pension Scheme ranges from between KHR400,000 (approximately $100) up to KHR1,200,000 (approximately $300).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Kyrgyzstan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 15% and 8%, respectively
of the employees&rsquo; basic salaries on monthly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 14 &mdash;&nbsp;PROVISION FOR INCOME TAXES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cayman Islands</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NewGenIvf Limited was incorporated
in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law. In addition, upon payment
of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>HK SAR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the two-tiered&nbsp;profits
tax rates regime, Hong&nbsp;Kong tax residents are subject to Hong&nbsp;Kong Profits Tax in respect of profits arising in or derived from
Hong&nbsp;Kong at 8.25% for the first HK$2&nbsp;million of profits of the qualifying group entity, and profits above HK$2&nbsp;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&nbsp;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the HK SAR profits
tax is calculated at 8.25% on the first HK$2&nbsp;million of the estimated assessable profits and at 16.5% on the remaining estimated
assessable profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Thailand</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The companies incorporated
in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from or in consequence of the
business carried on in Thailand. The corporate income tax (CIT) rate is 20%. A foreign company not carrying on business in Thailand is
subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends, royalties, rentals, and service
fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%, while other rates may apply under
the provisions of a double tax treaty (DTT).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cambodia</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The standard rate of corporate
income tax (&ldquo;CIT&rdquo;) for companies and permanent establishments who are classified as medium and large taxpayers is 20%. For
companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive rates from 0% to 20%. In view
of the annual turnover of the company, the annual turnover ranges from KHR1&nbsp;billion to KHR6&nbsp;billion for service and commercial
sectors, the company shall consider as the medium-sized&nbsp;company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Kyrgyzstan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company is subject to
a corporate income tax on their aggregate annual income earned worldwide. Non-resident&nbsp;legal entities carrying out business activities
through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that permanent
establishments. During the year, excess tax payable of $486,706 were deemed to be no longer payable and reversed accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Profit tax is calculated
at a rate of 10% of aggregate annual income less allowed deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Significant components of
the provisions for income taxes for the year ended December&nbsp;31, 2024, and 2023 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Current tax provision Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: justify">Over provision of tax in prior year Kyrgyzstan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(486,706</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Current tax provision Cambodia</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total tax (income) expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(486,706</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify; padding-bottom: 1.5pt">(Loss) Income before taxes</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(960,807</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">108,418</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">343,988</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Tax credit (expense) at the effective tax rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(179,863</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,732</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(124,591</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Tax effect on non-taxable income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(81,323</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,173</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Tax effect on non-deductible expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,814</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Change in valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,991</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Tax effect on utilization of tax losses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(127,521</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,369</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Tax losses unable to be utilized</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Over provision of tax in prior year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(486,706</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Tax (income) expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(486,706</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">208,141</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax asset, net</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Significant components of
deferred tax assets, net were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, <BR> 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">&ndash; Net operating loss carry forward</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">160,432</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">28,441</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(160,432</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(28,441</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, the Company had net operating loss carry forward of $972,316 and $164,721. The Company believes it is less likely than not that
its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry forward. As a result, the
Company provided 100% allowance on deferred tax assets on net operating loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 15 &mdash;&nbsp;DISAGGREGATED REVENUES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s main business operations are
to provide: (i)&nbsp;IVF treatment service; and (ii)&nbsp;surrogacy and ancillary caring services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended<BR> December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Revenue from external customers</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">IVF treatment service</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,433,375</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,021,696</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,819,163</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Surrogacy, ancillary caring and other services</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,114,457</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,125,027</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total revenues</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,433,375</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,136,153</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,944,190</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Geographical information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Revenue from external customers originated from</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">HK SAR</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">34,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,656,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,123,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,060,973</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">601,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377,608</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Thailand</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,175,253</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,356,903</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">505,609</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total revenues</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,433,375</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,136,153</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,944,190</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The revenue information above is based on the
locations where the revenue originated.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Long-lived assets located at</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">HK SAR</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,081</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">584</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>China</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,370</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Kyrgyzstan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,513</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cambodia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">137,472</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,085</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Thailand</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">312,313</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">307,948</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">254,745</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">371,666</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">446,004</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">506,343</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s long-lived&nbsp;assets consist
of plant and equipment, net and operating leases right-of-use&nbsp;assets, net.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 16 &mdash;&nbsp;RISKS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">A. Credit risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Accounts receivable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to minimize the
credit risk, the management of the Company monitors and ensures that follow-up&nbsp;action is taken to recover overdue debts. The Company
considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk
on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Company compares
the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.
It considers available reasonable and supportive forward-looking&nbsp;information, such as GDP growth rate and nominal GDP per capita.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account receivables as of December
31, 2024 and 2023 to be $19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash and cash equivalents</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The credit risk on liquid
funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&nbsp;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Deposits and other receivables, amount due
from shareholders and loan to A SPAC I</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company assessed the
impairment for deposits and other receivables, due from shareholders individually based on internal credit rating and ageing of these
debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition. Based on the impairment
assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables, due from shareholders
as of December&nbsp;31, 2024 is $4, and $17,818, respectively. The loss allowance for deposits and other receivables, due from shareholders
as of December&nbsp;31, 2023 is $14, and $17,818, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">B.&nbsp;Interest
risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cash flow interest rate risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is exposed to
cash flow interest rate risk through the changes in interest rates related mainly to the Company&rsquo;s variable-rates&nbsp;bank balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company currently does
not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors
monitor the Company&rsquo;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sensitivity analysis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The sensitivity analysis
below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied
to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is used when reporting
interest rate risk internally to key management personnel and represents management&rsquo;s assessment of the reasonably possible change
in interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If interest rates had been
1% higher or lower and all other variables were held constant, the Company&rsquo;s net (loss) income for the&nbsp;years ended December
31, 2024 and 2023 would have increased or decreased by approximately $26,894 and$541, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Foreign currency risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign currency risk is
the risk that the holding of foreign currency assets will affect the Company&rsquo;s financial position as a result of a change in foreign
currency exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&rsquo;s monetary
assets and liabilities are mainly denominated in HK$, THB and RMB which are the same as the functional currencies of the relevant group
entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered insignificant. The Company currently
does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related foreign currency
exposure closely and will consider hedging significant foreign currency exposures should the need arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">C. Economic and political
risks</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&rsquo;s operations
are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&rsquo;s business, financial condition, and results
of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&rsquo;s operations
in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include risks associated with,
among others, the political, economic and legal environment and foreign currency exchange. The Company&rsquo;s results may be adversely
affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary&nbsp;measures, currency conversion, remittances abroad, and rates and methods
of taxation, among other things including natural disasters and wars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">D. Inflation risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management monitors changes
in prices levels. Historically inflation has not materially impacted the Company&rsquo;s consolidated financial statements; however, significant
increases in the price of labor that cannot be passed to the Company&rsquo;s customers could adversely impact the Company&rsquo;s results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 17 &mdash;&nbsp;RELATED PARTY BALANCES AND TRANSACTIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The summary of amount due from and due to related
parties as the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Relationship</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Due from shareholders consist of the following:</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&nbsp;Siu Wing Fung, Alfred (&ldquo;Mr.&nbsp;Siu&rdquo;)</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center; padding-bottom: 1.5pt">Shareholders and directors</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">404,549</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">354,285</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Due to a related party consist of the following:</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Ms.&nbsp;Fong Hei Yue, Tina (&ldquo;Ms. Fong&rdquo;)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Shareholders and directors (note 1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(497,200</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Harcourt Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">A related party (note&nbsp;2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(61,802</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Fong is the spouse of Mr.&nbsp;Siu. The due to shareholders balance as of December 31, 2024 was $92,651 while the due from shareholders balance as of December 31, 2023 was $354,285.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&nbsp;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The balance due from shareholders consist of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Due from/ (to)shareholders/ related party</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(154,453</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">372,103</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: allowance for expected credit loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,818</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(154,453</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">354,285</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Balance at beginning of the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(17,818</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(17,059</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Reversal of Provision / (Provision)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,818</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(759</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Ending balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(17,818</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Directors&rsquo; remuneration to Mr.&nbsp;Siu Wing Fung, Alfred</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">190,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">125,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">120,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Directors&rsquo; remuneration to Ms. Fong Hei Yue, Tina</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Waiver of related party balance of Mr. Siu Wing Fung, Alfred</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88,151</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>NOTE 18 &mdash;&nbsp;LOAN TO A SPAC&nbsp;I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June&nbsp;12, 2023, NewGenIvf
Limited (the &ldquo;Legacy NewGenIvf&rdquo;) and A SPAC&nbsp;I Acquisition Corp (&ldquo;A SPAC&nbsp;I&rdquo;) entered into a First Amendment
to Merger Agreement, pursuant to which the Legacy NewGenIvf agreed to provide non-interest&nbsp;bearing loans in an aggregate principal
amount of up to $560,000 (the &ldquo;Loan&rdquo;) to A SPAC&nbsp;I to fund amounts required to further extend the period of time available
for A SPAC&nbsp;I to consummate a business combination, and for working capital and payment of professional, administrative and operational
expenses, and other purposes as mutually agreed by A SPAC&nbsp;I and the Legacy NewGenIvf. The Loan will only become repayable upon the
closing of the Acquisition Merger. As of December 31, 2023, $140,000 was outstanding under the loan. The Legacy NewGenIvf completed the
business combination with A SPAC I Acquisition Corp on April 3, 2024. After the combination, the balance of loan to ACSA was eliminated
in the subsequent period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>NOTE 19 &mdash;&nbsp;COMMITMENTS &amp; <FONT STYLE="text-transform: uppercase">CONTINGENCIES</FONT></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, the Company was not a party to any legal or administrative proceedings. As of December 31, 2024, the Company had commitment as described
in Notes 10 and 11 to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is also committed
to honor its obligations pursuant to the convertible note agreements as described in Note 10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>NOTE 20 &mdash;&nbsp;<FONT STYLE="text-transform: uppercase">DISPOSAL
OF SUBSIDIARY</FONT></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 18, 2024, the
Company completed the sale of its First Fertility Bishkek LLC to an unrelated third party for total consideration of US$11, consisting
of cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As part of the disposal,
all the outstanding account payables and receivables as well as all outstanding balances between the First Fertility Bishkek LLC and Harcourt,
FFPGS, and the Director were transferred to the Seller. Any tax liabilities in Kyrgyzstan arising from the transfer of these balances
shall be borne by the Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
the financial impact of the disposal:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration received: Cash of $11 </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net assets acquired of&nbsp;$486,706</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal of excess tax of $486,706</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The disposal was accounted
for in accordance with ASC 810, Consolidation. As a result, the Company deconsolidated First Fertility Bishkek LLC and recognized a write
back of tax (after netting against the cash consideration received) in the amount of US$486,706 in the consolidated statements of operations
for the year ended December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The disposal did not represent
a strategic shift and, therefore, was not classified as a discontinued operation under ASC 205-20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>NOTE 21 &mdash;&nbsp;<FONT STYLE="text-transform: uppercase">BUSINESS
ACQUISITION</FONT></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 17, 2024, the
Company acquired Bi Clinic Ltd (&ldquo;Bi Clinic&rdquo;), which holds a license for the provision of IVF treatment, surrogacy, and ancillary
caring services, for total consideration of $15,000. The acquisition enhances the Company&rsquo;s position in healthcare fertility sector.
The transaction was accounted for as a business combination under ASC 805, Business Combinations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the acquisition date,
Bi Clinic had not yet commenced revenue-generating activities but had established the necessary regulatory approvals and licensing framework
to operate as an IVF and surrogacy service provider. These approvals, along with the Company&rsquo;s planned integration of medical personnel
and operational processes, provide the necessary inputs and substantive processes required to meet the definition of a business under
ASC 805.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since Bi Clinic had no other
assets or liabilities, the entire purchase price was allocated to intangible assets, specifically the IVF license and regulatory approvals.
No goodwill was recognized in connection with the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As Bi Clinic had no prior
operations, its financial results have been included in the consolidated financial statements from the acquisition date, with no historical
revenue or expenses impacting the Company&rsquo;s consolidated results. Pro forma financial information has been omitted, as the acquisition
is not considered material to the Company&rsquo;s financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>NOTE 22 &mdash;&nbsp;SUBSEQUENT EVENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon
this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or
disclosure in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 11, 2025, the
Company carried out a 1-for-20 reverse stock split of its issued and unissued shares. The effect of the reverse stock split was to consolidate
every 20 issued and unissued shares into one share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (&ldquo;ASPAC&rdquo;), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the 150,000 (equivalent to 15,000 post Second Reverse Stock Split) Class A Ordinary
Shares to ASPAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 27, 2025, the
Company received a confirmation from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved
and that the Company&rsquo;s securities were transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025.
On March 10, 2025, the Company received a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of Nasdaq&rsquo;s
listing requirements, including shareholder equity of more than $2.5m, as required in the Panel&rsquo;s decision letter dated February
19, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 28, 2025, the
Company completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&ldquo;GIVF&rdquo;). Pursuant to
a Purchase Agreement dated January 21, 2025 between the Company and GIVF (&ldquo;Purchase Agreement&rdquo;), the Company purchased all
of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Ordinary Shares (&ldquo;MicroSort Acquisition&rdquo;).
Under the terms of the agreement, the Company acquired the technology for US$5 million, which was satisfied through a combination of US$750,000
in cash and the issuance of 2,500,000 ordinary shares (as was adjusted to 12,500 ordinary shares after the Reverse Stock Split on February
11, 2025 and the Reverse Stock Split on May 5, 2025) at a deemed value of US$1.70 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 18, 2025, the
Company entered into a cooperation agreement with FERTILITY GROUP LLC (&ldquo;BOBCARE&rdquo;) to jointly develop fertility services in
the Kyrgyzstan market. The collaboration aims to combine NewGen&rsquo;s technical expertise in fertility treatments with BOBCARE&rsquo;s
market resources in the region. This strategic partnership is anticipated to contribute to NewGen&rsquo;s market presence over the next
three years, improving the competitive position of both parties in the Kyrgyzstan market. Both companies will work together on several
initiatives, including enhancing clinical protocols and patient management systems, knowledge exchange between fertility specialists,
coordinated marketing and brand-building activities in Kyrgyzstan, and developing specialized fertility treatment options for the regional
market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 31, 2025, the Company
terminated the binding term sheet with healthcare company European Wellness Investment Holdings Limited (&ldquo;EWIHL&rdquo;) regarding
their previously announced reverse merger transaction. On the grounds of non fulfilment of certain criteria as contained in the term sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 31, 2025, the Company&rsquo;s
Board approved certain amendments to its Share Incentive Plan of 2024, the awards of which are valid for a period of 10 years from March
28, 2025, whereby the maximum aggregate number of shares with respect to which Awards may be granted under the Plan shall be 105,426 Shares,
which may be increased from time to time as determined by the Board or Committee of the Board, in an amount equal to 20% of the then outstanding
ordinary shares of the Company at the time of such increase. Shares may be made available from Shares held in treasury or authorized but
unissued shares of the Company not reserved for any other purpose. To date, no shares have been awarded under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 1, 2025, the Company
entered into a new Securities Purchase Agreement (&ldquo;2025 Securities Purchase Agreement&rdquo;) with JAK, pursuant to which, amongst
other things: (i) the Company agreed to sell, at an initial closing, a senior convertible note in the aggregate original principal amount
of $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms; and (ii) the Company may require JAK (or JAK may require
the Company, as applicable) to participate in the sale of one or more additional convertible notes (which aggregate original principal
amount for all additional convertible notes shall not exceed $25,600,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 2, 2025, the Company
consummated the fourth tranche of its debt financing under the terms of its existing Securities Purchase Agreement with the investor,&nbsp;At
the closing of the fourth tranche, the Company sold&nbsp;to&nbsp;the investor a senior convertible note in the principal amount of $2,000,000.
The Note&nbsp;bears an interest rate of 14.75% per annum and may be adjustable from time to time pursuant to its terms. The funding from
these arrangements with the investor is intended to be used to finance the establishment of a fertility clinic in Dubai.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Mr. Yip Eng Jeremy Foo, a
director of NewGenIvf Group Limited (the &ldquo;Company&rdquo;), has resigned from the Board of Directors of the Company, the Audit Committee
of the Company, and the Compensation Committee of the Company due to personal reasons, effective April 4, 2025. Mr. Foo&rsquo;s resignation
did not result from any disagreement with the Board or the Company on any matter relating to the Company&rsquo;s operations, policies
or practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ms. Florianna Ann Chi Wan
Chan will be appointed as a director of the Company, effective April 15, 2025, to fill the vacancy on the Audit Committee and the Compensation
Committee created by Mr. Foo&rsquo;s resignation. Ms Chan has over 20 years of experience in project management, real estate development,
and luxury hospitality, and is a proven leader in driving growth and operational excellence. Since 2015, Ms. Chan has led Lab Concept
Company Limited, a subsidiary of The Lane Crawford Joyce Group, where she successfully restructured operations, spearheaded rebranding,
and digitized processes, achieving significant revenue growth. Previously, she held senior roles at VCC Company Limited, Eton Properties,
and Crown Macau, excelling in real estate development, marketing, and VIP services. She holds a Bachelor of Hospitality Management from
Central Queensland University in Australia and an Advanced Diploma from William Angliss Institute of TAFE. Fluent in Cantonese, Mandarin,
and English, Ms. Chan brings a deep understanding of Asia Pacific markets and a strategic vision that will drive the Company&rsquo;s continued
growth and success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 15, 2025, the Board
of Directors approved another reverse stock split of all of the Company&rsquo;s issued and unissued shares, including the Class A ordinary
shares with no par value (the &ldquo;Class A Ordinary Shares&rdquo;), Class B ordinary shares with no par value and preferred shares with
no par value, at an exchange ratio of one (1) share for ten (10) shares. The Reverse Stock Split became effective on May 5, 2025, andits
Class A Ordinary Shares began trading on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) on a post-Reverse Stock Split basis on such
date. The Reverse Stock Split was intended for the Company to remain compliant with a minimum bid price of $1.00 per share for continued
listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No fractional shares will
be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary
Share to any shareholder at a participant level who would have been entitled to receive a fractional share as a result of the process.
After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to
the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other
convertible securities are exercisable or convertible by ten (10) in accordance with the terms of the plans, agreements or arrangements
governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subsequent to the year end
and to the date of this report, $3,150,000 convertible notes outstanding as of December 31, 2024 had been converted to additional 259,425
Class A ordinary shares while Promissory Notes of $500,000 outstanding as of December 31, 2024 were settled. A further 166,000 shares
totaling $5,193,763 were issued under the Equity Line of Credit with White Lion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than the events mentioned
above, there have been no other subsequent events noted till the date of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>NOTE 23 &mdash;&nbsp;RECLASSIFICATION AND
COMPARATIVE FIGURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain prior year amounts
have been reclassified to conform to the current year&rsquo;s presentation. These include the re-presentation of share-based compensation
to consultants pursuant to service agreements. In the prior year, compensation for future services to be rendered were recorded as subscription
receivables in the Statement of Equity. In the current year, these compensation for services has been reclassified and measured at the
fair value of the shares issued as compensation at grant date in accordance with ASC 718. This reclassification had no effect on previously
reported&nbsp;net&nbsp;income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The comparative figures
in the consolidated balance sheets, statement of equity, consolidated statements of cash flows, together with the accompanying notes,
where relevant reflect those of the Company after the reverse takeover and reorganization process in 2024, and accordingly differs from
those audited and reported on by the predecessor auditor on NewGenIvf Limited, the legal acquiree and accounting acquirer, arising from
the application of ASC 805, which requires retrospective application. The difference mainly impacts the equity in the consolidated balance
sheets, the statement of equity and the consolidated statements of cash flows, including the relevant notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 6. Indemnification of Directors, Officers
and Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">British Virgin Islands law
does not limit the extent to which a company&rsquo;s memorandum and articles of association may provide for indemnification of officers
and directors, except to the extent any such provision may be held by the British Virgin Islands courts to be contrary to public policy,
such as to provide indemnification against willful default, civil fraud or the consequences of committing a crime. Under our Memorandum
and Articles of Association, we may indemnify our directors, officers and liquidators against all expenses, including legal fees, and
against all judgments, fines and amounts paid in settlement and reasonably incurred in connection with civil, criminal, administrative
or investigative proceedings to which they are party or are threatened to be made a party by reason of their acting as our director, officer
or liquidator. To be entitled to indemnification, these persons must have acted honestly and in good faith with a view to the best interest
of the registrant and, in the case of criminal proceedings, they must have had no reasonable cause to believe their conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the&nbsp;Securities Act of 1933&nbsp;may be permitted to directors, officers or persons controlling the
registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the&nbsp;Securities Act&nbsp;and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7. Recent Sales of Unregistered Securities</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are the sales
of all securities by the Company since the closing of the Business Combination which were not registered under the Securities Act. The
Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2)&nbsp;of
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 3, 2024, the Company
issued to certain investors 295,000 Class A Ordinary Shares (equivalent to 295 Class A Ordinary Shares post Reverse Stock Splits) which
were converted from the ordinary shares of Legacy NewGenIvf pursuant to the terms of the Securities Purchase Agreement by and between
A SPAC I Mini Acquisition Corp. and certain investors named therein (the &ldquo;February Buyers&rdquo;) on February 29, 2024. Pursuant
to this Securities Purchase Agreement, A SPAC I Mini Acquisition Corp agreed to issue and sell to the February Buyers, in a private placement,
an aggregate of up to $3,500,000 principal amount of convertible notes, consisting of one or more tranches: (i) an initial tranche of
an aggregate principal amount of promissory notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500,
and (ii) subsequent tranches of an aggregate principal amount of promissory notes of up to $1,750,000 and including an original issue
discount of up to aggregate $122,500. The closing of the Initial Tranche took place on April 3, 2024. The Company also closed on a subsequent
tranche of the aforementioned promissory notes in the principal amount of $250,000 by issuing and selling to the February Buyers shortly
after the closing of the Business Combination, resulting in an aggregate principal amount of notes of $2,000,000 sold to the February
Buyers. The form of these promissory notes is included as Exhibit 4.2 of the Form 6-K filed on April 4, 2024. The aforementioned Securities
Purchase Agreement is included as Exhibit 4.1 of the Form 6-K filed on April 4, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>2024 Debt Financing</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2024, the Company
entered into a Securities Purchase Agreement (&ldquo;Securities Purchase Agreement&rdquo;) with certain investors named therein (collectively,
the &ldquo;Buyers&rdquo;), pursuant to which, amongst other things: (i) the Company agreed to sell, at an initial closing (and such initial
closing, the &ldquo;Initial Closing&rdquo;), (a) a senior convertible note (the &ldquo;Initial Note&rdquo;) in the aggregate original
principal amount not exceeding $1,100,000, convertible into Class A Ordinary Shares pursuant to its terms, (b) a warrant to purchase 1,325,301
Class A Ordinary Shares (such warrant, the &ldquo;Series A Warrant&rdquo; and prior to any Reverse Stock Splits), and (c) a warrant to
purchase 180,722 Class A Ordinary Shares (the &ldquo;Series B Warrant&rdquo; and prior to any Reverse Stock Splits); and (ii) the Company
may require each Buyer (or each Buyer may require the Company, as applicable) to participate in the sale of (a) one or more additional
convertible notes (which aggregate original principal amount for all additional convertible notes shall not exceed $9,500,000) (the &ldquo;Additional
Notes&rdquo;) and (b) related Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 148; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Securities Purchase Agreement
is filed as Exhibit 4.1 of the Company&rsquo;s current report on Form 6-K dated August 16, 2024 and is incorporated by reference herein.
The Initial Note is filed as Exhibit 10.25 of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in connection
with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with certain holders of its convertible
promissory notes (the &ldquo;Existing Notes&rdquo; and each of such amendment and exchange agreements, an &ldquo;Amendment and Exchange
Agreement&rdquo;), pursuant to which the Company exchanged the Existing Notes by issuing, among other things, (i) senior convertible notes
in the aggregate principal amount of $2,700,000 (the &ldquo;Exchange Notes&rdquo;, and, together with the Initial Note and the Additional
Notes, the &ldquo;Notes&rdquo;) and (b) a series of warrants to initially acquire up to a certain number of Class A Ordinary Shares to
the holders of the Existing Notes set forth therein (the &ldquo;Exchange Warrants&rdquo; and the Series A Warrants and the Series B Warrants,
the &ldquo;Warrants&rdquo;). The Exchange Notes are in substantially similar form to the Initial Notes, which are discussed further below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exchange Warrants expire
nine years after the issuance date and are initially exercisable for an aggregate of 3,253,012 Class A Ordinary Shares (without reflecting
any Reverse Stock Splits), subject to adjustment as provided therein. The Exchange Warrants may be exercised at any time after the exchange
date, subject to the Maximum Percentage (as defined in the Exchange Warrants). The initial exercise price of the Exchange Warrants is
$0.913 per share, subject to adjustment as provided therein. If at the time of exercise of the Exchange Warrants, there is no effective
registration statement registering our Class A Ordinary Shares underlying such warrants, such warrants may be exercised on a cashless
basis pursuant to their terms. The form of the Amendment and Exchange Agreement, the form of Exchange Notes, and the form of Exchange
Warrants are filed as Exhibits 4.2, 4.3, and 4.4 to the Form 6-K dated August 16, 2024, and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Initial Closing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 12, 2024, the Company
and the Buyers consummated the Initial Closing. The Initial Note sold in connection with the Securities Purchase Agreement bears an interest
rate of 14.75% per annum and is convertible into the Company&rsquo;s Class A Ordinary Shares as follows: the Conversion Amount (as defined
in the Initial Note) into validly issued, fully paid and non-assessable Class A Ordinary Shares at the Conversion Rate (as defined in
the Initial Note); subject to adjustment as provided therein. No fractional Class A Ordinary Shares are issuable upon any such conversion.
A holder may convert the Initial Notes at any time after the initial issuance date of such Initial Note, subject to the Maximum Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The form of the Initial Note
is included as Exhibit A of the Securities Purchase Agreement filed as Exhibit 4.1 in the Form 6-K dated August 15, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Initial Closing, the
Company also sold to the Buyers Series A Warrants to purchase an aggregate 1,325,301 Class A Ordinary Shares (without reflecting any Reverse
Stock Splits) and Series B Warrants to purchase an aggregate 180,722 Class A Ordinary Shares (without reflecting any Reverse Stock Splits).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Series A Warrants</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Series A Warrants expire nine years after the issuance date and are initially exercisable for an aggregate of 1,325,301 Class A Ordinary
Shares (the &ldquo;Series A Warrant Shares&rdquo;), subject to adjustment as provided therein. The initial exercise price of the Series
A Warrants is $0.913 per share, subject to adjustment as provided therein. If at the time of exercise of the Series A Warrants, there
is no effective registration statement registering the shares of our Ordinary Shares underlying such warrants, such warrants may be exercised
on a cashless basis pursuant to their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>Series B Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series B Warrants expire
nine years after the issuance date and are initially exercisable for an aggregate of 180,722 Ordinary Shares, subject to adjustment as
provided therein. The Series B Warrants may be exercised at any time on or after February 12, 2025 (the &ldquo;Initial Exercise Eligibility
Date&rdquo;), subject to the Maximum Percentage. The initial exercise price of the Series B Warrants was prepaid, except for a nominal
exercise price of $0.001 per share, subject to adjustment as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The form of the Series A Warrant
and form of the Series B Warrant are included as Exhibit B of the Securities Purchase Agreement included as Exhibit 4.1 in the Form 6-K
filed on August 16, 2024, which is incorporated herein by reference.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Second Tranche</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 28, 2024, the Company
closed on the second tranche of the 2024 Debt Financing pursuant to the terms of the Securities Purchase Agreement. Under the second tranche,
the Company sold the First Mandatory Additional Note in the aggregate principal amount of $500,000. The First Mandatory Additional Note
is in substantially similar form to the Initial Note. Upon issuance of the First Mandatory Additional Note, the number of Class A Ordinary
Shares issuable upon exercise of the Series A Warrant automatically increased to 2,236,446 (equivalent to approximately 2,236 Class A
Ordinary Shares post Reverse Stock Splits). The First Mandatory Additional Note is included as Exhibit 4.1 in the Form 6-K filed on August
30, 2024, which is incorporated herein by reference.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Third Tranche</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 11, 2024,&nbsp;the
Company <FONT STYLE="background-color: white">closed on the third tranche of the 2024 Debt Financing pursuant to the terms of the Securities
Purchase Agreement. Under the third tranche, the Company sold the Second Mandatory Additional Note in the aggregate principal amount of
$1,500,000. The Second Mandatory Additional Note is in substantially similar form to the Initial Note. </FONT>Upon issuance of the First
Mandatory Additional Note, the number of Class A Ordinary Shares issuable upon exercise of the Series A Warrant automatically increased
to 5,874,383 (equivalent to approximately 5,874 Class A Ordinary Shares post Reverse Stock Splits). <FONT STYLE="background-color: white">The
Second Mandatory Additional Note is included as Exhibit 4.1 in the Form 6-K filed on November 15, 2024, which is incorporated herein by
reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fourth Tranche</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 2, 2025,&nbsp;the
Company closed on the fourth tranche of the 2024 Debt Financing pursuant to the terms of the Securities Purchase Agreement. Under the
fourth tranche, the Company sold a senior convertible note (the &ldquo;Fourth Tranche Note&rdquo;) in the original principal amount of
$2,000,000. The Fourth Tranche Note is in substantially similar form to the Initial Note. Upon issuance of the note, the number of Class
A Ordinary Shares issuable upon exercise of the Series A Warrant automatically increased to approximately 159,223 (on a post Reverse Stock
Splits basis). <FONT STYLE="background-color: white">The Fourth Tranche Note is included as Exhibit 4.1 in the Form 6-K filed on April
3, 2025, which is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fifth Tranche</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2025, the Company
consummated the fifth tranche of <FONT STYLE="background-color: white">the 2024 Debt Financing</FONT> under the terms of the Securities
Purchase Agreement. At the closing of the fifth tranche, the Company sold to the Investor a senior convertible note (the &ldquo;Fifth
Tranche Note&rdquo;) in the original principal amount of $2,000,000. The Note bears an interest rate of 14.75% per annum. The maximum
number of Class A Ordinary Shares of the Company, no par value, which this note is issuable into is 6,923,990, based on a conversion price
of $0.63 and assuming an interest rate of 14.75% through the fifty-four (54) month maturity of the Notes. Further the conversion price
of the Note is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar
transactions, and full-ratchet adjustment in connection with a subsequent offering at a per share price less than the fixed conversion
price then in effect. The holder of the Note may convert any portion of the outstanding portion of the Note into validly issued, fully
paid and non-assessable Class A Shares at the conversion price. No fractional Class A Shares are issuable upon any such conversion. If
the issuance would result in the issuance of a fraction of a Class A Share, the Company shall round such fraction of a Class A Share up
to the nearest whole share. <FONT STYLE="background-color: white">The Fourth Tranche Note is included as Exhibit 4.1 in the Form 6-K filed
on July 16, 2025, which is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between November 7, 2024 and
the date of this prospectus, the Company received gross proceeds of $7,850,000 and issued an aggregate of 573,837 Class A Ordinary Shares
(on a post Reverse Stock Splits basis) to the Buyers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may receive up
to approximately $18,540,961 in additional net proceeds from the 2024 Debt Financing if all remaining Additional Notes in the aggregate
principal amount of $3,150,000 (together with the <FONT STYLE="background-color: white">Fourth Tranche Note and Fifth Tranche Note,</FONT>
the &ldquo;Remaining Additional Notes&rdquo;) issuable pursuant to the Securities Purchase Agreement are sold and (ii) the Series A Warrants
are increased by 10,157,580 assuming that (A) all Remaining Additional Notes are sold and (B) an Additional Share Price is equal to $1.3513
and (iii) all of the Warrants are exercised in full, based on the following assumptions (x) approximately $23,909,021 in net proceeds
are received from the exercise of the Series A Warrants, assuming that the Series A Warrants are exercised in full at an exercise price
of $1.8258 and the number of Ordinary Shares issuable upon exercise of the Series A Warrants equals 13,095,093, (y) approximately $1,485
in net proceeds are received from the exercise of the Series B Warrants, assuming that the Series B Warrants are exercised in full at
an exercise price of $0.020 per share, and (z) approximately $3,005,784 in net proceeds are received from the exercise of the Exchange
Warrants, assuming that the Exchange Warrants are exercised in full at an exercise price of $1.8258. The foregoing is subject to adjustment
as set forth in the respective Notes and Warrants, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>White Lion Equity Line of Credit</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the
Company entered into a Common Shares Purchase Agreement (the &ldquo;White Lion Purchase Agreement&rdquo;) with White Lion Capital, LLC
(&ldquo;White Lion&rdquo;) and a related Registration Rights Agreement (the &ldquo;RRA&rdquo;). Pursuant to the White Lion Purchase Agreement,
the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars
($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to Three Hundred Million
Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement) and a further
option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000) has been
issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth in the
White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration statement
filed on December 5, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 10, 2024, 700,000
Class A Ordinary Shares (equivalent to 700 Class A Ordinary Shares post Reverse Stock Splits) were issued to White Lion, in consideration
for White Lion&rsquo;s commitment pursuant to the White Lion Purchase Agreement. Between December 12, 2024 and August 5, 2025, the Company
received gross proceeds of $11,659,051 and issued an aggregate of 1,108,600 Class A Ordinary Shares (on a post-Reverse Stock Splits basis)
to White Lion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>MicroSort Acquisition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 21, 2025, the Company
entered into a Purchase Agreement with Genetics &amp; IVF Institute, Inc. (&ldquo;Purchase Agreement&rdquo;), pursuant to which the Company
purchased all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to
the MicroSort Business (as defined in the Purchase Agreement) from Genetics &amp; IVF Institute, Inc. for a cash consideration of $750,000
and a share consideration of 125,000 Class A Ordinary Shares (equivalent to 2,500 Class A Ordinary Shares post Third Reverse Stock Split)
(&ldquo;Share Consideration&rdquo;). The Purchase Agreement is filed as Exhibit 10.30 in this registration statement. MicroSort Lab Services,
LLC (&ldquo;MicroSort&rdquo;) was incorporated by Genetics&nbsp;&amp; IVF Institute, Inc. in January 2025 to hold all of the Assets (as
defined in the Purchase Agreement) to be transferred to the Company at closing. The Company&rsquo;s acquisition of MicroSort was completed
on February 28, 2025, and the Share Consideration was issued to GIVF on the same day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>ASPAC Consulting Services Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (&ldquo;ASPAC&rdquo;), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the 150,000 Class A Ordinary Shares to ASPAC (equivalent to 3,000 Class A Ordinary
Shares post Third Reverse Stock Split).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Financial Statement Schedules:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All financial statement schedules
have been omitted because either they are not required, are not applicable or the information required therein is otherwise set forth
in the Company&rsquo;s financial statements and related notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.&nbsp; </B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000121390025061753/ea024817101ex3-1_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Memorandum and Articles of Association of the Company dated July 4, 2025 (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 6-K filed with the SEC on July 7, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex2-1_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Class A Ordinary Share Certificate of the Company (incorporated by reference to Exhibit 2.1 of the report on Form 20-F filed with the Securities and Exchange Commission on April 9, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex2-2_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Warrant Certificate of the Company (incorporated by reference to Exhibit 2.2 of the report on Form 20-F filed with the Securities and Exchange Commission on April 9, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000110465922025006/tm225054d14_ex4-2.htm">Warrant Agreement, dated February 14, 2022, by and between ASCA and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit 4.2 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 18, 2022)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000121390023087023/ff42023a1ex4-7_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Assumption of Warrant Agreement (incorporated by reference to Exhibit 4.7 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea025420501ex4-5_newgen.htm">Form of Ordinary Share Purchase Warrant</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Ogier</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex2-1_aspac1acq.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger Agreement, dated as of February 15, 2023, by and among ASCA, NewGenIvf Limited, certain shareholders of NewGenIvf Limited, A SPAC I Mini Acquisition Corp., and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 16, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390023048612/ea180200ex2-1_aspac1acq.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to the Merger Agreement, dated June 12, 2023, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I Mini Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 13, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390023093702/ea189487ex2-1_aspac1acq.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to the Merger Agreement, dated December 6, 2023, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I Mini Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex2-1_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to the Merger Agreement, dated March 1, 2024, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I Mini Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000110465922025006/tm225054d14_ex10-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Escrow Agreement, dated February 14, 2022 by and between ASCA and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit 10.5 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 18, 2022)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex10-1_aspac1acq.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting and Support Agreement, dated as of February 15, 2023, by and among A SPAC I Acquisition Corp., A SPAC I Mini Acquisition Corp., NewGenIvf Limited, and certain shareholders of NewGenIvf Limited (incorporated by reference to Exhibit 10.1 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 16, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex10-2_aspac1acq.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 16, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex4-8_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Lock-Up Agreement (incorporated by reference to exhibit 4.8 of the Company&rsquo;s report on Form 20-F filed with the SEC on April 9, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-1_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated February 29, 2024, by and among ASCA, The Company, Legacy NewGenIvf, the Buyers and Merger Sub (incorporated by reference to Exhibit 10.1 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-2_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note between The Company and the Buyers (incorporated by reference to Exhibit 10.2 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-3_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acknowledgement Agreement, dated March 1, 2024, by and among ASCA, Legacy NewGenIvf and Chardan (incorporated by reference to Exhibit 10.3 to ASCA&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-19_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power Generator Lease Contract, dated January 10, 2021, between BD &amp; H TECH Co., LTD. and First Fertility Phnom Penh Ltd (English Translation) (incorporated by reference to Exhibit 10.19 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-20_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property Lease Contract, dated June 22, 2020, between SOK HEANG and First Fertility Phnom Penh Ltd (English Translation) (incorporated by reference to Exhibit 10.20 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-21_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MicroSort Lease and Services Agreement, dated March 29, 2019, between First Fertility Phnom Penh Ltd and MicroSort International (incorporated by reference to Exhibit 10.21 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-22_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management and Administrative Services Agreement, dated November 1, 2022, between First Fertility PGS Center Ltd and Med Holdings Ltd (incorporated by reference to Exhibit 10.22 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-23_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MicroSort Lease and Services Agreement, dated April, 8, 2019, between First Fertility PGS Center Ltd. and MicroSort International (incorporated by reference to Exhibit 10.23 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-24_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Consulting Service Agreement, dated January 1, 2021, between First Fertility PGS Center Ltd and First Fertility Phnom Penh Ltd (incorporated by reference to Exhibit 10.24 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-25_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables Purchase Agreement, dated December, 28, 2022, between First Fertility PGS Center Ltd and Mr. Siu, Wing Fung Alfred (incorporated by reference to Exhibit 10.25 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-26_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Services Agreement, dated December 21, 2022, between First Fertility PGS Center Ltd and First Fertility Phnom Penh Ltd (incorporated by reference to Exhibit 10.26 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-27_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Agreement for Storage of Embryos, Eggs, and Sperms Service between First Fertility PGS Center Ltd and Reproductive Expert Co Ltd (incorporated by reference to Exhibit 10.27 to the Company&rsquo;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex4-21_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of NewGenIvf Group Limited 2024 Share Incentive Plan (incorporated by reference to exhibit 4.21 of the Company&rsquo;s report on Form 20-F filed with the SEC on April 9, 2024)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-1_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement between A SPAC I Mini Acquisition Corp. and JAK Opportunities VI LLC dated February 29, 2024 (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s current report on Form 6-K filed with the SEC on April 4, 2024)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-2_aspac1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note between A SPAC I Mini Acquisition Corp. and JAK Opportunities VI LLC dated February 29, 2024 (incorporated by reference to Exhibit 4.2 of the Company&rsquo;s current report on Form 6-K filed with the SEC on April 4, 2024)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024069887/ea021151801ex4-1_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement between the Company and certain buyers dated August 7, 2024 (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s current report on Form 6-K filed with the SEC on August 16, 2024)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024076330/ea021292701ex10-25_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note between the Company and JAK Opportunities VI LLC dated August 7, 2024 (incorporated by reference to Exhibit 10.25 of the Company&rsquo;s registration statement on Form F-1 (File No. 333-281964), filed with the Securities and Exchange Commission on September 6, 2024</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024074614/ea021297701ex4-1_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note between the Company and JAK Opportunities VI LLC dated August 28, 2024 (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s current report on Form 6-K filed with the SEC on August 30, 2024)</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024101682/ea022147001ex10-27_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Agreement between the Company and White Lion Capital, LLC dated November 21, 2024 (incorporated by reference to Exhibit 10.27 of the Company&rsquo;s registration statement on Form F-1 (File No. 333-283421), filed with the Securities and Exchange Commission on November 22, 2024)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024101682/ea022147001ex10-28_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement between the Company and White Lion Capital, LLC dated November 21, 2024 (incorporated by reference to Exhibit 10.28 of the Company&rsquo;s registration statement on Form F-1 (File No. 333-283421), filed with the Securities and Exchange Commission on November 22, 2024)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024099047/ea022145801ex4-1_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note between the Company and JAK Opportunities VI LLC dated November 11, 2024 (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s current report on Form 6-K filed with the SEC on November 15, 2024)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390025021404/ea023310401ex10-30_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement between the Company and Genetics and IVF Institute, Inc. dated January 21, 2025 (incorporated by reference to Exhibit 10.30 of the Company&rsquo;s registration statement on Form F-1 (File No. </FONT>333-285629<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">) filed with the Securities and Exchange Commission on March 7, 2025)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390025021404/ea023310401ex10-31_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Services Agreement between the Company and A SPAC (Holdings) Limited dated February 24, 2025 (incorporated by reference to Exhibit 10.31 of the Company&rsquo;s registration statement on Form F-1 (File No. 333-285629) filed with the Securities and Exchange Commission on March 7, 2025)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390025028370/ea023707201ex4-1_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement between the Company and certain buyers dated April 1, 2025 (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s current report on Form 6-K filed with the SEC on April 3, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1981662/000121390025033966/ea023590401ex8-1_newgenivf.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries (incorporated by reference to Exhibit 8.1 of the Company&rsquo;s annual report on Form 20-F filed with the SEC on April 22, 2025)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent Letter from WWC, P.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent Letter from J&amp;S Associate PLT</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ogier (included in Exhibit 5.1)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1981662/000121390024070853/ea021122901ex97-1_newgen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback Policy of the Company. (incorporated by reference to Exhibit 97.1 of the Company&rsquo;s annual report on Form 20-F filed with the SEC on August 20, 2024)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee Table</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed by amendment.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned Registrant hereby undertakes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act or Item 8.A of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The undersigned Registrant undertakes
that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to
such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.4pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned Registrant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned Registrant; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.4pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned Registrant hereby undertakes that:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by the undersigned,
thereunto duly authorized, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEWGENIVF GROUP LIMITED</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wing Fung Alfred Siu</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS
BY THESE PRESENTS, that each of the undersigned constitutes and appoints Wing Fung Alfred Siu, his true and lawful&nbsp;attorneys-in-fact&nbsp;and
agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities,
to sign this Registration Statement on Form&nbsp;F-1,&nbsp;or other appropriate form, and all amendments thereto, including post-effective
amendments, of NewGenIvf Group Limited, and to file the same, with all exhibits thereto, and other document in connection therewith, with
the Securities and Exchange Commission, granting unto said&nbsp;attorneys-in-fact&nbsp;and agents, each acting alone, full power and authority
to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and
purposes as he or she might or could do in person, hereby ratifying and confirming that any such&nbsp;attorney-in-fact&nbsp;and agent,
or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 27.55pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 27.55pt">Pursuant to the
requirements of the Securities Act of 1933, this registration statement on Form F-1 has been signed by the following persons in the capacities
and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Wing Fung Alfred Siu</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director,</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wing Fung Alfred Siu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Hei Yue Tina Fong</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chief Marketing Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hei Yue Tina Fong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Hok Man Jefferson Au</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>, 2025</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hok Man Jefferson Au</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Florianna Ann Chi Wan Chan</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>, 2025</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-top: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florianna Ann Chi Wan Chan</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Tam Chun Wa</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tam Chun Wa</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Ho Fai Chung</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ho Fai Chung</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE
UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Securities
Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America of NewGenIvf Group Limited,
has signed this registration statement in on <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> , 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 157; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.5</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORDINARY SHARE PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>NEWGENIVF
GROUP LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Warrant Shares: [*]</TD>
    <TD STYLE="font-size: 10pt; text-align: right">Issue Date: August [&nbsp;&nbsp;], 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS ORDINARY SHARE PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [*] or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is
entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the Closing Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on that date that
is the three (3) year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, the date that is the
immediately following Trading Date (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from
NewGenIvf Group Limited, a British Virgin Islands holding company (the &ldquo;<U>Company</U>&rdquo;), up to [*] Ordinary Shares, no par
value per (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one Ordinary Share under
this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Placement Agency Agreement (the
&ldquo;<U>Placement Agency Agreement</U>&rdquo;), dated August [*], 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise of
Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed copy submitted by
email (or email attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
one Trading Day following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares
specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within three Trading Days of the date on which the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of
Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares so purchased. The Holder and the Company shall maintain records showing the
number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within
one Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The exercise price per Ordinary Share under this Warrant shall be $[ ], subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).
The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
If at the time of exercise hereof, there is no effective registration statement registering, or the prospectus contained therein is not
available for the issuance or resale of the Warrant Shares to or by the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">(A)</TD>
    <TD STYLE="width: 0.25in">&nbsp;=</TD>
    <TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Ordinary Shares on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Company&rsquo;s receipt of Holder&rsquo;s Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two hours thereafter (including until two hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(B) </TD>
    <TD>&nbsp;= </TD>
    <TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(X)</TD>
    <TD>&nbsp;= </TD>
    <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Ordinary Shares are then listed
or quoted on a Trading Market, the bid price of the Ordinary Shares for the time in question (or the nearest preceding date) on the Trading
Market on which the Ordinary Shares are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Ordinary Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Ordinary Shares are not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Ordinary Shares so
reported, or (d) in all other cases, the fair market value of an Ordinary Share, as determined by an independent appraiser selected in
good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Ordinary Shares are then listed
or quoted on a Trading Market, the daily volume weighted average price of the Ordinary Shares for such date (or the nearest preceding
date) on the Trading Market on which the Ordinary Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Ordinary Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Ordinary
Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are then reported on The Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Ordinary
Share so reported, or (d) in all other cases, the fair market value of an Ordinary Share, as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 0.5in">c)</TD>
    <TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i. <U>Delivery of
Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares issued in connection with an exercise of the Warrant to be
transmitted by the Transfer Agent to the Holder by either (i) crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance
account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant
Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by
physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice
of Exercise by the date that is the earlier of (i) one Trading Day after the delivery to the Company of the Notice of Exercise and (ii)
one Trading Day after delivery of the aggregate Exercise Price to the Company (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Delivery
Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share
Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares
subject to such exercise (based on the VWAP of the Ordinary Shares on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after
such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain
a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery of
New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon
surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the
rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(c)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than a failure that is solely due to any action
or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in
an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, Ordinary Shares to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the Ordinary Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant
Shares that the Company was required to deliver to the Holder in connection with such exercise by (2) the price at which the sell order
giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant
and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of Ordinary Shares that would have been issued had the Company timely complied with its exercise and
delivery obligations hereunder. For example, if the Holder purchases Ordinary Shares having a total purchase price of $11,000 to cover
a Buy-In with respect to an attempted exercise of the Ordinary Shares with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the
Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver the Ordinary Shares upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iv. <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the number of Warrant Shares to
be issued shall be rounded down to the nearest whole number and the Company shall pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">v. <U>Charges, Taxes
and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation
performing similar functions) required for electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 0.25in">e)</TD>
    <TD STYLE="text-align: justify"><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Ordinary Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Ordinary Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(d) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(d), in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Ordinary Shares outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Ordinary Shares was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of the number of Ordinary Shares outstanding immediately
after giving effect to the issuance of Ordinary Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(d), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<FONT STYLE="font-size: 10pt"><SUP>st</SUP></FONT> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on Ordinary Shares or any other equity or equity equivalent securities payable in Ordinary Shares (which, for avoidance
of doubt, shall not include any Ordinary Shares issued by the Company upon exercise of this Warrant), (i) subdivides outstanding Ordinary
Shares into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Ordinary Shares into a smaller
number of shares, or (iii) issues by reclassification of Ordinary Shares any shares of capital stock of the Company, then in each case
the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares (excluding treasury
shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Ordinary Shares outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Ordinary Share Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all (or substantially all)
of the record holders of any class of Ordinary Shares (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the
Holder had held the number of Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on
exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Ordinary
Shares are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent
that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
Ordinary Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of Ordinary Shares, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of Ordinary Shares acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Ordinary
Shares are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the
Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then
the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Ordinary Shares
as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, <FONT STYLE="background-color: white">after giving effect
to such transaction, the stockholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power
of the Company or the successor entity of such transaction, </FONT>(ii) the Company (all of its Subsidiaries, taken as a whole) directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares,
(iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged
for other securities, cash or property, <FONT STYLE="background-color: white">after giving effect to such transaction, the stockholders
of the Company immediately prior to such transaction own less than 50% of the aggregate voting power of the Company or the successor entity
of such transaction, </FONT>or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger
or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
Ordinary Shares (not including any Ordinary Shares held by the other Person or other Persons making or party to, or associated or affiliated
with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share
that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of
the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Ordinary Shares of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares for which
this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the
exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share in such
Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to
the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the
Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything
to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the
Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not
within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, Holder shall only be entitled to receive from
the Company or any Successor Entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration
(and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to
the holders of Ordinary Shares of the Company in connection with the Fundamental Transaction, whether that consideration be in the form
of cash, stock or any combination thereof, or whether the holders of Ordinary Shares are given the choice to receive from among alternative
forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Ordinary Shares
of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Ordinary Shares will be deemed
to have received Ordinary Shares of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such
Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing
Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a
365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in
cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest
VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable Fundamental Transaction
(or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&rsquo;s request
pursuant to this Section 3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable
Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by
wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s
election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations
of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Ordinary Shares
acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such
Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking
into account the relative value of the Ordinary Shares pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number
of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice to
Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall deliver
to the Holder by email a notice, within 2 calendar days after such adjustment is finalized, setting forth the Exercise Price after such
adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such
adjustment. If the Company files a current report on Form 6-K containing this information with the SEC, no separate notice to Holder is
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice to
Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Ordinary
Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares, (C) the Company
shall authorize the granting to all holders of the Ordinary Shares rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Ordinary Shares, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary Shares are converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice (unless such information is filed with the Commission, in which case a notice shall not be required)
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Ordinary Shares of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Ordinary Shares of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon
such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any
defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.
To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three Trading Days of the date on which the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this
Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No Rights
as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or
other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth
in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section
2(c), or to receive cash payments contemplated by Section 2(d)(i) and Section 2(d)(iv) herein, in no event will the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft,
Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to
it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Ordinary Shares a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of this Warrant. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant
Shares upon the exercise of this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market
upon which the Ordinary Shares may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of this
Warrant will, upon exercise hereunder and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof.
Each party agrees that all legal Proceedings concerning the interpretation, enforcement and defense of this Warrant shall be commenced
in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;New York Courts&rdquo;). Each party
hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any
provision hereunder), and hereby irrevocably waives, and agrees not to assert in any suit, action or Proceeding, any claim that it is
not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such
Proceeding. If any party shall commence an action or, claim, suit, investigation or proceeding (including, without limitation, an informal
investigation or partial proceeding, such as a deposition), whether commenced or threatened (&ldquo;Proceeding&rdquo;) to enforce any
provisions of this Warrant, then the prevailing party in such action or Proceeding shall be reimbursed by the other party for its attorneys&rsquo;
fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or Proceeding. Notwithstanding
the foregoing, nothing in this paragraph shall limit or restrict the federal district court in which a Holder may bring a claim under
the federal securities laws..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at [__] Attention: [___], email address: [___], or such other email address or address as the Company
may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the
Company hereunder shall be in writing and delivered personally, by email or sent by a nationally recognized overnight courier service
addressed to each Holder at the email address or address of such Holder appearing on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the
next Trading Day after the date of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth
in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading
Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the
party to whom such notice is required to be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Ordinary Shares or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><B>NEWGENIVF GROUP LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: newgenivf
group limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment
of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(2) Payment shall take the
form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
[if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 78%">Name:</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify; width: 20%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Please Print) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Signature: __________________________<U>&nbsp;</U></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Address: ___________________________<U>&nbsp;</U></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P +(# 2(  A$! Q$!_\0
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M5BL-)*$5%\CE)1M&*YDXM\KU4M;+1J^N_P"64*N9X?*Y9-C,GXBGFLI<1?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Y G # 2(  A$! Q$!_\0
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M_AYE^U;_ -##H?\ X)__ *U'_#S+]JW_ *&'0_\ P3__ %J^ :*/^(?\(?\
M0H7_ ("O\A_\1^\6W_S5G%#VV??;:3WZ=^ES[_\ ^'F'[5W_ $-6A?\ @G7_
M  JM_P /,OVK?^AAT/\ \$__ -:O@FBC_B'W""_YE"_\!C_\B'_$?O%OKQ9Q
M1_7S/O\ _P"'F/[5O_0Q>&O_  3G_P")H_X>8_M6_P#0Q>&O_!.?_B:^ **7
M^H_"'_0GA_X!#_Y!B_XC[XM?]%7Q/_7S/O\ _P"'F/[5O_0Q>&O_  3G_P")
MJO\ \/,?VK?^AB\-?^"<_P#Q-?!%%'^H_"'_ $)X?^ Q_P#D0_XC[XM?]%7Q
M/_7S/O?_ (>8_M6_]#%X:_\ !.?_ (FC_AYC^U;_ -#%X:_\$Y_^)KX(HI_Z
MD<(_]">'_@,?_D0_XC[XM?\ 15\3_P!?,^]O^'F7[5O_ $,.A_\ @G_^M1_P
M\R_:M_Z&'0__  3_ /UJ^":*7^H_"'_0GA_X!#_Y /\ B/OBU_T5?$_]?,^]
M_P#AYC^U;_T,7AK_ ,$Y_P#B:/\ AYC^U;_T,7AK_P $Y_\ B:^"**?^I'"/
M_0GA_P" Q_\ D0_XC[XM?]%7Q/\ U\S[V_X>9?M6_P#0PZ'_ ."?_P"M1_P\
MR_:M_P"AAT/_ ,$__P!:O@FBE_J/PA_T)X?^ 0_^0#_B/OBU_P!%7Q/_ %\S
M[_\ ^'F/[5O_ $,7AK_P3G_XFC_AYC^U;_T,7AK_ ,$Y_P#B:^ **/\ 4?A#
M_H3P_P# (?\ R ?\1]\6O^BKXG_KYGW_ /\ #S']JW_H8O#7_@G/_P 35?\
MX>8_M6_]#%X:_P#!.?\ XFO@CR/?]?\ ZU%'^H_"'_0GA_X#'_Y$/^(^^+7_
M $5?$_\ 7S/O?_AYC^U;_P!#%X:_\$Y_^)JQ_P /,?VK?^AB\-?^"<__ !-?
M %%'^H_"'_0GA_X#'_Y$/^(_>+:U_P!:^)^_Z]S[_P#^'F7[5HZ>(O#0_P"X
M.?\ XFD/_!3?]JT]=;T,_6RS_6O@&EY_T?R/^/BZ_P"//^?\N/6B7!/ F#C+
M&8S*(6C%NSC&RLFU[K5EMU2-,'X]^,\Y+ 0XJXH;S^2@GNKRDH)NU]G)7\DS
M]5O@;^W1^UI\6/B-H'A5=:TQ=/-Z;[6?L=D!NTP]=&X')/<]>!SSQ_1OX$&J
M_P#".:?<:I,+JZ/!/MTP3^)Q^9S7Y ?\$X/V:8/#7ARW\1ZK8VQUC5/^)U=W
M7&;$]AZ?K[^M?M-%##!:P01G"VP  &<CGO@>_7Z5_('B#B,EK\026399&E"+
M:NN5**3:Z62O;2RM?7=W/]=? K)N+<L\.\I?&.:RSO.9Q4_>34DI*,ES7UYK
M26CZK[MNBCK17Q)^TA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT/O_ /: ^#?A'X\?#/7_  'XNLK:[T[7+5C;7/#&QU,;ET75TP1\ZN 1D%2
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M5-?W!X<IOPYRM+=J27>[32_%G^'GTBVH^-?$LGM&I3D_2-2G)_\ I+/Z+O\
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MBBBBZ[K[U_F%GV?W/_(****+KNOO7^86?9_<_P#(****+KNOO7^86?9_<_\
M(****+KNOO7^86?9_<_\@HHHHNNZ^]?YA9]G]S_R"BBBBZ[K[U_F%GV?W/\
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M]1_AWX_,4?\ $4.+/^AJ_P 37_B6GPC7_-*07RBOT1_.Q_PZ*UK_ *'G4O\
MP#_^M1_PZ*UK_H>=2_\  /\ ^M7]$ODOZ#\Z/)?V_.C_ (BAQ;_T-7][,/\
MB6CPD_Z)2'_DI_.U_P .BM:_Z'G4O_ /_P"M1_PZ+UK_ *'C4O\ P3__ %Z_
MHE\E_;\Z/)?V_.C_ (BAQ;_T-7][#_B6CPD_Z)2'_DI_.U_PZ*UK_H>=2_\
M /\ ^M1_PZ*UK_H>=2_\ _\ ZU?T2^2_M^='DO[?G1_Q%#BW_H:O[V'_ !+1
MX2?]$I#_ ,E/YVO^'16M?]#SJ7_@'_\ 6H_X=%:U_P!#SJ7_ (!__6K^B7R7
M]OSH\E_;\Z/^(H<6_P#0U?WL/^):/"3_ *)2'_DI_.U_PZ*UK_H>=2_\ _\
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MVO\ AT5K7_0\ZE_X!_\ UJ/^'16M?]#SJ7_@'_\ 6K^B7R7]OSH\E_;\Z/\
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MO'58H'  ]**\\]O;0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4_\ Y82455^V0?WOY?\ Q5)]MM_[X_-?_BJ>G\R_'_(S^NT_^?M/_P &0_\
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M&#O^/]*]@_7DTTFG=-)IK9II-->3337DRQ1110,**** "BBB@ HHHH ****
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MRQ7ZHP:E^R5INL^'K[Q'_P *EN?"%KJ_VWPA:>'[3^TO$Q\,?\(6?[>_X3C
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M?%O_ (3FC?X4>PX3\OO_ ."8_P"J7T,?^CA\7_\ B/S_ /D3[7_X>]?L5_\
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MPABL%E3C%\54KIWMR>TI*\HK1I+?1JZ9_;!9D2*,=%'';@],?US^%6?^6O\
MG^]3+/\ U0^@_E3Z_=5LO1?DC_=*G_#I_P#7NG_Z;IEBBBBF6%%%% !1110
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M6$(MIN,(1;75QA"+?S<6_F6**K^?[?I_]>CS_;]/_KTO;KM^'_!++%%5_/\
M;]/_ *]'G^WZ?_7I^W\OP_X(%BBJ_G^WZ?\ UZ//]OT_^O2]NNWX?\$"Q15?
MS_;]/_KT>?[?I_\ 7H^L1[K\/_D@+%%5_/\ ;]/_ *]'G^WZ?_7H]NNWX?\
M! L457\_V_3_ .O1Y_M^G_UZ/K"\OZ^8%BBJ_G^WZ?\ UZ//]OT_^O1[==OP
M_P"".S[/[G_D6*#T/?BJ_G^WZ?\ UZ//]OT_^O3]OY/[F)[._P")Y1\72?\
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M'.OH0^*$<8L:O$&TMUNM5KK9+2^_E?=G\<6O?$CQ7XDTO2-#UWQ']IT[2_\
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MO_R7H?U9Z:P_X79XHN 1SX'TI<G&"?-QM!'?V!SGM7K893_$I^A'^-?QT_\
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MS6@U?=*3[ZJS::Z^EB'].7A"+:?"7$ZE_*XI._9J44_)Z'];'GV_]X?]]?\
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M^?7_ ,-U?ME>5C_AI/XH_P#A2?A_/]/RK[W_ &9/VL_VF?$OPA\0:IKWQO\
M'VIW]M\1]+L;.ZO-7!']E_V-R.G;CCITXK\S\7_#?-O!3@?->/LYS.GG>4Y-
MK+V*:E)O7W6]7H[1NGK8^^\'^(L+XQ<<99P'DZ_L7.)-J+JWE3U;OS-*SBW\
M5FWJ^I_8]!YX_P!:XZ#N#CCCC\.,=L>]8_B<C_A&_$/[L$GP[J_?_J$-QGU
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M'^&7_"$?VW<:7XC-Y>:K=V?]I#^R_7'<^E?$'P9_<_"_QQG[3_R.'A>R[?\
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MR(/3^7Z<]?Z^OZ$1?M1?!:;_ (1^Q\5:5XUUO2+7_A%[W6-)N]'T;^R_"/\
M86B?V#_Q(\=O%A_PZUX_$67X?ZTFLKJ/3F]V4]=$[*TDFWLEHN^C/N/#OB'$
M_5,VP>.XIIY&TY*+J1@^Z7QQ;MHKV=[7,C3?VR_#FF6OC"QL? &MZEI_BC1]
M+LO[)^V:+_9EAJFA9_XDO;'AWZ?AWHUC]J[0]'NO(_X4Z=#U#[)]BO/^$AL]
M&TW@=-%T/_J7>?PY[\UP_P 8/&_P>UCP3X?@\#^'/#>A^)_%'C#4[W6/[)LS
M_:F@^!-")_L/Z^(<8 QSU/0UY_\ '[XD>%?B1XH\+ZKX.G\27.CZ%X/TO1?^
M*AL_^)F>^=<Z?C^/7BN?+<OPSQ>N4U%O>_/T26[=FFMGV739[<2<4YIA,')0
MXHX7SQVDH\L8J6L9)?#%/FU7_;QQW@^\^V>,O%%]!!]E^U>&_%%[]D_Z!_/Z
M?3_Z]=3\$OBU_P *E_X3">?PY_PDEOXHT?2[+[)C/V#_ (G1/;W/U_6N'^&_
MD0ZSJ'_8A^*/3T[C\/8_2O/YO]4?W'^D<?YSGMU_3-?3O+<IQ2?_  E/2_=;
M)]-'NC\SP^=XK#X;*\8W%YLY:MV<$G/=IW7*DV]5LC](-'_:C\':/X;T?QCK
MGPL_X2/4-4O/L6L:5_PC8TW3+#_H!:U^.#SC//H*X>S_ &QO#EG=3SV7@[4K
M;[5X;U3PQK&DVEYHW]F6&J?VT=>_XD?4>_/3IQ6?IGQ]^'-E\+_"/@[7(/$F
MM_V9X/TOP7XE\/7=EHW_  C.1K0UW^VO?MC';M6Q\6OB?^SUXP^'/BC5? /@
M[0]-\0:I9Z7X+\-VEW9_V9J@TO\ YCNM:WV]B>O&>_'P[RS#_7&O[(J:N4;K
MF:24I*._5W3NEIK=NR/VROQ#FF)R>+P?$_"J:46X\D%.Z46U\*=[IK_$BQ/^
MU;H>FZ7^X^#MSINKW5GFSNKNST8:98=QK6AGW^OZ9%?*]YXD@\8?%_\ X2JQ
ML;?1+?Q1XDTN^O-)/6PZ#M^?M78?%3XF^'/&'PT^$'A72CK>I:AX.L]4^V:K
MXA TWT_XDN?Q'? ]^:\G\'_O_&7A?S_M/_(8TO\ SP./3\Z^IRW+'A<*VXRO
M=Z.^U]$KWZ6^1^8<5<4YIF>;Y5@\7F=-Q6[A"*4DDKZQBM&D[7?5'H'@_P >
M0?#'XM:SXPOM*MM;M[6\\465[I/>_P#[=_/D>X_I7U_H/[5WA6?PW<:YJOPR
MNM2U#0?%^E?V/X?M-'&I:9_PBX[_ -N=,Y^O7TKX \2?N?%'B"?'_,R:IQGK
MC_/_ -:OI#X,_'CP=\-_AK_PCFN?\);<:A:^)/%&M?V3I/\ R#?%O]NZ)_8/
M]BZY^.?USS7/Q%DLL5A4\'EDNE^64K]&[6:LWK9[WMJCV> ^(7ALWS7!RS-9
M-E&MG./,G*SL_>C+1RM>W1L] TW]LSP=I&L_VYI7@#4M$%KK'BC_ $32?[&_
MT_2]=_YC73UQZ]R>V<^']K3PY-HUQ_Q:3[3_ ,3G2O\ C[']I>&K_5!_8'_$
M[US/_,Q<9Y]*Z#6/C!^S7K'@/Q!/I7@'3=-U#P;X;^Q:.;NS_P")G?\ CSCC
M\NW/7'M7SY-\6/ __#.Y^"4'A#5-.\3GQ:/$EYXJX*WV&+$C W9;.#DD848
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M;BX4U-<L5S*S@GS1::]5U+,/[5&B:Q_:'G_!W6]2N->_X\Q=_P#$QU/7L?\
M0<'_ $+O7_D4P>1Z5\[_ !F^,$'Q@E\/WO\ PC=MHFHZ"=4LL6EG_9O_ '!<
MC@_Y->T?"7]I;PYX5L/AQ8^*H-2N;CP'X;\4>&+SQ#I-GC[!_;NM?\2+1N/^
MP'SD<\5\?Z]J4&L:]?ZK!!<VUOJGB35+VSM,=O?D^GO_ %KV<FR>>5XMWRR>
MJ;^*;6MW_,]D[GP?&?%.*S/+,I7^L\<Z:E%2481CM)7VBG;=*_2Q\[_M4?\
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MH+'^S;?5-9U76K.T./\ 0/[=_P"8*>G7C/'<XQQC]%_V1/\ DB/B'_LJ0_\
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M#_#Z?3OQ_2C_ ,&_G/[-GQ(&"0?B>^0/4:.F/YG\N/?^=7]J?XM? _XIZGX
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MJ\]J<RVV:BVGZ-6>VQ_.YJ__  2'^,]YJ>L7T'Q&\  ZG>:G>6@-GK.5+=F
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MC)P#Y ?^#?[]I(<GXM_"_P _K_QXZW]>F/\ (]N:_KHBYCQ,Q'/3(]3V]?\
MZ^*4>4.,YQZ[<_C7;0\<?$3"JT<V271.*:_-+\+GZ?EG@MP+E.$6"P<6HQ45
M&\ELDEIK=.RL^SO8_D>E_P"#?[]I(@0CXQ?#  _\O9L=<!Y]5(#>N>..??"?
M\0_W[3/3_A='PQ\__G[_ +/US/3TVY_3VK^N'RX?[R_E]?\ /X?7)MC_ +Q_
M3^I/]>GURGX]^)^[S2/S@M?Q_#S/2_XA3P1M:2_[>2_KU/Y%O^(?W]I,C/\
MPN#X4?0V&M9_+;FOJ;X)_P#!(/XW?##X<:SX?U3XC> -4O\ 4O&0\1VEU9V6
MLEO[._LCR\88C^(^OKT[_P!(92 $ C\?\C_"D+#)7R0",=_4?3@_7ZU\/QYQ
MMQ)XI\*9KP=Q?)5,FSA7J0C&,9.VMTU)\E[;6LT[+5GVWAYDN#\-.*\LXPX/
M:IYSDJ:A.5I:N]O=E93M?9O5JSW/P8/_  2Q^,4O7QOX)'''^B:N#Z\@L/H<
MGKBJX_X)8_&B+IXX\)XZ\JP]>.0/Y\Y'J!7[W;V_NC_OM??V_P Y^N#>W]U?
M^_@]_;_.?KC^8_\ B7CPQLE_95VK*[;UMIW?8_IA_2A\6VW_ ,*U-W;WR&#Z
MOM+_ (<_!";_ ()9?&>;KXX\*#_@#>OTJR?^"6/QA_Z'+P3_ .5KW]_\Y'OC
M]Y=Q]!_W]_SZC\Z QR.%ZC_EKGT[8YZCCOD>M/\ XER\//\ H5V[/F>B_33M
M87_$T'BU_P!#6'HL@IJ_K>3^_P"9_/5\3/\ @DI\:/'OPC\8> K'XB> ]+U#
M7M7\,WMI<WEEK/\ 9X_L/(&54DG/8#.1^(KXO_XA_?VDYO\ FM'PPMNG^BBQ
MUK&>?;W Q[U_7B(#C[V3]?7GT_PXJL+<CJQ/U/\ ];_/'X_T9X<\2YSX5<.Q
MX1X/G[+)N92:DE-IWOJY32TMNM79:[G\X^(N783Q5XB_UNXQO5SFR3E'W8RL
MK7<4VEW25U&]E:R/Y%_^(?S]IGRO^2Q?"?[1TQ]AUO/YX_3-$W_!OO\ M)D?
M\EH^%_;K8ZV.<^A7TYZ>]?UX^4/[P_/_ .M_GGT-'E#^]^OT_P!GW_S@U^D?
M\1Q\1;6><)JUK<BVM:WQ=M#X'_B%/"%[_P!F->?,_F_B7J?R#1?\&_W[3((_
MXO%\,/L_(S]AUL_R7VXX]3VK]P?^"8?[&'CG]C'X1>+? ?CSQ5HGBR_\0>+W
M\2VMYH"E+!4=""%5E5@2ZH3QCY22,XQ^ERQ#D[CC/?CN>G!S[_X5?4*H)!R.
MG (QGK_/Z5\MQ'XH<7<594\ESJ<993?F248Q>C;3:4G+=WO;M8]C(^ >'N'\
M9]=RE-3VL]6GV;:7Y_(DP,8P,>G:DP!T 'X4M%?%'VXF!Z#\A1@>@_(4M% !
M28'H/R%+10 4444 ,?H/K_0U%5BJ] /8^8?VG?VC_!'[+/PNN?BKX\L];U'0
MO[6TO1/LWA^R.IZB'ULX#&+<-PR"3\XRN "0<C\WO^'V/[-Y \GPQ\1]W0'_
M (1O2P #Z#SR<XXR6SS[UZ)_P6BE\C]CC6I_^?;Q?X6/4<99S[<\_7-?ACX5
M_8TL?&'@CP_XCT/Q_HEMK&N_"OPOXTL])N]8_P")G8ZIKNM?V#QH?&?#HYY!
MZ]>E?'\19YFN#Q2PN"4;-*2E:-[-+2[UU6EMKG\3^.OC)X@\)<<KAOA#V?\
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M%% Q,#T'Y"C ]!^0I:* # ]!_G/^)_,T8'I_G_)/YT44"LNR^Y?Y!1110,3
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MS5U<Z:I\#T'Y"H(._P"/]*L5]1L?TC:/9>ME_D%%%%(8F!Z#\A1@>@_(4M%
M#5^Z/Q_F:KS$(&)Z#&?IU]JL+]T?C_,UCZE_JKC_ *\V_K2;LI/>R;^Y-_C:
MQQXN?LZ52I;X*<YV[N$*D[?/EM\SY3U']M7]E[3=6NM+O_C1X(T^YMKLV%U;
M76L*K+J! (CY.3@YYY!."<8%9S?MQ_LIFX./C?X!^S%0/,'B2+((&<XW D9
M., 8Z "OXU_C#9V4/Q:^+.;&U)_X61X\/&/^@UUR.O\ ,]L<UY]-9P?\^-M_
M7GW]^O7_ .O^=8KC;%QDXK*DW%N.K[2:OO=?#?MK]_\ FMQ!]-OB#*,=G6 P
M?"BG_87%%2A>5_>C&<X='L^6]EIJ]-3^W/\ X;B_9%_Z+K\.#]?$:\]?]KW/
MYFI?^&X?V1?^BZ?#G_PHHO\ XJOXA_L<'^C@6(_TK_CR]#T[^OZ"CR8/]?\
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M_6K^83X>P^*O&'C?P?X.\.>*M;M=0UZ\TOPQ9ZM:7I_XD.E^WK_PB?U_^O\
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M+=3M]4T?2[RS\0V=YK&G:G?:9KF01QQD'(/H0015G]B>;_C+[]G?S_\ 2?\
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MH?<_\SE_XEX\$TE_QKGA[5+_ )AY=E_?/PU_X<9_!/\ Z+9\8?\ P'\(>_\
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MX_S-5Y?N-_NC^0II)WOM9Z=^GZG+BDI0E&23BXR33V:<9)I^J;3]3\1O%?\
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L&VM-4DI7TZ)=.EK%X=!VHHHK4^S6R]%^2"BBB@84444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! A # 2(  A$! Q$!_\0
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M[7LARA)*\5S>6W^98HHHK0D**** "BBB@ HHHH **** "BBB@ HHHH ****
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MY\(M6O?$'QKUGPWXY\6:KX&V@?V%HG_",E S,1M#?>;@!CQ6+_P5D^(_P_\
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M6C:=_P )WIH&]AKVN!O^$CUUAM7:[MP20K ,=WZ)T4 >9>$/!WAKP7X1\+>
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M)KZ:HKGIUL32_A5G'Y/?NK-6?FK/5V>KOYOL,.[N5)2;ZMZ^KT=]=7W9\!_
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M0H*I[2%-0?9/3\OT"BBBF:A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %3#2],8].G]/?U-5_F
M'^I(QGC_ #P?3_#%:=%9\G][\/\ @F%2@IZ\\U*]^;F=_1;604445H;A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%,WCT/Z?XT /HHIDGW&^E #Z9O'H?T_QJE--_D_Y_(9]23212Y'\\?A_
M];(_$&LG5BJOLFFG;?=7[:)B6JYG91_FD[+\?/0T:*9O'H?T_P :?6HPHHHH
M **** "BBB@ HHHH ***9O'H?T_QH ?1110 4444 %%%% !1110 445!-_J3
M]!_*@"3>/0_I_C3\CU%8<0;DC:.OS8R0,#\S^=0*"9,,V[WQC^+]?T_&B7NU
M.5J7L[?Q%&4EJKK1+;I>YSK$<W+*&&Q;IZ^UDZ48NEYN#J7:Z[K34Z.BL_SI
M_P#GB?R'_P 3_G)]L2[Y?^>)_(?_ !-<WUE?\^JO_@$O_D37VE/^;_R6I_\
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M_7]Q^GKS=UVJ?^"I_P"17O\ _/C$_P#@J/\ \L-3(]1_G_\ 6/SHR/4?Y_\
MUC\ZQ///J?\ OV?\:!.<CD_]\$?KGBG[O]__ ,%3_P B.>I_T"XO_P %0_\
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MGY?^#G[.7Q+^.OB/7]*\(66AZ7I'@^^-AXN\5^(;PGPUH;;6?:J@$LP56<@
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M>>N>#R:^/OCGKWPTUVVTBX\4^-M0\%?\(Q=ZC>6>JFT(;.N:.VA$YP<X4Y'
M).02 01O@L-5QM7V<(-:[I<S^45JWY=VCR\SSC 951E5QE94[)NS5NC>[M^6
MU^Q]00>*?#MYY'D:KIMQ]JM#>VGV:[!W:9@8?Y6Y! Y'!]0,4@\5>'O*,W]J
MZ=Q9?VO_ */=J<Z8.DA(8;@< 8&.>PK\H--\._LP:/\ 9_L_[1/_ #"/$UE>
M?96 U*_77B-S9&3E1G Q\Q"C(!W+ZS\-]?\ V4OA];:O!8_&'1-1O]=\-_\
M",7EV;T'[%I>T\  \8)')],8'WJ^CJ<.8B*7)A,TJ/\ [%\H^;UYWT3MWT6[
M/@,/XF9/7YN;,\LI)7WS3 O17MI[9;Z:=-;[,^_M(\<>$-=L-.U32O$&BZG8
M:H!_9%XMZI%ZQSG:6P6(Z#Y>1C@9.+7_  E?A;R\?VUIN,?8_P#C]'_?(&<Y
M[\C'3G!./RNL](_93$FDWU]\>[:ZN-+N@0#;#3--+:%G*G1,$#;QSE@>WH=#
M2-._99LXQ;ZI\=;;7)_MVJ7K7EX_(U+^V-!.<;65B'T-4VY&02V< !M/]78?
M] F=7M?_ )%:2OZ^T>G?KN[=!/Q-R;;^T\LZK_D:X'SZ>V[=O1:V/U(AO+.\
MC:>WFM[F"Y5=MU;'@G'8Y/)!]>N,\&OS>_;.\*^')O'GPBOI]%T9]0U_Q/IF
MC:O=M9#^TK[2L XUDJ!N0'(!8L0<KNP% ^@?A!\8?V?--\.Z=X&\*_$K1-3&
MF'%I:W=\/[3 YR3D GCL <X)Q7A'[:&L:5#XC^".N?;;8:/:>,1>W=W]KP"!
MJZ_='<=NN 05[5.3\^69JY8F$J<8QJWNG%V5-ZM.UM(]$TW=)Z7.+CO'X#/N
M'HO 9EEE7]YPY)VQ:;UJ1;2]UMM;)=?F?H?HUEI6A:5IUCI<%OINGVMH+.SM
M+6TP+'@<+MYV@X^4C!P<YY->;^)/'L]W?W'A;P18VWB/7\'[9=$9\-Z$<Y!U
ML@DG('"@,QX'!&*^?W^-3?%.7^RO 5GXD/A<$A?$.CV3+_;R';C^QM<+L-"T
M$8YDPI.3M502#Z3H7AGQO%86]E9?V;X!T_&/[(\/V9U/4>N?^0V>,Y_BZ].<
M<5^*XWC7)\=B,UP^"Q#JN,FI35[MJ;4MUJVTU=]5YGZ11G6J4,HIT,+7A#DB
MG4K0E1B^6$5[JE'9ZV>WDPUCP5%X6DTCQQK=\/%?B'3+K[9JVKWEY_9^--.2
M?[%7@84XX#'/."!@UTWPXUGP]XIUSQ!K?A9A_P (C]DTZT^4?V?IM_XD#9X7
MJS!"JD@'YR#ALA2ME\,M$CF:^U73-9\6ZL"-MYXTO@WV(8Y_L7*X7.<;5.<
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M0M9L-=T_[=8V]S;6_P#T]V7]G'KZ')Q[BO-M0U.>T\3>)_(TJZUG_2]*^6U
MXSHHXX]3Q\I[YS6AZ67*,N925_=?6S^3LTMO^ 6=-T[P?J-_]ALH=;/^A_\
M'V+O61^66(SVSD#ITJ]XD\+Z)9:'J]] -3\^VLR?^0OK'&,8S\Y)Z]EYZY'=
MT/B/7#:^?!X5-O<=.?YY&.G3_P#74^I:MJEWH.O07VE7-J!I&IXNAT/RL,<X
MZ _ACZUIR>??H6Z6NBLKVM>-]W?IKIYW.RTB4_V7I_\ UY:8!]#U]A_GO7YF
M> _^4POQY_[,<^#_ /ZL[Q!7Z4Z#_P @?3_^O/3/YBOS5\!?\IA/CS_V8[\(
M/_5H>(:=)>Y+RBU^1YM5^SK.EOK:^WX:_F?JI11160PHHHH **** "BBB@ J
MO/V_#^M6*0\@_0T <Y-;"66;]U\H0K@G.<XQ_P#J XQTXX_EP_X*._LX'X*_
M&/\ X2K1;#[+X)^(EZ=8M!:68S8:H"1K>CX!; =<.!DG##/S X_J86 P!5Z]
M2>2>I./U^O(KY+_:Z^ ]C^T'\'?$_A":*V;7;8'6/"5V0!_9^K)O_L23.0!\
MPVL  .0<CO\ ;^'O$DN%N(Z6(G5;PDY*$J/-R+EDVE)2>C2F[M6V;LM#\%^D
M-X=8?Q%X%S"E1P\:^:\.0E6R;$*DIS4E!RG&,4[[*2TE9M+1-Z_R/4LW^I/T
M'\JGU+3;[0=4U#0]<@NK;6- O-4LKRTO/^@IZ=^/\_6O7]N4ZOM:&$Q%-*<<
M7%27+)-0NE)*ZO?==C_&K$X.I@\1CL+BJ<J&(P;FG3FN5S<7)/=+EUB^C/T/
M_P""9.HP:1^T7XAUJ;%S;:9\*_$]X1URNA'YAU[KD#C^5=O\:O@%8_$']MKX
M;CPY"UWX'_:)_LOXFD\-IQTM1_;WCDL1@;F&&QU^;MG%?,_[(7Q-\$_";XE>
M*/$7CW5AH>@:I\+O''AFSO"./[2UN168=SDJ&"YZ,1Z&OI_X0?MB_#7PK^SV
ML'BB^6X^.WPZ\-^/?!GPNN[RTUDZI_9>N@_V#C6]O))(W,SC"K@#)-?B7%='
MB.AQ=C,VP&"K0EB<K66WC*324E).JFHVE;3FC9:/=G];>'&?\#XKPGX?R7BG
M,L-3J87-O[3C"I3@YR<))JDVY)QO96GKM\/4^N/C[KFA^*/C9^PAKFA$?V3;
M?$CQ]9Z/:V@/_(-T/13H6[;Z9)(&>G&>E?,!U*\\.?"W_@I;XIT2?^S/$/\
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MZI^T'X<_9JN++XF?#GPE?V?P4\+Z*=)\:W9T_5=1U3:I/]@JNYF(SM  ).,
M&OC?QAX*_8I\*^$_$]]X=^+/CWXH>+[K1=3LO"'A^STDZ=IMAJW/]AC6P4 *
MCC#9R022HP >>_:E^)G@CXCVWP"F\'ZG-J-_\.OA%X8\-:M=I9$:IH7B?0U4
MDZ-QC>6#9(Z@*3R2!]!F-/\ UGJ</T<CP-7+UAHS5>K6PSC&O-0>ZDJ:2YKQ
M3NTVK>9^6\)U<J\/\IXK7$V8\/YM@\SK0G0H4<WQ"QN$3KJ2:QBK5I5&DT[<
MD++2VEG^APA\/6G[6_[*?[/<^H:CXMU?]G_P'JMIK_B+5;( WNI?V"HT')Y!
M._0V;/3:5'.*_(3XS:[KGB3XM?$CQ%JNJW.I>(!XP\3WO]K?;-8Q8?\ $ZQH
M7]A@#_BGL>O3 K[$^(W[4'AW5]>_9R_:*\.WUM=?&;P=I)\,_%[PE=V9T[^W
M=*T3[VL'7#VW9(ZC:0N!M%:/B73?V#OBSXAO_BGK?Q3\>^#+K7;S_A)_$OPG
M;PX;_.J8_P")[HQ*HP!+=0!@ Y]%'CY5@,QX>KSJ9GEU>M&:G2Y'A98K53G%
MR5^;EC-OGC))IIJ5]#W.*<1#BNCC\'D'&^!RZ<,_H<5.O'B*GAU_8\(4;Y?*
M"IP;K\L'&5-SYGK[EY-GL_Q,^./_  J'7OV,_P!H37-+N?$NH:I\+M4T7Q>
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M67*LH.I*]_:*I%Q;LELSL?V088(?@=^V)!Y6V ?#G2\#'#?(_P IX[??_P"
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M\>5+@!E+>\V?Q.\4Z%%;S>.?#NM6VD<7Q\;>$ROB3P1?:9CJ<9\3>'SC!QR
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MS^(/([Y]1WZIXFG'W:BJ1D[^ZH-O]#>5>FW?7Y-)/6ZOIT_4L:#_ ,@?3_\
MKSTS^8K\S_ 7_*8GX]?]F._![_U:'B&OU'@B$,:PPXMX8 5XZ8 W'\!WY_\
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MNVI\U5*UVUKKIM\NA\ 45]__ /#L_P#:9_Z%[3/R/^-'_#L[]I__ * NF?\
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MXA6\_:O^ -OXC8'PPND>*+OP[:71!TV^\4X! ?GABA4G/4$'N,]-_P $R?\
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M,*NX@$J,?+_<?%_KIOJ/YFB6($9Z_P __P!?I^1K^O\ J?Q2OQ/P-_X(%?\
M!+&R_P""97[(]AI7C);BX_: ^,1TGQ_\:R+A?[,T/5%11H?@Q%7:,^%(]R%R
M"S.79LG)?]V-2F$%K<3@D&WM#T]@>?7 /'\ZS[R:"TM;B]N)C:P6XP;HL>
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M2I[-;7^=OZV/U3HJOYL/K^I_QJ7>/0_I_C69H/HIF\>A_3_&H?M</J?R'^-
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MW^R7]B2::;]D#]EXS_Z__A0WPNZX[>#-!ZX] ?TYXH ^JZ*** "OR,_X*_\
MC;]I/X:?LC7_ ,2_V:?C ?@IXG\&_$;P$_B_Q$_AK1?$QOO VM:VNB:Z-&&O
MC8'4ZXK(5)^8%E " M^M&.1R>YX)]0![]#C^M?DA_P %M-0ET?\ X)G_ +3&
MO0 %M)T;PUK M>IO1HOC3P\[+GK@X0D=]H/O5T:<Z]3#TX*\\1*,5%;IRM]]
MFTNAS5<3"CA,7BIZ+"IMQ;MS)*^[VTN]G:VIX-\2?V>?V]/AU\+_ !/\1;__
M (*T^+6MM$^&^J^/])TG5_@_\,M.U*^71-#.O'?N.2IP$( 8DE>-H8K]C?\
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MM)7?J=AJ:-C1M7T;:R@E3N"X<;6)RIV-D [OP3\6_ /Q"U7Q/I/A;5EU&_\
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M/=MWO<SK*T^(O@2T-^-=N/B1;6MY]MUCP]JQ_LW4[_M_;6AZYV/^)&0:^_\
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M\?\ X=_$C]HCX=_!_P#9HT^#_A0WCOP+X67Q_P"+,[/%?A77M>T)_'.N'0=
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MC2OA#\3-3&G^)]#QNT9FT'PRVXJ-VT$ -P&P#E>_^#/_  5K_8A^/WQD\+_
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MV_X*&C]CO]EGPE^TM!JWQX \7W?BSXIK\-SH3#6?$7]B*GF!PVY%.["@@%P
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MLOE^I^J=03?ZD_0?RJ>JMW_JOSK/?3OI]^AT+;Y?H?S[?LX_$#P=\%?VD/\
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M3_PA/AG_ /-)0!_1K_P\Q_X)_?\ 1Z'[-G_AU_!__P OZ\&_:$_X+#?\$_\
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M;&K]_G*G XZ':QP.F#[BO/\ X??LV6.@ZO!JWBB^M=:GM;P7UG;6UGM2PU+
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MFK5[[=SP\=P[@<QS'"9IB4Y8K"[32MSV=]==/Q[;#H?]2/H?Y5/56*56&V(
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MB?#GP#X7LEN]9\6^*[Q=-\-Z>O4%R6!*Y!/&3G. <&OS0#_/M_:H\1_M!_\
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M_P!D4TC_ -#>OUSK^4S_ ()%_P#!9#_@F-\!_P#@F]^R3\*_BW^V+\)? _Q
M\"?"O2M$\7^%-5UG6/[4T#5 S$_VYN1ARI  )(/. A&6^^/'G_!?#_@E)H_@
M[Q=JWA;]M?X)>)?$^@^&O$^L^'/#YUG6<ZYXET+13KVB:.O[K+;W"*REE7&2
MI5D"N ?MD)O.'[D_B>G]<?\ ZQUI:_ S_@@A_P %0OC!_P %0OV>/B_\6/C#
MX5\%^'M?\ ?%_4?!.C?\(6K6&G7_ (8;11K>B [BS,0"59W;)4L\F<D5^_=
M!5?S_;]/_KTLW^I/T'\J_(O_ (*"_P#!2"__ &9/AGJ&N?LVZ3\'OVA?BQX.
M\>>%O#7Q'^&&L_%71?#FJ^ O#.O:U_81\9:[HB.WB4!>%P,+P0"X;- 'ZY3
M39ASUY)]L?TS_@<TD7^M/_ J_$_Q%^T)_P %AO#GA/6?&^J?LD_L=?\ ",:#
MH^I^*;VZ_P"&A-:'_%+Z)HQUP<GPW@YV]CQUZ$$^W_\ !/[_ (*!6?[5'P@^
M&/B+XT3_  N^#GQW^)]IJ>M:-\!=(^(^B^)?$Y\+@YT76AHA(\3?,/E!XY)(
M;D8%*$O@ES?*PDXR^!\WJK?YGZET4S>/0_I_C3Z!A1110 4444 %%%% !111
M0 4444 5O*'K_/W_ -GV/Y4>3GH?SS_@/>K-%*4826L?N=ORM^8DZBWDFO.*
M?YE?R/?]?_K58HHK.G2C2346]>[&]5I9>:27Y!1116H!1110 5^5G[;7PN_;
MD\>?%OX(:G^RSXYTOP!X(\&7L=]X\N;SQ*-/:^W.5UC1_P"PN3X@#>'U^0D#
ME3S\I(_5.J] '\_OQ9_8I_X*+>+/!G_" V_[0'B/QQX6U^]TJ]U>UNOBK_PC
MGB6P\4-HGA[^W-;US71X;_XJ'X='Q'HNMD?"X<8;/ KZ4^/O[.'[<'B_XJ77
MB_X0?'74?!/A?2?"7@3PSX/\))X@DT[PN=4;2?$.A_%/6];T/:=S\Z$W@PKP
MK[F.T<U^NU% 'X61_ [_ (*2>*M>T[5OB!XIMCX/NO\ A)K&R^'OAWXO'P\W
MA'4W\&KH"ZWXXUM/#1/C_P -[AK;'PQC8HUTNQ"J6'FWPL_9A_X*J?"K5/$
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MW'PZUC_@I'\/OV7OC_KD>B>*_$OQ^TKPE\&/^%/6GQ/T<>)!?ZP-(7_A:?\
MQ)/#_&X2 ;1U+[<?,!G]R?+E\O&1GT_#\O;_ .MQ4'V67S,Y&.N?_K>F><=?
M:@#\%-9_:/\ ^"L,TT$WA[]G.UM]1OOA'I-^/#GB3P,6TNQ\6)X)UXZWXTUC
MQMH/B4A?$:_$6+0O#8^%<8 '@Y6EP'+L:$.O?\%6_#7Q7\8:5Y&L_$>%OC7X
MIT;PY\0M6\!Z+IG@C0OA;K>C? ,Z'K>AZ'X?\29\0JK2?%0DD8#:'VW<_P!
M7E3;,>=SZXXQ]?3\.G&:SOLLW/\ Q[< 8QC_ $' S\N3SC'7VSTYH _"W0_V
MP_VU_#O[2W[+WP0^,6B:-HFH>,6\!VOCO2=(^',FI+XNTS7?&7C[P_KOC,ZT
MK > 4\*#0]")C^XS:_N*[OFK][*XM= L1K,&N3Z5HW]L6MF;*TU7["/[2LM,
MXSI UKE@"Q/&0#DG#$ACVE !1110 4444 %%%% %>?M^']:_+3P'_P IA?CS
M_P!F.?!__P!6=X@K]2Y^WX?UK\M/ ?\ RF%^//\ V8Y\'_\ U9WB"M:/PO\
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M]&Q77_A>>+__ (NOWGE\7>%!_P S5X=_'6])..W=VZ=!S]:_*F;]G;]JB?\
MX*;V_P"U;;_MK:,G[()^%@\+WG[+GVT&PO?$_*G6A\S1$$D.<AV^50!DLK '
MS=%_P;%_\$;(O-'_  R_=8'_ "W;QYXQ+#U"GS-J\]=N?;I7XT_\$[/^"'__
M  3<^.'[!'[2_P 9OB5\"KG6OB#X#^)/[6NB>'/$'_"8ZR&LM'^%>L:\G@K;
M\PQM&C+O.&#*3&1EP1_;K+XP\*^2<^*O#<'^C'&/$.D<<?[3-G_>7"^@S7\\
M'_!)CQ%X<M?^"7?[7\,_B/1+:YG^+/[=[?Z7K.C]]8\0KT!&?O<@JP/H, J
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M?^%9KKH&Q0I50%W*2[JP1PT@K^YZ:+SHP._\_7^M>8^&/AEX!\(7>LZKX/\
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )F @8# 2(  A$! Q$!_\0
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M+^%3*0Q8!L'Y??\ ]F[]N#X=_M*?LS^(?VGM,\+_ !&\ :!X,?Q[H_COP/\
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MU6T_M'3;Y6YP01T. ?F4X(.T@@X +OAWQ!IWB?1M)\0:3.MWH^MZ5I>L:5>
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M^+7A#5K?QQ^QS^Q)I&E?$SP?K%G=+J'AKXF?M9_%70_^)&2-Q!'[/OPZUMF
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M/"?ASP/X7T#P;X5T*U\.>&?#>D:7HOAW0-*M_+TW0])T-8X]'TJ-1NV^4FS
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M\"_%#PYKS>&O$1'B M&-A1MF<B0G(_2VT_U7Y5\H_LQ_M2_LP?MD^"(/C/\
MLS?$SP%\8/#\]F]DWB/PI>1ZAJNAL2)&T?6X\CQ%X?D\S<6\-2HA1@VU<.6K
MZQA_U(^A_E0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNI0/'7[.?Q2^,?P7^*/A]L#5?"OBG1?B9XA\0E=9#8.2FLA\]&0[APN:]_\
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M^SYXBTO3-,^+:@*H_P"%K?"[Q-X9\7?#+QY(S. ?$DOA-I#R2SE6(Y#XM_\
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M?^&?%_AB0QOM*%47!$8)WKN(!^3/@+]D'X6?L-_\'#'P5\+?L9V'_"N_AO\
MM)_LG?&'X@_M&_ ?PJOV'P-H*>'=871/#GC5=#W.V@_\)-XC6-4'R[6CS&BC
M;G^KN&+R8R._\O3^E?G]^S%^PY\.?V;_ !7X_P#BW<>,OB!\<OVB/C(NEV7Q
M&_:!^,6L:7XA\=ZYH^BDKH/@W15*P>'?#?P]\+1JP7PKX450D@9@79%-??UI
M_P >P^A_]!% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX4OK4/YH?^!1_P#DPL^S^Y_Y#J*;O7U_0_X4;U]?T/\ A1]:A_-#_P "C_\
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M&L?XT?\ "5>*O^AK\2?^#G6/\*Y^BCZT_P"9_>__ )(/J6"_DA]T?_D3H/\
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M?1]9T_7+&?[/<:7>?Z'_ -/_ +>_^1TK])O"GB*R\5:#8Z[8MFVO+4,!SQ@
M$?3@GMU_&OJ,MQ/UK"-=5IYO56;6_0_+^(\M^IXQM)J+OLM%?SLEJK=?D=50
M>AST[T4'H<^E>MTT[:?=I^A\^505 X/4^_4U\K_%G_A*O#>L?;;'6]2_L?4^
M+3%W@6&J>W^RPZ>@KZF4*0>".?7//7^OI7(>+/#=CXBT>^TN?:!<\6Q)Z:B
MQ!]."!U[$XZ5\[Q%EV,S+*IQP7N9FHKD:DU:RES:)K2RNK'?EN)AAL5%XFS@
MW:UE;EE9)[;J^O3?R/BS_A+_ !3_ -#'KG_@;4?_  E_BG_H8]:_\'"_XU1U
M+3;[1]4N-*OO^/BU(_TO_(_S_+/K^?<5F>=8-O!O-IJ46^;6=U9NZWOT=C]7
MPV%P,HI\L6FKI\L7NK[V:_$W_P#A*?%,Q'_%1:T/^XQK.1UX_P#K=>F:/^$I
M\118_P"*BUH^G_$WUGW[<]?;\NE8%%<_]MX__H:RO_BG_F=7]EX'M#_P"/\
M\B=!_P )7XC_ .ABUS_P<ZQ_A[#\J/\ A*_$?_0Q:Y_X.=8_P]A^5<_17/\
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M_P -_&M]H_B*W@U6^U*ZT_5#]B'VR\_X\#Q_7MU].E?9T0##(.>?7CMU_/\
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MV:'_ )YP_P#?*^WM["G_ &&N_P"'_ %_KL_^A8OGS?Y,_+O^S+[_ )\=1_\
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M3A<JQ:QCCS-:KR?ES)[WM\S\\J*_1#^P=$_Z!FG_ /@&O_Q'N/SJQ_8^E_\
M/C:?^ @_P]Q^=?G'_$+\6[WS57>^WSZ>I]C_ *[+_H6I_P!>I^<]%?HQ_8^E
M_P#/C:?^ @_P]Q^=']G:7_SX6G_@&/\ 'W'YT?\ $*/^IH_Q_P A?Z[K_H6+
M[U_F?G/17Z/?V=I__/G:?^ @_P ]Q^=)]BL/^?*W_P# /_/J/SKH_P"(7?\
M4S?W,/\ 7?\ ZEB^]'YP^3<?\\!_G\*/)N/^> _S^%?I#]BL?^?>U_[Y_P ^
MO\_0T?8K'_GWM?\ OG_/K_/T-/\ XA=_U,_S#_7=?]"Q?>?F_P"3-_SQN/\
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ME7J'PF^#/BKXA>/- \.3:'K>FZ/=79OO$EW=V>/L&F=@,\<]/\.*_>=H8?\
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MYSWXK?+?]\=NZV/&XELLH=[+6.]K[]GKV/LJBBBOL3\H"BBB@ HHHH ****
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MJV[/&,4A <9'&..?\_YYXKGC)PDL7A+\R:>C:O9KO9]&@:Z,_ 'XI_!OQO\
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MYXW\.>,_C)\-O@YX+\.G0!HL4?PD\4? KQEXA\>^!/''@G<SG7=>D\2:P/\
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M"?/PT\'V/B'QWI"?$[XS_#_]G)G'Q2_L;XHOXC$GP\^,_A4*5\$^*75"TBN
MH(VJ ?T\2>-O!T<L]G-XJT5=0M]5_L:ZM3JVDC4;'5&"M_8[1,597!SE6 D
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MPU?P@/">N7'[,WP@\-?%ZSTNZT:\TV^^,/@'PAH'AYV5=$&?$.O1KH^LH\R
MHP?<A_>(#^A,/^I'T/\ *@">BBB@ HHHH **** "O+_%'Q'\$^$-9T#0?%'C
M/PYH>M>,6EL_#FE:MJR:;?ZX^C9?65T=-P=BB,A(4J">2PXQZA7YH_M<? ;X
MF_$?]J']@GXP?#WP]9ZSX9_9U\?_ !2\4_$0G5M%T[4AIOCOX9'P-HHT====
M0["4R%PC(6P06#98@'VQ>_%+X<Z=H6G^(;[QQX<M] URZ^Q:-JQU?2A'J&HM
ME=NC,24E?Y6.#N9,JQ50P+U[OXL_#.RT.#Q3?>/_  G;>&+K5QHUIJYUC2?[
M+;5\\:.K^80->!#?N025!&< @-^,7PB_X)M_'#X/_M!_"?\ :8U3Q5IWBRP\
M,_'G]K+XM:M^S[:73/X6\!:;^T?'H9T+_A5PUW[GB'PD-!R2[(I/B#Q&BN9&
M"UG^%?\ @FI\=_"W[3.@?M9W'BS3M=TFT_;+^,/[1=Y^SFVK*/#>B^!OBIX)
MT#P+HK:)M1?"G_"Q?"G]AGQ22JA VNE1XU&"H /V>LOC5\);O7= \-P_$?PC
M<^*/%%WJEAX:T#_A(](&K:]J.@C&M#1=&,A9F3+$L6&XMD8.XG0M/BE\,KS7
MM(\*:7XW\-W'B?5EU2ZTCPK9ZQI']K:B-#)76@NCJ_F#8"V6(!W-O5EPQK\Z
M?BM^SC\8O&_[6_[)/[5N@> O".A6/P'\2?':S\1_#^VU;2#XU\6>&/BQX,T'
M0%\:'705\+MXB#:$,H&##(SXX7<A/GW[3O[#7Q?^)'B3X1?%+X/W^B?#_P#:
M1_9[\2>*?BA\'_&NJ:QK#>"+/Q-XX\:#_A._AKXU1"\GB'PWXI^'C^6WRA@Z
MD8(*LP!^GNH?';X+:</%-OJWQ2\!:=+X$UC3/#'BY;[Q-HUA_P (KXGU[=_8
MFCZZWF,-"UV16&Q' *\D@# 2VOQE^$TFLZ1X:_X6/X);5]>UD>%]$TC_ (2/
M1_[4USQ-_8BZY_8FC:*\C&5_^$?WN6 4[2$*EP&D_"?XO_\ !.+]HKQ;H?\
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M"P+C9CQ(,E>) X+-^\^7?\Y7?[<7P17Q%\'M$LM<N=3T#XVGXSV>C^-OL?\
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MG"^H#]H'X,?VH-)/Q&\-_P!KW>DG7+72C>LVIZAX8&C+X@&LIH;2%M<\._\
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MD!UT8?B?X D\/:CXH@\8:'<>']$LM-O]6U6TNO[0TZRT[6F/]BNSID8<%"O
M89.1GY0 >JT5\A_$W]K+X6?#^;P/IEIJ=KXT\0^.[WQ]8Z+I/AZ\5C>_\*HT
MA]<\=,'QQ_PC"8+*!D D;B1NKMO#G[0'P@\5>%?#_B[3_B!X0M-%\3^'-'\:
M61U?5]'L,Z/K;_\ $FU=@[<[]>&P,6.'8RE254$ ^AJ*\F\*?%+X<^-M5O\
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M?!/@>W\;:KK'A\>&#XDN3X.U?3=-T+_A.=$.OZ"NM,Q54)\/!3N<E01U'#*
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MT76@OSI@:&\F20N>?\>?MG^#?!,ESJD$)\6^%K;X/^//BU9GP[>G4=5U[2?
MWC'P]X?;6=#D!'AP^'C_ &UD/N#C:O.%P0#GO#G[ _@?0O'6@^,AX^\;7,&D
M^)?C)XIM?#9_L@Z</$GQS\'G0/'+C6%0R%FC5VC7;\S@(,X)'5?#7]B_P!\.
M-3TZ_@U6;Q=;'X5^ _A)JOA[QKI.CZII>H^%OA5K&O:_X%/]BA1CQ#X5;7"
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M:U\.OLQ?3_'/B[2?'6B:_KNO:QK.AZ_(OE^'_"@ PR@A3\VQF-?HS']Q?I0
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M>?M,?$OQ)H/PFU/P?X+GT[5?C'9+>V6D>+?#>LZ;I?PR\,>'F4_%/QI\4M:
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MUEX;\-'2_&WP3UC3+/X/^*K3PWJNHKXYTW7M&T'Q ^M'0]>&YG\+E]<\,/\
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M\U?'#XRWOP?U#X+6-AX=M]:/Q9^-.D?"8W5WJW]EKH1U_1-?UP:TJ/EM<XT
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M9CO<GC9A6X&3P6;HO[._PKT/4/&NL:+X2&EZS\1CX)3Q?>VUUJP;7U\!Z/\
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MWQWJVIZOHQTM?BEK7Q0T#7/$(T71 S!M 7X?KX@_X0H@+L(\,(R[XRS?1/\
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M (&^*</A#_A+[?4;J?P!XN7Q]X:N=(U;6M+>P\4#1=?T--8)T-EY$>O:WPV
M&8$G)(KVZB@#XJD_8P^!4]]K&JWVE>--:U'7G\!W>KZMJWQ'\::GJ5^? ?C3
M7O'?@<,6\2+@^%/$VMMXE0]#E3M;)4[4O[(/P)O;R&]GT/63/9^/?'GQ-M,>
M,?&7'BGXKZ+K^A>.=9(_X23(/BM==UHGIG<".#7UW10!\=67[(7[/D/AMO!]
MQX 6Z\/VO@'PM\,OLUWK&KZDJ^&/ FLMKG@<8$C$^(_"#ZUGP7XH+#QD X E
M.QL=!XR_9F^$WC>_\/:KXAT/7-0UC0/"/B?P5:ZNWB#6M.U*_P# 7CAO^)_X
M*UO6LQMXA\.L"0GAGQ5YB _,0P7!^I:* /.O G@/PW\.?!WAWP%X5T\Z;X9\
M*Z/IGAK1;0W9O_L.E:&"NB [AGODK@#.W)'4>BT44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 445B:E86^IVM]97 S!J-H;.ZZC!PR_3@,1@
M>H]Z +4LN) (/LYXZGK^.,>OZ>U>.>%_C;\+?&OP]G^+7A/Q3I>N> ;8ZJ+K
MQ#:$WZC^P=7;0];W$9.,J%;:"<'=MQQ7QA\)OV//BG\-OB+X=OK_ .)FB^)/
MA?X8TC4_A[_PB5U_;']IWWPPT+6QX[^%.M,0VP?$7PCXD_XI8^*=V3X+&U-S
M8!\!\*_\$[?CMX#^&>@>!_#GQ \ :;J-S\-OVM/!?Q(%G_PF6G:;XNU/XZ>-
M-!U[X3ZUQD_\6G(UX#U_MXC% 'Z[>,OB%X-\!> ]:^(WC#6[71?!'AC1CXEU
MCQ!>'Y;#2P"1K#$*V =V?NG@YP<XKI=)UC2]?TRPUO29;:ZTG5K+3;^PO+?!
M2]T[6<>63@<!LAN"3QC"G-?F%XS_ &//BIX_^$/[1/@#Q)XV\.^(O&7Q8M-7
M7X;^--8UCQAIK>!%USP?H7AU?!^N#PZ6_M_PUX8\MGB)(W(3N56!5>V^&7['
M_C'PJ/CMX(\1^+-*;X0_%GX1_##P9HGA_P +?VO_ &GX2\>Z%X,?0?'OC%"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 44F1ZC\Q1D>H_,4 +1110 4444 %%)D>H_,49'J/S% "T444 %%%% !11
M10 4444 %%%% !1110 4449!Z$&@ HHHH"Z[H****!77=?>O\PHHHH&%%%%
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MPRV\\$_V;[)>&]L\_P#Z_P"7Y]:^W?A[XJ@\7^';&^+?Z1;D6EV#T&I*%#
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MVN;W1[L?\O\ I?TXP?;'&#D<<><5^)8KB/B/!XV6">:6:;W5FK-]&EM8_?\
M!\)\(XW!1QL<KNFD])-III-/XMFFOO/TG_X>/>,?^B<:)_X./_K4?\/'O&/_
M $3C1/\ P<?_ %J_-BBN;_73B#;^TEV^'Y=CI_U*X3_Z%7XO_,_1W_AXSXQ_
MZ)WHW_@XU;_"C_AX[XQ_Z)YHO_@VU;W_ -GW/YFOSBHH_P!;.(_^AI^"-_\
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M@LO#OC[PW=:@1@V5W>_V?J) ST! R2.V,<<\U_.SY'O^O_UJ/W'_ #PXM?\
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M77Y<;'P>">&P &! 7HV.?$8:UM?\^^MGZ+?L?5E%%%!@%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110#V?H_R9QOC:\FTWPGK][!_Q\6NCNP]B.#W
M']X]Z^ :_0;Q7ILVL:#K&F0$>==61%IR  V5 Y]L'@^HZU^?/D^3^Y_Y]?\
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MB@ HHHH **** "BBB@"O7R]\4_AC?37]QXC\.67VK[5Q>6MIC) '7&,=#S@
M=AU%?4Y"D9[<G/\ .H::=OO/.S++<)FN$>$Q:6UXM;IZVZ?X>I^:]%?=NL>
MO"VMR";5-,MS<#_E[MPUBW/;(8'C/4[C[X K)@^$'@>&7SVTI;DCJ+H[O3U5
M3_GO7?\ 6?/\?^"? O@K%)V4ERW:6ZTOIIZ>I\D>'/"NN>+[_P"PZ58XM_\
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MV=DK5%%%?8'R(4444 %%%% !1110 4444 %%%% !1110!7G[?A_6OR=_;H^
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MW$B  _0^BLJSN(+RVAN(9H)X+FV%T+JVP V<'>I&<@AC@\'@@@8K5H ****
M"BBB@ HKYD_:M_:*\.?LF_L[_&']I/QCH6M^(O"WP=\&ZGXU\2:/X?'_ !-;
M[2]$&6&C Y&[)R<YSWSG)^5/C)_P4T_9C_9[F$/QUUS7/AJ-4_9]/[1WA)=7
MT5M13Q]X%C?1#KVCZ#'H0QKOB/PK+K^B>'#X<0;I/[=C.^1 AH _4:BORY^/
MW_!3S]GC]DRS^&_B+]JBXU?X*Z#\5O ?B;QIX$\0>(T74]-O=1\#:&-?UOP5
MJ_\ PC^"GQ!.@:PL@\+GS%+1LN0R IT/QG_;OL?@=^SO'^U!XU^"7Q:7X<GX
M;M\3=7>U31?[3\(^&B/#_P#8&D:[_P 5&HT/Q%XG_MQ0O)!V[7)9<J ?I+17
MQ7\??VN=!^ ?P@U'XV:UX \:^+= T#X0/\9;W0/"874O%!TM&T)6T31-$'/B
M#Q &UO<%7;RN>AVUXUXH_P""D7P TGPE^R#X]\/#Q)\0?#/[9_C[P#\/OA;>
M^%K+3-271-7\>:1KMQH>M^-ED8C05C;1-9\,>+W5Y/LS;XHV4QNA /TYHK\R
M?A;_ ,% ?#7QR^#D_P <OAQ\'?B?K?A'2O&GQD\!:Q;6T^AOJ>@ZM\*=:UWP
MZ7US0QXC5AH7BK7-",$<F[*H0'67 4U_AE_P4>^&7QS^$&@_$[X+^#?'OC+Q
M1<>/%^&7B'X*W5KI'AKXO_#7XG*I;6O!?CS0M>,9T!49G#>)"S1LA#;@794
M/T^HK\;-9_X*[_"/2/AM\8?B[JWP7^.Q^&_P(^+_ (F^!/Q(\0>'O#4?B4:#
MX]\/ZWH.AZV2= \0EO\ A'E;7=P\4YPI&0H.2?K;5/VO?!.F_ /XP_M,I8CQ
M%\)_A3X0U;QI;>)O WB31/&NG^._#6A:&NN:U)X'UOP_K[HS ( #)A0%4;9
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M.RLK*&7SX;>U%K]I)!;Y55%8@$C/RCO@<9)ZUJT5B7=Y;V?D^?<6\!NC]DM
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MW#XDTO6=6T/2OAK!J=SJ=GI?B?X69\2(-,\?>%_[$T+7=<!UM5"^'O$0_MX
M>%_%(5B%7<2 17Z,S:-I<QMH9M+TZX^RG-H/L:D67 P>AP.X *\\^AJS_9FF
M?\^.G?\ @$O^% 'Y.VG[<'BCQ!X_\1+X.\-_\)6+?]GK2_']MX(U/66\#/\
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M1EF/_":9(1">-H %?3_AKQMX7\;6VH7W@_6]-\16^E:OJ>C7MWI-VI2QU;1
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MG8Z?:_%CX7^.M4\,GP[?:T,^*_"VA:-H#Z[XST7'ATH63^W/^19R3QGS&ZD
M\]?_ ()[Z3JD?Q%L_$7Q;\7^+X/B9\(?#'P-\177B#2])O?$8\"Z'JTNM?\
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M^'&T[Q0/"YT?^WM'UA=$U\QLN5"['#9#?,5^0*0#A?#G[$?@W2/C7X&^-_\
MPD.K:AK^@^+OCIXW\2>']7M!J'AS7?$_QTT?P_H.O'1-SAO#WAZ(:&&\'!NJ
MG&)"Q2MGXR_L:^#/BQXZUKX@6'B_Q)X(U;4[3P&?LGAX:.NG67C_ .%FMEO
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M>#6_$UKXOO\ Q=\/?&KW=O'IB#3-3\'>$-8^'EL=()B)B\W0?$VJ1[G VM*
M01DUG^'?V,O"_@)/ _B#P=XLU[_A)?AS?_%ZX\'W7B KJ5DNM_'V5X]0U3Q!
M#N#ZT^A'6'-H)BGG!6#!, $HH ^B/@1\'?#GP!^%'A#X2>&);FYTCP:^IQ"^
MNRK7M[JGB35=3\3ZSJ3O]U7N=:\2:E<!65MJRXR<8/M]%% !1110 4444 %%
I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: ET# 2(  A$! Q$!_\0
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M^??P3_X*#_C7P?12_P!1N&_^A5'[_P#@A_KKQ9_T-F?>'_#PS]H7_GW\$_\
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M7_4E_P#@I_\ LJ^$:*/]1N&_^A3'\/\ ,?\ KOQ'_P!#5_<S[N_X>)_M!?\
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M?\4QX@_/_"O)_#?B3XC:;\/M0\ ?\)_X_MO!^O?VI8WGA[Q%XD_X23_B5?\
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M9'AO6+?Q)HVC^([$?\2_7K/2]:LS_3/^?RZ<N/B1\,O-_P"1X\)?Z5_Q^?\
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M>NEHFHWO=/2S=_O/%XBRYYKD^98.+:E*/NVO>ZBY*UFGUM_PY_-[17NWB/\
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M8-E$UPJF)-N%#<@"0EZ_$.-.&O\ 5_&76L)6<-W;LKVLU9KS6VR/VW@OBO\
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M[K_C\M;JS_X_^1U_I_DU\G^-O =]\,?^)KH<%SK?PWX^V6G_ "$M3\!^F?\
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MAER;223DW=M))+76[5M-['J__#9?[1?_ $0;X<?^'4UK_P"9NG?\-F?M*?\
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M!-0N;'6[^Z\2_#?72+'PY\0M*!TS4K#/(T?6\@?V!X@/9ERA(*ALJ0OZ"?\
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M?+1+>R^\^9[/X WMY87$_B+XC>)+;6+J\Z^$_P#D&6&E_P#4#_P[=>*S]8^
M_C^SE\CP/XXTVY\/76/^1WL_[2U.PX'77./^$@[_ ,_2OJBDA_UP^I_G7UV'
M^D-XN4,U>*?%<I1DFN1N4HOF3T<6VM>;JK:G.LCRBZMEBN[)/1:NR3W76S/
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MOO[$UC_C]_LGQ#9?\(UJ=_\ ^%![GIUZUPO@G6+&\\9?$"QL1]IT\7FEWO\
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M7^RWXD\!^.?#&K?LF_&"Q-TOB6[U?6OA'KUU9L3H>HD9.CIK2([Z%*I4!%7
M96=>6*D>=?#CX@_%G]A[XM:]X7OK"YNM/M;P-XZ^'W(\->+=*)5O^$T\#$8;
M_A(C@;AT8## C(/SC-J5]H/V?Q'I4_\ 9NL>%[S2]:T>[_ZB>A>N!U_ST&:_
M8S]J;X$^,/VCO@O\,?BUX6\/#3?B_H7A'2]9N_#UU@:EK>F:]HJ#7-!)!^\S
M/E00&^;;GH3^.<387"93G+PN,UR?/;O5WY:EM''FORW=KI-6DE+2[/VCAG$X
MG/LI6+P>F;Y'9.UTI0T3NE;FTO:]^JZ'W=\*OBIX*^,'@_3_ !QX!U2WU+1]
M34*3D+J%GJ8&7TG6%!D97#-M(8YQ@;B0#7KL.!USU..2>3C_ #S7XQ?L)?!K
M2X/A1IWQ1_9]\5:WX*^(T.LZIHGQ>\$^*O$FL^(?!.M^*-#U=O[>_MW1#)NT
M#Q&></$ 5WJ-H57DK]B[.2:2& 7@'V@VI-V,$ $CD\#OR3C'0U^0YG%87%O"
M85-QYI6<EM%-I:ZIZ6:=]59M)W/V7+<2\5@TVM5%<WK97]-;K6UORVZ***Y[
M75G\SJ/FO]IO2-5O_@YX]DTG0;?Q<+;PWJEW=^";BR744\;A4XT5ANR =I"[
M0<$JI '->5_L#_"36_A/^S?X,L?&>A6GA[QYXIEU'QKXPL;7:1IVJZRX:/2A
MU)>/0UBQTV'+') Q]1_$>QT_4? GB[2]3GM[;3M2\.ZI8W5S<\(O]LJ\9R/[
MH+'(').W PIQ/X"\/P>&/"GAOP]#//=6^A^'M+TA;NZNA?\ VT)$B$LQ.7.5
M^^0#L94PRH">CZT_JOU._7FZ]MOO\NRZ'-]4C]:>,25VK/17;[[;_,[X=!GT
MHHHK Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,@]
M"#^-+0 4444 ?'7[:_BL^#_V;_B=JOV/QK<6Q\-O::UJGP_NM&T_Q1H.F9(_
MMA'UYE4;#E6!5R1QE>I_FU\$V<'V#^U8)[:YT_7K/2[W1_\ F):G_9?/']N'
M'?/7UK]A_P#@H+\,_P!KGQW%JUGX1O\ 3/&G[/.K'PPNJ_#3PIX<(^)=GJ>C
ML6UP:QKK$C7_  ](5#F)3O7 # A48_E/#-;^;<6,$']FW&E_\?FDW=G_ &;J
M=A]-"_GTXZU^R^&&&P:<L7)PYKV2]WF2:TNF[IMK31:=]6?B/B?B<8TL)%2Y
M=[KFL]4]&E;9EBBBBOVO>]E=:[:_+2Y^*[;Z-=]-5ZVZF?J6FV.L1?8=5L;;
M4K?/VW[)=#_/Z^XJO\/O'VJ^ OB]X?\ @]I?A;Q'XCT;XBV6[PAI6E'^T=2T
M[QV,YT71-$X_X1[PX #G..E&L33PV%QY$'VFX_X\K/\ $_K]/\C]_P#]D;]D
M[X+_  +\%^!_$7A_1=%\1^-_^$2%I=?$RXO%\1ZGJ"Z\(]:UN+2==<EO^$?D
MF9VCV; RJJD\,K_S[XZ<,\(<5Y LISG)X^TDW:?LX\UUK=S<.;K=7EOY7:_4
M/#G)\5F>*^MRE:"W3DTK+M%M7T72/_!^;M"_8[^-^KZ"=<U75?"GA/4%&ZT\
M)W2MJF>__$[UP ECSP$W'MU(SXOXY\ >*/A?XB@\+>+SHEU/J>DMK&D:MX?#
M+IM]IB,588;#<$=<8888$J03]U?M??M4V_P(TO\ X1;P\=2?XC:O9Z??:26\
M.'4].L])+L=8UC<I"MK:H[@1LK+@J<;@6/YW>(_$7Q%^(_C'1_&_BGQ]_;0_
MX1TZ,=('AO1M,R6)9FP.Y))/<YW=^?\ .'Q9X:\.>$\G_LG!1Y<Y2TT5DK/1
M^ZM=$M&OF?L&98;!X6*NO>^]:)WTMIK:RO\ >+1##YO^?\\]>]9&O:E_8^C:
MQJL$'VG^R]&U2]^R'U[$'K^''O5^'X2^./%7@W4-<USXC?V9;Z]X;^VZ-I/P
M]T?^S=3_ .0+WUS\/ZYZ5^+\!>''$''[:RBR2=G>RLD[:WM96VO;R/'PV&>+
MVOOIY_/[O^'.'A_X5S-XCN/!UO!X2_X2BULQ>WFD_8_^)G_91_XGPY_P_.MB
M\\$^#M2ET^^G\*Z)]HTN\^VV?^A?\>&J>G^'Y\5XK^QK^S)X>^(/@G]HW7-:
M\1:T=?\ @YX__MGX=7GBV\/AO5!XFT+0W_MPZT /^*A\/>+- " YX"ECV%>U
M>&_%6E>*K#^U;'[3;7'_ #&-)U:S_LW4]!U3G_D._J/ZC%?1>(WA?G? *RJ7
MORNO>:YI:[.[7-Y[OLSIQ.&QF$5[R:?F]+=W^.^VI8_X1O0YI3.-#T3_ $K^
MU/\ ESZ_V[D:YZ__ *^N,&K$/AO0[/\ U&AZ);?Z9]LS9V?O_P#7]^G:MBBO
MR9XG&ZW;TWO?\==#SOK6,_F?_@7_ -L<M_PA_A;[5I]]_P (YHG]H:#_ ,@>
M\%G_ ,@$_P#ZNG^.:T9M!TJ;[1Y^E:;_ *5>?VU>#['_ ,Q0YSK7K_/I^6Q1
M2^M/^9_>_P#Y(?UK&[\S^_\ X)S$W@_PI-%]AG\.:)<V^/\ CTN[/UQCD=>W
M3IFNGHHK#ZS?1R;OOJWOI_,Q?6L9BK7?5;O>W9MA7B_[0DQ_X49\4.O_ ")_
ML/Y?Y/X<^T5\S_M:Z]XJT'X(^.!X<\.6VMZ?=:/]B\27?VS_ ) 6E_\ 0:S^
MI]:]#+,*\;C88'!VYIN,5T;E)QBM=/M21]+P;IG_  S=*ZXEE?37^'+Y_>'C
MSQYX_P##>J?#?PYX.GT2VM]5^&_]M7G]K6?]I?;_ /D >W;G/'7MS7F^L7OC
MCQAXC\/ZYXJ@\):;<:#9ZI8_:_#W]L_VGK^EZ[G_ (DI_7WYQUQ7,0CXC>)+
M_P #^(_$FN>&[G^PO#?]B_9-)T?^S?\ B5]1HO./>N_K_7[Z/_@+PYPMPYD^
M>\0Y4GQC)1G&:[249Q]Y;Z2B]S\5\2^(\7_K-G&"PG_/R:=]M9S37:]KZ?AH
M'D>_Z_\ UJK:/-KG@GQ'I_CCP!/;:)XPTK_ISQIFO:7VT77/3PZ/7/YU9HK^
ME<^R#)N(L%+!YOE$')PE",G"+=W&48Z\KEU7VD?#Y5G^<</8R.,P<Y*"E%M*
M<N56E%OW5)+H^A^LOP<^)\'Q?^''A_QU#9?V9<:G_H.L:2>18:KHA US1O?&
M1SUP3BO88CYRY&1D'&,YR/IG'/U_*OQX^$'QF\?_  4TO4/#?AW2?#?B7P?=
M:OJGB:TL]7']G:E8:IKW&#KG7GI^78U[CH/[;OB.#4#_ ,)Q\(_LWA_C_2_!
M'B3^TM3L?^X&/Q]\?6O\WN+_  $XXRO.<VED^4MY-SSFK>][O-*5DDF]NQ_H
M5PCXX\$9ID^4QQV:Q6;\D(R3NGS**B[N32M?37[]3S;PW\1_VO9OBCX(\'ZI
M!XD_X0^U^.^J:UXE\5W>C\7_ ,,-=).A^#/KX4[G'/!/OW'@_P =_&Z\\4^.
M()];\?7.L?\ "'_&:^\7^'M6T<#PSX#U71,?\*I_X0?UW=2><X&>AK[7^'WQ
M?^'/Q/A@'@_Q3IFIW!LOMAT@@:=XFL?KH?)Q_ATKTD<<?N./7_//X5^*YG'&
MX#%_4<?E,H2CH^:+B_=NK^\HO==?O/V_"9G@<WPJQF =.<;7O!PEJ[/[/-:^
M^C7D?EMX)^(W[6DWP^^)]AXWL/$=KXO\+> _A=]B\0:1HW&O#7-:QXX\9Z&.
MA\0KX<)(&" >0,BN@@^('Q$O/A9X?N+[Q'\6O#7A _$GQ1HVL>-AH_\ :7CD
M>&/[%(\#-CG_ (I\^(CM9NX ' Z_IE1Y'O\ K_\ 6KSO[3Z*-MUMY^AU>VCI
M[L;W36BW2LK?+1=+6TT5OA3X<?%+XC:;XV^!]A\6CK>FV'C/X0:I_; .C'%]
MX\&MC^PQK@'_ "+_ (A_X1SDKWY!(SQS'QA\=_M&6?PKN=*^&>A>(M2^)^O?
M%3Q/965Y:V0_XD/@70\ZX?09((4=\$CT!_0J:'M^'^?Y@X]B*L4WB;Z;[]+O
M5?UT[A;K?TN]-+_G?776RV2L<9\/O$L_B[P1X7\53V&HZ)/K^CZ9>WFDZL?^
M)G8:E@%M';Z$GIZ\]ZZOS_;]/_KU.1D$?G_.OG?]H_XRZK\$O ^G>*M)T*UU
MN?5/$FE>&,:M=_V;IFGC7!C^VM;]AC@#K^=&79;C,UQJP6"7O2>B>C;>B2V>
MK:77<\[,<QPF582>+QGPJ^MOAT;N]+:)WUMMII>_L.O>%?"GBK^SO^$J\.:)
MXD_LN\^VV?\ :UG_ &E_9_\ +I^G;C-?-_Q(^)W[.?P'O]0\.3^#M-N?&'BB
MS^VWG@CPGX/_ +2U/7M+_P"HW_\ 7]_K7A_BK]LSQCKWA+^RO#G@#4O!/Q N
M_P#0O^$AN[S1O$GAG0=,[:WH8_YF#TZ^_P!?E_6+SQ)XJ\4:AXX\8^([GQ;X
MPU2STO1;S5KNS_LW_B5Z%_S!?[#_ "'MP/I_47A;X$<>YGBX_P"L52ID62*T
MDHSJ)-:--)325U;HM[G\O^)/C-P=E>$E_9$*>>YU[R;<*;:;NFFW![-]7T^1
MC>,-8T.\\1_VK\,OA7XN\$Z?JFL?\3CP]=^)-&U+PS_9?&-:Q_S .._K6S11
M7][<.<.8;A;*%@\-FTIM62<W*;:22WDY/6W?J?QCQ%Q'B<_QCQF*RF,$[NT4
MHI7=]5%16E^W0****^G6U[_,\CY6\NP5Q]YX#\':E+<3WWAS3;FXNN;R[_Y_
M_P#ZWL<=,<]NPHI-:/3H^GD_(+^?X_\ !.7\5:;]L\&^(-*L8/LP_L?5/L=I
M:?C].U6/!VI0:QX7\/WT'_'O=:/I?_'WZ\_R]N.O8UP^IZ]XXO/&^H>%=*_L
M31-/M='^VV9\0V?]I?\ "6]/^0&<\],?6NP\$Z/?>&_"^CZ'?3VUSJ&E_P#'
MY=VOY<>V>G/MBN##)_7'H]'+OH=.*M]4NK;*S77YK?[V:&I8^R]OL_VS3/MG
MIG^V^/P^OX\5_5[X:$,OA?P]Y&/L_P#8^F?8^_!T@;01V(7/ZXK^9GX0>!/^
M%I_&/X8?#.>">XT_7O$>EWNL?9>G_",:'_Q/=<R1G SC)[=:_J"M;>"RMHK*
MVB%O;VULEK:J1T  4  ?[@/!Y.>@K\.\4\8J^;9;AO\ GW%SMKLKOIMM?9:)
MG[=X385K*LRQ5K<\E'S>E[+:_;J?AE^TAX;^)O['W[3&@^/?@);:G<>'_COX
MFTQ;WPG=W;+X&UWQX#G6M'UIC_R+[>*EV$2(<*XP"&7C]3O@#\7M6^+WA;6+
MCQ3\.O$GPP\<>%]7_P"$9\7^%/$)&HBRU08).BZXI5-?T%VW,)%55!.T@8&;
M_P :/!7C[Q?H/V+P#XC\(Z)K-J#=VC>+/#G_  D>F+JD;,NBZR 55AKJ,,(1
MG.[(^4AF^4OA;^V7J^A2W'A;]H/3/[&U[0]6&AZSXTTNS TDZGUW:UHJC=X>
M8@XR=RX"X Y)_+\?F*7+]:?9*3TOZNRU^:^1^PY)P]C,6\T^I*4[)2Y(ZR2^
MTXPOS-))JT5=W[H_3($<#.3T/7J.M#("<]/7OG]:X*S^('@B\T<>(8?&/AVX
MT KDZJ-8TLZ=QCCS@X7/L6.>H!KX0^*_Q^^*GQD^)7A'X3_L?^+]#MM/LM<\
M36?QR^*]SX>_X2'3/ VEZ*J(-$T8.4C;Q.\K,(P3M),; A_NB:>S3ZZ-/?T;
M[BQ$9X56G"2:=FG&2?S3BG<^P/%WB0^*3K_@+P1J_@C6O%VFW6E#Q=X<U^Y7
M41HGAG6PQ,FM:&I9B&0#:N25"^IQ7K=G:V]G%;P0X6"U7[):@<[1C!]CTQ^'
MIU\J^'?P?\&_#BY\4ZWX>LU3Q/\ $'68]=\>^([G_D)>*O$D&D)HO]L.20%+
MJ!\H&%4GDC!/M%,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M12'H?H:  '(S[G^9Q5<\#Z8_G_+U]O6@?ZH_4_R-?/O[2OB^;P)\'_&^MV>M
MW/AS4!9_8='U>V +6.JZPWRN3QG#9<'LQ!')R.7%XM8/"3QC5U"+DX]TDW;Y
MV>^UQX9<S45]II:]+M+Y[GOMN5?/'))Y!SZ?7_\ 4<\5(9WR, $9ZG&?YCCZ
M<^_:OR7\.?%/QAX=U31]<^%OB+Q9\4KBUM ?$GAX^)!XE\#:Z5;=KAT/7""/
M^$B#8(ZX(!^OL_P]_;O\+_$BUU'^PO /C0:SH))\1^'A=:1J6IZ#U^]AQN/;
M.?KTKX?+_$;AW$86>*Q\_P"QU%M-591>SDGK9?$U?5=='<]?$<.X[ZS]5PJ<
MMI747;9/K^C^X_0=2N> 1ZDG@=..OK^-+\H[YSC/S=OQ//3IZ?K^=^O?$SXL
M_$<?:(=4U+X7>%CC['I&D_\ ([W^ >-:UG./#V>>$&3W!.*Y"ZTCQ1/';FW^
M*?Q1MKFUNQ>VF?%QU#33J8)(R& ;:"6*G'!)QCFOD,R\>N",LQGU1U)R5]9*
MUM7OI=6Z[]CW<-P!G^)PKQ-H1ZJ#TEUTLUOI^+WM<_3B91W'?N<YR3S_ (]\
M=<U\=_M*_LD> ?VA-':_!_X0OXCZ4N/#?C_2+-!J=@ZC[FLY*G7]!/RYCD8
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M_$';Z?08'B_@_P -_&G6/!OB#2O^$<\(W.C^,_&&EZT=6\/>//\ B5W^E_\
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MWOH[%A.A^O\ 04^D''&?;^7^(_.ER/4?Y_\ UC\Z]D^""BBB@ HHHH ****
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M>&[#0?$NJ>&+P:MC-_J>AG&N# QQDX&?3K74_P#"$> 8;_3YQX7\-6NH6O\
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M1K'[*=U9)K%E\.O'MUX,\,Z\H-[I%Q9#Q%_89P,_V"LC@)D\A7<E1P6/4_<
M0@]0/3U_+_Z_>HB1T/?VZ_TKYW,>',FX@;EF^50FTT[M1;=FG=M)M[>AWX?,
ML;@U;!U))--64GRJ]ULWRWUW26Q\AZM^RGX1M-,@/PSG'@'Q-IEJH75+)/\
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M#\HEC6[N$7S-W;]R+^*^OWL_E/.XM9SFJP2>CL[+;WFNUE\K&AYW7R/^/?\
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MPXZX&_1170<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+PGXD_M+[?GOKFNX_P"$G\09_4#ZUYAH/@.^A^(VH>%? %CIO@#QQ\.?AO\
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M><8ZG-=]<Q0:KI^H65P,6]U:?8KO/!QT!Z_Y_2OAGQ+\??AE\'_BSJ'B*_\
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M2^WIO9ZZGDOP9^$OAOX*>"+?P#X6OM1U'2+36-5UNTNM6O#J6I9US6#KI4L
M.!DGMTS7J4T/^3_G\CCU!%6**\[$XIXII[.ZMTN[W5MF]>Q5E9];JS??2WH?
M,^O0WWA7XJ_$&#2OLWVCQYX"_P"$G\-W=W@_\5/H7_$A_L7C@#N/;TYS\WZ!
M\!_BW\5+74-<^.'B3_A&]8U3^R[VSTG2;W^TM,L-+_YCO\NOO[5];?':;X<V
M?@VYU7Q_I.FZE/:_\2;P?]J/]G:G_P )1KV-"T/^Q-;Z@EB3QG/7(X%:7@G1
M[[1_"/A?2K^?^TM0TO1]+LKS5N-2-^>G^?7\Z_T \ ^(L9G_  E]2Q?_ #([
M+U2LDWKZ=3^=N/L/_J_FW-A4O^%N_,[*RM>^Z5MGV.?\$_"OX?\ P]M?(\*^
M'--TVX^QZ797FK7=G_:>IW_/'?GM[CZUW&I7ECH]A<:KJM];:;I]K_Q^:M=W
MG_UL_P">*T)C!!_KS]G]/M?'3V[?Y]Z^9]-\'^%?C-KWCC5/'$]SXDM_"_CS
M[%H_AZTU?_BF;#2]!_XGVA?\2/\ YF#\O?%?T!\K?*Q^<XG%/%;MVV>O;RN6
M(=2\#_&#XH:/?6.N?\);X7\+^&_MWV2T_MG^S/\ A*/[:X_MS\>_Y^E?2%9Y
M_LK3/W_D:;IOVK_C\N_^)-IOL>/_ *^*\O\ &'QX^$?@G[/_ &[XXT2V^U?V
MI]C^R7G]I?\ ("_Y#WZ=?I2;2W:3\VE^J##87%XI7PBT6KTZ+5].R9T_CSPK
M8>)+#3]5_M6YT36/!MY_;7AOQ#:\_P!@ZIC\OUY K0^#/C;Q'\0O"_\ ;GB/
M2K;3<WALM'U>T_Y!GBS2\?\ (;T3G@<'IT[=Q6!\3O&'_"*^"-0OK&W_ +;U
MC5/]"\-Z3CG7M4UW_'\/TQ7H'PW\'_\ "!^"/"_A6?5;G6[C0;/[$+O_ )_^
M_P!/3UK^=_'/^QU_9=K?VPM7;MOK;R[_ )'[!X7K&WS-/_D4WLGY[/\ &]K'
M/_'&\\9:/\*_&.K> /#FA^+?$%IH_P!L_P"$>\5_\@S7=+_YCFBG@'H.@P!G
MOUK\=_#6)K"XOOL.FZ;I^J7G]M6?A[2?^)EIF@Z7KO\ S!>,8_/O^%?O!-")
MH;B _P#'N/\ )[ <8SZ9KX&^(W[&VD/%J&N? Z__ .$2U ?Z:?!&KW9_X0;7
MM4[X.,: #ZCCOGBNOZ/'B?P_P5FV9X+-[I9VXI6ORQ=XI6M[L=>R1\YXZ>'6
M?\:94L9D[CSY*G*,=.>I%*[M]J7N[_%9=-#XXHKAX/&%]YOB#S_ _BW^S_!M
MY]B\2>(;2R_M+3+#_L!_]#!X<Y_#GBNHL]2L=2M;>^L9[:ZM[K_E\M/7&/\
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MQ6+Q>,E*6+G*3DVTN9O=MJRV6C6WSON)L'J?T_PI]%%=1S678**** "BBB@
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MBBB@+KNOO7^84444!==U]Z_S"BBB@+KNOO7^84444KKNOO7^8PHHHI@%%%%
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M\AW_ #TSCUK[ \8>%-*\;>'-1\*ZK]I_L_5/^/R[M/\ B6:F/\]N/IVKY?\
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M_P  _73CU7\C_A]?S]A@X]5_(_X?7\_88_(S_AJW]M?_ *%7]G#_ ,'?C/\
M^+H_X:M_;7_Z%7]G#_P=^,__ (NL?]6>(_\ H4R_\!?^0?ZR<)_]%3PY_P"#
MO_M3]<^/5?R/^'U_/V&#CU7\C_A]?S]AC\C/^&K?VU_^A5_9P_\ !WXS_P#B
MZ/\ AJW]M?\ Z%7]G#_P=^,__BZ/]6>(_P#H4R_\!?\ D'^LO"?_ $57#?\
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MQ_\ !UXQ_P :#^U7^VNW^I\*?L\'COK'C,CN/Q^H]QWX/]4^)/\ H5/[G_\
M(A_K+PE_T57#?_@[_P"U/UTX]5_(_P"'U_/V&#CU7\C_ (?7\_88_(G_ (:R
M_;2_Z%;]G'_P=>-*?_PU;^VO_P!"K^SA_P"#OQG_ /%UC_JSQ'_T*I?^ B_U
MEX3_ .BIX;_\'_\ VI^N?'JOY'_#Z_G[#!QZK^1_P^OY^PQ^1?\ PU9^VO\
M]"M^SC_X.O&7_P 51_PU9^VO_P!"M^SC_P"#KQE_\56W^J?$EO\ D5/[O_M1
M_P"LO"?_ $57#?\ X._^U/UTX]5_(_X?7\_884$ CE>OH?\ #Z_G[#'Y%?\
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M=]$UPD+D=U) )&..<5WX66ROMY^GGZGGXF[ON]^[[BT445TG.%%%%%PVVT]
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M$%<G#9!)YJC#^TA;WGVB?_A67C_[/:WGV+[7]C/';GKT[=OI7[@?MH?LM_\
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M'-0U7Q%8Z)IOA>U_TW6/^)/_ ,2RP/I[\\]/RYKO3NKG#]5;?PO5_P KZO\
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M73K?0;JYU2\\!>+-3NTTUK(H2T8'F83_ (1_Q4Y+1ESM1R3E06S^5G_"T_\
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M.T?\-H_LK_\ 1>OA5_X6FB?_ !VC_6#)/^AU2_\ !M'_ .6C_L7./^A7B/\
MP55_^4GU1@_W1W[C_:_E_P"R_D8/]T=^X_VOY?\ LOY?*O\ PVE^RG_T7OX4
M?^%GHW_Q=._X;1_97_Z+U\*O_"TT3_X[1_K!DO\ T.J3]*U%_E5$LES?_H58
MCYT:G_RD^J.?0#KW'^U_+)_+\E.>>!W[C_:_Q/Y&OE;_ (;1_97_ .B]?"K_
M ,+31/\ X[1_PVC^RO\ ]%Z^%7_A::)_\=H_U@R3_H<TO_!M'_Y:/^Q<X_Z%
M>(_\%5?_ )2?5&#_ '1W[C_:_E_[+^1@_P!T=^X_VOY?^R_E\J_\-I?LI_\
M1>_A1_X6>C?_ !=._P"&T?V5_P#HO7PJ_P#"TT3_ ..T?ZP9)_T.J3]*U%_E
M5$LES=_\RK$?.C5_^4GU1@_W1W[C_:_E_P"R_D8/]T=^X_VOY?\ LOY?*_\
MPVC^RO\ ]%Z^%7_A::)_\=H_X;1_97_Z+U\*O_"TT3_X[1_K!DG_ $.J7_@Z
MC_\ +@_L7-_^A77_ /!-3_Y2?5&#_='?N/\ :_E_[+^1@_W1W[C_ &O\_P#
M?R^5_P#AM']E?_HO7PJ_\+31/_CM'_#:/[*__1>OA5_X6FB?_':/]8,DO_R.
MJ7_@VC_\M#^Q<W_Z%=?_ ,%5/_E1]5;?]D?F/?V[9_3Z9 .0=HZ^H_P[9_3Z
M9^5O^&T_V6?^B]?"?_PO-"_^+J]H/[6W[-_BC6+#P]X=^,WPXUKQ!JES]DTK
M2K/QAHSZC?,!RJ(K[B>O"C+'@9SSNL_R5M)9Q2;=DE[6DVWHK6]IK=M+Y@\E
MS=:O*JR2ZNE47?7^$MDFWV2^_P"GJ*C$JD C)!^G^-25[2:LFFK/9Z6?Z'!M
MH]&NG8****8!1110!5DCS&RYR1VZ<?4]1SC@?3M7Q%^WU\O[*/Q='KX?L#^>
MMZ&Q_')_G7V]PHX[ \=O7_\ 5^->,_&GX6:7\9_AKXU^'6MWES::?XOT=M%>
M[LP1?V8DY+QMSD[AGG'#,"><UXF>826.R3-\#A5><Z52-NG/.E4BDM].:2[Z
MG=DN(PN$XARG&8IM1A4IMR2UC%582DTD]+1NW9[)Z.Q^9GCOPWJGC#X&>*?"
MNA_9O[8\4_"QM&TC_L*ZWHI!]N,'CIWXKY0\;?LR?$:#P'\,/"O@CQ)XMUJX
MT#P'X\T;Q+=^+/&']I:G8>)]=\%Z!H.A:+HA/'_"._4Y&<FOM72_V7?VU]!L
M(=,A\>_ +6K#3+46=IJFL:1XRT_4[_30,?\ $[52Z@X!W;.N"6)(-6I_V=?V
MW\\^*OV>OPTCQGT&?0CK_D$\U_FM5\!/%G+L?4G@LJYHRJ5))V3NI3G)6:;6
MTOZV/Z6K<2\)XO$)_P"M*C9+3WDEIUO%-/RM=.Z;;U/A#Q5^RCXCO->\0:'X
M'\*Z'IO@_P 4?!/_ (5_K%WXAUC^TM,_M0:+_P P/G_A)_#_ (B'B/'?GK7I
M/C'X*>*O&O[+_P +_A+8^'/^$ \0:#K/PO\ [8TKP]XEXT'3/ QQKFM:'KGJ
M21QW/'6OJ?\ X9T_;>_Z&S]GK_P4>-*/^&=/VWO^AK_9Z_\ !1XT_P :TQ'@
MIXR8I_\ (IVL](I=F]K&7]N<)?\ 15+[W_D?%_C7]F_QE>?&GP]K<.J^/_$G
M@?2_^$7_ .$;\5_\)+HW_"3>$SH6M?V]KW]M_P#"0#./%GKCITZ@5D:/^RQK
M>@:I\'O'%QX T/Q9XQT+XD_%#6?'8N]9QJATSQUK.OG0M9&N>OA,#0S]!DXY
MK[E_X9V_;>_Z&K]GS_P3^-/\:/\ AG;]M[_H:OV?/_!/XT_QK;_B#GC*E;^R
M$]+?"NUNPO[5X2M_R52^]^6_N[[^1\$Z#^S?\8;._P##$^J?9OL]KK'@+^V;
MO^V#F^TO0M:\?'7<_P#@\T+\J\OO/@%\3?A]X-^!_P .?#?ARV\):QXG\8>*
M?A'X\/AV]&IZ9KWPPUS6SX[/C/\ ZE_D$$8['T-?J1_PSI^V]_T-G[/7_@H\
M:4?\,Z?MO?\ 0U_L]?\ @H\:4/P<\8WI_JMOI=I==+_C<:SWA*Z_XRI?-NW2
MU]-N_EL?/_Q.^ -Q\3OBUX7OKZ_UK3?AA:_"O5?!7B.T\/:Q_9FIZ]G6M!QH
MNN GGPZ!UYZYXQT\8A^!OQP\$W^C> /AS8W.F^$-+^,'_"P-&\;^'O&/]FZ9
M_P ('KNM?\3WP7XXT/\ YF'H?"XQV^E?<H_9\_;E[>(/V?.__,*\8GT]9/\
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M^'I_!^E6WPWT>U^)&J^-+/X3GQB-1TS0?"XT7^P3X,_MS'_,V?0=1[5^EO\
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M)WXHT+XG#7M>T4ZYC'_%6>&\>%SG\Z^N?V5_ACKGPK\$>,-*USPMIO@DZ_\
M$CQ3XTT?PGI.L?\ "2?V%X7UT?\ $CT7^W.^,>G R/<ZGAOPA^VAXC^'^K?$
M.#5/V>M-T>UL_$][9G5?^$T(O]+T/.-:) X!*\C.W. >2,\!X=U#]J[Q)?>
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MSK'A^YO1J#7VJ/K3!]:WLV-WB=,3<8.W P<J3[L8@.I_S_WS7*07=[9:A?\
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M^S7\2(M8&A^%O">G?V%9Z7K.L6GBSP)HWAL?V7KN/[#UO_B?[?\ BGOQX/(
MYKU$^%?@[#=6%C/X<^%XN-4&;.TNM'\&YO\ \O\ )_&OBWQ5^QK?#X:?#>#P
MK-J6M_$#0+OPN?B/::KXP/\ Q5FE:#HO]A?\(7HFM>(/^*:'A_PIDX '7/\
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M?A;P!]H\3ZQI>BZ/9VGAS1=2U*_U37>G_$DQD9].HY KXVO/V4OB;-YVM_\
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M ?Q(U7XF_#JW\0^)+?38-6M=7U71;RZTLDZ7J#:*2HU?1L[B$<M\O&U=A R
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M9%PRL0QW@;*Y'_@H+XAN/@IK6@?M!65@WBSX8_$2[\*^&O$EYI=W_P BD'W
M>--PRC>'QX=!#A68AL'@,N>'\<^!M6^%WBM?!.K7EOXATF[T4:WX1\4-:(=/
M\4>&2H8QN8WD3>H89V.ZGJK,I#'S+Q)XU^+7A7X?'X66/@WPC\;/@Q@#_A6?
MC< >)['^W-;) T371S_Q2620,\9)[FOP')^-'A,+FGAMQVW=>Y0E)ZV4FJ2C
M*6K6E/:3MZ;^EP5Q8^%<YAB\8VDI*+TO>#TM?2UM&GK;5;/3S;PA^U;I47A;
M3_CM9>%;FYT_P)\:SHNC^'OMG_$S\6C_ )@6M>GM^7T/[MZ;^T1X6U:Y^#-Q
M8"Q.@?&'PWJWB>Q\07=\NGZ?HPT/15D907('S,#&-[J ,_,@P1^(OANS\ ?$
MCP9;S_ ^#1/'_@__ (3S_A"[/^UK/_A"?$WPT^*&A?\ 0\:'Z^$_^AIXK]9/
M@3I'A#XF>%].^'/Q:\ ^"M2\8?!ZSTN\^UVEFI\,W?\ ;B.W]MZ"FT-H62H!
M4%FYRH 4FOW7POR[%99@LTPN(;=-V<)+6/*U[MFKK2+CL^Y^F>(V=\/<08K*
ML;@;M\OO<K6_+?7_ +>UU^>AZ!+^U'X<F_:0G_9HLMX\0_\ "&_VY::^W_(.
M'B<Y?^PBJ$KN7PX?^$F&W.?NY8\UY/\  ;]HCXHZEX<^-&B?%+PY;:C\2/@3
M>^)K/Q?>:/C2],U_5 S2:%HNAXVDAO#S:*6\4$D'<W!W/G[8_P"%>^"8=6.N
M_P#"+:-_:_VLZP=4^QJ=1.J9SYH.TON*X &_'(RH/S#Y&_:Y^,VF_L_>%[^_
M\*_#31/'OC_XBW+)?>'+@K8#7_#6B",ZY)K,C#)$?AW>HW* Q)+I\JU^@9CB
M\'E>$>,QDDHQLF[I)7[MM)?.Q^=?6,+^6K5M;K6^F_\ P31\'?M66VN?#'P_
M\1=5T/3=-NM5^*6F?#'5]*M=8!TW0-1UPKG6-;(&2J[EX)SEL@GDU\S_ +2G
M[<?A;Q/X[\:_LB?#J:PO_%'B?P@^/&FE7JZCIFG[B5UO165,@^(E4D*I. #E
MP9%4K\T_&OXO_!?XX^&?@#\._AUX>U/X<>#S\1]3^('B3P]_8YTS2M=&@Z.Y
M&-:)(5O^$B;:S#!<*"<  #SFS\8?!W1[_P ^#PY:Z);VMYJE]9^(K3PW_P 2
MR_U3G^WO[#USKQ^!K\>XU\4X96OJN3RA=I/GYHNSW;NI-=;_ "ZZGZ)PSP_P
MWB+8SB.HHP5VH<\%[NG*[J=]$G9+I+WEH@^,VI>.->T;X?Z'KFJZ;IEQI6KZ
M7HNC_P#")WG_ !4U_P!#KNM=>>/\!UKP?XY>"?'%G=_!?PK\.?$?Q:MKCQY\
M8/"_ACQ)XA\/>,,_8-+_ .HX/$'_ $-?;U[5[QH^IV/Q"\97'BJ"#6[;1_"]
MG_8OAO\ M;1_[-^WZIKO_(=!SWSZ>]=QKUG/J6@ZA8P06UQJ!_TVSQ_T%#_R
M L]/?N:_FO'>(V+QG'63XK.$L\4I025KI>_%*R2::6FR>Q\'QGQ-A<IXB^I<
M,R:R;;W9OTUM*SZ[G[9?"#X->"O@OX.L/!O@?1S!I%MJLFN+_:EX-0U ZIK3
M :SJ[.> [ALY&%X?H "?<RGRXZGM_GM_4U\S?LX?%O1/B;X*L9['Q.^MZMI5
MAIEIXDTK5;0:?XDT/5.,IKB;MWF<9&$((X#Y8K7I^J?$_P !:-XGT_P;J?B[
MP]IWBC5;7[79^'KJ\C75+U2.7 8@;!CCC>>P(QG^Z\'F>"^HT\6G&G&48-I.
M,4KQC9;Q2M>W_!/-^L_6U]:<OB5VY2U[[MZ_>NUKGIHXKSCQMXAUWPZWAA="
M\+77BJ'5O$.FZ/K!MKM;$:!ILN[=K#*>'6-B,@%0RX&<8KM!J-E*.;BV/L+M
M1S^!']>_O7SKIWQL^&?C;XT7/P<TL:EK?B_P=HY\2WFJ:98[_#6A,S!!HYUP
M/M_MX@;F4!3M))*G*UZ,<9@Y?\O(.]M$XO==;2=]^P]'V?W7_P SJ/AO\.?$
M/A#QI\7O%FM^,M0\2V_Q#\6:9K/A[0+S T_P?I6BZ*FB+HVB@ %5<*2W"\JF
M!@9'NO\ G\Z^2?VK?CAJOP!^#'B#QAH=OIUQXG%T-&\-G5@!I8U-A@:MK++C
MY!LW..,DH<D$K7$_L,^,_P#A-_A+?:M<_%/6?BWJ]SXEU.^UG7]8TC^S5L-4
MUQT?^R-#&"#H$90-&Q^ZW.1FL/[2PSQ?U-.TK:;VO^>X'W9111D>HYZ>]>@V
MENTO5I?FT 444F0.I _&F M%)D'H0?QI: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"GRHPJMVYSD]>_4>OX5G3:C;PRB*XFMX6N#FSS=+F\) SM &X
M8&/NEB>W%6IC]GB^9CST '';T_#WSGFOA[]I/PKXPU;QW\&+_P 'W.IPZSX8
M;Q]XHLWM0!IM_J6B:1H+)H>N;0/D\4!_+7." N3DY-=N H1Q6)^JN48Z:3;L
MMKWO)V5K7?E?KJ>+G.98O*\JEC<)ESJ-6O'=I==%=[)ZV?32Y]L0ZI;7<?GV
MQ\^ CJ,<?@<Y_/O3Y;O  \CZ$_CSQ^.!^)K\GO GQ&^,%IX<\ :59+J'@K^W
M[+Q1K-I_PD5D"3XG_P"$T(_L37?7 9AW'S'CFM[7_C1^T#X<\6:QX5^P:EK=
MOX8O?^$-_M:S\.?\A_5/'C ^!]9[X3PL5_>*/ED!;=DL<^@^%<4L4TLUA;5\
MO,DK:O>UO+]3XW#^(E!X3ZU+**J=[?#-^]JM-$[)_=Z'Z<_V[8PR003W%O:W
M-T/]%MKFZ +8!Z9SS]/<#!Z:,5V9G($&.V<X_7N._2OR>U;4M;\-^-);[Q#X
M<;Q9\7O^%HBRL;7Q'HVMAK[P%A=NL^"=;T,?\(YX>;'7> P((D&ZNHT;XI?'
MN\TGXC:H+W[-J^EVGB>R'A^[M&.IZ%J@UK^PM!.B:+G+#J26)W,><YY'PX[7
MCFL;VOKHF]-FDVUK>]K/2VKTVP_'DGIBLHJ:Z*T97MT=DG9[/6_FW;7].)KH
MPD$X\C&"1GCCH/?/Y=L 5G#4+<1-,)[<0'G=]IQP1V(XZ=NO<#K7QAH6H_$B
M[^$_QUT3Q?>ZAXCU?PO::M9>'M5-F=-U._!T-B" !PV_')Z@MW(QXOIVC^*(
MO&?@[X46]EXC_P"$7^)MCX&^)EYJX.=+T#^PM&'_  D&BG //BLI@@<@@@C/
M3##9.KS4LS5HRMJHVDDD^973NDFU;1W35]F=^8\52PL<MQ4<JJ/G3T2DVF[J
M*?*G;IOWOY+].+/5[&^EFM(+VVN+FU7_ $I;:ZY4D>W(XX(SQTZBM?EL!E/'
M?I^..G^3@5\7?LM^$/%6D2^-_%&MV>CV=AKOB7Q,VD%+/51XFQ_;3G_B>F0,
M",KR$^8':<@$U]G^:K#B;H1D$$9YSGE>G^37/CZ$<+BI8524K:.2Z-*[7NNU
M]=NESWLFS+%YIED<7B\N=.4FVH]6F]'9V>UM5T1>HJOYT/\ SV_\>/\ A4N\
M>A_3_&N$]A#Z*9YB?WA47G0_\]O_ !X_X4#+%%5_.A_Y[?\ CQ_PJQ0 44S>
M/0_I_C47G^WZ?_7H"Z[K[T6**K^?[?I_]>K% !1110 4444 )@#H /PI:**
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MKH65WX@M-&U8^"DU,X8H=='F1D@\'!9#C@L,-7C_ ,%?AOXDT[XM?$V]ULW
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M330^0Q&6O"XVZO9N^BTU?DK>O^1^AOPQ_8=T33?A-XITG2_B9X_TR?XQ^$/
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M<UOJ0"ZY(!&2,D$X/Z:?&K]B[X/?M!R_$V?XBVFLW'_"V?AOIGPR\2+9W_V
MV6E:%K!UO1=8T0NI?0?$"2.I,@VMP%8#G=L^,?@'X%^*7P?T?X(6WB7Q5HMA
M\,-5\#6ECX@TI]OB2RU/P)M.AD/AN/NDD ]<]#FOF,R\+N$,WQ;Q>-RJ-WS7
M:Y;J]U=]M6WY=3O>&X?:RSW7=/W]+W3NY-6UT[.S?:Q^,?@/4_C#>7_Q?\ ^
M,/AS;7/Q?^"6KZI9^+M)\#WG]I>&3I7]B_V]H6M_VYX@(_YEP_ID=:^O?^"<
MWQX^(MAX(^!7PY^+?PDT7P#<_&GPAX[\9^'/$&DZQ_:&IZYJVA:ONUT^-M&P
M"/$3(X#%3C'R\'>#^AOPD^ G@[X/^&_%.B6=SK7BF^^(>L:EK/CSQ7XLO/[2
M\1^+-5UM1HKMK,C!=R&,[00%"A7!!YV^<?"/]C3P-\)?'&D^,K?Q1X[\6?\
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MIKSU33UWZG\\^O?#?7/ =_K$'CCX<ZWX;U#0=8^Q?\)9I/AK6=,TR_TO0O\
MD!:WH>N>'^N/2O3OAC^U]\1?A]IO_"$Z'XQ\%>-M/TM=NCCQNVMCQ)CKG^VB
M=OB!L_Q?>QQG%?M'J:)<:!>B=5F!#Y$JB0'#KCAPPX[>E<%XL\#>";CPO?PS
M^#O"TT7V(_NI?#^DR1]#_ ]HR_I7X3F/ACBN'\5FV+X=XRX@RJ3IRJNG"LJL
M-8RFXVDVK7T^&UNAXU6C]1YGAY.-HRD[W=[7;MK]Q^5$/[1OQ\@\0WWB>'QQ
MI]N-2NP+KP3>:0VI^"+#2PNW^QM#<DN6VDY?=O;)RV3FNQ\$_MQ?M,^*_$>L
M:7?^ ?@'X)T?0?$AT7_A(/%OQ*.FKK^E$<ZUHF@9_P"$E(] 0<=0,U^@$?@K
MP:&CQX2\,C'3&@Z5QR>G^B4Z7P#X%N+RU-QX+\)3GUF\.:/*?O-_?LV]!7RW
M!/$O$F%QW+F.;ULV3GROZQ'E;NTFW:35]?ON<]'&8A:N2:NM+/K9]?7H;&D:
MK\3/%$_@;6[./P;;^$+JUUAO%MI::N_B._O04 T/6/!FN1!(G3.YOWV>6&#N
M :O<*X7P39V>F^!_#5OIUK;6%ND,!6"R@BM85+-(&*Q0)&@+  $A1D 9Z5Z%
M7].X9WBGWBF_5J+_ %/H%MZ_Y%>:'S?\_P _;IWKR+X5^%M(\%:/J'@_0O!U
MOX+T'1/$.JG1[2SNQJ&G:@-8/]NG6!G!!#R$$.P*.2/E.:]EHKILM=%KOHM?
M737YW'9=E]R_R,V6R@FB,,X%Q >MM<D$'L.2 3[9XQZUS_BKQAX4\":-<^(O
M&.NZ9X;T"T ^UZMJUX-.T]2PQGDD<@=\\#J>:[*O-OB%X8\->+/"]K8>*O#V
MA^); WNF.;+Q!I-AK-H7\Y!N-MJ-O<PEL$C=LS@D9YK#I;IVZ?=M^ #?"_Q-
M\#>-H=/N/!^NZ9XCTW7K,WVE:OI3F_TR]3DDAUQ@8&>2..I4CC6M-=$4=A!X
MD&GZ-J^IW>H6MEI1U16%\5+9*':26('& 2A(*_> JOX*T[3](\*>&;+2K&ST
MRS5$Q::?;0V5L,^9G$%LD40S@9PG.!Z5SWCG3M/N/%_PPN[BQLY[NW\1:G]G
MNIK6"6X@_=*?W,SHTD7//R,O- 'C&L?M6:3+\>]-_9S\$>$/$OBOQ=:A;SQY
MJN5TK3? GAEL#^VV;70HU]B2 HCVC/=@<#TKXZ_!NQ^,WP<^)'PD-[;Z'!\1
MO#FJZ)JVJ6UH"V-:."W4DY/4DGC:3C=7?:5X:\.0>-_$VNP:!HD.MW$&D"XU
MB+2K&/59QY$IQ-J"0"[E&0#AYF&0#VKO:4TJR2DK*5MO,#YI_99_9W\.?LK_
M  ;\,_!?PKKGB3Q)H_AC[?\ 9-5\67O]H:M>%GP=S9X&-I"C!X;DAAMZ[XO>
M-O W@7P3JVK?$2[MK?P]<6O]BW=J]F=1-^=9W1_V4-& ;S&D0@ %AE,EF&<'
MVBO%_B#I>F:LW@S^U=.L=3QK Q_:%I;WF./^GF.2O*SV7U/)ZT:$5%6<6F[I
M\RDG=;/276_W:&%[J3WLG:[?FOU/Y\/@UXJU7Q7IGC#^U+>VMK;PO\1_$_AC
MPV/L?]G?;_"^A:U_Q(QKFAX&0.@/_P!?/["_L(0P_P#"J-?N,_:9[KXC>*OM
MMUC_ (_SN0CGT'(_EQ7J&C^!?!-O]I^S^#O"L&-4D(\GP]I$6"-N#\EFO3MZ
M5Z?X T[3])\-K#I=A9:;"=3?,6GVL%G&?G0<I;1QJ>"1R.AQ7\^>%O#^#H<8
MYMBX7YY.4DK6M>3OJO72UCQ\OPZ^O?6+^\U+2W35?+Y'J=%%%?U">^%%%% !
M1110 4444 %%%% !1110 5F7%_\ 9I/+$/09[XY ]!^M:=9L_P#K6_SZT ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Y G # 2(  A$! Q$!_\0
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M/K_]?H/8U^R7[/O[&?P%_9VTBWM? _@O39]=16%YXSU^SCU+Q+J+'^*21U)
M QM"%,9);?T7ZJ5>3\[-ZYSC\CQ^E?@.<<?93/%-X+A/AR,4VHMP:DTG9.RO
MRMZ-)V=^B/\ 07AOP5XDPN"B^(O%/BB>;M+FE&2LG9/?J[OH_0_G8U?XW_\
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MW6C]R&G3K#3\#Y7_ (C]XS*__&5\3JSY7[UK/LWS*S]=5O;0^_O^'F7[5O\
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MTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?S%_\%@O^3B?!W_9.6_]/E?E'7ZN_P#!83_DX;P?_P!D
MX?\ ]/CU^45?W!X;MQX$RIZV2;\M%?TZ'^'/TE4Y^-'%,$[>TJ0C:^C<Y0CJ
MKV>LNJ9W_P +/A-XB^/OQ4\$?!?PJ<7_ (QU@G6;RUX&G^%ASKNM'_ZV/>O[
M*/@O\(O!?P-^'7AKX:> M*MM-\.^&;)+.)+:U1#=R  '4W*ELR,X))!8#) X
M4%OPN_X(N?#&RUCQ=\;_ (T7M@+FXT(Z7\/O#=WG&W@G73CN<X&..N<\8/\
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MKY7U/UL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCC&,G"@D+@'YU7^2[6=1OM>U34/$>JSW.I:QKVL:IK>L7=Y_R_ZIKO7TX_\
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MJK&W7:S]5:WGL?SL?\.A=5_Z'*Y_\ C_ /$T[_AT7JG_ $.^H_\ @&*_HG_
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M:-G^=W_V-'_$3^+?^AH_O?\ F'_$LO@W_P!$FOP/YV_^'16M?]#SJ7_@'_\
M6H_X=%:U_P!#SJ7_ (!__6K^B39_G=_]C1L_SN_^QH_XB?Q;_P!#1_>_\P_X
MEE\&_P#HDU^!_.W_ ,.BM:_Z'G4O_ /_ .M1_P .BM:_Z'G4O_ /_P"M7]$F
MS_.[_P"QHV?YW?\ V-'_ !$_BW_H:/[W_F'_ !++X-_]$FOP/YV_^'16M?\
M0\ZE_P" ?_UJ/^'16M?]#SJ7_@'_ /6K^B39_G=_]C1L_P [O_L:/^(G\6_]
M#1_>_P#,/^)9?!O_ *)-?@?SM_\ #HK6O^AYU+_P#_\ K4?\.BM:_P"AYU+_
M , __K5_1)L_SN_^QHV?YW?_ &-'_$3^+?\ H:/[W_F'_$LO@W_T2:_ _G;_
M .'16M?]#SJ7_@'_ /6H_P"'16M?]#SJ7_@'_P#6K^B39_G=_P#8T;/\[O\
M[&C_ (B?Q;_T-'][_P P_P")9?!O_HDU^!_.W_PZ*UK_ *'G4O\ P#_^M1_P
MZ*UK_H>=2_\  /\ ^M7]$FS_ #N_^QHV?YW?_8T?\1/XM_Z&C^]_YA_Q++X-
M_P#1)K\#^=O_ (=%:U_T/.I?^ ?_ -:C_AT5K7_0\ZE_X!__ %J_HDV?YW?_
M &-&S_.[_P"QH_XB?Q;_ -#1_>_\P_XEE\&_^B37X'\[?_#HK6O^AYU+_P
M_P#ZU'_#HK6O^AYU+_P#_P#K5_1)L_SN_P#L:-G^=W_V-'_$3^+?^AH_O?\
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M>SOWT['[)D/#N4<.93#)LFIJGE4;<D(\NEK*RM&*5K=$MAG_ "R_S_=JQ0.
M!Z45YY[@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 5Z*L44679 5Z*L44 5Z*L44 5Z*
ML44 5Z*L44 5Z*L44 5Z*L44 5Z*L44 5Z*L44 5Z*L44 5Z*L44 5Z*L44
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M ?*.I)].^3TZ]/?O7\]'_!#'G3OCL!][^W?#>#Z'[-<XS[?GR:_H7 ( #/\
M,2,#'OU/7 _3VP:_7N'L1/%Y12EB7=RYF[W::;T:ZZ6O>^[T/]:_HV9EC<X\
M&^$L=C\QE7JU*<^:4Y.I*7+)1Y7.;E)W=W>[O>_4MT4@Z#Z"EKV3]Y"BBB@#
MX8_:!_;F_9V_9JUO1_"OQ7\;C2/$&NVAU>SMH=*U>_WZ:C%2V8HW7G!Q@#I]
MT'FO#Q_P5_\ V) A8_$J4$]0- UO'KU^SC/K_P#6S6!^VQ_P3-\.?M@^/O"W
MQ$N_B%K?@O4?"^D-HUGI-EI&CZBH)8LS%F)*Y8DXR<#VP3\>1?\ !!3P\(X
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M]!XIM[;Q/XR\=ZGX+\-^%;PC3=*.J-D'6>"6\0$8&<@+AEVLQ#!?6=-_8/\
M&/\ 9>LSZYXKTW^V+3^U/^$;M+2S_P")9KWX_P#,O_C^=>;Z/^S3X_UZZ\GP
MYXJTVY\'^%_$@^QZM=W@TW^P-4XU_P#MK0]#_E_^JMC6/@_^U1J4OBC7+[X@
M?\))J&E_V7_;%W:>,/\ F%Z\,_A^G]*_/\/A_P#9+Z^>K\S^*\MR/ Z?VQPK
MQ(W;[/+9M:77J]?1HOZ1^P)\</$@N)_#NJ^$];ML&RO+H7FM::;'4QZ#Q!R3
M[ '/ Z]<#X;_ ++L_C:UU#S]<^S:AI?Q4\4?#'6/[)L_[2TRP_L+1?[>_MK7
M??\ SG&#74>*O@S^TU9RZ/KD'Q;N=;U#5+/2[*RN[3QC_9NEG_H!:+H7_4Q
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M\BQ11106%%%% !1110 4444 %%%% !1110 4444 %(>A^AI:0]#]#0]GZ/\
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M>_Z#O]A_F,^O?BL?QY\'_P!HSP3X(\4ZYXQUS4O^$/M;/_BI+3_A)#J7V_\
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M]*_GI_X(6_\ ()^/'_8<\-?^B9Z_H63^+W5,?I7[5PU_R)LL7_3N5_O2U/\
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MY_M^G_UZ//\ ;]/_ *]/V_E^'_! L457\_V_3_Z]'G^WZ?\ UZ7UB/=?A_\
M)!9]G]S_ ,BQ15?S_;]/_KT>?[?I_P#7H]NNWX?\$=GV?W/_ "+%%5_/]OT_
M^O1Y_M^G_P!>CZPO+^OF(L457\_V_3_Z]'G^WZ?_ %Z/;KM^'_!'9]G]S_R+
M%!Z'OQ5?S_;]/_KT>?[?I_\ 7I^W\G]S$_-'F7Q<.SX9>/PH("^$_$/7J?\
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MVMI_RX>OIW/MCCUS1K'QL^)NO:-K&AZYXQN=2T_7O^/SV_R.OTSR*_KKNO\
M@G+^QS;VTT^F_ /P+<WP0FVMA8E<L!R.9& &/F.00.F><CPC]G_]@+]GC6?#
MGBC_ (6%\$_ VL7%KXO\56-GJUO&9 =,.L_+HV!)&?E/)&[G.,@D&C_4G-;V
M_M:&O7I\_=_0/^)//%RZ3\0='UO)KY_\,]T?R]Z]\6O'_BKPE;^!]=\57.I^
M%]+O-+O?[)S_ ,Q3N?P_*L^'XJ>,;/4-8U6#Q5J5MJ&J>&]+\,7EU]M_X_\
M2^O]B_UZ^OUK^QL_\$WOV*Y>?^%">!??_B7.>?PE^O./7FI!_P $Y/V,NO\
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M^GZGI5CS_;]/_KU]<\1\_.V_XG]W?=\MOEY=O*Q8HJOY_M^G_P!>CS_;]/\
MZ]+VZ[?A_P $=GV?W/\ R+%%5_/]OT_^O1Y_M^G_ ->CZPO+^OF(L457\_V_
M3_Z]'G^WZ?\ UZ?MUV_#_@@6**S_ #_;]/\ Z]%=%GV?W/\ R%==UKYK_,T*
M0\ GT!JAY_M^G_UZ//\ ;]/_ *]*Z[K[U_F%UW7WK_,EE.0#CDX!/T!QW_SS
M7\V__!=6X\KQ-\"R#P+?Q. ,'H(U_G^/3L#7])/L,8(..>GK^&3_ #^@^=?B
M_P#LS_!?X[W6D7OQ6\!Z#XRET%V;2+C68F?^SRYSF/;(@^8G)SNZG%>3G.$E
MFN"E@\.TG*UI2YHI:M:.Q^4^,_!.*\0N!<VX.P<U&6=I+G;TC;=Z*3T=FK+I
MT/X4_.@E]#_V^8_SC!JQ_:4_^D?Z?J7^E9^V?\3@_P"G].HYQ^?6O[0_^'<O
M[&F/^2">#O\ P7RX_P#1W]:X7Q__ ,$\/V5],\%>)9_"?P%\"_\ "06NCZF=
M)%Q&5%F2CYU<%I7("_?Z%B!@' ;/Q&'X QG_ $-UUT3;:WTVWZ+;<_@%?08X
MYP6N"XNA%[V4Y*W]W11T5K/7:[/X]I]2OKS]Q/?7-S;VH_X]+N\Y]3_/'?'\
MCS8?7]3_ (U_6W\ _P!@']EWQ%\*_"&J>-_@OX(UW6KC1]-+^(+.TU7.ND#(
MU=@SJ59@0PSQP2Q4$$^T'_@F_P#L9<_\6+\'VY)P/W+G/MQ*0.^?SI8C@#&-
MIO-;[;WN[-.VSW7F<^(^@SXCXUK%SXLX;EWC*524FKI-:\WO-::=6?FI_P $
M*YLZ=\? >^M>%P?QT*0#I[D=!R,Y%?T+HF$C]EZ]_EW8_3I7S]\&_P!F[X.?
M &/68OA1X%T?P8FO7AO=6&C1M&;^_(."Y>1R6XZ *N>=HQ7N,TWDQ>>.V 3V
M/YCZ?3H:_0<LR]X+!QP2DI-+=7:UW[-/R[G^AO@]P5BO#_P]R?A'&2A*>21<
M>:,FU+FU=KI:7;:MT?R-#/[S..V<?\"SBOQ"_P""6G[>?QI_:Z_:=_X*;_"_
MXHG01X6_9<_:-TWP#\*TTBP.G:I9^&6T6?='K4D;C^V7=HA*99!U& I9TD/D
M/_!2/_@L-\0_AC\6=5_86_X)V_!/Q1^T[^W3=V>FV>M16&B:L_PS^!B>(2O]
MB:]X[UF6./P[YBY++$+B)#M D8#@?RE_\$R_VB/^"S?['G[2/[>GQ]\,_!FT
M_:GT#PM\<]+M/V__ (9^'CI6I^([_P =K]I=_%G@U=!0G[3X7C&L&&6V(A1!
MB=-TDTL'=HM-=/\ (_3_ &&)WTL]5JM+O_+0_P!-BBO@?]A#]O?X(?\ !0SX
M&VGQN^ E]X@32K/5Y/#'CKPIXMTAO#WC?P'XYT,*^N^#M?T0_<U]7)5@CLA4
M*P*E@D?WQD#J<4#VWT]3"68K"-K*2I.&)"\G\>3D9Y'M@]0D=T93N:2-3SDL
MZCGTY.,DC'X<XQBOY;/^"X_[27[0?P2^.WP=\-?"SXO^,O 'A_6_!.KZO=:1
MX;O?[/74=0_MA2C<C@D,<C&.W<U^-GA#]J__ (*%_$.34+?P3\7OB_XMN-,L
M_MMX/#]RF+$GIQ@@\Y_7ZU^<YUXC83)\X_L:65RG).[<>5WT3NK))*W1*V_9
MG]S^%_T">//$[PVRCQ7I\?\ ">0Y'GD?<^M^V@XR4YTO?O*T5SQY>;FN[IWU
MC?\ T*]T9^_<HH]Y$^N<9'MBH,QC[ERC9(Z.A/X $G@=N/;W_P [H_MU?MI_
M:A9?\- ?%[[0+S[$+3[0O^G9[@[<CWP1QW-+J'[;_P"W#HU_?Z7JG[0/Q5TV
M_M;P6=U:75RF!JAZ:,"!Q[$>V#7E5_%:-_=R>J]=+J_6R^S<_35^S&\17AN9
M>+' KBTG_%J7Y&EK+]Z[1L^_+9ZM79_H@%Y0,QLHF.,!B%/)_P!K'UX'/;C.
M;(N)DCXBZ9(P=P(].G7CIGIUQTK_ #O]3_;;_;DT*_N-*\2?'SXKZ=J'%Y]D
MN]74ZF!V'Z=OT'->]^&_VTOVMIOA)X7U:?\ :%^)']H77C#Q19?:_P"V.NEC
M^P"/Z_CVK[KPYXB_XB5Q%'A' Y;*&</5WUBE9/FNK/W5KN[69^,_2,^A%QY]
M';PR_P"(DYUQ7PKGV2:/_C&7*4M6M92;<;.[U6[O9W/[N+[2]/UC3;VQU.QC
MN[#4K1K2[M+I5Q=V#K(#I;#S%;!#." =QWD;LDD?D/\ \%8? ?[2-S^Q=J'[
M(G[!O[-/AOQOJ_[1=KJ?P6U:\M[[1? _PT^!/@;7](:/7/&6NA0BLN65(D ^
M9CN(>0JU?SCZ/^V-^V7K&J:?H>B?'?XHZGK%U>?8;/2K36-9_M._U3^?\QTK
M?\8?M0_MW>"?W'C#XP_&+PW]JO/L=E_:VKC_ $_IR/T_+BOZ3_X@7G$6E+BC
M#Q2:;4H25FFDTTVE[JNK^3Z7/\^%QMA+)_V7-Z)[;Z+RZ[G[G?\ !&;X4?M6
M_"']D<?\$_OVZ/V:/#GAJQ_9N\-:/\/?"?CG1=6T/QM\)/V@?A_KR3R1OY;1
MLQ\1^%VW1>,XY5(\QP47<'5_VWT+0M+\,Z-8>&_#FGVFAZ#HEGI]CI&EZ99I
M8:;8Z;&F(]-TH)Y8"@1@$*1MW1K\K8"_PMS?MF?MI0V%OJW_  O?XL_V?JEY
M_8NCW8UC6?[,O]4T(_GZ?S.3BJW_  V_^UM-+^X_:,^*/3'_ "&/P]._'K^'
M;MCX!9QBW_LG%7##=K6N_P 5>]^CLM^O07^ON$O_ ,BJ:6FS2VWZ/S_I']Y1
M:9!^^:., _Q<?3/?UY)'?%-%Q"Y \R(X/7=CGC( S^A_&OXN/A+^UW^U#J7P
MY\8:K??'#Q_<ZA:^)-,LK.[N]8YL/K_]?I[#%=Q/^TY^U1#8:?JL_P 6_B1;
M:?JG_('U;[9_:6F7_?\ EC&/;N*PQ7@%FV%5\9F_#B?>,K?/6-_374_!.._I
M<<*<%<1?ZN8O)Z]2=MZ:D[M*[24:<M>BUWL?V*>=$3GY<D^O<_\  O\ /XTH
MF4'HO7U/O_M?3]:_CJO/VJ/VI],E\C5?BUX_TVXSI=Z?],_X\-+/T[_7KZU8
MA_:6_:NO+"YU6#XF_%#^Q[;^U/\ 2_M@SP>.>_MG']:X/^((9HW_ ,E/A_G!
M-+7OV6GRN?'T/IQ<*8BZ_P!4.*ERW_Y=R2:5]5[B>R=M-K']A_G@?_7_ !]6
MX[_E[57W#_GN/R_^O7\<$/[6G[30BS_PNGQMSS_Q^?3_ #S^E=QX5_:B_:,O
M/"_Q0GG^,7C:YN-+\-Z7?6=V=8_X\/\ B<GD#_#GKQBNY> N:VNN*N&7?I=-
M^G7WNGJ30^G)P1B+K#<)\4QM>ZDG&[3=U[RCNU9G]=WGCU_]!_QH\\?WO_0:
M_CIB_:C_ &J)M+_M7_A;?Q)&CVMY]BO-6^V>IZX_GV/UJO-^U1^U#9VAOI_C
M%\2+:WNK/[;9_P"F>N/Q_E7(_ W.%OF^'7GLO5>^M.JTV!?3AX4E=Q\/^*YI
M;N,927WQA)*_J?V.&=6_B!(^G\@1W_PI/E'&Q>,X^9>,^_6OX\]-_:;_ &KM
M1BN)['XJ?$BYMK7_ (_-6Q_QX<_AZ_7]:R(?VM/VFO\ 4?\ "Z?'_P!I_P"?
M3[9_4<\YY_E4_P#$#,U6W%&'].6^O79].A6'^F[PIB$[^'W%<5=MN46EI?6\
MHQ[:^1_8]YPY*XSR<XSC.?\ :X^O^%-)C/WF4GV; S^?L/RK^1KP'^U/^T7J
M>LZ@+CXT>-;JW'@_5+[_ )"XXQT/IGT/;J>,5R%G^TY^U1-:W$]C\6OB1J6G
MZ7_R&?LEY_:7V#^W.F>,_B?<BFO S-D_^2HPZU6O*UZWVTO;Y7O9I(C$_3DX
M1PML2N$^)VWHHI)OM;E2=_N/ZMM.91\;O$T^1AO FEJ.1M/_ !.">.3V!]1D
M5Z]N2.+AT)'H1GJ,]^<].G?KFOXX_P#AI;]IJ&(ZY!\5/'_^E Z+_:WVS/\
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MU=:[-'?_  ?^/%C\*_"^L>')_"MKJ5Q=>)/[:L[O['_QX#'IV_0#T-?2&O\
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M.*]G%REH^5:0=I25O+F?<YGXJ?$*#XJ>+=/\50:'_8=Q:V>EV5Y_H8_T_/\
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MEM.=0IK1:7YE!/;7?4["R_Y)AX@_[*1I?_IGKW#X8_M+0?#WX?>'_ \_@?\
MX23^P=8U7_B;7=G_ &E_Q*]<UH_\27W)_P XP#7@]E_R2[Q!_P!CYI?_ *9*
MY?0;R#1]?\/ZY/ +FWTOQ+I=[>'_ + 6M>WT/X]1UKZ#,LMPF)P>F5--=KK5
M7[6_7_+Y++>(<5E>;95B\-%)77-S04HQU5^92BTU%MM]TFC]#]>_:N^'/@DW
M_AS_ (4];>([>ZN]+UK^U?$.CCPW_;W'_$]T7/B ''_")\<\C';UXC_AKK0_
ML%QH<'@?6_%MO_;&J:U9Z3=_V-_I_'_(%_#]/TKIYOVG/@3J6L>?XJT3Q;XV
MT>UO/$][H^K>(;+1O[3_ .)YUT7U_P"$=\*=<Y/;KT/G'B3XG?!WPWXR^!'B
M/P=X<TW&@_\ %:?%/_A';/\ M+_B:#&@_P!B].OZ=Z_/_P"RY)M?V14U;_FM
MU>[O;:VR2;26ES]FQ'%69^[C<+QUPKT<H?ZMPY^71RA?DUE;FC?O[QT'BK]K
M7PY>6&H>'+?X5_V;<75EJEEK%WJUG_Q,[_2]=T4]^OX_GS7Q_P"%O^07XO\
M^/K_ )%L?\??]/?^N:Z_X[^.]*^)OQ4\3^,-#L;C3M'UV['V*TN_^):;_'']
MM'\..O7D'-<QX6_X\/&'_8M_X5]OE>6X7#8.+EE+4G9M.[Y9-1;5^J3;5[+:
MZLC\>XCXCQ6><09IR^S_ +(4;J4%"FI22OS1C%1LI25[*]E)(](^"GQL@^$M
MKXPL;[PY;:W_ &]>:7K5G]LQ_H&J:%HN.O\ AT^F:^EX?VHO _AOPYX>UR^^
M%=SXDU#7K/5/[8L[O1_[-TSPEJ?.=9/'_,V9'3GC/M7YT30YBN.GMV[]NO\
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M:VK_ %W^[7^;Z7_@CK\:)N?^%F>"_P#OC7/_ (G^@_6J'_#I/XM0ZG8:'/\
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MZ?Y_R3^=%% K+LON7^08'H/\_P#ZA^5&!Z#_ #_^H?E110,,#T'^?_U#\J3
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M?>O-X88,_P"HXY^O^>@_IWK!\<8O5O*TM[N[\_/IJSQLR^G+Q=E6*Y<;X?\
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MY?FK\-M!T']BWP%+J%C8>(_"6MG5+,WO_$VO/^$D[XT+6N?^1?X_Y'CPL?\
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M>O<YQ7]U6GMFVM5!QA% ^NT=![5_"[^S3>?VE^TM\%[[K]J^,'A>]-I:=_\
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M3XH\4>*I_C#\5K:Z\4ZQJFM75G:V_@Q19OK@)=5(\,L2%P>2H;KD 9-8*_\
M!#/X*'[WQL^,*_\ ;#P@3^GA;^M?MT.GXM_,UIP_=_SZFO)EPWDCCS2R^C+G
M=W=-[W;ZV>[W1^'/P&\&LVQ[Q6+\/,AG6J2<Y35*JI.<I2;DW&I%N3DW*^]V
MVFM#\.(O^"'7P:A_U'QS^-5O@_\ /OX,!'('?PS[C@_D<BG?\..?@Q_T7/XV
M?]]^#/\ YF_<?KUXS^WC=3]3_.A>H^H_G6/^I7#/Q?V5AKVO?D5]K[\K?XGM
M_P#$N?@]_P!$9@4NRQN=V7R_M:WX6/P[_P"'''P:_P"BZ_&O_P !O!OO_P!2
MQ]/U].;'_#C[X-_]%Z^-?_?7@OW_ .I:^GZ^G/[AT5G_ *F<,?\ 0HPO_@$?
M_E9'_$NWA$DU_J=@+=OK>=6^[^U[?@?A[_PX^^#_ /T7OXV?GX,]_P#J7/I^
MOIS6A_X(9_!B&$P?\+U^-A@Y)!;P8.#[_P#"-=^.H[G!]?W+I5ZCZC^='^IG
M#&W]D8:W;DC;[O9V_ ']';PCO?\ U/P#?=XS._\ Y[7MY7/PR_X<>?!#_HNO
MQJ_\!O!/_P SM(/^"&WP-BZ?&_XQY]K7P1^@'AYO\].]?ND>OXC^:4@[?A_[
M3KH_U5X;2Y5E.'4>RT7W*"7X'D_\2^>#KE=\ 9"Y7MS<V<\V]KW><MWZ[[GX
M;C_@AU\&(;K[=_PO3XU_:<9^T[_!A('.,_\ %-<>YZ?U;_PXZ^#7_1=/C5_X
M#^#/_F9K]QVZGZG^="]1]1_.L/\ 4[AJUGE.&?K%6^[E/77T=_"-;<'X!76M
ML9G:OIUMFZNNEG?0_#'_ (<;?!#_ *+K\:__  '\$?\ S.TO_#C?X&9 _P"%
MW_&7)X'^B^"NOOCP\?\ (/I7[J4P]?Q'\TKHPW"W#V%O[++**;ZWM_Z3&/XM
MO8\:I]'SP;Q,HQK>'W#\TI+XI9Q/[27V\WFK_+?IO?\ #?3?^"(GP4T[5=(O
MT^,GQ<NGTO5]*UI(63P<H9]#("(P'A1L9)49RV<@*&S7[7:39PZ=8V=@@.RS
ML[&S!.?F\M@#U[%NGMC(YYU;?[K?[Q_F:F3K)_G^*O1P^783!-K#4E3V6GKN
M^[U\EY'Z+PAX:<#>':S;_4[A_"Y*LRY7BEAW-J?*DTESN323UM?];VJ***U/
8M5LO1?D@HHHH&%%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- @\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%[< K>R:)XAMX[^SLY5_A%O'*F2>0 0<C!.1N>H4444 %%%% !1110 4444
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M !$CT'7/%GA;4$U+7H_#VOW'P_EDN+JVMIP\"N[&- "%_3#Q1^S?^P#^Q/\
M\$TOC?\ M+_\$SY_!5[^V)>?L,ZKJF@?%KP;\29O'OQH\4:9K&@:;?\ C3QU
M+H+Z]J,MYKT N+O6+J[_ +&BEL9V<H(FM]A_>3]F_P#8!_8Y_9%\!>+OAA\
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M **** "BBB@ HHHH **** "BB@G )]!F@ HI@=3TS^G\\T[(]1^8H 6BBB@
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M110 4444 %%%% KKNOO04S>/0_I_C22\QM@XR  <9QDCG'\6.NW^+IWKX^\
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MS/"1KX^(4U_U*?\ [;4_J"$Y)'[F7DCJ3^O_ .JI?,DS_J^/P_P_I7\NT_\
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M_P#-Q%9WLWD[LTNM^:S7S\S^HCS9CP4X/!Z=#QWI-Q'/E$>_%?R[_P##T_\
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MLPSM!+' '$=E^TIX2N?$NE^%IM+UNWU_5-2.DQP;&NM-2\B;$I6=1M**,D2
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MR"I)Z4__ ()_SF]F_:%\ W'FR>%/$OP6\1:YJ^A$M+I\=];+/:6]S;([%8V
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M!/72UFEMLXJ5_-Z778\_\8^._#NA:I/8ZGX677+?2="N-=OM2F2Q,J:1</\
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M,"\ZE1EL*I(&3WY.!GD^G?ITK\V?VL++0[SXR_":35/& T9_[2THQ:3<6_\
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M'6O GAOQ/K&B:V_B+P_9QZC?VEQX?O3>1(R3!D+%VX#C:0 K9 (K^-;XB_\
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M=.VL]?\ @F'H4,LLZ?'3Q*L[0(&N6MM,7./XL&8@#' ..X[ YY@ZY\)AD_\
M",^'KEL]?^%M:L#D  9_XF W'I][TK/3Q3\+(1(;GPIX?^^%)_X6SJV,9&<@
M:AT()QZ=N]?A>*\0_#'$IXO&4,1*3O>']C5]6F[J_)HFUO:ZW/HH^'F>:?O:
M:B[:K.8O33=*?;6UO);':3?\$O-"G<3C]H#Q<Q^5@0NF-&2"#@XF^9<CY@>N
M>!R<^_\ P%_8FT#X,>-[;QW<^/\ 5O'=_::/<:%:V.J6MC;V,*WLGG;T$>\%
MDQN49+# ('(-?'?B/QO\,-,T#4KJQ\%:5=&RL+B=/LGQ6UAF9WDP@1%ORTC@
MD%$0%F("J"2!7Z _LB>#_$/ACX:->^)78GQ9J:^)]$L'U"^U%]-TJ\M(9(8=
M^J$RH54C*X!'3 -?8<"UN$<YQ#S;(<KJT]).]2-2-MTGRS4;->GET/*S'*LR
MR1^SYXM.\6U54[K1.S4I=&W?MK='UQ%$88AD G &?3D@8SG  [ #@8XS7Y9?
ML]?\I6/V\?\ LD/[/?\ Z1:A7ZM?P?\  ?Z5^4O[/7_*5C]O'_LD/[/?_I%J
M%?L5/X)]/W:_]*CH>2?JY1114 %%%% !112$X!/H"?RH 6D+ 9&1D#.,\_E6
M=J&H6VF6-YJ.HSQ6NGV=K/>W5U*P2*UM+6%[BXN9GR-D,$,;2R.<!54DD<"O
MY]_B'_P<X_\ !(;X;>.-?\#:G\>/$&JZKX7OK[3=4U#P[X+U+5])FO-,NI+2
M\TZ#4A@3^3<HQ38%:4(P0E10!_0OO'H?T_QH#@XQSGH1@CWY!(X[U_-X/^#J
MO_@CJY"-\:O':*_R,X^'&L@H'RI<%2&!0$N"O((&.:_GP^-?_!P5_P %$/VU
M?VV_'7PF_P""8'QD^#GPE^ WA?2UE\%7OQ;F\*>%H_$NFZ>$-[KFH:]XM8-#
M=WEQ,<6"G>/E4DE@  ?Z*M-W?[+?E7^>.?VO?^#E".5T;]M+]B88D16+?%7X
M0LJY;&1\^=O/S=\=.>:X;XA_M[?\'&/PN^'OC#XF>(_VT?V0)M#\&V$GB#5K
M71/B/\*M;UN>QMY2/+T_1H)&EEBEV%?)A42.K<?,0: /]'#>I.."01W4X]S@
MG%/K^-[_ ()]_P#!V#^QQXA_9C\):A^WAXVU+P;^TGIMQ?:)XRM/"/@RZU#2
M/$-M:3 6'B&V%@_DQ"[0;V@#!E)QRN:^U7_X.K_^".SHR?\ "X/'?S#:,?#K
M6$(+< ARX"D<'<2-N,GH,@'])>1DC(R,9'IGIGZ]J#C'.,=\]/UK^?GX0?\
M!RI_P29^-OQ-\'_"GPK\<]6TCQ-XVUFTT71KSQ-X3U'1=$FU*\9+33[&\U68
M^5YM[<R)#$'X,CC+%<FOWO@FCN/)F@F2XCGABN/,3!M+FVD(\J6 @L,\JRX.
M#D=10!K;%]/U/^-&Q?3]3_C3J*=WW?WO_,=WW?WO_,0X ). ,')]!]:A66)C
MA9=Q] 2?S %2/D(Y7:"$;!;A00#C<>R@]?09K\6/^"O'C#]JGP+X._9NU_\
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M\R?\-E_\%J<\?\$LOAH.>,_M V''_DI1_P -F?\ !:O_ *19_#7_ ,2"L/\
MY$H ^EO^'*G_  2L_P"C'_@C_P""6]_^3J!_P13_ ."59//[#OP/8' *MH5U
M(K@'.UT>]*2+DGY'RA[@9-?-/_#9G_!:O_I%G\-?_$@K#_Y$H_X;,_X+5_\
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MW#&!O('[S )"[LX'T&(KI6CCDEGD$<$4<DLTN.(XHT=W;O\ =0$@ #IV'%7
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M'PWX;TF\*'*LVE:7!9W:AAD%?M2-@C.]0#R#7\=G_!M'^QS\4/VA?B1\9/\
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M7@C7EUDW?C"/Q!K5N+4J%T[P>OVE"=R@!-^T[L8)';@5]RRQ@J_3D-T. .,
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MW^S#KOQ^NM7TOX>>+_B5X2T8Z%<WF@VCZA=6J>1+YJ[UB*C9A_F'&0*^=O\
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MC#X3^ O$VN7Z>,-3M3?ZSKWAVQO]6E95(("7<LI1%P0& 3:2PKW<_P#!L/\
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M(TYY_9EO5)(&!XR\0#K_ -M"./\ ]9I3_P &PG_!&P#)_9GOE!_B/C37<#/
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MWV^ $\_0 9['CBOZA: *MV0(7+-L549F<9.Q5&YFP,$[0,\$'K]:_&/]N?\
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MP2%4M@<DX!) ]2>W;-?SQ_\ !R[J'A_3?^"8GC#4_%$'VOPE9_%3P"WB6S<
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MD8@5 ^5D(/7)]J\I/[H(],+CKGIC'7GZ\]>:DH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***1NA^A_E2>S]'^0%:7H/^ _^@U^5G[/7_*5G]O+_LD'
M[//_ *1ZE7ZJ-_JD^G]17Y5_L]$?\/6?V\AD9_X5!^SUQD9_X\]2YQUQ[UK3
M_AR_P/\ .!G'5W[R_1O_ "/U=HHHK,T"BBB@ HHHH 0@'J >GZ=*&Z'Z'^5+
M10!6NSB%VP#M1VP3@' !P3V!Q@^U?#_[5UA^U)>:U\*9?V8]=\/Z?>V6H>)E
M\?Z+K=]"AO/#FJ:2UI8:U8V+,6O+G0M0FCO[6$@K-+ L'\9K[>N81(K,0" I
M)4XPP &0V2!@@$<Y'J,5\'_'W]E3QA\8/B&_CSP-\:M?^$FJ/X7B\,+J6A6<
ML^L6Z1S+<^7I[RL-.AC?:%^T0IYB$[U8N,T >/\ @"/_ (*3:?X6?0?%$?A2
M7Q3IE_:1R>(IC9ZIIOB#088;@W>J)'A6MM=U29+?SM(;"V32-MS&N3(WB?\
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MO)[W6+3PUX;TO2X-9N9PPEGU9-+MHUN)9BY:0SF4%LY.#7JE-( !.!T]/\*
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1NA^A_E0!%,
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )F @8# 2(  A$! Q$!_\0
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M\>IZ=XLFT?2/%-[K*Z2--;[3*RZ=OCAR6C)^8_"?_!0+]G;Q+^R5_P &QWQ
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M/[77PMU.VO\ 4/#G[/VL^/?AMJXVRV1OO$>C)_PBNL(02!Y3:I;SJ03\Z(&
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M,WQV\!>$+/Q])H7Q$L++4_!GB[P7)?"Q35?!?Q T:X;1-8D2^;9) F)8PI+
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MH>XZ'O1@=,#'I@>F/Y<?3CI2T4 )@8VX&W&,8&,>F.F*,#C@<=.!P/;TI:*
M$VKQP.#D<#@^H]#[TM%% !@>@Z8_#T^E)@>@_+TZ?E2T4 )@<\#GKP.>,<^O
M''TXI<#&,#'IVHHH 3 YX'.<\#G/7/KGO2T44 ( !G  R<GCJ?4^]+@>@_\
MU=/RHHH 3 YX'/7@<_7U_&EHHH 3 '0 <YZ#KZ_7WI:** $P/0?D*,#T'Y"E
MHH 3 QC QZ8X_*C ]!UST'7U^OOUI:* $(!QD9P<CV([T8'H/RI:* $P/0?D
M*6BB@!,#T'Y"C YX'/7@<_7U_&EHH ,#T'7/X^OUI,#G@<]>!S]?7\:6B@!N
MQ2 -JX'08'&>N/3\*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(2 ,DX'
MO1N4=2!QGJ.GK]/>BZ6[2]6E^8"T4F1ZC\Q1D>H_,5/-'^:/WK_,=GV?W/\
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M>A!I-R_WAUQU'7T^OM2<HQWDEZM+\V@%HI,CU'YBC(]1^8I<\/YX_P#@4?\
M,+"T4F1ZC\Q1D>H_,4<\/YX_^!1_S 6BDW+_ 'E_,>_^!_(T;E_O+^8]_P#
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M?9_<_P#(!U%-WI_>7_OH?XT!T8D*ZL1U 8$CZ@'(HL^S^Y_Y .HHHI %%%%
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M#_T,6L_^#.^_Q_SCZ9RJ*.:7\TO_  )_YA]3P/\ S[I_^ Q_^1-7_A(_$/\
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M&,]>*3/[G!ZEL<\9&/0\XQQ^E>#?''QJ?#/AXZ58S :QKN+50#M-GI[ B23
M(()&5!SDY8G/RFN7%5XX>+O:UFOP:T7SM]_0WPF'>*Q<,/!7;E%\R6RNFV[;
M6M?>VQ\E>-)M+F\6:_/HL*V]@+PARO"LP8Y*@?+@G^[@9/XUS% &,C.>Y//S
M'U.>23ZGFBOB96<F[)W;>RZMO]3]NP<>6G3@_L4X1UU^&$(ZMZMZ:O>^P444
M4&CW?J_S"BBB@04444 %%%% !1110*Z[K[T%%%% PHHHH !CCT]OZ?A7UO\
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MG:3U/)Y.>YXSGOG':BCZ'(['U]_QHK]:, HHHH **** "BBB@ HHR/4?Y_\
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MM_SZVG_?I/?V]O\ .12_9K;_ )X6_P#WPO\ \31+PN[9E\K_ /!$^-M-,O\
MQ?ZZ'YU?9=0_Z!MU_P" ,G^'M_+VI1::CVTVZ]>+&3V]O8?D*_1GR+?_ )YP
M?E'_ )[?YR:3[/;_ //.'\H_\]O\Y-'_ !"_OF/KK]_4?^NT_P#H71_\F_R/
MSE_LS4?^?"\Y/_/G)R>/]GKTJ?\ LW5O^@=J?_@$X_7;Q]>U?HI]F@[6]O\
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M-B-/:Z^5;RVR4W' !('W02>F <9]:^:R" "0P!X!8$9/X@4F!]1[\G]<X/\
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M="U_0_%.EV^M:'JMMJ>D70#6UY:7&Y">ZL0?E<$\HV&'''.*_G,Y^Z.QX4]
MW88/0_3G&>V:^E/V:OCAJWPK\9Z=H][<O/X.\57BV&J:7<N?L&FZB[*%U9"S
M':"2 0H"GN<BO)SOA)4XO$X)Z15U%-ZI:Z:OHO0%B5?=:_TNK_#IH?N'28'H
M/R%5+.>":!9X9Q/"RAEGS\K A6&.@(P001QV%7*^)>CL]'KIUTT9T"8'H/R%
M&!Z#\A2T4 %%%% !1110 4444 %%%% !1110 4444 %(W0_0_P J6B@#SWXA
MW\^F^"O$-Q /](MM*8Y&3PV5.T]QM8DG&>H[U^<*G.#P2><G!R&Y(^AR1MR0
M>E?I+XTTV;5_"^OZ7 OS7FDW]M;X8DYVG.>#T  7OW'3G\V5@,'[@Y!LR;%B
M0<@AL%F)Y&".I[G\*^8SIOZSUVWUMW]%^C/ON"FN::3UNK]_AMLG<IW,%[.E
MO!HES;6FH7-Q);6M_J[ :9IVU&?+Z8V!L4KDEC@C([C/YO?\$P?VG?BS^U!X
M._:;UCXU:WX9\0^)/A#^U1X_^#OAR\\-V<>DZ</#&CR,NDLVE1LQ;('^L;AV
MY!/2OTHU"TL]0L9[.\@@GL;D&SO&N"P:]XPP!4AQG.&*D''!ZUYC\,O@5\%_
M@>?%/_"G_AMX;^'*^,M6_P"$D\3VGARSDM_^$L\3,<OK3&1F =LDNYPS'DFO
M./L97^MO>VO>VS78]3(QUP=N>PX()SCT^G&*^A_V<=2FA\4ZOI!P;:[TU+OI
MG+;ERPR,;N/O<D]37SR><D_Q9)^IZ\_7.3SSGFOI;]G#0YYM4U?Q).!]GM[;
M[%9$ XXX)./;(Z\]L5T99_O;MM?M9;=+?U]YXW$MEE,N:U[VL[<VK:6C5^J/
MLE>@^@_E2T@Y /J!2U]@?E(4444 %%%% !1110 4444 %%%% !1110 57GSC
M@D'!.1UX#'^E6*K21 ^X/!SZ<Y'ZG'XBN/&<WU6=KWY'M?\ E=O^"./Q1]5^
M:/SPUZ99]?UF9N2=9U $DGDC. W.3].>O&*QI3B"Z.0"L,S*[ E(Y%C<QRR
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M)>9\:QL "/'!-R7M95!317"21$D UQVL?\$6/A#K*>,+P_%_XF7/BO4_!GP
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M)":.-)RC%<.S;2Q^7 ^<?C9_P2I^%_QE^,OQ_P#CSK7Q"\;Z#\1/C+K?P/\
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M \/66N^%?V=O''Q!\2?$&%K^RLM0?3O%GA%M TV+34OR!<;IR[2JN<(6*X<
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M^)7PE\;7VH7S>$K?5O%GB-!XU^'7C6"$_P#$_P!'U[PE)(D?F*Z)<XV@+M-
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MXCU'QEI\EM9ZOX?T.]BTUC>:E8ZMXKU :;H@DTD?O8X=8E./,*;55&89VL
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MVA_L!>!=$U+PY/8^+]3:^\-ZA\>=6M-VEZ>UD;[XZB1?%9EC926$8O/W(?<
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MVB?@AJ-O+<VWQ4\'/9MINHZ]#=+K-FMA<:'I$PAUG48'=T633M#D&SQ 8B3
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M _*CP%_P3>T:_P#V=_#/PE^,/B:0>*_#_A_XV^&M)UGP>EE&=$TSXT>(7O\
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M)*EL$*=Y^7D>3>"?V]/A%XPTGX3R+H/C"T\7_&/PUXV\9^$?!VG:3_:VO?\
M"->!M7FT;6];D<%8HX0T.XR,Q!CY)XS0!Z;JO[.FB:Y\!-"^!^H^)M:O4TX^
M&I)O&][%&_B'4=0\(ZA9:C;ZKJSN#OU9_L*1I(Q)9%5MP6N(\)_L8?"_PKHW
MC'PU')_PDNC>+?%GB;QO<6_C&PL]<GT[Q!XY"1>)VCDY>/2==1-Z(I MI,;-
MI4&M+7?VT/@?X?@\<7&L:]J^F77P_P!'\%Z_XNTE=%N[Z_M-"^(NJ1^'?"&I
MC9NC9)]7<1S;"2@+<D98W(?VL?@\-7;P_>:K=Z)KJ>*=4\"W5EK%HVCQ0:_9
M6$>HPV%QJ;GRH1KL<R2>'VDDC#R;EX) (!@_"S]D#P?\'/'&@^.O"WC+Q9>W
MGA[P[K/@ZUT_7;A-;M8?!.K:U_;K>%=)DE DB6#4+<"(N[,L>(U&U0*S?B#^
MQGX,^*7C7XG>,/&GB;Q#J1^(VH_##7+71K46UHOA'5_A'J0U3PGJFD-@-*N9
MRFOK+\TJX5" :X_P)^V_X?\ %GQ,^(?@W6;:#PI9>"/%/BKPA8^&)[9[_P"(
M_BMO 6@V7B'6?%< A+:8='5;S:B1[IWP.I;->X_#K]JOX7_&#Q9K?@CP/;^,
M=5USPY'H[^);B3PS>:?9:"?$VFOJFE1ZLTFPQE]/12V0/4@9% '#^(?V)/AO
MXH\-?$6QN=7UF/Q5\3/BOX:^-OB3QG:N4O;CQSX/:Q_X14OINX1/H&E+8I&^
MC, DNYG<OG%<EJ7[!'A[6[KQO+JGQ=\?&Q^)FN^+/%/C[0[.+3;+3M9U/Q9X
M>L_#?VD;;$&W?0%M%G\/HH4J6^;.,UWG@#]KCX<^+AX2TG6[VQTKQ'XMO_$"
M^'-)B:]CTO4;/PEXLO?#+C3=9=5@U+7)+^T5FT4RB5LLH4J%SM^/?VP?@Y\/
M-9^)>C^*;[7X/^%/2>$;GXDZK;Z:6L?"NG>,<#1=5U5E(*Z2Q8#*AR"#MY&0
M <%X$_96M_#GB[2-7U"[:WM_"GPM@^"DEPEZNL)\4_#>E6-K%X6\5^-]':R7
M3GUS0/F59G+R$,_[S;M%6M$_8WT'P=\-OB+\,_ WQ*\=>$[#XB:YX?U]S:RI
MJ"^&IM*N%FU2+PG8R;DTK1=?=-DD;,PCWDH !QMW?[;'[/%IX>\/^+V\:3GP
MMXSM_%$_@'5HM"U"]'BN/P0RCQ,^BI'&9-56,1SM]T!8[9G' Q7/^,_VT/!G
MA&<:I:0CQ7X7;X7Z]\2K+^P;E;O6-9L="U_3=)%[ISH1I\.F1MJ*K<6\A6>%
MPRR1@K0!R_AO_@G[X \/>--!\6CQ[XRN[/1]4^)NKVGAQULGLQK7Q9\.G1?%
MKIJ>TNK21;G6)0$,IV;<Y-=I\,_V+_ 'PSUVPURVU2;Q9%_PKKPM\-=5T#Q?
MIMC?Z5>>'O VIWFK^%)8=, VPZYH,UWD2I@S!59MQ  T_$7[6G@OP;\2M9\'
M^,771['2].^%<S75I:W=U_8-]\7+B>T\-CQ>P TS2-*%_"T3:SNV))\CE:Z"
M[_:L^#&B>(O&/ABXU'6+WQ'X*U;P[I'B>TT[2+[4C8R>+=0&G^&+@,F[=;W!
M(<7"@1^4?,+D%2 #JOV>?@!X<_9X\'ZWX1\/:A=ZS;:Y\1_'/Q,N[[4[51J*
MW_CW6KG7M2MU8#=Y<-_<[8DR%2(*@  KZ03D9[D]^O0=:CB/[H9/WEW#/4@J
M""/7@\]>3UJ>@ HHHH 0D $GH 2?H.M?(OB7]F7PGXA^*_Q(^)=YK>IN/B]X
M$T;X>^,/"MY$;_3$T[PTM[<:9K.@LQSHVNJ+UF,R*-Q56.YEQ7UTPR"..01S
MTY'?V]:^:?B!^T9\*/AMXE\1>"]9U"_E\;:%X';QK=>&+'3KRYO]4\/0I>.?
M[$DD9()[@"TN?W2,TAPHP1B@#YE\8_\ !.CP!XW\(> O!>K>._%-O%\+?#%U
MX5\)7-M#:AY= U#Q'9:X$\0'(.MR;M+MH-TQ,@1F 89(KJ;;]BS1M+\5V_CC
M3_&]]-J>F_%36_BI;Z:-$L+&Q;4M8\&R^#H_"BE )%T)B5N)8QC#[G9<@&O1
MM*_:^^$6I>!O!/Q UF+Q-X5\-?$"PT#4-(N?$FC7=J]A_;6I?V1HRZXBDOI"
MRZIMBCDD 20D;2<X'G_BC]OCX->'3;OIVE>/?%=J_P :8O@5J5[H?A2\N]+T
M7QQ)=BSO]^J''[H&1&4\_*2P S0!\_?#O_@G5>7G[/WPP\#?%?Q7/HGQ"^'V
MA?$+0;*Y\+6UDMC:Q^,/&$VNWE],0-^MJ--9((UG+K$6)0 IBO:]*_X)_P#P
MPA\&?$GP3JVJZIXFL/'\VJZG8:AXC-K?ZCX)U_7M#BTO4)-'#'#(1"DL5LQ,
M49;8B@ UI?&C]M;0O@I^T5HOP@\;^&]6;P7>? _6?C)J?C?1;"]O]3\(V/AS
M78]+O6U[3;)2RZ*PDC::3:"@W,20N:].\1_M6?"#PO>+;ZUJVJ7,M_HUSXAT
M8:7HMW>_V]!IWA]/$Y'A-4#'59%T0_VFT6/,PK#!(Q0!Y!>_\$_/ACK;?$B/
MQ;K>M^*].^*_@'P'X&\56>H16\0TQ?AWH/\ 96A^+?#OED'1-:!5&98 $9AD
M@MFM'P1^R%K'PZUOPOXO\)_%R_?Q;X8^$N@_!#1]8U30["0OX&T?Q$OB"-]8
MP#OUR1%&F+.<[AF4D,21WNK?M8>";A?A+=>$$G\1Z)\7]9\-V6A>(Y["]M/#
MZV'B'3;_ %2V5]3 *G7HEL)$FT9B'1P4<*<U@>&OVX_V>/$5G?7UOXJU*STB
MST/Q)XELM<UKPUJ.EZ?JFB>$-7;1/%":'\N=7DT75QY+ *2"X(8@9H I?'#]
MB_0_C7%\>[>?QGJOA*W_ &BO!OA;POXR.G6EC=W]D/!=Q#/I>I:7(?F\N4Q%
M)T=ON2$8'2N'B_X)X>#T^,US\8W\?^*+K4IKKPS=V?A.X@1? UII6A^#(O F
MK6#:(A6(R>(M-1I992H992[*<D&OH_PM^T/\/_&UMX_O] CUZZT[X=#2[?Q'
M"VG&._GO];L8]1MM,M].DVK-OTV2)_W3D@R8(+C%>!^.?VY?#VE:MX0M?AMI
M,'C;3-;M_C%9>(;FY=K+4O"WB+X1^#W\4:AX2ETMD5EE>.-4<G=Y:G(8T >A
M?$C]D/P-XYT7X>V>D7=YX$N/A,%M?AWK?AF&VMM0\,NNIBZF4M*S1R:)*H:,
MZ2RL06SG)->87W[ _AD:S!J.G_$3Q7!80?$CQ]\6=+TY;2SO!9>)/B#X7/A;
M6I2N?^)C"6NGU=(I,*DAVA1MS7<^%/VQM U/X:_LI>-?$OA'Q#;:U^U58Z?'
MH>A^'+8ZQI_AS5+O1)O$&[5& 5C%LC$1<999"Z\[<GSGX(_\%#?AW\0=!UB_
M^):-\)];TNY^)<D2:E!='P]J_AWX=^(3HVIZKH^K.HWZTQ5-^B*Q<.V.G4 Z
M_P *?L.>"/"UU^S1+'XMU74A^SEX&\=>"H+:YTK3\^/=.\<Z?)I^LS:V6#?8
M98/-:2W<AVBD \LJ=S5Y[XQ_X)V^%=6^%_A;PAH'B?5[S4_AAX?\5Z5\+H=9
MNFBL-/E\3ZS_ &S_ &KKAT]EDUY[-U MDN"Z!0J< FOIJ+]J'X,#PEXP\?77
MB"_L?#OPYM-+O?%EYJ6CZC:ZAI,?BTH='D&E")GGCG2169E#X5LX7DUSNF_M
M??#75_B3KGPYTS2?&=[/HWPQA^*<7BVQTB8^'-0\.S7B:?&ND2[V3SB[JH1V
M7$IV,NXXH ^8]+_8;^)?B+0/B#HGQ3^)>DZ</'NC:CI&JGX:>'OL=[XFU+65
MTTV_Q#U)K^Z\W2?&F@'3TB2. C2I(QC 9BI]$U']A7POJ^H^'-5OOB3XL:ZT
M'XE^"?B68X[>QM'U?QAX2\.)X4+ZZZ@&?1=?TFT66;2)<Q#6)#+G)Q7IFL_M
MH? O2DTT7-_XFU'4]6US7?"UKH.E^%]0O_$,?BWPMH1\2ZSX7U33;#<PU9-&
MW:M'G]V8^^0 >1^*'[;_ ,+/"_PB\0_$;X=79^(>J:/X%TCXE0^';2TO+F2+
MP]K=Y%I&GOXO*Y;1F%PUXC*Y!62S;)))R =SX_\ V3O OCOX=>%OA[H=S=_#
MUO OC=_&_A?Q/X:AM#J&DW=W?WEYX@MU\TD+!XF@OK_2->C#;&63*+PIKD=#
M_8P\,:)X6^#_ (5TSQWXBCTSX3?%^?XF: DUO9_VI/HMJFH6=C\/FGX8Z)HT
MM^\L8)(W%05(+9[W4?VL/@YX7?3M.\6Z]>:'XAN/"FJ^+K?2Y["\9-8TSP]H
MUAXG\6C16CW?VH?#NFWVYP<.-AR,YKSSQ7^W'\)[/X<>,_%W@:W\1>(?$/A?
MX7W'Q:T?PYJ'AV^T^;5O!$D*WNF>*@+X*5T'6=^T:OG!9=KJK 4 >8:5_P $
MX/#%I#X+2S^+WC5H_!L7QEBLYH-/TY-3OD^,/Q*TWXBZL-18'!&B:EI8TJ +
M]Z,AG ;&2OT%^'OC9?&'PW\#^.DTH6K>,?#>B^(VTN-T8V7]NZ?'J13?R&7=
M(1D9R3G)QR4 >G$9!'J,5\X_%SX)^&OB5XJ\#>.+XW^G^./AA;^*)? GB'39
M_L7V.3Q'I$NBZOI.JL=PDTK6U:UWQ!=Q^RC##+*?HUC@$X)X/ ZGV%>-^/\
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MA\3-!^+U_9:'=78\-:!\1O"K!M*UKP=I5]A=%. )9U4+'+)F1\L0:])\$_M
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M\,/CSK-FVHJ^HOX;^(VIC2?[*TF/&^76?#[,'D!0AHP< %LUYQ^RG^WOXO\
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M,/P.TJ#0[33?!EK#;^'1KT?@ZSBFN&TWP0?%/R>*AX0B93'I"W/)957:-S
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MOB72-4T8HT6HC6M,*RL T: I(758U$6"!@)8?L*?L^VNI7.N6^A>($O+R_\
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MBU(!E76M>BD1D!/'"2;2,4 27/[&7[/^J6FF6E]X/O[E=*L_ HT>.XUR]-U
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M]GGXS77PV\<ZSJFK7A9O"5HUBB>*M)"VI0SM+?1QG1R<[S][#9(!]&:1\#?
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M>+K#Q18WE]K%_J6DZJ8PFE: RX4*OFLGSB,G:1^C<8PBCT&/KCC/X]<=LXH
M?1110 55FB!4\A005R0" "".5Z%<$\=""5(P:M5F3^3Y=YM!,GDS85>,GRWP
M%W?+N)P%[;L4 >7)\&_A;)>W&H'X=^#TOOLFHV!NQH=B+W^S=99O[8A+!1B+
M7F5_-B3:CX)=2PKH/#_@+P'X>-A<>&_#/A_0IM,M#H^F#3]-33OLVG'!_LYE
MC""7;A@"X<KT7"\5^1_[,_QD_:6MI-.T/XZ^'_$UOI/B?Q?\5K;X(?$Z\&H3
MZ?I_C32]?U.PT7PG\9M*"A](T.73DLQX7UM\:+(I/SAB"?;;S]JKX_3_  ^^
M#?B33?A4MIXI\5?'32/@K\1]%N=)OY_[#U*.XOM/\1>,=&= 5?P,?LUG+#K6
M[;MNSM..: /T$D\">"$O;^[_ .$-\/+=ZVP?59I],L2M\ZCB5DP5-P6^;SPH
MF+C>SE_F.?J?PP^'&MV-G9:MX'\+:EI^G7#76FVUWIED39WL@*3%W #2>8IQ
M<>8SK,@V3!P!7YL0?M8?'?Q-XTNOAOI7B?X.:-\3?"6J_%NVU3PCYL\:>++G
MPA^]\ :1X?O-45(I)O$=LEY_;Q27.E2A F[<*]6N_P!IGXI^(]"^$NH>#O M
MUI^O?%^W-S:Z'XCT#4;/2_AGHWAT[/B+XK^(.JA,,RW$;KX1T1/WFO Q,@(.
M: /I#1_V=_A?I'Q2\1_%NS\/PMXD\0^$="\!WEL;>R_X1VS\->%KS[?INF:5
MHP41+E\DL$*9!8A:[C3_ (4_#?1C;RZ)X#\+:6]OJE_K,4FGZ/96#)J.K8.I
MZDDD*!_[3D(W,=^"V&V@A<?GEXE_:-_:(N?$O@OPW-X+O])CT[QWI.H>*O&W
MAWPSJ6H>"O$OPUO[J\LX7@B8?VII?B!VB3^V=&(W+O0*0K G#\:?MQ_&S28=
M;U+X??"35O$MMJ_@67Q-X%NM;\'>(M()\5Z;XYLO"VM> M8TW;YFF:JFBE]=
M@=\K)$ 0S!C0!^E6J_"[X>ZU/JFH^(?!OAG4-3\1V]A::S>:CI=G=:CKEEHS
MK)H^GZPY!;4Q"Z;X48[4*J5&X5LV_@SP=;1:C#%X3\/QPZZ%76((])L$@O\
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M/+(\KH-@.!7Y[>./VN/CG;^,OVA/"_PK\ Z3XQUGX(_$WP/X)TGPQ]FNS?\
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M\,6GQ-M/#]P;F^+:=%\7;F2[^(B1$OU\1/=R%B<\,ZK@=,WPA^R%^SGX)N]
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M_"_QKX!O/BIX2\5:;K?@:RFU""^UVU<7;13:1J3Z3J:2QY\Q DZ-&V4"@KG
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M&Y0> 3SE023P<<YR*=]IM"F\7%N8]Q7?YL93<G++NW;=R=2,Y7J17YZ?"?\
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M7UII^@:%I-]K-YJ/G1M#:Z7I4;32R*^XB0+&KG(8Y'RD<8KBX/B1\,=5\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!28&",<'.??/6EHH 3 XX''3@<<8X]../IQ1@=<#/KCTZ?E_G%+10 F!Z#KG
MH.OK]??K2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !129'J/S%&1ZC\Q0 M
M%%% !129'J/S%&1ZC\Q0 M%)D>H_,49'J/S% "T444 %%%% !1110 444F1Z
MC\Q0 M%)D>H_,4M !1110 44F1ZC\Q1D>H_,4 +1129'J/S% KKNOO%HHHH"
MZ[K[T%%%% PHHHH%==U]Z"BBB@+KNOO04444#"BBB@ HHHH **,CU'3/X>OT
MHH **** "BC(YY''7V^M)D>H_,4 +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 PX;)/(4'UYS^73'?-?/OC;XIZWX0UB?2YO#L,]
ML5^TV5VMT0+T9QCD###@8SD=,'D5]!':O7@,""<_3KG/6O)OB3X*'BK0;F"
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M %#\J3 ]!^7^?0?E1]6\OP_^U,/]8\W_ .AG+[W_ )'O'_"__$7_ $ -._\
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MC&!0%"S>MFF^O78^H?\ AX_XI_Z)EHW_ (.[S_XBD_X>,>*?^B;Z'_X.KO\
MQK\V\^_7/?KZ_P#UZ*YST/JWE^'_ -J?H[_P\>\4_P#1-]"_\'-Y_C2_\/'_
M !?_ -$YT7_P/O:_.&B@/JJ[:=?^!IIH?H__ ,/'/%0_YISHQ_[B%]_7BFS?
M\%(/&/2#X<: 3C +:E>]N@XQG'T-?G%105]6PW1Z^;W?G\S]%HO^"D/C@_\
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MY_\ UJ[GBDNKM\_\]#\X_P!2\VDY2YE=MN6JN[ZJ_=:]V?)]%?6__"B/"O\
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M9_33H'BOPWXJM&O?"VO:=K=LN"]QIEXEZZANF^,,60'."& (S[&NJC^:)22
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M%TKQ))J>EV5Q)K0RS-:;6##(/ZA?*>>#COP<8]_:D^7G[O3YNG0CO[$>O44
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M4]0U6'Q):O8V0EM_%%M<:@9K'7X72;1)(X6A<,!6/\%O^";?PQ^"GQ*_9_\
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M*]".HJJ7&C1:>ULL_E,Y\[=DJ2!7U?\ \('\/(OL\/\ PAGA"/:V;)#HVCJ
MRGS%2)#""1&_[R.-!B-OGC5&&X=(--TG[=_:"V%J-1*"S:\2U0.P51L25T&Z
M147"H9&8(!A-HH U( !& #D D9/.<<=>_P!>_6BG1XP<=B1].!Q10!)112'H
M?H?\XX_F*  D8//8],>F>_'3GGCUXKY(^-WPM^)/Q \:_!KQ#X-\6FQ\,> ]
M;\57GCOP1<7$MA8^.=/\0:+<:-IA_M"QR$U3PWJ3KJJ+)\C8,;#<P#>-3?\
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MMX0\:CQ[X>M_#'Q'TXZEX/U&ZU-+637K"*S-])'I,9.YY[7:XN8@#+&T<@8
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MH)[  '% 'YD_&C1OCW+\8?V/-:34-;-[X9^'OQE'Q4\>^"M#:_\ "]KXCO\
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M+6U\6^&/CC<:-IG@B3P^UWX?UOX'R:I96%AXITG5F(;4]<332VJM'D;""NW
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MFK^$M*T#P-X@U:'6/VG'_9@\27-_!]CU+_A(H?#[ZL-5T-!D:NK(FU5 PQR
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MQS#;3>'=4EGD&EZD^H2-INGQOJ& FE3OJJ2:2+9OG,V8MNX$#F?"G[4OP?\
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M$MMJD+Q2'<,,C# 7&/8E    P , >@]* %HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\^USP/X/\;+;Q>*O
M#6C^(!X?U:2_T]M5M%N9;#4?*"O=Z7,Q\W3V=&*.L+!9%)5P1110!B:7\/?A
MUX7DL)="\'Z%H=Q86,D6E3Z+HUC8RV>EF8WIL-\6UF0S.TA4DH79F 4LQ.3:
M?#+X:^&K^PU.R\#>%]/U7PS<:WJVEZCI6AV-O<:9J'C>Z<>)M3L"RX74/$N<
M:]*VW[2HP&;)!** +,'P[^&FE0:;HMGX$\-6ECX3U+[5X>L[+1K*UM=!UC7S
MYNH:EH2HI;2Y+HR%KC[-M+N26W5!JGPC\+S-K,VAVEOX0O/%=S::OXSU7PY:
MV=KJ7BVWL;$Z>=,U^5[1QJ5K- YC<3$90D8'0E% &WHW@3P%X:30H]$\+Z7I
M@\): 8?#@M+"VC70M(D;+V.F(NU8=\A9W)&"6.&&<#U-2&56&<,JD9ZX(R,@
M<9YYQ110 ZBBB@ HHHH **** "BBB@ HHHH **** "D.<'!P<<'K@T44 ?"N
MN?LD:9JWQ(\>>,/#7C/7O!5A\4O%_ACQ_P"+=(T20(+KXC?#JT.C6&JL[J5N
M=%US36MXM<TB7RUEEM8Y8W+$D>/^'_\ @GMHG@[XUZ/JFD^++M_A<?@M\3OA
MMK6B7LK7?C#49/BEXP3Q)KPCUB6P,,&BM/=W,:VRRB959%"D*""B@!GP8_8
M\+^#['XP>%_$^HVNJ^!?$WQSLOBM\/-!TOS(6\++X?\ #UOX3\-:;J4L]C$;
MB72C;OJ*S6\D@DG<!V<9KW/PO^Q!\+_#&@>#]%T[4-<-_P"#_ _C7X90Z[<S
MI-?ZMX&\=ZE-J.OZ+J9(572=I98T=!N56')Q110!Q-Q^P3\)HM,MO"?A35?$
M/@]I/AA>_"$WND2Q@ZG\*)+AI]/\+:]&[_\ $RN?#T\4K:+JTA^U1)<,DGRJ
M ;VA?L+?#+0)_#US;>(_%#/IOQ,T?XM1N5L?,U#7O"WA<^%; ZDQ!+A;20NP
MC.V0C#]3110!F7'_  3[^&T?AEO#]YXQ\;W/A>P72+Y/#O\ :"_V=8:CX:\6
MWWC&PUC1%.&TW43J5X_F%"T3*-IRO7I-#_8Y^%6B?$+PKXXMKS7;SQCI$/C>
M?1+K5A::AI+^%O'<L5QXO\-ZOI<A6&YBUB3F:50S>XR1110!QL'[#7PZT_Q7
MK:Z5J&IVFC^-/BO:_&N>XMYVT_7O"?C'P[8IIUUIW@NXL52+2?"NL:/MTV[T
M@.(S%N)!.*]_\=?LT?#SXC>,[[QY<1WVE>(=?^'-]\(O$5S97!VZI\/M0D$S
MZ,R2!D1@X!\P+D$D@Y&244 >)I_P3D^"/_",:IX0:[\0GPIJ/Q/TCXJS:<+E
M1*-1\->'9/"ECHPF'S'21IC$%"VYI,;@0*]8T_\ 9<^'7AKX3R?!W3Q,FB:M
MX%G^%=AKOV*R_P"$FL?!%Q*;I]&N=2V[]1@#R%%$V $' !HHH X'Q!^P5\-]
M=L_$5OJ6N:T+/Q!;_!BVO[:Q$-F)(/@>I3PLI>/YB=FX2>FX@'!-8WC+]@#X
M'>+_  )9> ;U=;@\)Z7IWBO1O">GP70#Z);_ ! U2#6O$#-(26N#<7,TBE6<
MC:V"< "BB@#IT_9(^'EEX]USXHV6L^(K/Q9<:[X(\0B\MELXQIMUX1\.3>#+
M4:6!Q"9M)GE1W(4@L"=V*S]"_8J\*> $\%:YX0\4ZW_PDOP\N?B?/X0O=:*7
M=LFJ_&5Y(]1U'68X\2:E)I8OG-JCD*6&2!@9** /H7X$?!SPW\ /A7X5^%'A
MB2YN=+\)O>AKZZVM=7NK:[?7>N:KJ']V,7&I:G<RK'@A$8*!\H->Z444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P +(# 2(  A$! Q$!_\0
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M5BL-)*$5%\CE)1M&*YDXM\KU4M;+1J^N_P"64*N9X?*Y9-C,GXBGFLI<1?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  %0# 2(  A$! Q$!_\0
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M2:)KNB75YI>LVEYI"Q@FTU"(V]Q/-%+$ZSZ9.'CB:-E@8IL2O</V4?BU\/\
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M=M<1/DR+-;:=>V\$COEF:4H92S%BY8YKZA_X=M?\%%/^C!_VT_\ Q%GXY?\
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/JL9)J&J<7333[II-'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>fin_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $? G # 2(  A$! Q$!_\0
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M P3R3@D@#=\H%=17R#_PWU^Q9_T='\#?_#CZ%_\ )-'_  WU^Q9_T='\#?\
MPX^A?_)- 'U]7Q_^P]_R0*'_ ++9^UG_ .M7_&*G?\-]?L6?]'1_ W_PX^A?
M_)-8O[ ^KVFN?LV:1KFEWL&H:)KOQ:_:=UK1]4LU/]FZCH^N?M*_%C6M"U+2
M&9PHT:71[J%X!\FY"BA222X!]L4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[-/1_9UMWNOQ.:_^TKT?7R_KH=U11169TA1110 4444 %%%% !1110 4444
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M[./_ (>WX:?_ #35Y=X5E-YK_P !-+UCP)\,KJS^+?@SQMXQU=1\.-(TV_\
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M/^SCT_Z+;\-/_FFH_P"&Q_V0O^CIOV<?_#V_#3_YIJ]:_P"%<?#S_H1/!O\
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MD:+-;3++ I5 (UWD;<NX!]KT444 %%%% !1110 4444 %%%% !1110 4444
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M_"2>'8+>8KH<4DDI82,_T%I>FV>CV%EIEF9OL]M;"TM3<7#W;;%'&]G=BY
MRWR@@;>!7SE_PW'^Q;_T=M^S5_X?#X:?_-+1_P -Q_L6_P#1VW[-7_A\/AI_
M\TM '+?L7_\ ($_:&_[/(_:>_P#5F:S7V=7PA^P?XH\/>,/ /QJ\4^%=<TOQ
M!X8\2?M6?M+:SX>U_0+R/5-"UO39?B;KB+JFCZQ )(M:C=HF5IHY'B,D3"/*
MH&/W?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUMO_  %3_P")JW110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%7R()1DPP'\ ?Y*/;U[4GV.T_P"?6V_\!4_^)JW10!4^QVG_ #ZVW_@*G_Q-
M(;.TP?\ 1;;H?^79!^NWBKE(W0_0_P J *'V2UP/]&M^O_/NGH/]G_\ 5WKS
M/P5K5_KGBGXI:7J,%B+'PCXLTG0]("VR\6$O@WP]KW))"[E?6V 8 JH+ #!
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M_)H?_)A]8H=U_P" O_(]PHKP_P#X6]K?_1%?C%V_YA'@?MC_ *J)_LC]:/\
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MPOX4\4OJ\L\?Q2,KLYC2(Z*(U\LL,U?[1_X*!_\ 0D?L=_\ AU?C/_\ .4H
M^RJ*^,+C6OV^8(I9I?!G['D$%N";FYG^*WQD V@ DG_BRRH  0.3R< #-8T/
MCO\ ;@FSY'AW]B6?_CQ^[\:/C'G&KN/[$Z?!1N;@_P"J ^:1?F4+P: /NBBO
MAR7QG^W''=_8I/#'[%L%[_H2M:7'Q?\ C']O#:K(R:,IC_X4L"7DD#*H".'*
MDY498VX?$_[==Y=WUC!X2_8TN+VP %W;6WQ@^,9OK+>. R_\*4++NZ99%&3@
M\D"@#[8HKXU_M'_@H'_T)'['?_AU?C/_ /.4H_M'_@H'_P!"1^QW_P"'5^,_
M_P Y2@#[*HKX;C\6_MR36<6I0^%_V+;BSGNOLGVM?C#\8S9OJ6\:484=?@L0
MP,@,93?R00&V,KG2N?$'[?%E;2W=]X+_ &-K6VMK<W%W<7'Q>^,JK9X7+%C_
M ,*45=@ .&9E)(( ;(!'MIN![E\8O'?@_P"''PU\6^*_'WB73/"'A>UTC4+6
M^U_5KL66GZ>^L.-'TMI'/&6DFC7CYE<EU&"VW0^%GBSPSXP^'G@WQ#X3\0:;
MXJ\.W.A:6NG^(=!O%OM,U+RX4TWS(9%)+Q^8K,V2"KH^[ 7!^1?B=X*_;-^,
M/P[\8?#3QQ\.?V/=7\(>.O#FK^'-8L_^%K?&3]]IFLQ&)@0?@H=P"E2!\H+*
M&R<',GPVTC]L?P'X)\,>!/ GP]_8OLO!_@?2=*\':18Z;\7OC&R:?IN@1)I"
MZ40/@HX1HO(V*"582J=R,6#MUVPW]F)W?]J>T=U=<OL^2RTM>_/?1/LW=)(Y
M/]K^MV?+_9BCZM2UZ[V]?^&_0:BOC7^T?^"@?_0D?L=_^'5^,_\ \Y2N;TWX
MM_M-^$_B_P#!GX>_&+P'\!+7PQ\8=8\:^&K77?A=\1_B'JGB+1=8\'?#;Q)X
M^,IT#Q!\,_"EI_8LK>#CHDKKXI#GSX)61U98CR'6?=U%%% !2-T/T/\ *EI&
MZ'Z'^5 $/8?4_P EKQGX9_\ ([?'7_LH^E?^JS\ U[-V'U/\EKQGX9_\CM\=
M?^RCZ5_ZK/P#6]#_ '7,O1?^G8G-6_CT_P#$CVVBBBN=;+T7Y(Z0HJE=W(M;
M:XG(XMK9K@_\!5R1CWVG_/3\^OA;\5_VXOBS\-?AU\4=%^&W[)VCZ/\ $OP)
MX4^(.C:7J_Q<^,3:E8:=XTT31-=72M8 ^"(3S1_;(!\M!M(B4*!@4P/T2HKX
MU_M?_@H#_P!"-^Q[_P"'7^-'_P Y6C^T?^"@?_0D?L=_^'5^,_\ \Y2@#[*H
MKXV_M;]OO_H2/V//_#K_ !G_ /G*4G]H_P#!0/\ Z$C]CO\ \.K\9_\ YRE
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M[KPIHEVLUU)X9/C'2KU"HAUK2HM>F\$ZXS?(K+K?AGQ+H\GARXW2.P9EC!<
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MN@KK.D:SXE\+O%#<Z%H.N3>;F:14T212N\;$Z;_AL&__ .C2OVS/_#1:'_\
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M0M;\.Z[H^C6Y\0>(Y5UP;]!BW^)/%,2>,965#+*&"XGL+O1M.MKC2[3X"_\
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MSKXI?\DU\??]B-XI_P#3/+0!\Z?\-@W_ /T:5^V9_P"&BT/_ .>)1_PV#?\
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MB1M):3E=I(*;O[N#Z!_PV#?_ /1I7[9G_AHM#_\ GB5]H44 ?%__  V#?_\
M1I7[9G_AHM#_ /GB4?\ #8-__P!&E?MF?^&BT/\ ^>)7VA10!\7_ /#8-_\
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M#XO_ .&P;_\ Z-*_;,_\-%H?_P \2C_AL&__ .C2OVS/_#1:'_\ /$K[0HH
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MGF;Q%#NB\T.O[?UYG\-O^/7Q7_V4;QS_ .GR2M%+1Z;+O_P /GO_ (;!O_\
MHTK]LS_PT6A__/$H_P"&P;__ *-*_;,_\-%H?_SQ*^T**S ^+_\ AL&__P"C
M2OVS/_#1:'_\\2O,=0\>^,OCI^T1^RW?Z7^S]^T#X$T'X:>+OB5XH\6>*?B7
MX-TGPSX=M=-UKX,_$'P7I$>[_A);N277)?$&MZ,4ABMV>*(2A"P(,?Z/44 %
M%%% !2-T/T/\J6D;H?H?Y4 0]A]3_):\5^%O_(U?&[_LJ(_]07P-7M78?4_R
M6O%?A;_R-7QN_P"RHC_U!? U;X?_ '7,_P##_P"Y8G-7_CT_5'N-%%%<ZV7H
MOR1TF9J4,L]A?0P<7$]JRKV&[!7OTX)'K7YI_LX_M >+/A;\ /@9\,?%7[)?
M[6S>*?AS\(/AGX"\0C2?AEX0U'36\1^"_!6BZ!K/]EZFOQ&$<T1GT:8(2P&U
M4VL9%;/Z?T4P/B__ (;!O_\ HTK]LS_PT6A__/$H_P"&P;__ *-*_;,_\-%H
M?_SQ*^T** /B_P#X;!O_ /HTK]LS_P -%H?_ ,\2C_AL&_\ ^C2OVS/_  T6
MA_\ SQ*^A?%OBN\\,^(OAIHMM90W%MX[\9ZEX:O+F=L&R,?@GQOXVQ@=<_\
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MO_$-OVE__G:4?\-G> O^B2?M=?\ B&W[2_\ \[2D]GZ/\F!]:X. /5CC]/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH$]GZ/\F> ?!J2"RTSXG7$T\4%O;_&CXG7-W<7! 51_;9)
M;.5 P"!GK@ *"2!6GX,^.GPT^("^&+KP?XC77+#QC:_;?#>IV=KJ?]G:CG1?
M[>$2%X$7<_A\C7$5B@,+!BXE-?*FM_%WX:^#;7Q5\+_&"_%[5_$'Q ^)_P 8
M/$VCZ-\&_AA\2/BMXEN_#'@7QKX?3Q#-K"_#KPGXO7P]H)UO7M)\-R_\)2+:
M.0Z[% &2*1Y;?Y>^'>MZ?\+=:\(^-M%\*_M&ZSX^\)>$+#P0OB+5OV1/VK--
MTW7O#4083>"M9T/0?@HR_P!@0>(M6?Q5X,\3A3XTC:-_ [J/ @8UTXQ-8A7Z
MM-:6NG3IZ_.S[6M;H98;_=5W2?YL_2R__:0^%5EJ)L&\2&6^NK#Q1JVFV%O;
M&[;7/#7@I]93QGXKT2= _P#;?AWPT^@ZTLCP$YD6TCCAE_X2?P@;O3\*?'?X
M<>/->MO#O@_5M0UR[N#J;:/JUEX8UMO"]^V@C;K)TKQF^A#PU-';R.=#DVW2
MS%D80EY&#-^86OZ?\*=2UO7?$?A_X>_M7^%M4M+#Q'X-^$CV7[+'[;P_X53X
M9\>:SK^M?%77]$5?AN /$/C!M9=8_"XQX*;_ (1_PPJYVX7K+'Q'\-_"OCOP
M)JG@#X??M2^%_ '@NQDT<^%-+_9%_:LTWYA)HVMZ-J\H3X9 :YKL'B5-;A'A
MHAO!V=<?QO*N^-F?F-C]BJ*^0_\ AL[P%_T23]KK_P 0V_:7_P#G:4?\-G>
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M2O:?^%>_ NWU#[+_ ,(/\*8=6U*[-T;)O#GA$:G>Z@,-Y@3R?-EF.,!?F)Y
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M#IO@+X<:EXBU*\\1:]XP^/OQ1^'=D\-YH^@C5-,T+QG\7!H+EGT&3=H">'/
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M>%OVL/@!XX^)GB_X0^#?B=X<\0^-O FF"^\6V6E7HGT[0G;5/[$_LNXUW!T
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M-/R;_.)87H/H/Y4M(O0?0?RI:R.D**** /F#XO?LT^%?B_XQ\'>/I_&OQ?\
MAWXN\%^'/$_@W3_$'PI^(VK^"+RZ\->--7\-Z[K6CZTT*S+K,3Z_X(T&6%7
MD0[L%E=?+XO_ (8VA_Z.D_;1_P##\ZG_ /,]7VG10!\6?\,;0_\ 1TG[:/\
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MJ?\ \SU'_#&T/_1TG[:/_A^=3_\ F>K[3HH ^*_^&-[?_HY_]L[_ ,/SJ_\
M\SM<WX>_92MM<M;Z8?M-?MF6XT[Q'J^B #]H'5SN;1=7DT9CG^P%&U_+)*\[
MCR6 )=?OBO,_AM_QZ^*_^RC>.?\ T^25HI7OY?/O_D<_Z[>?H?/'_#&T/_1T
MG[:/_A^=3_\ F>H_X8VA_P"CI/VT?_#\ZG_\SU?:=%9G0?%G_#&T/_1TG[:/
M_A^=3_\ F>K0\(_LA>$_#7Q"\$?$S4_BK^T'\2->^'=YX@N_"5G\2?B_J_B?
MPOI.IZYH.M^"M:U9-%FA2*367\.^(-:MTF.%#2-@0R+E?L.B@#Q[1_@M\*=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&KRJSAE?Q@IF7= -U '7^./@]K'@7PQ=^+==_;3_ &P)='AO?#-BK:&/V?\
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M(J /TBHKXP_X8]N_^CN/VS?_  [VA?\ S 4?\,>W?_1W'[9O_AWM"_\ F H
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97\JDHH"R[+[E_D%%%% PHHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
